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Myeloproliferative neoplasms (MPNs) are a heterogeneous group of haematological stem cell 
malignancies characterised by proliferation of one or more cells of the myeloid lineage. The molecular 
investigation of MPN was revolutionized in 2005 by the finding that approximately 95% of cases with 
polycythaemia vera (PV) and 50-60% of cases of essential thrombocythaemia (ET) and primary 
myelofibrosis (PMF) are characterised by a single acquired mutation, JAK2 V617F. My study has 
focused on four principal areas: 
(i) Involvement of V617F in other myeloid disorders. After developing sensitive methods to 
detect and quantify V617F, this mutation was identified in 17% of cases of atypical chronic myeloid 
leukaemia (17/99) as well as other atypical MPN, thus demonstrating that it was more widely 
involved in myeloid disorders that initially thought. Homozygosity of V617F was shown to have arisen 
by acquired uniparental disomy (UPD) and examination of two cases with V617F plus either KIT 
D816V or BCR-ABL demonstrated that the mutations had arisen in independent clones.  
(ii) In vitro assays to predict imatinib sensitivity. Haemopoietic colony and liquid cultures were 
used to determine if peripheral blood or bone marrow cells from atypical MPN cases (n=200) were 
sensitive to imatinib. Of those that responded in one or both cultures (n=185) some had known 
abnormalities of PDGFRA or PDGFRB, but a significant minority proved negative for all molecular tests 
suggesting the presence of uncharacterised imatinib-sensitive mutations. 
(iii) V617F as a marker of response to therapy. JAK2 V617F was used as a molecular marker to 
monitor the response of PV patients (n=21) to therapy with imatinib and interferon-α. Neither 
therapy eradicated V617F but there was a modest reduction in %V617F which correlated with 
haematological response. By contrast, in those patients that did not respond (n=13) the %V617F 
marginally increased.  
(iv) Genetic predisposition to MPN. Whilst investigating the possible contribution of JAK2 single 
nucleotide polymorphisms to the phenotypic diversity associated with V617F, marked skewing of 
alleles associated with the mutation was observed. Further investigation revealed that V617F-
associated disease is strongly associated with a specific constitutional JAK2 haplotype, designated 
46/1, in all three disease entities compared to healthy controls (PV, n=192, P=2.9x10
-16; ET, n=78, 
P=8.2x10
-9 and MF, n=41, P=8.0x10
-5). Furthermore, allele-specific PCR demonstrated that V617F 
specifically arises on the 46/1 allele in most cases. The 46/1 JAK2 haplotype thus predisposes to the 
development of V617F associated MPNs (OR=3.7; 95% CI 3.1-4.3) and provides a model whereby a 
constitutional genetic factor is associated with an increased risk of acquiring a specific somatic 
mutation. 
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1  Introduction 
1.1  Normal haematopoiesis 
The process of normal haematopoiesis originates in haematopoietic stem cells (HSCs), 
cells with the unique ability to undergo self-renewal and generate progenitor cells for all 
haematopoietic lineages on demand. Haematopoiesis is delicately regulated, giving rise to 
cells with functions that vary considerably, from immunity to the transport of oxygen. 
HSCs give rise to committed progenitor cells, which in turn proliferate and differentiate 
into functional mature cells. The formation of new committed progenitors is balanced 
against the rate of cell death by apoptosis, as most of these cells have a limited life span. 
Moreover, the haematopoietic system is also adapted to greatly amplify cell numbers in 
response to biological stresses such as bleeding or infection, which then return to basal 
levels once the stress has resolved. The numbers and distribution of the different cell 
types in the peripheral blood exhibit little variation under steady-state conditions, an 
observation that indicates the production of differentiated haematopoietic cells is tightly 
regulated 
1.  
In adults, the major site of haematopoietic cell formation is the bone marrow, where an 
associated stroma of endothelial cells, fat cells and fibroblasts provide a supporting role 
for HSCs and progenitors. As illustrated in Figure 1.1, a HSC makes an early important 
fate-determining decision to commit to one of two major pathways, myeloid or lymphoid 
2,3. After this point, the progenitor cell progressively differentiates, taking on 
characteristics of its chosen lineage and losing the ability to proliferate and self renew 
4-6. 
Mature cells arising from the myeloid lineage include erythrocytes, neutrophils, 
monocytes/macrophages, eosinophils, basophils and megakaryocytes/platelets, whereas 
mature cells arising from the lymphoid lineage become either B cells, T cells or natural 
killer cells.  
   2 
 
 
 
Figure 1-1. Haematopoiesis.  Every mature blood cell is derived from a multipotent 
haematopoietic stem cell (HSC). CFU-GEMM ; colony forming unit granulocyte erythroid 
megakaryocyte/macrophage, MEP; megakaryocyte erythroid progenitor, GMP; granulocyte-
macrophage progenitor, BFU-E; burst forming unit- erythroid, CFU-E; colony forming unit-
erythroid, CFU-M;  colony forming unit macrophage, CFU-G; colony forming unit granulocyte, 
CFU-Baso; colony forming unit basophil.  
 
Haematopoiesis is subject to a variety of control mechanisms, influenced by inherited and 
environmental factors, which ultimately operate to maintain a balanced production of 
diverse blood cells 
7. Within the cell, a series of transcription factor networks programme 
progenitor cell fate and diversity 
8. Differentiation is also controlled by paracrine 
stimulation by growth factors and cytokines secreted by other cells and cells in the 
microenvironment within which the progenitor cell resides. Indeed, cytokines and their 
cognate receptors play a critical role by fine tuning regulatory pathways that mediate 
both basal and emergency haematopoiesis. Once cytokines have bound their target cell 
via cell-surface receptors, they stimulate biological responses such as proliferation, 
survival, and differentiation through a variety of signal transduction pathways which all 
serve to modulate gene expression 
9.  Signalling networks that contribute to myeloid 3 
 
differentiation are well characterised 
10; some of the most prominent pathways include 
JAK-STAT, RAS/MEK/ERK, PI3K-AKT, and p38 MAPK/JNK/SAPK  
11. Although defined here 
as discrete pathways, interactions and cross-regulation also contribute to the complexity 
of intracellular signalling. Excessive stimulation may be controlled by several mechanisms, 
for example, the JAK-STAT pathway is direct targeted by specific antagonists such as SH2-
containing phosphatases (SHPs), and the suppressors of cytokine signalling (SOCS)
12,13.  
 
1.2  Leukaemia 
Haematological malignancies are characterised by alterations in the balance between 
stem cell proliferation, lineage commitment and differentiation. One definition of 
leukaemia is that of a ‘multi-hit’ model, whereby critical cellular pathways are 
deregulated by accumulating genetic damage, resulting in an autonomous, proliferating 
clone. The phenotype of the malignancy is determined by the pathways that are 
subverted, and sub-types of leukaemia are classified partly by the predominant types of 
blood cell. Clonal proliferation of abnormal cells within the bone marrow not only leads to 
an accumulation of blood cells in major organs like the liver and spleen, but normal 
haematopoiesis also becomes disrupted, so conditions such as anaemia, 
thrombocytopenia, and immunological dysfunction can also develop.  
As with other neoplasias, leukaemia is believed to arise from a single ancestral cell which 
has acquired a selective growth advantage due to an acquired somatic mutation. Normal 
individuals display polyclonal haematopoiesis, demonstrated by Lyon’s hypothesis of 
chromosome X inactivation 
14. In females, early in embryogenesis, each cell inactivates at 
random one of its two X chromosomes. This pattern of inactivation is passed on to all 
progeny cells, with the result that all women are mosaic with regard to X inactivation. In 
contrast, since leukaemia arises from a single cell, all the cells of a patient’s leukaemia will 
carry the same inactive X. A number of assays to detect clonality have been developed, 
many depending on differential methylation patterns between active and inactive X 
chromosomes at polymorphic regions in the genome. Determining clonality is a robust 
feature used for characterising, defining and diagnosing leukaemia 
15-17. Importantly, 4 
 
acquired cytogenetic or molecular changes can also serve as markers of clonality. An 
example is the Philadelphia (Ph) chromosome in chronic myeloid leukaemia (CML), which 
can be isolated in both myeloid and lymphoid cells, suggesting the mutation is acquired 
early in a HSC, before lineage commitment 
18.  
After the initial mutation, or ‘hit’, progeny acquire more mutations in a sequential and 
random fashion. Each new hit may confer an additional selective advantage leading to 
further clonal expansion and disease progression. There is some evidence that certain 
mutations can themselves increase genetic instability (Figure 1.2), for example, by the 
generation of reactive oxygen species 
19 or inhibition of mismatch repair which gives rise 
to further mutations 
20. 
   5 
 
 
 
 
Figure 1-2. Clonal proliferation in leukaemia. Normal haematopoiesis (blue cells) is subverted 
when one cell (green) acquires a mutation (yellow lightning bolt) which confers a small selective 
advantage. Over time, progeny of this cell acquire further mutations (purple, orange, red). Some 
mutations may be deleterious and cause the clone to die out (orange), whereas other mutations 
result in an increasingly aggressive phenotype as each mutation is acquired successively. Overt 
malignancy is characterised by the presence of a heterogeneous group of subclones (green, 
purple) plus a dominating clone (red). All neoplastic cells will share some overlapping mutations, 
but some cells may carry additional mutations acquired late in clonal evolution. 
 
1.2.1  Classification of leukaemia 
The World Health Organisation (WHO) has classified leukaemia into many distinct groups 
primarily based on the cell type of the presenting clone (lymphoid or myeloid), and 
whether the disease is acute or chronic in nature. Other features such as cell morphology, 
blood counts, symptoms, immunophenotype, clinical course of disease, clonal origins and 
any underlying genetic or cytogenetic abnormalities are also considered in making an 
accurate diagnosis. Acute leukaemia is characterised by a predominance of clonally 
derived precursor cells that have acquired a block preventing differentiation, plus a 
proliferative advantage, resulting in accumulation of immature blast cells. Acute 6 
 
leukaemia is often aggressive, and progresses rapidly with fatal consequences. 
Conversely, chronic leukaemia is generally slower to develop and progress. The 
predominant clone is typically comprised of fully differentiated cells that have undergone 
relatively normal maturation (Figure 1.1). Myeloid disorders are broadly divided into 
three clincopathological categories; acute myeloid leukaemia (AML), myelodysplastic 
syndrome (MDS) and myeloproliferative neoplasms (MPNs). This thesis focuses on the 
molecular pathogenesis of chronic leukaemias of myeloid origin, in particular MPNs and 
myelodysplastic/myeloproliferative neoplasms (MDS/MPNs).  
 
1.2.1.1  Myeloproliferative neoplasms (MPNs) and 
myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) 
The concept of myeloproliferative disorders (MPDs) was first proposed by William 
Dameshek in 1951 
21, who noticed there were strong similarities between the diseases 
chronic myeloid leukaemia (CML), polycythaemia vera (PV), essential thrombocythemia 
(ET), and primary myelofibrosis (PMF). The classification of chronic myeloproliferative 
disorders (CMPDs), recently re-termed ‘myeloproliferative neoplasms’ (MPNs) 
22, groups 
CML, PV, ET and PMF into the same category as chronic neutrophilic leukaemia (CNL), 
chronic eosinophilic leukaemia/hypereosinophilic syndrome (CEL/HES), mast cell disease 
(MCD) and unclassifiable MPD 
23. 
Although these diseases are defined as distinct entities they share similar biological 
features. It is now well established that CMPDs are haematological diseases that share a 
common stem cell-derived clonal origin, arising in a primitive bone marrow progenitor 
cell 
24-27. Clonal myeloproliferation leads to an excess of abnormal cells in peripheral 
blood, and together with extramedullary haemopoiesis often causes splenomegaly and 
hepatomegaly. Although the cells mature relatively normally, there is potential for further 
evolution of the neoplastic clone, which may result in bone marrow failure or 
transformation to an aggressive blast phase of disease.  
Another category of chronic myeloid neoplasms are the 
myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) 
23 which exhibit both 
proliferative and dysplastic features.  On one hand there is evidence in peripheral blood 7 
 
of effective clonal myeloproliferation, for example, eosinophilia or monocytosis. However 
the cells are often morphologically dysplastic, and occasionally there is cytopenia of one 
or more of the other cell lineages, due to ineffective proliferation or a decrease in the 
number of precursors. A hypercellular, fibrotic bone marrow and organomegaly are also 
associated features. Diseases included in the MDS/MPN category are chronic 
myelomonocytic leukaemia (CMML), juvenile myelomonocytic leukaemia (JMML), 
atypical CML (aCML), and MDS/MPN unclassifiable (MDS/MPN-U) 
23. How the MPNs and 
MDS/MPNs are currently classified into categories and their relationship to one another is 
depicted in Figure 1.3.  
 
 
Figure 1-3. Classification of adult MPN and MDS/MPN. ‘Classic’ MPNs are indicated in black and 
‘atypical’ MPNs in green. 
 
Discrimination between the MPN and MDS/MPN categories is made difficult by 
overlapping clinical, laboratory and morphological findings. An incomplete knowledge 
surrounding the underlying pathogenesis means diagnosis of these neoplasms is based 
mainly on the lineage of the predominant proliferating cells and in some cases the level of 
bone marrow fibrosis, but this is tentative in the absence of a pathognomonic marker. I 
will refer to both the MPN and MDS/MPN groups broadly as MPNs for simplicity. To date 
there in no single genetic abnormality associated with this category of chronic myeloid 
neoplasms, although a pathognomonic marker, BCR-ABL characterises CML, and JAK2 
V617F was initially isolated in the majority of cases with PV as well as other classic MPN.  
 8 
 
1.2.2  CML and the Philadelphia chromosome - the paradigm for deregulated tyrosine 
kinases 
CML is the most extensively characterised classical MPN, with an incidence of 1 to 
1.5/100 000 population per year 
28. CML typically presents in the chronic phase and, in 
the absence of intervention, progresses over the course of several years to more 
aggressive stages, accelerated phase and ultimately to a blast phase which resembles 
acute leukaemia. The natural course of disease progression from chronic phase to blast 
crisis is within three to five years, and it is thought this is due to the acquisition of further 
genetic abnormalities 
29. Chronic phase CML is characterised by an abnormal expansion of 
granulocyte progenitors; neutrophils that are at various stages of maturation 
predominate the haematological profile of peripheral blood. As observed on blood 
smears, the myeloid mass primarily consists of granulocytes, but also erythroid, 
megakaryocyte, and monocyte lineages that are derived from the malignant clone 
18,30,31. 
 
1.2.2.1  Molecular pathogenesis of CML 
The first chromosomal abnormality to be associated with a haematological malignancy 
was the Philadelphia chromosome (Ph). In 1960, Nowell and Hungerford 
32 first defined 
the consistent association between CML and the presence of a ‘minute’ chromosome, 
later named the Ph chromosome after its place of discovery. The cytogenetic abnormality 
was subsequently defined as a reciprocal translocation between the long arm of 
chromosomes 9 and 22 
33. The t(9;22)(q34;q11) translocation was finally characterised at 
the molecular level in the 1980s, as a fusion between the breakpoint cluster region (BCR) 
gene at chromosome 22q11 and the Abelson (ABL) gene at chromosome 9q34. This gives 
rise to a novel chimaeric BCR-ABL gene, which when translated produces a BCR-ABL 
fusion protein with prominent tyrosine kinase activity 
34. Fusion to BCR constitutively 
activates the ABL tyrosine kinase moiety, and this activation depends on the BCR N-
terminal coiled-coil domain 
35. The net result is deregulated autophosphorylation of the 
protein and activation of a number of downstream signalling pathways, which prolong 
cell survival and impact on cell proliferation 
36,37. Expression of BCR-ABL is sufficient to 9 
 
cause chronic phase CML in vivo, whilst disease progression to blast phase is thought to 
depend on additional cytogenetic changes 
38.  
BCR-ABL has now become the defining marker of CML, and by definition is present in all 
cases 
39. However, BCR-ABL is also isolated in a significant proportion of acute 
leukaemias; 30% of cases with adult lymphoblastic leukaemia (ALL) 
40, 3 to 5% of 
childhood ALL 
41 and in 2% of cases with AML 
42. Variations in the breakpoint in the BCR 
gene create three oncogenic fusion proteins; p190, p210 and p230. All variants have been 
shown to generate leukaemia in murine models 
38,43. The p190 protein is found more 
commonly in ALL 
44 whereas the p210 protein is the main form isolated in CML. The p230 
protein is much rarer, having been described in CML plus cases with CNL 
45. The 
mechanisms that underlie the different phenotypes induced by the different splice forms 
are still largely unknown, but attempts have been made to define distinct groups 
depending on the type of BCR-ABL fusion protein 
46,47. The Ph chromosome is now 
detected by routine cytogenetic techniques in 85 to 90% of CML patients at diagnosis. 
Apparent Ph negative CML cases are generally found to harbour cryptic BCR-ABL fusions, 
formed by insertion of ABL material onto the BCR region without the reciprocal 
translocation 
48,49. Although not visible cytogenetically, BCR-ABL transcripts formed by 
sub-microscopic insertions and complex translocations can be detected by fluorescence in 
situ hybridisation (FISH) and by polymerase chain reaction (PCR) 
50-52. 
 
1.2.3  Other classical MPN 
The three other classic MPNs, PV, ET and PMF, share several common features, namely an 
origin in a multipotent haematopoietic stem cell, a relatively normal cellular maturation, 
and in cases with PV and ET, a striking overlap in clinical presentation and the propensity 
to evolve into post-polycythemic or post-thrombocythemic myelofibrosis 
53. All carry the 
potential to transform into AML 
54, although this is much less common than in CML. 
Classic MPNs are among the most frequent haematological neoplasms, and usually affect 
the adult elderly population, but may be found at a much younger age in rare cases. 
Similarities between the three neoplasms suggest that each may share a similar 10 
 
underlying molecular pathogenesis, which will be discussed in more detail in later 
sections.  
1.2.3.1  Polycythaemia vera (PV) 
Primary PV is principally characterised by the clonal expansion of the erythroid lineage 
24 
which results in an elevated level of haemoglobin and a raised haematocrit, a measure of 
the proportion of blood volume that is occupied by erythrocytes. The elevated red cell 
mass causes a range of symptoms, most importantly the risk of thrombotic events due to 
an increased blood viscosity, but also splenomegaly, hypertension, pruritus, gout, 
stomach ulcers, headaches and fatigue. If left untreated, patients are at substantial risk of 
developing Budd-Chiari syndrome (hepatic vein thrombocytosis) 
55 and myelofibrosis 
56. 
Treatment currently focuses on targeting symptoms and reducing the potential for 
thrombotic complications. The removal of blood by phlebotomy is effective at reducing 
the blood volume and haematocrit, and is often combined with myelosuppressive agents 
such as hydroxyurea (HU) and recombinant interferon α (rIFNα) 
57. Approximately 2.6 
cases per 100 000 population are diagnosed per year 
58 and up to 10 to 15% have an 
abnormal karyotype at diagnosis. The most common abnormalities include trisomies of 
1q, 8, and 9, together with deletions of 20q 
59-61. An abnormally low serum erythropoietin 
(EPO) level is one diagnostic requirement for ‘true’ primary PV. Measurement of EPO 
levels helps determine if the erythrocytosis is a reactive consequence of either malignant 
or benign tumour tissue (hypoxia-independent EPO production), haemoglobinopathies or 
environmental factors. For example, serum EPO levels are increased by high altitude and 
carbon monoxide poisoning 
62,63. In cases with erythrocytosis and normal or elevated EPO 
a diagnosis of secondary PV or idiopathic erythrocytosis may be considered. Alternatively, 
marked erythrocytosis may be caused by congenital PV which results ultimately from 
either an abnormally elevated set point for EPO production, or abnormal oxygen 
homeostasis. In this situation, raised serum EPO levels are caused by mutations in the von 
Hippel-Lindau protein (VHL), an important component of the polyubiquitin pathway that 
degrades a transcription factor (hypoxia-inducible factor, HIF-1) responsible for the 
response to hypoxia 
64. Mutations in VHL are also responsible for hereditary Chuvash 
polycythaemia 
65-67. A different part of the oxygen-sensing pathway is targeted in primary 
familial and congenital polycythaemia (PFCP), where truncating mutations in the EPO 11 
 
receptor abrogate negative regulatory domains resulting in upregulation of EPO-
responsive signalling pathways 
68. Cases with this form of PV have a low serum EPO and 
when cultured in vitro, erythrocyte progenitors display hypersensitivity to stimulation 
with EPO 
69,70. 
Research into the molecular pathogenesis of PV suggested a defect in the signalling 
pathways that lead to autonomous erythrocytosis. In 1974, Prchal and Axelrad observed 
that primary PV progenitors form erythroid colonies in vitro in the absence of exogenous 
EPO 
71. In contrast, bone marrow cells from healthy individuals do not form these 
endogenous erythroid colonies (EECs).  EECs can be isolated in 97 to 100% of PV cases 
who have not been exposed to cytoreductive therapy 
72-74, and may also be cultured from 
a subset of cases with ET and MF 
71,75. PV progenitor cells are highly sensitive to 
stimulation with cytokines (for example granulocyte macrophage colony-stimulating 
factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), interleukin-3 (IL-3), insulin 
growth factor-1 (IGF-1), and thrombopoietin (TPO), but are surprisingly unresponsive to 
stimulation with EPO 
76-80. Similarly, megakaryocyte progenitors are hypersensitive to 
TPO, in ET and MF 
81. Since the principal feature of PV was autonomous formation of EECs 
without exogenous stimulation with EPO, it was logical to infer a defect in the normal 
erythropoietic pathways in the pathogenesis of PV. Based on this and findings of EPOR 
mutations in familial erythrocytosis, the EPOR and components of its downstream 
signalling pathway were investigated for abnormalities in primary PV, but the receptor 
was found to be structurally and functionally intact 
82,83. Similarly, no mutations were 
identified in another candidate, SHP-1, a tyrosine phosphatase previously shown to 
interact with the EPOR 
84 and be downregulated in progenitor cells isolated from PV 
patients 
85. Erythrocytes from most PV patients have elevated levels of signalling 
intermediates STAT3 
86, and PKC 
87, plus upregulation of the PRV-1 gene 
88 and an 
abundance of anti- apoptotic proteins like BCL-XL 
89. Unlike other malignancies where the 
INK4a locus is inactivated, PV erythroid progenitors exhibit increased expression at this 
gene 
90. It was only relatively recently that understanding of the molecular pathogenesis 
behind PV and other classic MPNs was furthered by the finding of a single mutation 
targeting the JAK2 gene.  12 
 
1.2.3.2  Essential thrombocythaemia (ET) 
ET is characterised by the clonal expansion of megakaryocytes, resulting in the 
overproduction of platelets. For accurate diagnosis the megakaryocytes should display a 
large and mature morphology, with little or no granulocyte or erythroid proliferation. 
There should also be no evidence of reactive thrombocytosis, and diagnoses of other 
myeloid neoplasms such as CML, PV, and MDS should be ruled out. Patients with ET 
typically suffer bleeding and thrombosis, plus weakness, headaches, pruritus and 
splenomegaly. A large proportion of patients remain asymptomatic throughout the 
course of disease, but some will progress into a myelofibrotic or even a leukaemic phase. 
As not all patients with ET will require treatment at presentation, cytoreductive therapy is 
only given to those who are at an increased risk of thrombocytosis or bleeding. Similar to 
other MPNs, myelosuppressive agents such as HU and rIFNα may be administered, 
alongside low-dose aspirin. Thrombosis is more specifically addressed by anagrelide, 
which appears to affect megakaryocyte development more specifically than other agents, 
and is a first line therapy for younger patients and those with a greater risk of 
transformation 
91. In ET, chromosomal abnormalities are found in <5% of cases, and the 
majority of these are represented by numerical gain of chromosome 9, but trisomy 8 and 
13q- are also seen 
92,93. 
 
1.2.3.3  Primary Myelofibrosis (PMF) 
PMF, previously known as chronic idiopathic myelofibrosis or myelofibrosis with myeloid 
metaplasia, is characterised by excessive clonal proliferation of megakaryocytes, with a 
leucoerythroblastic blood profile. The megakaryocytes may display abnormal 
morphology, such as an aberrant nuclear/cytoplasmic ratio, or hyperchromatic, bulbous 
or irregularly folded and dense nuclei, and are called poikylocytes 
22.  Moreover, 
deposition of reticulin and collagen in the extracellular spaces of the bone marrow 
(myelofibrosis) is a typical feature, and this impairs the patient’s ability to generate new 
blood cells, resulting in a progressive pancytopenia. Stem cells that normally reside in the 
bone marrow are forced into circulation, so haematopoiesis is shifted to extramedullary 
sites such as the spleen and liver.  13 
 
Additional diagnostic criteria are an increased serum lactate dehydrogenase, anaemia, 
palpable splenomegaly and hepatomegaly and there must be no evidence of reactive 
fibrosis 
63. Myelofibrosis may occur de novo, where it is termed PMF, or arise as a 
secondary event following PV or ET. Myelofibrosis leads inevitably to bone marrow 
failure, and the median survival is only five years. Other complications include cardiac 
failure due to fibrosis, haemorrhage, infection and thrombocytosis, and a significant 
minority transform to AML. Apart from stem cell transplantation, which is the only 
potential curative therapy, there are few successful maintenance therapies available 
94. 
Cytogenetic abnormalities are common in PMF and are similar to those seen in PV, such 
as 20q-, 13q-, partial trisomy 1q and trisomy 8 
63. 
 
1.3  Tyrosine kinases in normal and malignant haematopoiesis 
Within the human genome there are documented to be 518 putative protein kinases 
95, 
of which 90 are tyrosine kinases. Tyrosine kinases are enzymes that catalyse the transfer 
of γ-phosphate from a purine nucleotide triphosphate, such as adenosine triphosphate 
(ATP) or guanosine triphosphate (GTP) to hydroxyl groups of specific amino acid residues 
of their protein substrates. In contrast to the serine/threonine kinases, the substrates of 
tyrosine kinases are tyrosine residues. Tyrosine phosphorylation activates enzyme 
activity, but also allows the recruitment of downstream signalling proteins, by changing 
conformation and creating binding sites for proteins with Src homology 2 (SH2) and other 
phosphotyrosine binding domains. This process is a fundamental mechanism for the 
reversible regulation of protein activity and function. Phosphorylation by protein kinases 
is a central mechanism for intracellular signal transduction, mediating a range of cell 
functions from cell cycle progression, differentiation, metabolism, cytoskeletal 
rearrangement, apoptosis and DNA synthesis. Tyrosine kinases are categorised based on 
cellular location as either non-receptor or receptor, and there are 32 and 58 of each 
present in the human genome, respectively 
96. The receptor tyrosine kinases (RTKs) bind 
extracellular ligand, and span the cell membrane. The non-receptor tyrosine kinases 
(NRTKs) are located within the cell. Both RTKs and NRTKs and their ligands are important 14 
 
mediators of normal haematopoiesis, and as a consequence deregulation of these 
signalling pathways by intergenic or intragenic mutation can result in leukaemogenesis. 
The following sections discuss tyrosine kinases involved in myeloid haematopoiesis, with 
emphasis on mutations implicated in the pathogenesis of MPN. These mutations fall into 
two broad categories: 
•  Balanced chromosomal translocations, insertions or deletions that target tyrosine 
kinases generate fusion proteins, in which the extracellular ligand binding domain 
is replaced by the N-terminal portion of the fusion partner. The chimaeric protein 
retains the full catalytic kinase domain but is no longer responsive to normal 
mechanisms of activation and regulation. Instead, fusion proteins are 
constitutively activated, driving cell proliferation and promote cell survival by 
overriding apoptosis-related signalling 
97.  
•  Point mutations that occur in the activation loop alter the conformation of the 
kinase domain, switching it to an active state, a change normally induced by 
phosphorylation of an activation loop tyrosine residue.  Alternatively, regulatory 
regions that hold the protein in an inactive state can be targeted by mutation, 
causing destabilisation of protein conformation, and release of normal constraints 
on kinase activation. Extracellular domain mutations can also result in aberrant 
receptor dimerisation. In all situations, the tyrosine kinase is then constitutively 
activated in the absence of natural ligand or rendered hypersensitive to normal 
stimulation by ligand. 
 
1.3.1  Receptor tyrosine kinases (RTKs) 
Examples of RTK families with relevance for leukaemogenesis are given below. 
1.3.1.1  Class III RTKs 
The class III RTKs are characterised by five immunoglobulin-like domains in the 
extracellular ligand binding region, a single transmembrane domain and two intracellular 15 
 
tyrosine kinase domains, separated by a kinase insert domain 
98. This family includes the 
receptors KIT, FLT3R, PDGFRα, PDGFRβ and FMS. All of these except PDGFRα are believed 
to play important roles in maintaining a steady state of haematopoiesis, and are subject 
to tight regulation. As illustrated in Figure 1.4, inactive class III RTKs are thought to exist 
as monomers, embedded in the plasma membrane. Ligand binding promotes receptor 
dimerisation, juxtaposing the two catalytic domains to induce a conformational change, 
partially activating enzyme activity. Autophosphorylation of a key tyrosine residue in the 
activation loop heightens enzymatic activity and additional tyrosine residues are then 
autophosphorylated. Individual phosphorylated tyrosines serve as docking sites for an 
array of intracellular signalling molecules which subsequently recruit other downstream 
signalling intermediates to mediate a physiological response. Induction of signalling 
pathways JAK/STAT, PLCγ, PI3K and Ras-Raf-MEK/ERK are all observed in class III RTK 
activation 
99. 
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Figure 1-4. An illustration of activation and signalling from the RTK PDGFRβ. Platelet-derived 
growth factor (PDGF) ligand binding induces PDGFRβ receptor dimerisation, and the 
conformational change causes activation of two kinase domains located on the intracellular 
portion of the protein. Auto and transphosphorylation at key tyrosine residues creates docking 
sites for signalling molecules (yellow circles represent phosphorylated tyrosines). A cascade 
involving various signalling pathways is initiated, resulting in changes in expression of genes 
involved in the control of cell proliferation, differentiation and survival. 
 
1.3.1.1.1    Platelet derived growth factor receptors (PDGFRs) 
The PDGF receptors, PDGFRα and PDGFRβ, are two highly related proteins 
100, that bind a 
total of four ligands (PDGF A, B, C, and D), which exist in dimeric isoforms linked by 
disulphide bonds. Both receptors have a role in mesenchymal cell migration and 
proliferation 
101, but their involvement in the pathogenesis of MPN is better understood.  
 The most common PDGFRA fusion gene is now known to be FIP1L1-PDGFRA arising by a 
cytogenetically invisible interstitial deletion at chromosome 4q12 
102. The resulting 
oncoprotein was found to transform Ba/F3 cells to growth factor independence, similar to 17 
 
BCR-ABL. Moreover, the association between FIP1L1-PDGFRA and clonal eosinophilia has 
allowed unified molecular characterisation of a subset of patients with HES and CEL into 
one entity based on the presence of FIP1L1-PDGFRA 
23,103. Additional PDGFRA fusion 
genes have also been reported, for example BCR-PDGFRA was isolated in very rare cases 
with aCML 
104. Other rare PDGFRA fusions have strengthened the notion that 
deregulation of PDGFRα is linked to clonal eosinophilia 
105-107. 
PDGFRB is also targeted by balanced chromosomal translocation, and more than 20 
different fusions involving this gene have been recorded in patients with various MPNs 
108. The best characterised abnormality is the t(5;12)(q33;p13) resulting in a ETV6-PDGFRB 
fusion gene 
109. In an analogous manner to the BCR-ABL oncoprotein, pathogenicity is 
dependent on both the ETV6 dimerisation motif and the tyrosine kinase activity of 
PDGFRβ. However fusions involving PDGFRβ remain extremely rare 
110. 
 
1.3.1.1.2  KIT 
The RTK KIT and its ligand stem cell factor (SCF) are essential for the development and 
differentiation of mast cells, plus other cells of the haematopoietic system 
111,112. 
Originally identified in a series of mast cell lines 
113, constitutively activating point 
mutations in KIT have been isolated in a number of neoplastic conditions, most notably in 
the MPN systemic mastocytosis (SM) 
114 and gastrointestinal stromal tumours (GISTs) 
115. 
KIT mutations have also been identified in patients with other MPNs and AML 
113,116. 
Approximately 80% of all cases with SM carry the KIT D816V point mutation, and 
examination of the bone marrow for this change is recommended in all suspected cases 
of SM 
117. The mutated amino acid D816 is located in the catalytic domain of the tyrosine 
kinase, but mutations also target the juxtamembrane and extracellular domains. 
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1.3.1.1.3  FMS 
FMS (also known as CSF1R) is the receptor for the macrophage colony-stimulating factor 
(M-CSF), and is important for the growth and differentiation of the monocyte, 
macrophage, osteoclast lineage 
118. A missense mutation in FMS was identified in the 
imatinib-sensitive cell line GDM1 
119, and mutations targeting various regions of this gene 
are activating when expressed in cell lines in vitro 
120. However, a recent screen of the 
tyrosine kinase and juxtamembrane domain of FMS in cases with CMML did not reveal 
any activating mutations 
121, so it is unlikely disruption of this RTK is involved in the 
pathogenesis of MPN.  
 
1.3.1.1.4  FLT3 
FLT3 (Fms-like tyrosine kinase) and FLT3 ligand play an important role in the development 
and expansion of multipotent haematopoietic stem cells and progenitors 
122. Constitutive 
activation of FLT3 occurs either by internal tandem duplication (FLT3-ITD) of the 
juxtamembrane domain region or by point mutations usually involving the kinase domain 
123-125. Both types of mutation constitutively activate FLT3. ITD mutations are a common 
finding in 25% of younger adults with AML 
126, and approximately 7% of AML cases have 
point mutations in the activation loop of the kinase 
127,128. In AML patients, FLT3-ITDs are 
associated with reduced survival, leukocytosis, a high percentage of blast cells in the bone 
marrow, and an increased risk of relapse from complete remission 
123,126. Additionally, 
duplication of the FLT3-ITD allele by acquired uniparental disomy (UPD) and subsequent 
loss of the wild-type allele occurs in approximately 10% of cases, and this carries an 
additional poor prognosis with a high rate of relapse 
129,130. Cases carrying FLT3-ITDs often 
have a normal karyotype and a mutation in the NPM1 gene 
131, and it was recently shown 
that those positive for FLT3-ITD but negative for an NPM1 mutation were associated with 
a particularly bad outcome 
132.  
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1.3.1.1.5  Class IV RTKs, the FGF receptor family 
The fibroblast growth factor receptor (FGFR) family members FGFR1 and FGFR3 are also 
targets of chromosomal rearrangement. Translocations that disrupt FGFR1 on 
chromosome 8p11 are closely associated with a defined 8p11 syndrome that present as 
an MPN with eosinophilia and other features such as T-lymphoblastic lymphoma, 
granulocyte sarcoma and rapid progression to acute leukaemia, usually of myeloid 
phenotype. The three most common translocations involving FGFR1 are t(8;13)(p11-
12;q11-12),  t(8;9)(p11;q34), and t(6;8)(q27;p11) which result in the formation of ZNF198-
FGFR1, CEP110-FGFR1, and FOP-FGFR1, respectively 
133-135. The closely related FGFR3 
gene is transcriptionally upregulated by a t(4;14) translocation in 5 to 10% of cases with 
multiple myeloma (MM) 
136, and a small subset of cases with MM can also harbour 
activating FGFR3 mutations.  
 
 
1.3.1.2  Non RTKs (NRTKs) 
Signalling cascades from extracellular stimuli also utilise intracellular NRTKs. After ligand 
binding, a stimulated receptor activates an associated NRTK, and tyrosine 
phosphorylation subsequently recruits additional signalling molecules by providing 
binding or docking sites. Lack of transmembrane domains situates NRTKs either in the 
cytosol or nucleus. NRTKs are kept in an inactive state by intramolecular inhibition, or by 
association with inhibitory proteins or lipids 
137. NRTK activation may also occur by 
phosphorylation as a downstream target of signalling mediators, or by dissociation of 
inhibitor proteins. 
 
1.3.2  JAK2  
The mammalian genome encodes four JAK (Janus-Associated Kinase) family members, 
JAK1, JAK2, JAK3 and TYK2. Whereas JAK1, JAK2, and TYK2 are expressed ubiquitously in 
mammals, JAK3 is primarily expressed in haematopoietic tissue 
138,139. Haematopoietic 
cytokines, interferons, and growth factors all use JAK family members for signal 
transduction, placing JAKs in an important position for cell growth, survival, development, 20 
 
and differentiation of immune cells, plus the mounting of effective innate and adaptive 
immune response. All family members share a unique structure, with a relatively high 
degree of homology. As illustrated in Figure 1.5, there are seven so called JAK homology 
domains (JH) denoted JH1 to JH7 that characterise the JAK family. From the C to the N 
terminus, JH1 represents the kinase domain, JH2 the pseudokinase domain, JH3 and JH4 
contain an SH2-like domain and linker regions, whereas JH5 to JH7 contain a FERM (band 
4.1, ezrin, radixin, moesin) domain 
138,140. The most distinguishing feature characterising 
JAKs is the bipartite protein structure. The kinase domain, JH1, catalyses tyrosine 
phosphorylation of substrates and thus is responsible for signal propagation. The N 
terminus binds and stabilises other proteins, mediating the interaction of JAK with 
receptors and regulatory proteins 
141-143. The FERM domain of JAK2 is important for 
promoting cell surface localisation of particular cytokine receptors, such as the EPO 
receptor 
141 and thrombopoietin receptor 
144. The JH2 domain, despite carrying most of 
the conserved amino acids that are characteristic of a functional kinase, lacks all tyrosine 
kinase ability due to a lack of key residues required for effective catalysis and nucleotide 
binding. In fact, the JH2 domain, also referred to as the pseudokinase 
138, is critical for 
regulation of JAK activity, as it is predicted to inhibit the basal activity of the kinase 
domain 
145,146. Deletion of the JH2 domain in both JAK2 and JAK3 has been shown to 
result in increased autophosphorylation as well as increased phosphorylation of the 
downstream substrate STAT5  
146,147. Furthermore, a more detailed analysis of the JAK2 
JH2 region using recombinant proteins indicated that this domain suppressed basal JAK2 
activity by lowering the activation threshold of the kinase without affecting its affinity for 
a substrate peptide 
148.  While no complete three-dimensional structure for any JAK 
currently exists, the crystal structure of the JH1 domain has been solved for JAK2 and 
JAK3 in an active form, complexed with specific inhibitors 
149,150. 
   21 
 
 
 
Figure 1-5. Schematic representation of the primary structure of JAKs, JAK2 fusion proteins and 
point mutation isolated in MPN. The primary structure of JAK is comprised of seven domains, JH1 
to JH7 (panel A). The ETV6-JAK2 fusion proteins contain the entire JH1 domain, but variable 
portions of JH2, and were first identified in patients with atypical CML (panel B) 
151, and ALL (panel 
C and D) 
151,152. The PCM1-JAK2 fusion proteins all contain the entire JH1 and JH2 domains, and in 
some cases parts of the SH2-like domain, and have been found in cases with T-cell lymphoma, 
aCML and CML/ALL (panel E and F) 
153-155. The fusion BCR-JAK2 was identified in a case with aCML 
(panel G) 
156.The JAK2 V617F point mutation is located in the JH2 domain (panel H).  
 
Similar to most kinases, JAKs require phosphorylation of residues in their activation loop 
for full activity. A YY motif is present in the activation loop of all four JAK kinases 
148, and 
phosphorylation at this site is the first event in the activation cascade required for signal 
transduction 
157,158. The JAKs have different receptor affinities, for example, JAK3 appears 
to associate with cytokine receptors that include the γc chain of interleukin-2 (IL-2) 
receptor (i.e. IL-4R, IL-7R) whereas JAK2 is associated with a wide range of cytokine 
receptors, including those activated by growth hormone 
159,160, EPO 
161, prolactin 
162, G-
CSF 
163, and IL-3 
164, as well as some G protein-coupled receptors. JAKs play an essential 
physiological role, underscored by the observation that murine knockouts of JAK2 result 
in ineffective erythropoiesis 
165, and JAK3 deficiency is embryonically lethal 
166. It is not 22 
 
fully known by which precise mechanism ligand binding results in the activation of JAKs, 
however a model has been inferred based on the results from various studies, and is 
illustrated in Figure 1.6. In an unstimulated, latent state, JAKs form a complex with a 
native unliganded receptor, via non-covalent interaction with the receptor and the SH2 
domain of JAK. Receptor oligomerisation/dimerisation due to ligand binding results in the 
juxtapositioning of the JAKs, which are in the vicinity through either homo- or 
heterodimeric interactions. Recruitment of JAKs is likely to result in their phosphorylation, 
either by autophosphorylation or by cross-phosphorylation by other JAKs or other 
families of tyrosine kinases. The heightened JAK activity results in phosphorylation of 
receptors on target tyrosine kinase sites. These phosphorylated tyrosines serve as docking 
sites which allow the binding of other signaling proteins, such as STATs, Src-kinases, 
protein phosphatases, Shc, Grb2, MAP kinase, AKT kinase and PI3K 
167. In the JAK/STAT 
signalling pathway, phosphorylation of STATs causes dimerisation, followed by 
translocation to the nucleus where they interact with specific regulatory elements on 
target genes, modulating gene transcription 
168,169. This process is tightly controlled at 
multiple levels by protein tyrosine phosphatases, suppressors of cytokine signalling 
(SOCS), and protein inhibitors of activated STAT (PIAS) 
170-173. There is mounting evidence 
to show that STAT3 and STAT5 play an important role in growth factor induced myeloid 
differentiation 
174,175. G-CSF stimulation activates STAT3, and this interaction is critical for 
differentiation of granulocytes 
176. Mice with a conditional knockout of STAT3 show 
embryonic lethality, indicating a requirement for STAT3 in early development 
177. Results 
from a conditional knockout study, where STAT3 is not expressed in myeloid cells, 
showed STAT3 deficiency impairs immune responses, and has an important role in the 
function of mature myeloid cells 
178. Evidence suggests STAT3 may promote cellular 
differentiation by upregulating the expression and enhancing the transcriptional activity 
of CCAAT/enhancer binding protein alpha (C/EBPα), a key transcription factor that drives 
myeloid differentiation 
179. STAT5 is also important in cytokine-induced myeloid 
differentiation 
180. Successful differentiation of neutrophils, induced by G-CSF, is 
perturbed by expression of a dominant negative form of STAT5 
181. It has been suggested 
that STAT5 may be responsible for promoting the survival of myeloid progenitors via 
transcriptional upregulation of the anti-apoptotic protein Bcl-XL, thereby allowing myeloid 
differentiation to proceed 
182. Activating mutations of the EPO receptor, found in familial 23 
 
erythrocytosis, are also associated with constitutive phosphorylation of JAK2 and STAT5 
183. 
 
Figure 1-6. Summary of the JAK2 signalling pathway. Binding of cytokine ligand to the respective 
receptor induces receptor dimerisation, and transphosphorylation of receptor-associated JAK2. 
JAK2 subsequently phosphorylates signalling intermediates, namely STATs (yellow circles 
represent phosphorylated tyrosines). Activated STATs dimerise, translocate to the nucleus 
whereby they activate or repress target gene promoters. Other signalling intermediates are 
scaffolded onto the receptor-JAK2 complex and become activated, including PI-3-kinase, AKT 
kinase, MAP kinase and the Ras/Raf/MEK/ERK pathway. A negative feedback loop involving SOCS 
1 and 2 contributes to attenuation of the signalling cascade. 
 
Although key to growth factor and cytokine signalling, the JAK/STAT pathway is not the 
only means by which receptors transmit signals to the nucleus. Other pathways, equally 
important in driving proliferation and preventing apoptosis, include the Ras/Raf/MEK/ERK 
pathway 
184,185, and the PI3K/PTEN/Akt/mTOR pathway 
11 . Each pathway may regulate 24 
 
the other at various levels by cross-interactions, heightening the complexity of 
intracellular signalling. For example, there is evidence to show STATs may be regulated by 
threonine phosphorylation 
186, mediated by ERK 
187, indicating a point of interaction 
between the JAK/STAT and Raf/MEK/ERK pathways.  
Constitutive activation of different JAKs and STATs are believed to mediate neoplastic 
transformation and promote abnormal cell proliferation in various tumour phenotypes, 
including haematological malignancies. For example, wild-type JAK2 is implicated in 
abnormal cell growth induced by BCR-ABL in CML 
188 but more importantly recent 
developments have implicated JAK2 as a principle target for activation in MPN. 
 
1.3.2.1  Mutations that target JAK2 
The first evidence that JAK2 could contribute to the pathogenesis of leukaemia came 
from the characterisation of various chromosomal translocations all involving the fusion 
of JAK2 to different transcription factors (Figure 1.5). The first to be identified, ETV6-JAK2, 
was isolated in a T-cell ALL patient 
152, and later in a child with early B-precursor ALL and 
in adult aCML 
109,189. Like other tyrosine kinase fusion proteins involving ETV6 
109,189, the 
oligomerisation domain of ETV6 facilitates constitutive activation of the kinase domain of 
the fusion partner, in this case the JH1 domain of JAK2. ETV6-JAK2 is capable of 
transforming a murine cell line to factor independence 
152, and reproducing features of 
malignancy when expressed in transgenic mice 
190-192. This oncogene has been shown to 
signal through the JAK/STAT, PI3K, Ras/ERK pathways 
193,194, plus upregulate NF-κB and 
STATs 1 and 5 
190,195. Another oncogenic fusion protein involving JAK2 is PCM1-JAK2 
155, 
identified in several cases of chronic and acute leukaemia, such as aCML 
154, acute 
erythroid leukaemia 
196 and T-cell lymphoma 
153. A single case of aCML was also found to 
carry a BCR-JAK2 fusion gene 
156.  Nevertheless, JAK2 translocations remain rare in MPN, 
especially when compared to the incidence of JAK2 V617F. 
In 2005 it emerged that JAK2 plays a very important role in the molecular pathogenesis of 
MPN, by the finding of a consistent, acquired point mutation, isolated in a significant 25 
 
proportion of cases with classical MPN. Approximately 80 to 95% of cases with PV and 
roughly 40 to 60% of cases with ET and MF were found to carry JAK2 V617F 
197-201, the 
discovery of which was simultaneously reported in a series of remarkable publications. 
Several groups claim discovery of the JAK2 mutation following quite different research 
strategies to arrive at the same result. 
(i.)  The observation that the spontaneous formation of EECs grown from PV 
progenitors could be blocked by JAK inhibitors led one group of researchers to 
sequence the entire JAK2 gene in a small group of PV cases, revealing V617F 
197. 
EEC formation was inhibited by short-interfering RNA (siRNA) directed against 
JAK2, but not siRNAs against other various candidate genes. James et al. (2005) 
also performed several functional studies to define the role JAK2 V617F plays in 
the pathogenesis of PV. When expressed in vitro, JAK2 V617F is capable of 
inducing constitutive STAT5-mediated signalling independently of any stimulation 
by EPO. Furthermore, expression of the mutant JAK2 (but not wild-type) induced 
EPO hypersensitivity and EPO-independent survival of cultured cell lines in vitro. 
When expressed in mice, JAK2 V617F induced a PV-like phenotype with 
splenomegaly and marked erythrocytosis.  
(ii.)  A similar approach was undertaken by Zhao et al. (2005) 
201 who isolated JAK2 
V617F in 20/24 cases with PV, and confirmed the mutant JAK2 protein had 
heightened kinase activity and cells transfected with JAK2 V617F displayed hyper-
activated signalling after stimulation with EPO.  
(iii.)  Recurrent abnormalities of chromosome 9 have been previously linked to classic 
MPN, and include trisomy 9, unbalanced translocations involving chromosome 9, 
amplification of 9p 
93,202 but the finding of loss of heterozygosity (LOH) at 9p  
proved to be the most significant finding. Using microsatellites analysis, 
chromosome 9p was found to be a region where there was recurrent LOH in 33% 
of PV cases 
203. Cases with 9pLOH retained two copies of chromosome 9, 
indicating that LOH had occurred by acquired UPD following somatic 
recombination 
203,204. Markers for the 9pLOH region were subsequently 26 
 
investigated in four families with PV, but as they were found not to cosegregate 
with the PV phenotype, this suggested a somatic event was responsible for the 
LOH 
199. By increasing the number of microsatellite markers, Kralovics et al. (2005) 
mapped a minimal region shared by all patients carrying 9pLOH and MPN, and this 
common 6.2Mbp genomic interval contained the JAK2 gene. With this knowledge, 
the DNA encoding JAK2 was sequenced to reveal V617F. Furthermore, 
homozygosity for V617F correlated with 9pLOH, and the incidence of this was 34% 
in PV, 22% in MF and 3% in ET.  
(iv.)  Two further publications reported discovery of JAK2 V617F after a high-
throughput sequencing strategy that focused on screening a set of PV cases for 
mutations in the activation loops and autoinhibitory domains of tyrosine kinases 
198,200. Both groups confirmed JAK2 V617F is acquired, by showing only the wild-
type allele was present in the vast majority of T cells 
198 and buccal cells 
200 
sampled from cases carrying V617F. 
 
1.3.2.2  Structure and possible mechanism of JAK2 V617F 
The JAK2 mutation, located in exon 14, changes a valine to a phenylalanine at amino acid 
residue 617 (nucleotide substitution 2343 G>T RefSeq ID NM_004972 www.ensembl.org). 
At the protein level, the amino acid change is located in a highly conserved region, in the 
pseudokinase or JH2 domain. As previously mentioned, the JH2 domain is predicted to 
interact directly with the true kinase domain JH1, and negatively regulate signalling 
148. A 
homology model of the JH1 and JH2 domains of JAK2 based on the crystal structure of the 
FGF receptor kinase has been proposed, and is shown in Figure 1.7. In this model, 
residues V617 to E621 form a loop connecting two beta strands of the N-terminal lobe of 
the JH2 domain, with C618 contacting the kinase activation loop. It has been postulated 
that V617F, C618 and other local residues hinder the movement of the activation loop 
from an inactive to an active conformation 
205. Based on this it may be inferred that V617 
plays a direct role in negatively regulating JAK2 signalling. Substitution of valine at residue 
617 with the large aromatic amino acid phenylalanine is likely to disrupt this highly 27 
 
balanced negative regulation, although this remains to be proven biochemically. 
Interestingly, the first evidence suggesting that the JH2 domain played a direct role in a 
leukaemic phenotype came from studies describing a point mutation in the JH2 domain of 
Drosophila melanogaster Janus kinase, Hopscotch 
206. When overexpressed in Drosophila 
cells, Hopscotch carrying the E695K mutation resulted in hyper-phosphorylation and 
constitutive activation of D-STAT, the STAT equivalent in the fly.  
 
 
Figure 1-7.  Predicted structural model of JAK2 domains JH1 and JH2. In an inactive state, the JH1 
kinase domain is held in close spatial proximity to the JH2 domain, which performs an inhibitory 
function. On closer inspection (yellow box), the L1001 and P1002 residues of the activation loop 
are held closest to residues V617 and C618 of the JH2 domain (adapted from Lindauer et al. 
(2001) 
205.  
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1.4  Inhibition of tyrosine kinase signalling by imatinib 
For CML and other aggressive forms of MPN, allogeneic stem cell transplantation is 
believed to be the only curative therapy currently available, but only a minority of 
patients are eligible for this procedure due to a limited number of HLA-matched donors 
and the fact that only relatively young patients can tolerate the procedure. 
Characterisation of the protein structure of kinases enabled researchers to rationally 
develop drugs which inhibited tyrosine kinase activity 
207. Like other tyrosine kinases, the 
kinase domain of the ABL moiety catalyses tyrosine phosphorylation by binding ATP and 
transferring the γ-phosphate to target tyrosine residues. Competitive inhibition with ATP 
for the activation domain was postulated as an effective mechanism to prevent signalling 
from the aberrant kinase 
208,209. A synthetic compound, imatinib mesylate, also known as 
Glivec® (Novartis Pharmaceuticals, Basel, Switzerland) proved to be strikingly effective at 
inhibiting proliferation of malignant cells and inhibiting apoptosis induced by BCR-ABL in 
vitro 
208 and in experiments performed in primary CML progenitors in vivo 
209,210. Imatinib 
lacks the essential phosphate groups provided by ATP, thus phosphorylation of substrate 
proteins cannot occur and ultimately downstream signalling is prevented 
209.  The efficacy 
of imatinib was confirmed in a large randomised trial of chronic phase CML patients, 
where over 1000 cases were given imatinib, or rIFNα plus cytarabine. After 19 months 
over 75% of patients receiving imatinib achieved complete cytogenetic response, 
compared to less than 35% of those who received rIFNα. In addition imatinib was more 
easily tolerated that rIFNα 
211. However, despite the high rates of haematological and 
cytogenetic response with imatinib, one drawback has been the emergence of acquired 
resistance in a minority of patients brought about by mechanisms such as point mutations 
in the kinase domain 
212-217, overexpression of the BCR-ABL 
218, and overexpression of the 
multidrug resistance P-glycoprotein 
219. Furthermore, imatinib is not effective in treating 
advanced stages of CML in blast crisis 
209, or BCR-ABL positive ALL where resistance 
develops rapidly 
220. In an attempt to overcome some of these drawbacks, a series of 
second generation ATP-competitive ABL kinase inhibitors were developed. Compounds 
such as dasatinib (Sprycel®) and nilotinib (Tasigna®) are more active against BCR-ABL than 
imatinib 
221-223. However, neither compound is able to overcome the resistance displayed 
by the T315I mutation in BCR-ABL 
222, and have demonstrated off-target effects through 29 
 
non-specific protein binding 
224. This might be circumvented by other inhibitors such as 
the aurora kinase inhibitor MK-0457, which has shown activity against the T315I mutation 
in patients with CML 
225. 
1.4.1  Imatinib and other MPNs 
Analogous to BCR-ABL positive CML, it was suggested patients carrying other deregulated 
tyrosine kinases could also be amenable to treatment with targeted inhibitors, like 
imatinib. In fact, imatinib has been shown to occupy the ATP binding site and inhibit 
phosphorylation from kinases other than ABL, including ABL2, KIT, PDGFRα, PDGFRβ and 
FMS 
226. Tyrosine kinases FGFR1, FGFR3, FLT3 and JAK2 are not sensitive to imatinib. 
Although rare, MPN patients carrying translocations that deregulate PDGFRA 
102,103,227,228 
and PDGFRB 
229-237 have been treated with imatinib, with a large degree of success 
238,239. 
Moreover, the recurrent but cytogenetically invisible FIP1L1-PDGFRA deletion was only 
identified after a series of HES cases were found to be sensitive to imatinib in vitro, and 
were investigated for deregulated imatinib sensitive tyrosine kinases 
102,240. A small 
number of HES cases that lack PDGFRA and PDGFRB rearrangements have been reported 
102,227,241 , and together with data from our laboratory, this suggests that additional 
imatinib-sensitive lesions remain uncharacterised.  
Imatinib has also been shown to have a positive effect in PV, by reducing the need for 
phlebotomy 
242. Investigations in vitro showed imatinib strongly inhibited or even blocked 
spontaneous erythrocytosis, a hallmark of PV 
243. It was first suggested imatinib was 
acting on an unknown mutated tyrosine kinase, but now it is thought that imatinib 
reduced signalling from normal KIT 
244, which is known to play a role in erythropoiesis 
76. 30 
 
1.5  Aims of this study 
Initially, the general aim of this study was to further the understanding of the molecular 
pathogenesis of PV and other MPNs, focusing on the hypothesis that they were driven by 
deregulated tyrosine kinases. After the discovery of JAK2 V617F, my research then 
focused on: 
•  Characterisation of JAK2 V617F in different MPNs.  
•  The development of robust, sensitive molecular techniques to detect JAK2 V617F 
and exon 12 mutations. 
•  The development of culture assays to predict the response of patients to imatinib. 
•  Evaluation of the response of PV patients to imatinib and interferon using JAK2 
V617F as a molecular marker. 
•  Identification of genetic factors that predispose to V617F positive MPNs. 
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2  Materials and methods 
2.1  Patient samples 
Patient samples were either referred from hospitals throughout the UK for diagnostic 
analysis or provided by collaborators from Europe and the US. Research described here 
was approved by the Salisbury and South Wiltshire Research Ethics Committee in the 
study entitled ‘Mechanisms and consequences of tyrosine kinase activation in chronic 
myeloproliferative disorders and related conditions’ (LREC study number O5Q2008/6), 
either following informed consent or anonymisation. The cohorts of patients used for 
specific projects are described in their respective sections. 
 
2.2  Separation of cells from peripheral blood and bone marrow samples  
The precise procedure for cell separation varied from sample to sample depending on cell 
count and reason for referral. Typically, mononuclear cells and granulocytes were 
separated using lymphoprep and red-cell lysis. Cell pellets, GTC lysates, cytogenetic 
cultures or cryopreserved samples were then prepared depending on requirements.  
 
2.3  Cell counting and assessment of viability 
To count nucleated cells in PB or BM, the sample was diluted 1:10 in 2% acetic acid 
(Sigma) to lyse the red blood cells, and cell number was then counted using a Neubauer 
haemocytometer (BDH, Poole, UK).  Cell viability was assessed using trypan blue, which 
stains dead cells blue but is excluded from live cells. Typically, cells were mixed 1:1 with 
trypan blue and then counted using a haemocytometer.  
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2.3.1  Separation of mononuclear cells 
Mononuclear cells (MNCs) were separated by density gradient centrifugation over 
Lymphoprep
TM (Axis Shield, Norway). Two x10
7 cells were diluted in Hank’s Balanced Salt 
Solution (HBSS, Invitrogen, Paisley, UK) to a maximum volume of 25ml. The cell 
suspension was layered slowly over an equal volume of Lymphoprep prior to 
centrifugation for 30 minutes at 1800 rpm (revolutions per minute) in a Centra CL3 
bench-top centrifuge without braking. After centrifugation, MNCs were removed from 
the interface using a sterile pasteur pipette (BDH) and transferred to a clean tube. The 
recovered cells were washed twice in RPMI 1640 (Invitrogen, Paisley, UK) supplemented 
with L-glutamine, penicillin, streptomycin and 10% fetal calf serum, before counting.  
 
2.3.2  Separation of granulocytes 
Granulocytes are sedimented to the bottom of the tube during lymphoprep 
centrifugation along with the red cells. After removing mononuclear cells and discarding 
the supernatant, cold red-cell lysis buffer (see Appendix I for recipes of all buffers and 
solutions) was added to the cell pellet. Red blood cells were then removed by selective 
osmotic lysis after incubation on ice for 10 minutes. After centrifugation for 5 minutes at 
1500rpm, the cell pellet was washed twice in supplemented RPMI 1640, and then 
counted.  
Depending on the total cell number, MNC and granulocyte fractions were divided for 
different purposes. Cells were stored for future DNA extraction in 1- 2 x 10
7 cell aliquots 
at -70°C. For RNA extraction 1x 10
7 cells were lysed with guanidium thiocyanate (GTC) 
solution mixed with 7µl β-mercaptoethanol (Sigma, Poole, UK) per 1ml GTC. MNCs and 
granulocytes were also used fresh in the imatinib sensitivity in vitro assays.  
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2.4  Nucleic acid extraction 
2.4.1  RNA extraction and cDNA synthesis 
350µl of GTC lysed cells for RNA extraction were mixed with an equal volume of 70% 
ethanol and applied to an RNeasy kit column (Qiagen, West Sussex, UK). Following the 
manufacturer’s guidelines, the column was subject to several washes by centrifugation 
and the RNA was then eluted in 20µl deionised, RNase-free water. The RNA was then 
heated to 65°C for 5 min to destroy any tertiary structures and placed on ice. For cDNA 
synthesis, the RNA (1 to 5µg approximate yield)  was incubated with 21µl cDNA mix 
(50mM Tris pH 8.3, 75mM KCl, 3mM MgCl2, 1mM DTT, 1mM dATP, 1mM dCTP, 1mM 
dTTP and 1mM dGTP), 100µg/µl of random pd(N)6 hexamers (Amersham Pharmacia, 
Amersham, UK), 150U of Murine Moloney Leukaemia Virus (MMLV) reverse transcriptase 
(Invitrogen, Paisley, UK) and 15U of RNase inhibitor (Promega, Southampton, UK) for 2 
hours at 37°C. The reaction was terminated by enzyme denaturation at 65°C for 10 
minutes. All cDNA samples were stored at -20°C. 
 
2.4.2  Salt extraction of DNA from cell pellets 
Cells were thawed prior to addition of 1ml resuspension buffer (RSB, see Appendix I), 30μl 
10% sodium dodecyl sulphate  (SDS) and 200µg Proteinase K (Roche, UK) per 1x10
7 cells. 
The sample was mixed and incubated overnight at 37°C. Three hundred microlitres of 6M 
sodium chloride was added and the tube was shaken for 20 sec. After centrifuging at 
13000 rpm for 30 minutes, the supernatant was collected into a 1.5ml centrifuge tube 
(Sarstedt). An equal volume of 100% ethanol was added to precipitate the DNA, and the 
tube was inverted until the DNA visibly collected as a ‘hair ball.’ DNA was removed using a 
sterile hypodermic needle. After washing the pellet in 1ml 70% ethanol, the DNA was 
resuspended in 50 to 500μl of 1x Tris-EDTA (TE, pH 7.4) depending on yield.  
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2.4.3  DNA extraction from BM and PB slides 
Unstained BM and PB smears were scraped free using a sterile scalpel into 200µl sterile 
PBS, and genomic DNA was extracted using the QIAamp DNA Blood Mini Kit (Qiagen, 
West Sussex, UK) following manufacturer’s guidelines. DNA was eluted in 40µl 1x Tris-
EDTA (TE, pH 7.4).  
 
2.4.4  Whole Genome Amplification (WGA) 
WGA was performed on samples where only small quantities of DNA were available for 
mutation screening, using the GenomiPhi DNA Amplification kit (GE Healthcare, 
Amersham) according to the manufacturer’s instructions. Following this method, 
microgram quantities of genomic DNA up to 10Kb in length can be amplified from as little 
as 1ng of genomic DNA. The strand displacement amplification reaction uses Phi29 DNA 
polymerase, random hexamer primers, dNTPs, and input DNA to amplify DNA 
representative of the original sample. WGA DNA was diluted to 50ng/µl for use in PCR, 
and stored at -20°C.  
 
2.5  Cell culture 
2.5.1  Cell lines  
Cell lines were cultured in supplemented RPMI 1640 medium (Invitrogen) and maintained 
at 0.5 - 1.0 x10
6 cells/ml. Cultures were incubated at 37°C in a humidified atmosphere 
with 5% carbon dioxide. Typically, cells were split twice weekly or as required. In general, 
a change in the medium from pink or orange to yellow indicates that more medium was 
required. 
 
2.5.2  Cryopreservation of myeloid cell progenitors 
MNCs were stored for future use by cryopreservation, a method that enables the cells to 
retain all biological activity, when thawed out after a long duration at very low 35 
temperatures. Cells are mixed with the cryoprotectant dimethyl sulfoxide (DMSO) which 
prevents ice crystal formation before storage in liquid nitrogen. MNCs in 2-5x10
7 cell 
aliquots per vial were cryopreserved, by the gentle addition of the same volume of ice-
cold freezing mixture. The cell mixture was then dispensed into vials, wrapped in paper 
towel and placed in a polystyrene box, before being placed at -70°C. The cells are thereby 
cooled slowly for a minimum of one night before storage in liquid nitrogen at -196°C. 
 
2.5.3  Thawing of myeloid cell progenitors  
A thawing solution, warmed to 37°C, was required to thaw cryopreserved cells (Appendix 
I). Once removed from storage, vials were thawed quickly by 37° C incubation before 
transferring the cells to a 50ml tube. Dropwise, 20ml of pre-warmed thawing solution was 
then added. The tube was topped up to 50ml with pre-warmed (37°C) supplemented 
RPMI 1640, and then centrifuged at 1,500rpm for 5 minutes. The supernatant was 
discarded and 200,000U of DNase I was added dropwise to the cell pellet. The tube was 
gently shaken to disrupt the pellet and to prevent the formation of clumps. Ten mililitres 
of supplemented RPMI 1640 was then added and the cells centrifuged as before. The 
DNaseI and supplemented RPMI 1640 wash was then repeated before finally discarding 
the supernatant and resuspending the cells in 10ml supplemented RPMI 1640. To the 
resuspended cells 200,000U DNaseI was added and the cells were left for one hour at 
room temperature. The cells were finally spun and resuspended in supplemented RPMI 
1640 to determine cell count and viability. The cells were counted using a 
haemocytometer and live and dead cells were differentiated by staining with an equal 
volume of trypan blue.  
 
2.5.4   Growth of myeloid progenitors in semi-solid medium (colony assay)  
The clonogenic potential of haematopoietic myeloid progenitors was studied by culturing 
the cells in Methocult (H4434; Stem Cell Technologies, London, UK) a semi-solid medium 
containing recombinant cytokines (EPO, IL-3, SCF, GM-CSF, SCF) which stimulate single 
cell progenitors to divide and differentiate into microscopically visible colonies.  The cells 36 
are immobilised within the medium allowing counting of cell number using an inverted 
microscope. Reagents, such as growth inhibitors or cytokines can be added to the 
medium as required.  
Prior to use, one bottle of 200ml Methocult was defrosted, vigorously mixed and left to 
stand for 30 minutes at 4°C for air bubbles to disperse. The medium was then aliquoted 
into 3ml volumes into bijoux, and stored at -20°C until required. MNCs isolated from fresh 
PB were cultured in Methocult at a density of 2x10
5 to 4x10
5 cells per 40mm dish (Fisher 
Scientific, Leicestershire, UK) (in a final volume of 1ml), in triplicate, following the 
manufacturer’s instructions. Cells derived from BM were plated at a lower concentration 
of up to 1.3x10
5 cells /ml. The optimum concentration of cells produced between 25 and 
300 colonies per ml. Cells were mixed with the medium gently using a 1ml syringe, 
avoiding the introduction of air bubbles. Dishes were incubated at 37°C and 5% CO2 in a 
humidified atmosphere, alongside a small water reservoir to prevent medium 
dehydration. Colonies arising from a single myeloid progenitor are visible after 7 to 14 
days incubation and were characterised based on morphology, as described by 
Sutherland et al. (1989) 
245. The colonies were defined as either CFU-GM, CFU-GEMM, 
CFU-E  (one to two clusters containing up to 200 erythroblasts) and BFU-E (produces a 
single: colonies containing greater than 200 erythroblasts). CFU-GM are typically pale 
with dispersed cells, and CFU-GEMM colonies have a concentrated nucleus which is 
brown-red in colour also surrounded by pale dispersed cells. BFU-E and CFU-E contain 
haemoglobinised erythroid precursors and are therefore predominantly red in colour, 
more so after 10 days incubation when the cells have had longer to differentiate. 
Normally, BFU-E and CFU-E require the presence of EPO in the medium to stimulate 
division and differentiation, but in MPN patients they can arise spontaneously.  
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2.6  Polymerase chain reaction (PCR) 
 
PCR is a technique widely used in molecular biology for the amplification of DNA 
sequences from a template at low concentration 
246. A DNA polymerase is used to amplify 
target DNA by in vitro enzymatic replication, and the product is formed in an exponential 
fashion. The heat-stable polymerase Taq, originally isolated from the bacterium Thermus 
aquaticus, uses single stranded DNA as a template and DNA oligonucleotides (primers) to 
initiate DNA synthesis. Primers are designed at either end of the amplicon, and are 
complementary to the DNA sequence flanking the target DNA. The vast majority of PCR 
methods use thermal cycling, alternately heating and cooling the PCR sample over a 
defined number of temperature steps. The target DNA is sequentially denatured at 96°C 
and then cooled to allow hybridisation of primers. The temperature the primers anneal to 
their target is determined by primer length, the G/C and A/T ratio and the buffer that is 
used. The reaction is then heated to 72°C to allow polymerisation, forming two new 
strands that act as templates for subsequent cycles and thus products accumulate 
exponentially during the course of the process. PCRs were performed in a programmable 
thermal cycler (MJ Research) with heated lid, in 0.5ml tubes. The sequences of all primers 
used can be found in Appendix III.  
 
2.6.1  Amplitaq GOLD PCR  
Unless otherwise stated, all PCRs were performed using Amplitaq Gold (Applied 
Biosystems, Warrington, UK) in a volume of 25µl. Primers were designed using Primer3 
(http://frodo.wi.mit.edu/cgi-bin/primer3_www.cgi) with an optimal melting temperature 
of 60°C. A PCR mix was typically prepared using final conditions as follows: 
1 x Amplitaq Gold buffer 
1.5mM MgCl2  
0.2 mM each of dCTP, dTTP, dATP, dGTP 
0.5 µM of each primer 
1U Amplitaq Gold 38 
Typical cycling conditions for PCR with Amplitaq GOLD were: 
Step  Temp (°C)  duration 
1  95  10 min 
2  94  1 min 
3  60  1 min 
4  72  1 min 
5  29 times to step 2 
6  72  10 min 
7  15  hold 
 
2.6.2  Pyrosequencing PCR 
Pyrosequencing PCRs were made using Amplitaq Gold polymerase and were identical to 
standard PCRs except that the total reaction volume per sample was 50µl, and primers 
were designed using the pyrosequencing software (Assay Design Software 1.0, Biotage). 
The cycling conditions are described in Appendix II.  
 
2.6.3  High Fidelity PCR  
In some cases it was necessary to amplify regions in the range of 3 to 5kb in size, which is 
out of the usual range achievable using Amplitaq Gold. Here I used the Expand High 
Fidelity PCR System (Roche Applied Science, Uppsala, Sweden) which in addition to Taq 
DNA polymerase also contains a proofreading enzyme to increase the fidelity of 
replication. On ice, PCRs were set up with 10µl of Mix 1 (Roche) (containing 2µl High 
Fidelity buffer with 15mM MgCl2, 1U Enzyme mix and 7.7µl water) 7µl Mix 2 (final 
concentration of 200µM dNTPs), 500nM of forward and reverse primers and 1µl DNA to 
give 50 to 100ng DNA. The cycling programme is described in Appendix II. 
 
2.7  Agarose gel electrophoresis 
Agarose gel electrophoresis was routinely used to assess the size and quantity of DNA 
after various procedures such as DNA extraction or PCR.  An electrical current causes 
negatively charged DNA to migrate towards a positively charged anode through an 39 
agarose gel. DNA is thereby separated according to size as the distance of migration is 
proportional to the size of the DNA, with smaller products being able to move a further 
distance through the agarose. DNA is visualised using ethidium bromide, a compound 
that intercalates with DNA helices causing them to fluoresce under ultra violet (UV) light. 
Gels were made with 1.5% to 3% agarose, depending on the required resolution.  
Two percent gels were made by heating 1g of agarose in 50ml 1x tris-borate (TBE) buffer 
(Sigma) in a microwave, cooled to “hand-hot” before the addition of 0.4µg ethidium 
bromide then poured into the gel tank with an appropriate sized comb. Before loading 
gels with PCR product, the gels were immersed in 1xTBE buffer and the combs were 
removed. Typically, 10μl of a PCR reaction was mixed with 2μl of 6 x loading buffer (see 
Appendix I) before loading into the well. The loading buffer enables monitoring of the 
approximate location of PCR product as the gel is run, and the high sucrose concentration 
facilitates loading into the well. A 1kb plus ladder, 100bp to 12kb (Invitrogen) was run 
alongside PCR products, to aid sizing of bands (see Figure 2.1). Gels were run at 80V for 
approximately 30 min, and viewed using a UV transilluminator.  
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2.8  DNA Sequencing  
 
PCR products and plasmids were sequenced in this study using dideoxynucleotide chain 
termination, originally developed by Sanger et al. (1977) 
247. The PCR-based sequencing 
reaction generally contains a PCR product as template, dideoxynucleotides (ddNTPs), 
each base of which is labelled with a different fluorochrome, deoxynucleotides, DNA Taq 
polymerase, and one primer. The ddNTPs lack a 3’ hydroxyl group, required for the 
formation of 3’-5’ phosphodiester bond and thereby chain extension is halted when a 
ddNTP is incorporated into the product. The product will therefore be labelled with a 
single fluorochrome-labelled ddNTP.  A mixture of DNA molecules of different lengths is 
thereby created. The products are separated by capillary gel electrophoresis, and the 
nucleotide sequence, indicated by the terminating ddNTP, is read by a laser. 
 
2.8.1  ExoSAP 
To prepare PCRs for fluorescent-based sequencing, each product was first incubated with 
a combination of two hydrolytic enzymes: exonuclease I (New England Biolabs), which 
Figure 2-1. Gel electrophoresis of the 
Invitrogen 1kb plus DNA ladder. All PCR 
products were run alongside this ladder in 
order to determine product size. 
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digests excess primers, and shrimp alkaline phosphatase (SAP, Promega) which removes 
the phosphate group from nucleotides, thereby preventing them from incorporation 
during the sequencing reaction. Two microlitres of PCR product was incubated with 1µl of 
exonuclease I and SAP, (made up in a ratio of 1:4), incubated at 37°C for 15 minutes, then 
heated to 80°C for 15 minutes to inactivate the enzymes. The DNA from this reaction was 
then diluted by 5 to 10µl with sterile distilled water (depending on the intensity of the 
PCR product), and then used as a template for sequencing. 
 
2.8.2  Sequencing reaction 
The reaction mix for a typical sequencing reaction was as follows: 
1.5µl 5x v1.1 buffer (Applied Biosystems) 
200ng Primer  
0.5µl v1.1 Big Dye Terminator (Applied Biosystems) 
1µl template 
dH2O to 10 µl 
 
Cycling conditions are described in Appendix II. 
 
2.8.3  Removal of unincorporated dye terminators 
Unincorporated fluorescent ddNTPs were removed using the montage SEQ96 sequencing 
reaction clean up kit (Millipore, Watford, UK) following the manufacturer’s instructions. 
DNA from the cleaned sequencing reaction was resuspended in deionised formamide and 
loaded onto an ABI 3100 or 3130 sequencer (Applied Biosystems). 
 
2.8.4  Pyrosequencing 
Pyrosequencing is a modified sequencing technique that provides accurate quantification 
of allele ratios 
248. In order for a sample to be genotyped for a particular allele or acquired 42 
mutation, an assay must be designed using the manufacturer’s software (Assay Design 
Software 1.0, Biotage). This programme designs two primers to generate an amplicon 
flanking the target allele, plus a third primer used to detect the polymorphism, called the 
sequencing primer. In general, the sequencing primer is designed so that the first base to 
be added in the sequencing reaction is the site of the polymorphism to be detected. One 
of the amplification primers must be biotinylated to hold the amplicon to a small filter 
during the sequencing process. Amplification was checked by running 5µl product on a 
1.5% agarose gel. The PCR products were then subject to sequencing. The basic principles 
of the pyrosequencing reaction are shown in Figure 2.2.  
First, the amplicon is denatured to become single stranded, so only the biotinylated 
strand remains in the reaction. The sequencing reaction occurs when dNTPs are added 
sequentially to a mix containing sequencing primer, template, enzymes and substrates. If 
the dNTP added is complementary to the base in the single stranded template, it will be 
incorporated. This causes the release of pyrophosphate which initiates a chemical 
cascade. The substrate adenosine 5’ phosphosulfate (APS) (plus pyrophosphate) is 
converted to ATP by the enzyme ATP sulfurylase. Luciferase then catalyses a reaction 
between ATP and luciferin. Light is generated proportional to the amount of dNTP 
incorporated. An enzyme apyrase degrades unincorporated nucleotides. The flashes of 
light determine the sequence read by the pyrosequencing machine.  
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Figure 2-2. The principles of pyrosequencing. (A) A single-stranded amplicon spanning the 
polymorphism or mutation is quantified by the sequential addition of nucleotides onto a 
sequencing primer, and pyrophosphate released by polymerisation starts an enzymatic cascade 
resulting in the release of light. (B) The amount of light (y axis) is proportional to the amount of 
dNTP incorporated into the growing oligonucleotide (x axis). (C) The reaction is displayed in real-
time as a pyrogram. Here the addition of enzymes (E), substrates (S) are shown alongside addition 
of the C and A nucleotides being measured (highlighted in yellow). The enzyme mix (E) and 
substrate (S) are added into the reaction first, and are then followed by nucleotides. The variant 
bases being genotyped are highlighted in yellow, and are flanked by bases not part of the 
sequence that control for non specific emission of light. This is followed by a run of invariant 
nucleotides, necessary for allele quantification. The software provides the allele ratio in a blue box 
above the graph. 
 
To carry out the pyrosequencing reaction, details such as specific assay type, location of 
samples on plate, sample identifier, reagent type are entered onto a computer connected 
to the Pyrosequencing machine (PSG MA 2.1, Biotage). The process was performed 44 
according to manufacturer’s instructions, using the Pseq 96 SNP Reagent Kit (Biotage), 
which contained the enzymes, substrate mixture and nucleotides. Firstly, the PCRs were 
prepared. One PCR was performed per sample in a volume of 50µl, and this provided two 
aliquots of 20µl for subsequent analysis in the pyrosequencing process. Each reaction was 
made up with 3μl Streptavidin Sepharose
TM HP (Amersham Biosciences, Chalfont St. Giles, 
UK), 37μl binding buffer and 20μl PCR product and 20μl sterile distilled water. The 
mixtures were vigorously shaken for 10 minutes using a Variomag Monoshaker (Camlab, 
Over, UK). 
•  The sequencing primer was then diluted and aliquoted into custom 96 well plates 
with low wells (Pseq 96 Plate Low, Biotage), in the corresponding location to the 
PCR reaction. Each well contained 45μl annealing buffer and 0.3μM sequencing 
primer. 
•  Single stranded biotinylated PCR products were then prepared for sequencing 
using the Vacuum Prep Tool. The streptavidin beads adhere to the biotinylated 
amplicons and both are captured onto the filter paper probes on the Vacuum Prep 
Tool when the vacuum was applied. The Vacuum Prep Tool holding the bead-
amplicons was then washed with: 
o   70% ethanol for 5 seconds 
o  denaturation solution (0.2M sodium hydroxide, Sigma) for 5 seconds  
o  washing buffer for 5 seconds 
•   The vacuum was then stopped and the beads were released into the plate 
containing the sequencing primer and annealing buffer.  
•  The plate containing the bead-bound amplicons was heated to 80°C for 2 minutes 
and then cooled to allow the sequencing primer to hybridise to the single 
stranded PCR product.  
•  The plate was then placed into the pyrosequencing machine with a specialized 
pyrosequencing cartridge containing dNTPs, enzymes and substrates (all from 45 
Biotage), and the sequencing run was started. A luminometer within the machine 
then captures the amount of light produced by the luciferase-catalysed reactions 
that take place in each well. 
•  After the run had finished, the sample genotypes were determined using the 
Allele Frequency Quantification function in the software, which calculates the 
allele ratio using the peak heights of the invariant preceding nucleotides. Allele 
values derived from the same PCR were averaged to give one genotype. An 
example of the sequencing trace, or pyrogram obtained from a pyrosequencing 
reaction is depicted in figure 2.2c.  
 
2.9  Multiple ligation-dependent probe amplification  
Multiple ligation-dependent probe amplification (MLPA) is a PCR-based technique that 
provides quantification of multiple genomic regions in a single reaction. 
249. The basic 
principle is shown in figure 2.3.  
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Figure 2-3. The MLPA reaction. 
 
Each MLPA probe consists of two components; a target-specific probe (red portion in 
figure 2.3) and a M13 phage derived tagging sequence (black). Mixtures of several primer 
pairs (up to 45) are added to the same reaction along with DNA template.  When both 
probe oligonucleotides are hybridized to their respective targets, they become ligated 
into a complete probe by the action of a thermostable ligase. The outer phage-derived 
portions of the primer pair allow simultaneous amplification of all sequences in the 
reaction by FAM-labeled M13 primers. Only primers that correctly bind to their targets 
and are ligated will be amplified thus conferring a high degree of specificity. The ‘stuffer’ 
sequences (blue), which vary in length to give a unique size final product, allow 
identification of each amplicon by gel electrophoresis. The MLPA reaction was performed 
on approximately 50ng DNA, following the protocol devised by the MLPA kit supplier, 47 
MRC-Holland (Amsterdam, Holland). Briefly, the DNA was denatured to a single-stranded 
state by heating at 98°C for 5 min, then left to cool to 25°C for 2 min. Unless otherwise 
stated, 1.5μl of the probe mix (each primer was used at 1.33fmol working concentration) 
was carefully mixed with an equal volume of MRC probe buffer (MRC-Holland) and added 
to the denatured sample. After an initial heating at 95°C for 1 min, the reaction was 
incubated overnight (minimum 16 hours) at 60°C with a thin layer of mineral oil (Sigma) 
covering the reaction surface to prevent evaporation. Incubation at 60°C overnight 
allowed the primers to bind the target sequence. The temperature of the reaction was 
then reduced to 54°C and 32μl ligase-65 mixture was added under the oil layer. The 
Ligase-65 mixture was made up on ice immediately before use, and consisted of 3μl 
Ligase-65 buffer A (MRC-Holland) and 3μl Ligase-65 buffer B (MRC-Holland) and 1μl 
Ligase-65 (MRC-Holland) made up to 32μl with distilled water. The ligation reaction was 
left at 54°C for 15 min, and the ligase was inactivated by heating at 98°C for 5 min. The 
PCR mixture was made up on ice immediately before use. One microlitre of MLPA primer 
mix, 2μl PCR red buffer (MRC-Holland), 2μl PCR blue buffer (MRC-Holland), and 0.25μl 
Polymerase (MRC-Holland) were made up to 20μl with distilled water and mixed well. The 
ligation reaction was then brought down to 60°C and 10μl of the ligation mix was added 
to the PCR reaction. The PCR conditions were as follows; 35 cycles of 30 seconds at 95°C, 
30 seconds at 60°C and 60 seconds at 72°C, then a final 20 minute incubation at 72°C. 
Amplification was conducted in a thermal cycler with a heated lid (MJ Research). One 
microlitre of MLPA PCR product was mixed with 9µl Hi-Di Formamide (Fisher Scientific) 
and 0.1µl of ROX500 size standards (Applied Biosystems). The products were then 
separated on an ABI 3100 genetic analyser and interpreted using Genotyper version 2.0. 
Peak heights from each patient were then exported to an Excel spreadsheet, which was 
designed to assess the ratios of each test peak relative to all other peaks for that 
individual. The relative amounts of the probe amplification products reflect the relative 
copy number of the target sequences. By comparing the peak pattern of a given sample 
with that obtained on various reference samples, the relative quantity of each amplicon 
can be determined.  
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2.10 Cloning of PCR products 
In some instances, it was necessary to clone a PCR product in a plasmid vector prior to 
sequencing. Essential features of a cloning plasmid are i) independent replication within a 
host cell, ii) antibiotic resistance which aids future selection, iii) multiple cloning sites 
allowing insertion of foreign DNA. PCR products were cloned by insertion into a plasmid 
vector using the TOPO cloning kits (Invitrogen), and Figure 2.4 shows a map of the pCR4-
TOPO vector. 
 
Figure 2-4. The plasmid pCR4-TOPO. 
 
PCR-derived fragments less than 4kb in size were cloned using the TOPO TA Cloning kit 
(Invitrogen). Taq polymerase has template-independent terminal transferase activity, 
which adds dATP to the 3' end of PCR products. PCR products can then be ligated into 
linearised pCR4-TOPO vector, which has complementary single 3’ T overhangs.  
Two features of the vector allow selection of bacteria that have been transfected with a 
vector that carries an insert. Firstly, the vector carries a gene for ampicillin resistance; 49 
bacteria that are not transformed are therefore killed by ampicillin in the medium. 
Secondly, the pCR4-TOPO vector carries a DNA fragment derived from the Lac operon of 
E.coli, which encodes the β-galactosidase amino-terminal fragment, the LacZ gene. The 
fragment complements itself in trans with a defective form of β-galactosidase that is 
present in the host bacteria for transformation. When plated onto X-gal agar plates, 
bacteria containing the religated vector lacking an insert form blue colonies as the 
transformed cells contain a functional LacZ gene that can convert the colourless substrate 
X-gal into a blue coloured precipitate. If a PCR product is successfully ligated into the 
cloning site of the vector, the LacZ gene reading frame is disrupted so no active enzyme 
can be produced and the colonies remain white. These colonies were then picked and 
grown before plasmid extraction. 
 
2.10.1 Ligations  
One microlitre TOPO TA Cloning kit salt solution (Invitrogen), 2-3µl fresh PCR product, and 
sterile water to a volume of 5µl were mixed before the addition of 1µl PCR-4 vector 
(Invitrogen), on ice. After gentle mixing, the ligation was incubated at room temperature 
for five minutes, then placed on ice to await transformation. 
 
2.10.2 Chemical transformation 
For each transformation, one tube of TOP10 E. coli chemically competent cells was 
thawed on ice. Two µl of the TOPO cloning reaction was added and mixed gently, and left 
on ice for 20 min. The cells were then heat shocked by placing the tubes in a 42°C water 
bath for 30 seconds, then put onto ice. 250µl of room temperature SOC medium was 
added to each vial of cells, followed by incubation at 37°C in a shaking incubator (225rpm) 
for 30 minutes. The transformed cells were then spread in volumes of 10µl-100µl onto 
pre-warmed (to 37°C) LB agar plates, supplemented with ampicillin (100mg/ml, Sigma) 
and spread with 40µl of X-gal (50mg/ml, Promega, Madison, USA). The plates were 
inverted and incubated at 37°C overnight. Two negative control plates were included: 50 
untransformed competent E.coli and a control plate without bacteria. After incubation, 
plates were placed at 4°C to aid colour development.  
 
2.10.3 Culturing and extraction of plasmids 
Only white colonies were picked for culturing. Each colony was grown up in 2.5ml LB 
broth, containing 50µg/ml ampicillin, overnight at 37°C in a shaking incubator (320 rpm). 
A control culture of LB and antibiotic was also set up. Plasmid DNA was then extracted 
from 2ml of culture using the Qiagen Miniprep kit (Qiagen, West Sussex, UK), following 
the manufacturer’s instructions. The remaining 500µl culture was mixed with equal 
volume of 50% glycerol for storage at –70°C.  
Plasmids were extracted using an ‘alkaline lysis’ method according to the manufacturer’s 
instructions. Firstly, a high
 pH lyses the cell walls, then when the lysate is then neutralised 
and the salt concentration is reduced, proteins and bacterial DNA are precipitated and 
removed by centrifugation. The plasmid DNA remains in the supernatant, which is then 
applied to a silica column where the plasmid DNA is selectively adsorbed and after a 
series of ethanol washes is eluted with 50 to 80µl distilled sterile water.  
 
2.10.4 Restriction enzyme digests 
Restriction enzymes recognise specific nucleotide sequences that are usually 4bp to 6bp 
long. They cleave the DNA at these sites, generating either blunt ends or ends with short 
single stranded overhangs that are referred to as sticky ends. 1U of enzyme was used to 
digest approximately 1µg of DNA in the appropriate buffers, and then incubated at 37°C 
overnight. Digestion was checked by running on an agarose gel.
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3  Characterisation of JAK2 V617F in myeloproliferative 
neoplasms 
3.1  Introduction 
The original aim of my work was to investigate the molecular pathogenesis of MPN, 
focusing specifically on PV and pursuing the hypothesis that these diseases may be driven 
by activated tyrosine kinases. Shortly into my research, an acquired point mutation was 
discovered in the JAK2 gene in the vast majority of cases with PV and henceforth my 
attention was then focused on this abnormality. The initial reports identified JAK2 V617F 
(2343 G>T, NM_004972) in 73% to 97% of cases with PV, 23 to 57% of cases with ET and 
between 9% and 45% of cases with MF 
197-201. It was also noted in these initial studies that 
subsets of patients were homozygous for the JAK2 V617F allele, and it was suggested that 
this was associated with acquired UPD at the JAK2 locus.  
 
3.1.1  Aims 
Following the initial reports of V617F I then conducted my own screen to verify the 
presence of JAK2 V617F in our cases with MPN. My specific aims were to: 
1-  Investigate the involvement of JAK2 V617F in cases with classic and atypical MPN. 
2-  Develop sensitive and quantitative methods of screening for the mutation in 
patient DNA, for use in a diagnostic setting. 
3-  Investigate the relationship between the mutant allele burden, JAK2 copy number 
and acquired UPD. 
4-  Examine cases with both JAK2 V617F plus KIT D816V or BCR-ABL to determine 
whether the mutations were mutually exclusive. 
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3.2  Materials and methods 
3.2.1  Patient samples 
For the characterisation of JAK2 V617F, samples from a total of 679 individuals were 
studied retrospectively. Of these, 480 were patients with a known or suspected diagnosis 
of an MPN (268 males, 212 females) referred for analysis in Salisbury or laboratories of 
collaborating groups in New York, Mannheim and Athens. In total, patients were referred 
for PV (n=72, including one case who also had SM), ET (n=59), IMF (n=35), idiopathic HES 
(n=134), SM (n=28), CML-like diseases (aCML, CMML and related atypical MPNs (n=99) or 
unclassified MPN cases (n=53). All HES, SM, CML-like diseases and atypical unclassified 
MPNs were tested for BCR-ABL, FIP1L1-PDGFRA and other gene fusions as indicated by 
karyotype; SM cases were tested for KIT D816V. Samples from patients with AML (n=17), 
BCR-ABL positive CML (n=18) plus controls from normal individuals (n=160) and patients 
with secondary erythrocytosis (n=4) were also studied. 
 
3.2.2  JAK2 V617F genotyping by allele-specific (AS) PCR 
After initially verifying the presence of the JAK2 mutation in a small set of PV samples by 
sequencing, I devised an allele specific PCR (AS-PCR) to detect the mutation. From then 
on patients and controls were screened for JAK2 V617F using AS-PCR. This test employs 
two primer pairs which specifically amplify the normal and mutant sequences, alongside 
amplification of a control band, all within a single reaction. Primers were designed using 
an AS-PCR design programme 
(http://cedar.genetics.soton.ac.uk/public_html/primer1.html) 
250 and included 
mismatches of two bases close to the site of the mutation in order to maximise 
discrimination of the two alleles. Amplification was performed as described in the 
Methods section, following standard conditions except that the final concentrations of 
the outer primers and the mutant/wild-type specific inner primers were 1μM and 0.5μM, 
respectively. Figure 3.1 shows the strategy of AS-PCR. The PCR contains four primers; 
primers Forward Outer (FO) and Reverse Outer (RO) flank exon 14 and the 463bp product 
serves as a control for successful amplification. Primers RO and Forward wild-type (Fwt) 53 
generate a small wild-type specific product (229bp), and primers FO and Reverse mutant 
specific (Rmt) generate a slightly larger mutant specific product (279bp). Control 
experiments indicated that the assay gave identical results using 20 to 200ng input DNA 
(data not shown). A gel picture of AS-PCR performed on some V617F-positive cases is 
shown in Figure 3.2. 
 
 
 
Figure 3-1. AS-PCR strategy to detect JAK2 V617F. 
 
 
Figure 3-2. Representative results of AS-PCR to detect JAK2 V617F in genomic DNA. Tracks 5, 6, 9 
and 10 show a normal genotype; tracks 1, 3, 11, 12 and 14 show a mutant band that is weaker or 
similar intensity to the normal band and were therefore scored as heterozygous for the 2343G>T 
mutation; tracks 2, 4, 7, 8, 13, 15 and 16 show a mutant band that is stronger than the normal 
band and were therefore scored as homozygous for the mutation.  54 
3.2.3  JAK2 V617F genotyping and allele quantification by pyrosequencing 
In addition to AS-PCR, I also applied pyrosequencing for the detection of JAK2 V617F. This 
technique allows accurate quantification of the proportion of mutant alleles. The 
sequences of the PCR primers (JAK2_pyro_V617F_F and JAK2_pyro_V617F_R) and the 
sequencing primer (JAK2_pyro_V617F_seq) are listed in Appendix III. The results from 
pyrosequencing are displayed in a picture called a pyrogram and some examples are 
shown below. In this situation, pyrosequencing quantified the proportion of the mutant T 
allele, out of the total peak heights produced by the normal G allele and mutant T allele 
combined, to express the results as a percentage. Each test was performed in duplicate, 
and scored as homozygous if the proportion of mutant allele was greater than 50%, the 
maximum expected if a heterozygous mutant clone had expanded to include all cells in 
the sample. This was likely to underestimate the number of homozygotes in practice as 
our samples included lymphocytes (the majority of which are probably not part of the 
mutant clone). Based on the analysis of a series of normal control samples (detailed 
below), if the result fell below 5% the specimen was scored as normal and between 5% 
and 50% samples were recorded as heterozygous for JAK2 V617F.  
 
3.2.4  Measuring the copy number of chromosome 9p by multiple ligation probe 
amplification (MLPA) 
It was necessary to determine whether our patients with a homozygous JAK2 mutation 
acquired this genotype through deletion of one allele on chromosome 9 or duplication of 
the mutant allele via acquired UPD. To do this I devised an MLPA-based test to measure 
the copy number of the JAK2 locus. By comparing peak areas of homozygous JAK2 V617F 
patients to that of other peaks amplified elsewhere in the genome, and to that from 
normal controls, the dosage of the JAK2 locus could be determined. The finding of only 
one copy of the JAK2 locus in homozygous mutant cases would indicate hemizygosity, 
whereas two copies suggest copy-number neutral LOH, i.e. acquired UPD. 
The set of MLPA probes used here were originally designed by Kathy Waghorn to 
measure tyrosine kinase copy number changes in patients with MPN. Primers were 55 
designed to non-polymorphic exons of FES (15q26), JAK2 (9p24), SOAT1 (1q25), BTK 
(Xq22), TYK2 (19p13), MST1R/RON (3p21) and HCK (20q11) with a single primer pair for 
each gene. Hybridisation of probe pairs to genomic DNA, ligation and amplification 
procedures were performed following a procedure originally described by Schouten et al. 
(2002)
249. Here, the primers were used at 1.33fmol working concentration, and 1.5μl of 
the primer mix was combined with an equal volume of MRC probe buffer (MRC-Holland) 
and added to the 2µl containing each sample DNA. MLPA was then performed as 
described above. Using the Genotyper programme, the peak area data was exported to 
an Excel spreadsheet, and the ratios of each test peak relative to all other peaks for that 
individual were calculated. Ratios of the JAK2 peak to the other peaks of each patient 
sample were compared to the same ratios obtained for two normal individuals, which 
were included in each run. For normal sequences a dosage quotient of 1.0 is expected, 
whereas if a deletion or duplication is present the dosage quotient was expected to be 
0.5 and 1.5 respectively 
251. The gene BTK is located on the X chromosome and provided 
an internal control to check the specificity of the assay (i.e. a dosage quotient of 0.5 in 
males and 1.0 in females when compared to a female control). 
 
3.2.5  Development of MLPA-based test to detect copy number changes in JAK2 
 In order to detect subtle changes in JAK2 copy number, I developed a second MLPA-
based assay which contained more probes targeting the JAK2 gene than the probe set 
described above. To do this I modified a commercially available MLPA probe mix designed 
for detecting copy number changes in the telomeres of all chromosomes (P036B MRC-
Holland, Amsterdam). Four MLPA probe pairs targeting JAK2 exons 3, 9, 16 and 20 were 
designed so that they could be combined with the telomere probe mix, and tested on 
each case simultaneously.  The JAK2 probes consisted of adjacent 5’ and 3’ 
oligonucleotides which, when amplified by universal primers following the hybridisation 
and ligation steps, generated products in the size range 98 to 126bp. The 3’ 
oligonucleotides for each JAK2 probe pair were modified with a phosphate group at their 
5’ end, and each oligonucleotide pair contained a tag sequence recognised by the MLPA 
Salsa primers, so that the JAK2 probes were amplified alongside the telomere probes in 56 
one reaction. 1.5µl of the JAK2 primer mix (primers used at a final concentration of 
1.33fmol), was combined with 1.5µl of the MRC telomere mix (MRC, Holland) and 3µl 
MRC probe buffer (MRC, Holland), and added to the 2µl containing each sample DNA. The 
four JAK2 peak area ratios per sample were averaged to give a relative dosage quotient 
for JAK2 as a representation of copy number.  
 
3.2.6  Extracting DNA from myeloid progenitor cells cultured in vitro  
To investigate the genotypes of individual myeloid progenitor colonies, MNCs were 
cultured in vitro in semi-solid medium. After ten days incubation, colonies containing 
more than 100 cells were characterised based on their morphology and then plucked 
from the growth medium for DNA analysis. The pipette was set to 3 to 5µl and, using an 
inverted microscope, a well-separated single colony was plucked from semi-solid 
medium, placed into 100µl sterile distilled water and immediately vortexed to disperse 
the cells. DNA was extracted by boiling for 10 minutes, then vortexed for 10 seconds. 
Regions of semi-solid medium not supporting cell growth were also removed in a similar 
way to provide a measure of the background level of DNA. The amount of DNA obtained 
from approximately 200 cells was expected to be relatively low, so for DNA-based 
investigations 10µl from each colony prep was added to a PCR that was adjusted to 
accommodate this increased volume of DNA. The PCR products were then treated as 
normal. The remaining colony-preps were stored at -20°C. 
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3.3  Results 
3.3.1  The V617F JAK2 mutation is widespread in PV, ET and IMF 
Initially I aimed to confirm the presence of V617F in classic MPN as well as testing if it was 
also seen in other, atypical disorders. I started by using the AS-PCR test as this was the 
most rapid and cost effective screen. A total of 480 samples with a known or suspected 
diagnosis of MPN were screened for JAK2 V617F: 129 (27%) were positive using the AS-
PCR assay and 351 (73%) were negative.  
The results for classic MPN are listed in Table 3.1.  The proportion of positive cases for 
each disease subtype ranged from highly prevalent in PV [58/72 (81%)], to less common 
in ET [24/59 (41%)] and MF [15/35 (43%)]. The incidences of V617F in our classical MPN 
cases are similar to those reported elsewhere 
197-201. 
Reference  PV  ET  IMF  Normal controls 
James et al. 
197  40/45 (89%)  9/21 (43%)  3/7 (43%)  0/15 
Kralovics et al. 
199  83/128 (65%)  21/93 (23%)  13/23 (57%)  0/71 
Baxter et al. 
198  71/73 (97%)  20/51 (39%)  8/16 (50%)  0/90 
Levine et al. 
200  121/164 (74%)  37/115 (32%)  16/46 (35%)  0/269 
Zhao et al. 
201  20/24 (83%)  -  -  - 
This study 
252  58/72 (81%)  24/59 (41%)  15/35 (43%)  0/160 
Total  373/482 (77%)  110/339 (32%)  55/127 (43%)  0/605 
 
Table 3-1. Early publications reporting the occurrence of JAK2 V617F in PV, ET and IMF and its 
absence in normal controls. 
 
3.3.2  JAK2 V617F is also found in other MPN  
Strikingly, in addition to PV, ET and IMF, I also detected the mutation in a substantial 
number of patients with a CML-like disease (aCML, CMML and related atypical MPDs; 
now classified as MDS/MPN) and MPN-U. Of those with a CML-like disease, 17/99 (17%) 
were V617F positive, and 13/53 (25%) of those with atypical MPN were positive for 
V617F. The JAK2 mutation was also found in 2/6 (33%) of patients with CNL, 2/134 (1.5%) 
patients with HES (Table 3.2).  58 
These findings had not been previously reported and served to establish the importance 
of JAK2 V617F in a heterogeneous series of MPN. JAK2 V617F was not detected in any of 
the cases that also tested positive for rare tyrosine kinase fusion genes (n=24), nor in 
individuals with CML (n=18), AML (n=17) or healthy controls (n=160). Out of the eight KIT 
D816V positive cases with SM, one individual also had the JAK2 mutation but was 
considered clinically to have both SM and PV. Of the 14 JAK2 V617F mutation negative PV 
patients, 13 were male (p=0.005, χ
2) but no other significant associations between sex 
and mutation status were identified. 59 
Disease subtype  number  V617F 
positive 
number (% of 
cases) 
Gender/age of V617F 
positive cases m/f; 
median age/yrs 
(range) 
V617F 
negative 
number (% of 
mutants) 
Gender/age V617F 
negative cases m/f; 
median age/yrs (range) 
V617F 
homozygotes 
number (% of 
mutants) 
PV  72
a  58 (81%)  31m/27f; 57 (26-76)  14 (19%)  13m/1f; 57 (33-78)  24 (41%) 
ET  59  24 (41%)  15m/9f; 65 (5-88)  35 (59%)  23m/12f; 56 (24-88)  4 (17%) 
IMF  35  15 (43%)  10m/5f; 65 (44-78)  20 (57%)  15m/5f; 62 (41-92)  10 (67%) 
Idiopathic HES  134
b  2 (1.5%)  1m/1f; (64 (63-65)  132 (98.5%)  51m/81f; 54 (3-89)  2 (100%) 
Systemic 
mastocytosis 
28
c  0 (0%)  n/a; n/a  28 (100%)  16m/12f; 53 (4-90)  n/a 
CML-like MPN  99
d  17 (17%)  13m/4f; 62 (17-76)  82 (83%)  60m/22f; 66 (2-95)  8 (47%) 
MPN-U  53  13 (25%)  7m/6f; 63 (17-77)  40 (75%)  17m/23f; 61 (21-87)  7 (54%) 
Total  480  129 (27%)  77m/52f; 58 (2-95)  351 (73%)  195m/156f; 62 (5-88)  55 (43%) 
 
Table 3-2. Summary of results and patient details for the characterisation of the JAK2 V617F mutation. 
a Includes one case with PV plus systemic 
mastocytosis who was positive for JAK2 V617F and KIT D816V. 
b Includes seven FIP1L1-PDGFRA positive CEL cases, all of whom were negative for JAK2 
V617F. 
c Includes seven KIT D816V positive cases, all of whom were negative for JAK2 V617F. 
d Includes 17 cases with rare tyrosine kinase fusions (ETV6-
PDGFRB n=9, ZNF198-FGFR1 n=2, BCR-FGFR1 n=2, PCM1-JAK2 n=2, BCR-PDGFRA n=1, TP53BP1-PDGFRB n=1), all of whom were negative for JAK2 V617F. 
n/a indicates not available or not applicable.60 
3.3.3  Determining the sensitivity of the molecular techniques used to characterise 
JAK2 V617F  
The presence of JAK2 V617F was verified by sequencing, and some traces showing the 
point mutation are shown in Figure 3.3. As had been suggested by the AS-PCR, some 
cases appeared to be homozygous for the mutation and some were heterozygous. In an 
initial analysis of PV cases (n=51) sequencing was fully concordant with the AS-PCR result. 
It soon became apparent however that some cases had a low proportion of mutant allele 
which would have been difficult or impossible to detect by sequence analysis alone. This 
technique is generally accepted to have a sensitivity of only 20 to 30% depending on the 
sequencing context.  
 
Figure 3-3.  Sequence traces of three individuals found to be normal, heterozygous and 
homozygous by AS-PCR. 
In occasional cases the intensity of the mutant band by AS-PCR was very weak and it was 
difficult to decide if the patient was positive or negative. It became necessary therefore to 
clarify the sensitivity of the AS-PCR in detecting the JAK2 V617F. This was achieved using a 
dilution series made with DNA from a homozygous patient diluted into DNA from a 
healthy normal control. AS-PCR was found to reproducibly detect down to 2 to 5% mutant 
allele (Figure 3.4). Following this a more quantitative assay for V617F was developed 
using pyrosequencing. 61 
 
 
 
 
 
 
 
Figure 3-4. Sensitivity of the AS-PCR assay. The arrow indicates the AS-PCR PCR is routinely 
capable of detecting a level of 2 to 5% mutant allele. 
 
Pyrosequencing for the JAK2 mutation was performed initially on a set of 29 normal 
DNAs. The mean level of mutant alleles measured was 0.53% (range 0 to 2.90%, standard 
deviation 0.83%). From this a figure of equal to or below 5% mutant allele (average + 
5S.D.) was used to define a sample as normal for the JAK2 mutation. Next, 23 MPN cases 
found to be normal by AS-PCR were tested and all were found to be also negative by 
pyrosequencing. 
The accuracy of pyrosequencing to quantify V617F levels was then tested using a dilution 
series created by mixing PB granulocyte DNA from a 98.3% V617F positive patient with PV 
with normal DNA derived from PB total leukocytes. The dilution series was extended to 
include a wider range of dilutions, and the data is shown in Table 3.3 and Figure 3.5. The 
pyrosequencing results accorded well with the dilution level of mutant allele into wild-
type. 
Although there was general consensus in the initial reports that many patients with 
classic MPN were positive for V617F, inspection of Table 3.1 shows quite marked 
discrepancies in the frequency of positive cases reported for different subgroups, e.g. 65-
97% of PV and 23-43% of ET. The varying degrees of sensitivity for each molecular 
100%    50%     20%     10%       5%        2%       1%      0.1%      0%     blank       
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Control 463bp 
Mutant 279bp 
Normal 229bp 
 
 62 
method used to detect the JAK2 mutation are likely, at least in part, to explain the 
different frequencies of mutation found by different groups. In particular, those groups 
who just performed sequencing, for example, Kralovics et al. (2005) 
199 and Levine et al. 
(2005) 
200 are likely to have underestimated the true incidence of JAK2 V617F in their 
cohorts. Results from this study suggest a combination of AS-PCR and pyrosequencing is 
sufficient to detect and quantify JAK2 V617F routinely in a diagnostic setting. 
 
% 
JAK2 
V617F 
% mutant allele determined 
by pyrosequencing 
Mean average 
% mutant 
allele  A  B  C  D 
100  100  97.5  97.4  98  98.23 
80  79.6  77.3  77.8  77.6  78.08 
60  58.7  58  57.3  59.5  58.38 
50  49.1  48.2  51.9  48.7  49.48 
40  39.5  39.5  36.4  38.1  38.38 
20  21.8  17.7  20.4  19.2  19.78 
10  10.4  10.6  9  11.5  10.38 
5  4.9  4.2  4.6  3.4  4.28 
2  2.9  2.5  2.1  1.4  2.23 
1  3.3  0.9  0.2  5.3  2.43 
0.1  4.3  2.3  0  1.7  2.08 
0  1.8  1.2  2.1  1.5  1.65 
 
Table 3-3. Pyrosequencing results from a dilution series of JAK2 V617F homozygous DNA and 
normal DNA. The % JAK2 V617F indicates the proportion of mutant JAK2 alleles based on the 
dilution factor. A-D are quadruplicate replicates of the pyrosequencing analysis with the mean of 
these values shown in the last column.   63 
 
Figure 3-5.  Line graph showing %V617F as determined by pyrosequencing performed on four 
separate JAK2 V617F dilution series. 
 
3.3.4  Pyrosequencing analysis confirms that JAK2 V617F levels vary widely in MPN 
Pyrosequencing provides accurate quantification of allele ratios and provided a more 
accurate measurement of the size of the mutant clone in our cases. If the pyrogram gave 
a percentage of mutant allele above 50%, that sample was scored as homozygous. Below 
and at 50%, and above 5% mutant percentage, that sample was termed heterozygous for 
the JAK2 mutation. Samples with no evidence of mutation (i.e. <5%) were classed as 
normal. Pyrosequencing was performed on 90 mutant samples with a stronger mutant 
band by AS-PCR, and confirmed homozygosity in the majority of samples (%V617F >50%). 
Examples of normal, heterozygous and homozygous V617F pyrograms are shown in 
Figure 3.6.  
For some samples analysed by AS-PCR there was insufficient DNA available for 
pyrosequencing. These cases were scored as homozygous if the ratio of wild-type to 64 
mutant bands was at least as strong as that seen in the 50% dilution control (Figure 3.4, 
50% track) as determined by visual inspection.  
Overall 55 out of the 129 (43%) mutant samples were homozygous, and results for each 
patient subgroup are summarised in Table 3.2. The ratio of homozygotes to 
heterozygotes was not significantly different from the average of all cases in any of the 
subgroups, apart from ET where the proportion of homozygous mutants was significantly 
lower than that seen in other subgroups (P=0.009, χ
2). Other publications report 
comparable levels of homozygosity for PV, ET and IMF 
197-201.  65 
 
 
 
Figure 3-6. Representative pyrograms quantifying the JAK2 V617F mutation. Pyrograms from 
normal (A), one heterozygous (B) and two homozygous (C and D) V617F-positive individuals are 
shown. The sequencing primer is in reverse orientation (immediately abutting the site of the 
mutation) and the dispensation order GCAGCATAC was used (the two Gs are internal controls that 
should give no peak, E and S indicate enzyme and substrate, respectively). In a normal individual 
(sequence CACATAC) the peak heights of the first C and A are similar. In a heterozygous individual 
(sequence (C/A)ACATAC) the C peak is reduced in height and the A peak increased above all other 
peaks as both the mutant A and the following A are being read in the same direction. In a 
homozygous individual (sequence AACATAC) the first peak is either much lower than the A peak 
(trace C) or can be absent (trace D). The ratio of the normal (C) and mutant (A) alleles is calculated 
by the Pyrosequencing SNP analysis software. 
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3.3.5  JAK2 V617F and chromosome 9p acquired UPD 
Homozygosity for JAK2 V617F
 was established in 24/72 (33%) cases of PV, 4/59 (7%) cases 
of ET and 10/35 (29%) cases of IMF. This is strikingly similar to the frequencies of acquired 
chromosome 9 UPD that has been described in these diseases 
199. To determine whether 
UPD for chromosome 9 was associated with homozygosity for the JAK2 V617F, a 
colleague (Claire Curtis) performed microsatellite analysis on 57 cases (normal n=30, 
homozygous V617F n=27). In normal individuals, most microsatellites were expected to 
be heterozygous. Consecutive tracts of homozygous markers usually indicate LOH due to 
complete or partial chromosomal loss (i.e. hemizygosity), or acquired UPD.  
Significant tracts of homozygosity in the vicinity of JAK2 was observed in 4 (13%) of the 
normal cases and 25 (93%) of the JAK2 V617F homozygotes (P<0.0001) 
252. To determine 
whether this homozygosity arose through loss of the wild-type allele, I then measured the 
number of copies of the JAK2 gene relative to control genes in patient DNA using MLPA. 
Seven cases with a homozygous JAK2 V617F mutation and at least three consecutive 9p 
microsatellite markers were tested and all were found to possess two copies of JAK2, 
consistent with homozygosity as a consequence of acquired UPD for chromosome 9p 
(Figure 3.7). These findings are consistent with those reported by Kralovics et al. (2005) 
199.  An example of the calculations used to determine JAK2 copy number is included in 
Appendix IV.   67 
 
 
 
 
 
 
 
 
 
Figure 3-7. Representative results of MLPA analysis measuring copy number of the JAK2 gene. The 
relative peak areas for JAK2 are the same for two homozygous V617F cases with 9pLOH 
(V617F/V617F) and two normal controls (WT/WT), indicating the presence of two copies of JAK2. 
The second case is male, and shows a reduced peak height for the X-linked BTK gene compared to 
the three other cases, all of which were female. 
 
 
3.3.6  Is evolution of V617F-positive disease associated with amplification of JAK2? 
Acquired UPD of chromosome 9 is responsible for homozygosity for V617F in a significant 
proportion of cases with MPN. It is widely acknowledged that this mechanism of mitotic 
recombination arises as a consequence of genomic instability 
253. Recently it was 
suggested that this instability may also be responsible for amplification of JAK2 by 
tandem duplication in some V617F-positive cases, accounting for disease evolution 
254. It 
was proposed that cells with more than two copies of mutant JAK2 carry an additional 
signalling advantage. In a follow-up study the same group found that this phenomenon 
was most prevalent in PV, with more than one-third of mutation-positive cases 
apparently having more than two V617F copies per cell 
255. While increased V617F copy 
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number has been described in cell lines 
256, this was the first suggestion that JAK2 might 
be amplified in patients. Classical MPN is characterised by cytogenetically visible 
abnormalities of chromosome 9 which alter the copy number of JAK2, for example +9, 
+9p, del(9), and translocations involving chromosome 9, but these cases are relatively 
infrequent. In my MLPA analysis above no amplification of JAK2 was detected in 7 of 7 
cases tested and thus the findings of Hammond et al. were surprising.  
Here I investigated whether elevated JAK2 copy number could be detected with an 
alternative methodology to the quantitative PCR based method used by Hammond et al. 
(2007) 
255. For this investigation I developed a second MLPA based test. This was designed 
to be more accurate than the method above by inclusion of multiple JAK2 probes and 
building the assay onto an established commercially available subtelomere kit (MRC-
Holland) that was known to produce reliable and reproducible results. 
 
3.3.6.1  Validation of MLPA-based test to detect copy number changes in JAK2 
The assay was first tested on a series of control samples. Firstly, 21 haematologically 
normal individuals gave a median JAK2 dosage quotient of 1.01 (range 0.71-1.28). The 
dosage quotient for a fibroblast cell line carrying a der(9)t(6;9) was 0.50, corresponding to 
deletion of one copy on JAK2, which was further supported by deletion of one copy of the 
9p telomere probe. To control for increased copy number of the JAK2 locus, the V617F-
positive cell lines SET-2 and HEL were analysed. SET-2 has approximately 75% V617F 
mutant allele per cell, as determined by pyrosequencing, while MLPA here revealed five 
copies of the 9p telomere (dosage quotient was 2.47) and five copies of JAK2 per cell 
(dosage quotient was 2.50). This suggests that SET-2 has four mutant and one wild-type 
copy of JAK2. HEL had 100% V617F by pyrosequencing and MLPA indicated nine to ten 
copies of JAK2 (dosage quotient was 4.72), plus total deletion of the 9p telomere and 
other abnormalities. MLPA traces are shown in Figure 3.8, and accord well with previous 
estimates of JAK2 copy number in these cell lines, as determined by fluorescence in situ 
hybridisation 
256.  69 
3.3.6.2  Investigation of JAK2 copy number in V617F-positive MPN 
Next I tested DNA isolated from PB total leukocytes from 63 MPNs (PV, n=45; MF, n=5; 
other MPN, n=13) that were homozygous for V617F as determined by pyrosequencing 
(median %V617F=87%; range 63 to 99%). The JAK2 dosage quotients observed (median 
0.99; range 0.67-1.25) ascertained by MLPA were no different from the normal control 
group and no case was above the previously defined cut-off required to define a 
duplication 
251,257. An example of the MLPA traces, JAK2 dosage quotient and calculated 
copy number is shown for four homozygous V617F-positive cases in Figure 3.8. Analysis of 
a further 16 heterozygous V617F-positive cases (median %V617F = 31%), yielded similar 
results with again no evidence for increased JAK2 copy number. 70 
 71 
Figure 3-8 (previous page). Representative MLPA genotyper traces for measuring JAK2 copy 
number per cell. The JAK2 probes for exons 9, 20, 16, and 3 result in smaller bands than those 
from the MRC-Holland subtelomere probe mix, of which 1p to 12p are shown here. The JAK2 
dosage quotient and estimated copy number are shown on the right. The der(9)t(6;9) cell line, 
carrying only one copy of JAK2, shows reduced JAK2 and 9p subtelomere peaks relative to the 
other peaks. HEL and SET-2 show an increase in the relative size of these peaks, while no JAK2 
copy number alterations were detected in four illustrative patient samples with a high %V617F. 
 
 
3.3.7  JAK2 V617F-positive MPN and other genetically distinct clones provide insights 
into a multi-step pathogenesis 
In the initial study group of 480 cases I found one case that tested positive for both KIT 
D816V and JAK2 V617F. During routine screening, a further three cases with KIT D816V 
and one case with FLT3 ITD were also found to be JAK2 V617F positive. Anecdotal reports 
in the literature have described similar cases, but it was unclear whether the mutations 
arise in the same cell lineage 
258 or in independent clones 
259. Here I investigated two 
cases in more detail.  
 
3.3.7.1  JAK2 V617F and KIT D816V 
Firstly, it was possible to examine the molecular origin of clones carrying KIT D816V and 
JAK2 V617F mutations in one case with overt SM and thrombocytosis, for whom a fresh 
PB sample was available. Analysis of the whole blood showed that the levels of both 
mutations were low, with JAK2 V617F detectable only by AS-PCR and not by 
pyrosequencing indicating a mutation burden in the 2-5% range. Pyrosequencing for the 
KIT mutation indicated a level of 15%. The PB sample was separated by density gradient 
centrifugation following standard conditions and MNCs were cultured in semi-solid 
medium and exposed to cytokines that promote division and differentiation of myeloid 
cells, in the absence of erythropoietin. Colonies which are assumed to arise from single 
colony-forming progenitor cells were picked after ten days incubation, and DNA was 
extracted and genotyped for KIT D816V and JAK2 V617F mutations by pyrosequencing. 72 
The results from the JAK2 V617F assay were considered negative if they had a mutant 
allele level of less than 5% 
252 and less than 10% for the KIT D816V pyrosequencing assay 
(data provided by Kathy Waghorn, personal communication). Mutant allele values above 
these limits were scored as positive. Additionally, mutant allele levels greater than 50% 
were termed homozygous, and mutant allele levels below 50% were termed 
heterozygous. DNA was also extracted by standard procedures from total PB leukocytes 
removed prior to density gradient centrifugation. This DNA sample was also screened for 
both mutations using pyrosequencing, and additionally by AS-PCR for JAK2 V617F. 
In total 43 colonies were picked and screened for both mutations, and the results are 
listed in table 3.4. Seven colonies carried JAK2 V617F, 13 colonies carried KIT D816V, and 
23 colonies were negative for KIT D816V and JAK2 V617F. The mutations were mutually 
exclusive, i.e. there was no evidence for both mutations occurring in the same clone. The 
remaining 23 colonies were normal for each mutation, producing pyrosequencing results 
that ranged from 0 to 5% mutant allele for JAK2 V617F, and 0 to 8.6% mutant allele for 
KIT D816V. In addition to the colonies, aliquots were removed from the area of semi-solid 
medium not supporting cell growth to ascertain the background level of DNA that may 
influence mutation screening. Eight blank preps were genotyped and four failed to 
amplify on PCR, and four were found to contain DNA that was negative for either 
mutation on mutant allele genotyping. The pyrosequencing values for these blank 
aliquots ranged from 0 to 3.1% mutant allele for JAK2 V617F, and ranged from 7.9 to 
10.4% mutant allele for KIT D816V, and were thought to have resulted from amplification 
of low level DNA from background wild-type cells. 
 
Mutation status  colony number  
Negative for KIT D816V and JAK2 V617F   23 
JAK2 V617F positive  7 
KIT D816V positive  13 
KIT D816V and JAK2 V617F positive  0 
 
Table 3-4. Genotyping of myeloid colonies for JAK2 V617F and KIT D816V mutations. 
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The mutant allele levels for each mutation-positive colony are listed in table 3.5.  Out of 
the seven colonies carrying JAK2 V617F, five had mutant allele levels approaching 
homozygosity, and two colonies were heterozygous. For the colonies with V617F levels 
between 50- 90%, it was suspected that contamination with a background of normal cells 
lowered the overall level of mutant allele down from the expected value of 100%. 
Similarly there is evidence of contamination with normal cells in a series of heterozygous 
colonies 6 and 7 for JAK2, plus 12, 17 and 18 for KIT. Although care was made to select 
single colonies for analysis, the picking of overlapping clones cannot be ruled out. KIT 
D816V was isolated in 13 individual colonies, and all colonies were heterozygous for this 
mutation.  Ten of these colonies had values close to 50%, whereas the other three were 
lower, again probably due to a mixture of normal and mutant cells. Despite this 
uncertainly it was clear that no colony with both mutations was detected. Given the low 
level of both mutations isolated in total PB leukocytes, it was surprising to find this 
number of mutant-positive colonies, but this may be due to differential stimulation of 
mutant and normal CFU-GM by myeloid growth factors present in the semi-solid medium.  
   74 
Colony 
identifier 
JAK2 V617F 
%mutant allele 
KIT D816V  
%mutant allele 
 
1  72.4  5.2 
JAK2 
mutated 
colonies 
2  82.1  8.4 
3  82.8  0.0 
4  84.6  6.0 
5  91.8  8.0 
6  26.4  0.0 
7  34.2  8.6 
8  1.6  50.1 
KIT mutated 
colonies 
9  3.5  53.9 
10  1.4  51.8 
11  1.7  45.5 
12  1.5  21.1 
13  0.4  54.1 
14  0.3  52.8 
15  0.0  50.3 
16  0.1  51.0 
17  2.3  14.0 
18  2.2  16.0 
19  3.5  50.4 
20  3.5  55.0 
 
Table 3-5. Mutant allele percentages for KIT D816V and JAK2 V617F positive colonies. 
 
3.3.7.2  JAK2 V617F and BCR-ABL 
The second investigation was performed in collaboration with Dr Kramer (Heidelberg, 
Germany), who was responsible for the care of a patient with BCR-ABL positive CML who 
also tested positive for JAK2 V617F. It is widely reported that patients with chronic phase 
CML respond rapidly to treatment with imatinib, but this patient, who responded well to 
imatinib as determined by a reduction in BCR-ABL levels by quantitative PCR, developed 
splenomegaly and myelofibrosis. This prompted a screen for JAK2 V617F, and the patient 
was found to carry the mutation. Using pyrosequencing, I measured the level of the 
mutant allele in DNA samples taken at different time points over the clinical course. As 
shown in Figure 3.9, the JAK2 mutation was present at the initial diagnosis of BCR-ABL 
positive CML at a level of approximately 40% and this remained roughly constant during 75 
imatinib treatment. It was postulated therefore that BCR-ABL had arisen on the 
background of a pre-existing JAK2 V617F positive disease 
260. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-9. BCR-ABL ratio and JAK2 V617F allele frequency during treatment with imatinib in a 
patient with BCR-ABL positive CML. BCR-ABL and V617F levels were determined by quantitative 
RT-PCR, indicated by the green and blue lines, respectively. The V617F mutation burden 
measured by pyrosequencing is indicated in red (taken from Kramer et al. (2007) 
260).  76 
3.4  Discussion  
This part of my study was focused on characterising an acquired point mutation, JAK2 
V617F in MPN. I confirmed early reports that this mutation is seen in the majority of 
patients with PV and a significant number of patients with ET and MF. I also found V617F 
in more heterogeneous atypical MPN, leading to the understanding that JAK2 V617F is 
more prevalent than initially thought. The implications of a singular point mutation arising 
in diseases that are clinically diverse but clearly related remains unclear, but one 
possibility is that V617F serves to provide a molecular definition for a clinical entity with 
diverse features at presentation.  
 
3.4.1  The development of sensitive and quantitative methods of detecting JAK2 V617F 
In order to screen cases with MPN efficiently, it became clear that sequencing alone 
would not detect all positive cases, due to dilution of positive cells with an excess of 
normal cells. Therefore I designed an AS-PCR assay capable of detecting down to 
approximately 2% mutant allele, which was sufficient to detect V617F in the majority of 
cases. However I did encounter a small minority of cases with very low levels of mutation 
which proved difficult to categorically define as low level heterozygous or normal. The 
technical difficulties I experienced in measuring the JAK2 mutation may account for the 
published differences in the proportions of positive cases within MPN subtypes, where 
sequencing alone was used 
199,200. Baxter et al. (2005) 
198 state that direct sequencing 
underestimates the proportion of patients carrying the JAK2 mutation as sequencing will 
only reproducibly detect a heterozygous mutation if it is present in more than 40% of 
cells, or approximately greater than 20% of alleles. V617F may be present in PB at levels 
that range from low level heterozygous upward to complete homozygosity, and this may 
reflect progression of the disease from initiation to clonal expansion. 
JAK2 V617F was also detected using pyrosequencing, which provided an accurate 
measurement on the level of the mutant allele in positive cases. It was noted that the 
majority of cases affected by JAK2 V617F are heterozygous, i.e. the V617F-positive cells 77 
carry one copy of the mutation and retain one wild-type copy, and this is then 
superimposed on a background of normal cells. However, in PV, the mutant allele was 
found to predominate in 41% of cases. Investigations using microsatellite markers around 
the JAK2 locus and measurement of JAK2 copy number indicates that in these individuals 
mitotic recombination leading to acquired UPD has bought about homozygosity for the 
mutation. Whilst these results concur with the findings reported by others 
197-200, the 
incidence of homozygosity in PV also accords with results reported prior to the discovery 
of V617F, where loss of heterozygosity on chromosome 9p was shown to occur in 
approximately 30% of PV patients 
203. Such findings imply that, at least in a subset of 
patients, a minimum of two sequential changes are required for pathogenesis: acquisition 
of V617F and then mitotic recombination followed by selection for V617F homozygosity.  
 
3.4.2  JAK2 V617F is seen in diverse MPN, but not in disorders of the lymphoid lineages 
The heterogeneous group of diseases that are classified as myeloproliferative in nature 
now appear to be united by a single molecular marker, the JAK2 V617F mutation. In this 
study I found the mutation in HES/CEL, CNL, atypical CML, CMML and unclassified MPNs. 
Subsequently others reported similar findings 
261-263 . Table 3.6 shows a comparison of the 
frequencies of the JAK2 mutation in atypical MPN from these publications.  
 
Disease  This study 
Steensma et al. 
(2005)
261 
Levine et al. 
(2005) 
263 
Jelinek et al. 
(2005) 
262 
HES/CEL  2% (n=134)  0% (n=11)  -  - 
SM  0% (n=28)  25% (n=8)  -  - 
CNL  33% (n=6)  17% (n=6)  -  - 
aCML /CMML  17% (n=99)  -  8% (n=116)
  15% (n=68) 
MPN-U  25% (n=53)  -  - 
 
 
Table 3-6. A comparison of published mutation frequencies of the JAK2 V617F mutation in MPN. 
Currently we have screened the largest number of HES/CEL cases and found a very small 
minority with JAK2 V617F. Steensma et al. (2005) 
261 failed to find any evidence of the 78 
mutation in their HES cases, but this may be explained by their small sample size. 
However, this group reported 25% (2/8) of patients with SM carry the JAK2 mutation. 
Interestingly, we also screened a patient with PV and evidence of mast cell disease, and 
found both the JAK2 V617F and KIT D816V mutations. Both JAK2 V617F positive SM cases 
reported by Steensma et al. (2005) were negative for KIT D816V. Cases carrying two 
mutations are rare, and provide a unique opportunity to further understand the 
pathogenic nature of these oncogenic changes. This case was subsequently investigated 
to try to understand whether the JAK2 and KIT mutations occurred in two different or one 
single clone (discussed below).  
CNL is a very rare myeloproliferative disease characterised specifically by an expansion of 
neutrophils 
264. We found JAK2 V617F in 2 out of 6 (33%) cases with CNL. Steensma et al 
(2005) 
261 reported a similar number; V617F was present in 1 out of 6 (17%) of CNL cases. 
Regarding atypical CML, we found 17% (n=99) carried JAK2 V617F. The JAK2 mutation was 
identified in 25% unclassified MPNs (n=53). Similar findings for aCML were also reported 
by Jelinek et al. (2005) 
262 and Steensma et al. (2005) 
261. 
Other studies have shown that V617F is almost always restricted to the myeloid lineage 
diseases. Studies on ALL 
262, both T cell and B cell lineage as well as CLL 
263 have failed to 
find any evidence of JAK2 V617F in lymphoid leukaemias. Regarding AML, we failed to 
find the JAK2 mutation in 17 cases.  This was verified by Jelinek et al. (2005) 
262 who 
tested a range of patients with AML (M0 to M6) and failed to find JAK2 V617F in 28 cases. 
However, when AML was preceded by PV, ET or IMF, the JAK2 mutation was found in 12 
out of 22 (55%) cases. Levine et al. (2005) 
263 also report 4 out of 222 (1.8%) cases of AML 
with the JAK2 mutation, where 3 of these 4 positive AML cases had a preceding MPN. 
Campbell et al. (2006) 
265 subsequently described three cases with V617F-positive 
myeloproliferative disease which transformed to acute leukaemia. Interestingly, the 
leukaemic cells of these patients were V617F negative, suggesting that the leukaemia 
arose in a V617F negative cell. These observations suggest that acquisition of V617F 
might be a secondary event, following an initial pre-JAK2 phase of disease, which resulted 
from an unidentified initial mutation.  79 
In this study, JAK2 V617F was found in 81% of cases with PV, the highest frequency of all 
MPNs tested. Although it may be argued that some cases were diagnosed incorrectly, 
these results suggest that not every patient with PV carries V617F. Investigations into 
these rare cases subsequently revealed a series of mutations that target a different region 
of the JAK2 gene in V617F negative PV and idiopathic erythrocytosis 
266. My investigations 
into the prevalence and methods of detecting JAK2 exon 12 mutations are described in 
Chapter 4.  
As JAK2 V617F continued to be characterised, its diagnostic importance clarified and it 
has been incorporated into algorithms for diagnosis and classification of MPN and related 
disorders including the new WHO criteria 
22. The utility of these revised criteria have 
contributed significantly to an apparent increase in the incidence of ET in a well-defined 
population in France 
267. 
 
3.4.3  The role of JAK2 V617F in development of MPN  
Introduction of V617F into mice gives rise to a PV-like phenotype but there are several 
lines of evidence to suggest that the mutation might be a secondary event, at least in 
some cases.  Analysis of X chromosome inactivation patterns 
268,269, transformation of 
JAK2 V617F-positive MPN to V617F negative leukaemia 
265,270, growth of JAK2 V617F 
negative EECs from V617F-positive patients 
259,271 and an apparent familial tendency to 
develop an MPN 
204,272 all provide evidence that support this notion. On the other hand, 
introduction of V617F into mice reproducibly results in a PV-like disease suggesting that a 
single hit may be sufficient 
197. 
Although it is not known whether V617F is a true disease-initiating event, and what other 
molecular events are implicated in disease progression, it is reasonable to suggest that 
JAK2 V617F does account for some aspects of a MPN but not necessarily the complete 
phenotype. Figure 3.10 shows two possible pathogenic mechanisms that may account for 
the development of myeloproliferative disease. Kralovics et al. (2005) 
199 proposed, in 
model A that the MPN phenotype is initiated by a mutation such as JAK2 V617F arising on 
one allele of chromosome 9p, either alone or in combination with a hypothetical pre-80 
existing somatic mutation in an unknown gene. In model B, MPN is induced by one or 
more unknown mutations with JAK2 V617F as a secondary event. The proliferative 
advantage of JAK2 V617F causes the mutant clone to expand at a faster rate than the 
wild-type clone. In both models, a heterozygous V617F-positive cell then undergoes 
recombination at chromosome 9p so the V617F allele is duplicated by UPD to produce a 
cell with two copies of V617F. With no wild-type JAK2 now present, the homozygous 
V617F positive cell out-competes the heterozygous mutant cells and the wild-type cells 
towards full clonal dominance.  
 
 
Figure 3-10. Hypothetical role of the JAK2 V617F mutation in myeloproliferative diseases. Adapted 
from Kralovics et al. (2005) 
199. 
 
Accordingly, MPN patients without the mutation should be in the early stages of disease, 
or have a shorter disease duration that those with the JAK2 mutation. It would then be 
predicted that patients who are homozygous for JAK2 V617F should have a longer disease 
duration, a theory supported by preliminary findings from Kralovics et al. (2005) 
199. 
Clinical data showed a significant correlation between the presence of the JAK2 mutation 
and frequency of disease complications (secondary fibrosis, haemorrhage, and 81 
thrombosis). In addition, patients with the JAK2 mutation were more likely to be older 
and have received cytoreductive therapy, than those with normal JAK2. These findings 
have been substantiated in more recent studies, which provide evidence of a linear 
relationship between %V617F and haemoglobin concentration, spleen size, leukocyte 
count 
273-277, and an inverse relationship regarding platelet count. This last point is in 
keeping with the low level of mutant alleles found in ET patients, whose clinical 
phenotype is dominated by thrombocytosis 
278,279. Additionally it has been proposed that 
patients positive for V617F have a higher risk of post-PV MF than those who are wild-type 
for the mutation, and that disease progression occurs more often in cases with a 
homozygous mutation burden 
273,276. Concerning MF, there are conflicting studies as to 
whether V617F level can predict progression to acute leukaemia 
276,277. However it is 
highly likely transforming MF cases with wild-type or low level V617F carry other 
mutations that dominate myeloproliferation. 
The isolation of one mutation in a range of myeloid disorders was not anticipated, but as 
each disease sub-type shares many overlapping features, perhaps this is indicative of the 
underlying signalling pathways behind each disorder. The V617F mutation does not occur 
in non-haematological cancers 
280, but it is present in myeloid malignancies other than 
classical BCR-ABL negative MPNs. The question of how one mutation can apparently give 
rise to such distinct but related diseases remain largely unexplained. One clear correlation 
however is the level of mutant JAK2 signalling. Here I described a statistically higher level 
of homozygosity in patients with PV (41%) and MF (67%) compared to patients with ET 
(17%). The observation that mitotic recombination at chromosome 9 is a rare event in ET 
was later investigated at the haematopoietic progenitor level 
281.  When myeloid 
progenitors were cultured and genotyped for V617F, colonies carrying a homozygous 
JAK2 mutation were only isolated from PV patients, not those with ET. All 17 PV patients 
were found to carry progenitor colonies with heterozygous, homozygous and normal 
JAK2, whereas progenitors from ET patients were only heterozygous V617F positive or 
normal. One explanation for this observation may be that PV patients may have a longer 
pre-diagnosis phase of their disease, allowing more time for homozygosity to occur. 
Alternatively, mitotic recombination around the JAK2 locus may occur more frequently in 
patients with PV, perhaps as a result of an unknown mutation or genetic predisposition. 82 
Dose of V617F has been linked to the disease severity in mouse models, with a low level 
of mutation producing an ET-like phenotype, and a higher level resulting in erythrocytosis 
and fibrosis 
282,283.  
 
3.4.4  The JAK2 gene is not amplified in V617F-positive MPN 
Recently it was suggested that cells carrying JAK2 V617F could increase their copies of 
mutant JAK2 not only by mitotic recombination and acquired UPD, but also by frequent 
complete or partial duplication of the chromosome 
255. This mechanism associated with 
disease progression has been previously described, for example mutant EGFR 
284, MET 
285 
and RET 
286 are either duplicated, or the wild-type allele is lost, and all result in increased 
tumourigenic potential.  
Here I investigated the copy number of the JAK2 gene using MLPA, a technique used 
widely to provide sensitive quantification of DNA copy number 
249. To do this, DNA from 
homozygous V617F positive cases was hybridised to four probes targeting different 
regions of JAK2, plus a series of probes that detect every chromosome telomere provided 
by a commercial kit available from MRC Holland. My results showed no amplification of 
JAK2 in 63 homozygous V617F positive cases, or 16 heterozygous cases, clearly suggesting 
amplification of the JAK2 locus by tandem duplication is rare in V617F-positive MPN. This 
conclusion conflicts with results described previously by Hammond et al. (2007) 
255. 
Hammond et al. (2007) used a novel TaqMan assay to detect and measure average copies 
of JAK2 V617F per cell in absolute terms, as opposed to a ratio of mutant to wild-type 
alleles. The V617F signal was compared to that generated by a series of plasmid 
standards, and the results were combined with an additional test that determined cell 
number. I chose to test these findings using an alternative methodology capable of 
detecting minor changes in copy number of DNA. The reasons for these discrepant 
findings are not immediately obvious. Perhaps tandem duplication of JAK2 only occurs in 
specific cell types, such as differentiated erythrocytes and granulocytes. Hammond et al. 
(2007) examined granulocyte DNA, whereas only total leukocyte DNA was available for 
this study. However as previous investigations into the variability of mutation burden 
between different cell subsets did not reveal any major differences, this point may not be 83 
significant. Moreover, the main clone in PV is predominantly granulocytic and/or 
erythrocytic, especially in cases with high level V617F burden, so if there was any 
amplification of JAK2 it should have been detected. Hammond et al. (2007) also suggests 
their results may be attributed to in-frame internal tandem duplication of the V617F 
region, analogous to mutations observed in FLT3. To test this I determined whether 
amplification of exon 14, the location of V617, could be selectively amplified in 
homozygous V617F-positive cases. Using cDNA-specific primers to exons 13 and 15, I 
screened 15 homozygous V617F-positive cases by RT-PCR, and did not find any evidence 
of aberrant sized bands (data not shown). It is likely therefore that the discrepancy 
between the two studies is purely technical. The ability to accurately detect and quantify 
V617F is clearly important from a diagnostic perspective and this might be facilitated in 
the future by the availability of quantitative standards as well as consensus on the best 
techniques to use. 
 
3.4.5  Evidence of oligoclonality in MPN 
Mutations resulting in hyperactive signalling are generally mutually exclusive because of 
functional redundancy and so the finding of cases that tested positive for JAK2 V617F and 
KIT D816V, FLT3 ITD or BCR-ABL was a surprise. The first patient I found had symptoms of 
both SM and thrombocytosis, and was found to be positive for KIT D816V and JAK2 
V617F. My results showed the mutations appear to have arisen in separate myeloid 
progenitor clones. Whether the clonal populations share a preceding unifying mutation 
remains undetermined. This result contrasts with data published recently by Sotlar et al. 
258 who reported the finding of both KIT D816V and JAK2 V617F mutations in a small 
minority of patients with SM with myelofibrosis. Using laser microdissection to separate 
neoplastic mast cells from CD15
+ myeloid cells, both mutations were apparently isolated 
in both cell fractions. The authors argued both mutations existed in the same cell lineage, 
but concluded investigations at a single cell level were necessary to define this 
observation.  
The data described here contributed to a recent report by Beer et al. (2009) 
287 where 
four other cases carrying two mutations in different signalling pathways were 84 
investigated in detail at the progenitor cell level. The results showed the existence of two 
separate clonal expansions in all cases studied; JAK2 V617F-positive clones were found to 
be distinct from clones carrying other tyrosine kinase mutations; MPL W515L, and JAK2 
exon 12. However additional cytogenetic abnormalities, del(20q), trisomy 9, and trisomy 
8, tended to occur in the same clone as the activated kinase. X-chromosome inactivation 
patterns of 2 out of 3 female patients carrying both MPL and JAK2 mutations showed the 
clones had arisen from independently related progenitors, arguing against the presence 
of an unknown, preceding mutation, at least in these few cases. The clonality of cases 
carrying del(20q) plus JAK2 V617F were also investigated using colony assays by Schaub et 
al. (2008) 
288. Interestingly, there was no particular pattern for the occurrence of either 
clonal marker; each existed either in a mutually exclusive pattern, or within the same 
clonal population, and did not follow a strict temporal order of occurrence.  It remains 
difficult to determine, however, at what point of development the mutations arose, and 
whether the JAK2 point mutation precedes other mutations.  
The next case was diagnosed with BCR-ABL positive CML, who after treatment with 
imatinib, developed myelofibrosis later found to be caused by JAK2 V617F. Samples taken 
over a period of six years showed V617F was present at a constant level but symptoms of 
an MPN only developed after the drastic reduction of BCR-ABL positive cells. It was 
concluded that the JAK2 V617F mutation preceded BCR-ABL, however, as this case was 
not investigated at a single cell level this remains unclear. Certainly there was a 
substantial clone present that was positive for V617F but negative for BCR-ABL.   
Isolation of BCR-ABL and JAK2 V617F has been previously been recorded in cases with 
CML with underlying myeloproliferative features 
289-292, however the incidence of both 
mutations occurring in a single case is very rare 
262. A CML patient with a history of PV 
was subsequently studied at the single haematopoietic progenitor level by Bocchia et al. 
(2007) 
293. The results showed BCR-ABL transcript and JAK2 V617F allele were isolated 
together in the majority of erythroid and myeloid colonies cultured, at the time of 
diagnosis of CML. There were also a small number of colonies that carried only V617F, but 
there were none that were singly positive for BCR-ABL. Whilst this is evidence from only 
one case, it does suggest that JAK2 V617F and BCR-ABL can co-exist in an early myeloid-85 
erythroid committed progenitor, and that the two oncogenic tyrosine kinases may 
provide cooperative proliferative advantages to a neoplastic clone.  
Study into these cases with biclonal expansions has provided some interesting 
information into the phenotypic heterogeneity of MPN. In most cases that have been 
analysed it appears that V617F and the other mutation are in different clones, although 
co-existence in the same clone is possible. The finding that mutations are in different 
clones indicates that the patient literally has two diseases, e.g. ET and CML, ET and SM. 
Since these are such are such rare disorders the chance that they both arose completely 
independently is remote. Although one possibility might be a pre-existing clonal 
expansion caused by an unknown precursor mutation, the X-chromosome inactivation 
analysis by Campbell et al. 
265 indicates that this is not always the case. Another possibility 
is an inherited predisposition to the acquisition of mutations, something that is explored 
further in Chapter 6.  
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4  Predicting and monitoring the responses of MPN patients to 
treatment  
4.1  Introduction  
The most important reason for understanding the pathogenic origin(s) of MPN is to 
develop effective treatments that may alleviate symptoms and induce a sustained cure. 
MPNs are disorders that once initiated in a haematopoietic stem cell, cause uncontrolled 
proliferation of one or more myeloid lineages, forming a clone of mature neoplastic cells. 
MPNs often lead to thrombohaemorrhagic complications and in many cases to 
progressive marrow myelofibrosis, anaemia, splenomegaly and risk of transformation to 
acute leukaemia. 
Stem cell transplantation remains the only curative treatment 
294, but it is associated with 
substantial morbidity and is limited to younger patients with suitable donors. The main 
treatment strategies for MPN are to try to redress the phenotypic characteristics of the 
disorder, i.e. cytoreductive therapy and phlebotomy to reduce the number of abnormal 
cells and other treatments to ameliorate symptoms. The effectiveness of different 
treatment strategies are determined by measurement of haematological parameters such 
as the haematocrit, platelet count, phlebotomy requirement and spleen size. Response to 
treatment may also be measured at the cytogenetic level if the aberrant clone carries a 
karyotypic abnormality which can be used as a marker. However as clonal cytogenetic 
abnormalities occur at different frequencies ranging from 3% to 40% depending on the 
subtype of MPN 
92,295, this approach is not widely applicable.  
By contrast the situation in CML allows for both cytogenetic and molecular monitoring of 
patients treated with highly effective targeted therapy. The Ph chromosome not only 
proved to be a useful clonal marker, but the oncogenic fusion protein BCR-ABL created by 
the translocation is now the main target of therapy with imatinib 
296. The efficacy of 
imatinib may be measured accurately cytogenetically by reduction in the number of Ph 
positive chromosomes, and also by monitoring the level of BCR-ABL transcripts by real-
time PCR 
297,298. Thus, the isolation of BCR-ABL in CML serves as the paradigm for 
successful targeted therapy in MPN, a pathognomonic marker of disease that is 87 
effectively inhibited by imatinib. It was subsequently discovered that imatinib is also 
active against other tyrosine kinases activated by chromosomal translocation, namely 
PDGFRα 
102 and PDGFRβ 
299. Thus, identifying patients that carry PDGFRα and PDGFRβ 
oncogenic fusion proteins is important for their optimal management. On the other hand, 
the identification of imatinib sensitive patients may help identify new pathogenetic 
abnormalities, as was the case for FIP1L1-PDGFRA 
102. 
Aberrant activation of tyrosine kinases accounts for a significant proportion of causative 
pathogenic lesions in MPN, but the molecular basis of disease for many other patients 
remains obscure. The identification of JAK2 V617F in nearly all cases with PV, and 
approximately half of those with ET and MF not only furthered understanding of the 
pathogenetic mechanisms behind the disease, but  also has the potential as a useful 
molecular marker of clonality and a target for therapy.  
 
4.1.1  Aims  
The aims of this part of my study were to develop and evaluate procedures to predict or 
assess the response of MPN patients to treatment. Specifically I sought to: 
1.  Identify MPN cases that were sensitive to imatinib using in vitro assays as a route 
to help identify novel imatinib responsive abnormalities.  
2.  Use JAK2 V617F as a molecular marker of clonal proliferation to measure the 
response of PV patients undergoing treatment with imatinib and rIFNα.  
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4.2  Materials and methods 
4.2.1  The in vitro imatinib sensitivity assays 
The colony and liquid culture assays were established initially by Dr B. Schultheis 
(Hammersmith Hospital, London) and Dr. A. Chase (WRGL, Salisbury). Cells from BCR-ABL 
positive, untreated CML patients were used as positive controls and found to be 
significantly inhibited by imatinib in both semi-solid medium and liquid culture. By 
contrast, the cell growth and survival of all normal controls tested were affected by 
imatinib to a much lesser degree. A ‘positive response’ was classified as that which 
mirrors the pattern of samples with an established sensitivity to imatinib, in this case 
BCR-ABL positive CML. A measure of ‘responsiveness’ called the ‘index of response’ was 
devised for the colony assay, based on data recorded from positive and negative controls. 
A positive or negative response on liquid culture was determined by visual inspection 
only. Any deviation from the pattern of a BCR-ABL positive CML sample is regarded as 
unresponsive to imatinib, and was often similar to the results from normal controls. 
Imatinib was obtained from Novartis (Basel, Switzerland) and was used at concentrations 
ranging from 1μM to 10μM. It has been previously shown 1µM imatinib selectively 
induces apoptosis in fresh BCR-ABL positive CML cells with little effect on normal 
haematopoiesis 
220. The concentration of imatinib required to inhibit cells transformed by 
BCR-ABL by 50% (IC50) was 582nM 
300. Imatinib was also shown to inhibit signalling at a 
lower concentration for PDGFRα and PDGFRβ fusion proteins; the IC50 for ETV6-PDGFRβ 
was 15nM 
301 and FIP1L1-PDGFRα was 3.2nM 
102. 
 
4.2.1.1  The in vitro imatinib colony assay  
Colony assays were performed in triplicate using fresh MNCs isolated from PB or BM 
cultured in semi-solid media, as described in Chapter 2. Additionally, imatinib was added 
prior to plating, so that the cells were exposed to a final concentration of 0μM, 1μM and 
5μM inhibitor, respectively. The dishes were incubated at 37°C, 5% CO2, and colonies 89 
were scored at 7 and 14 days incubation. Individual colonies were counted if the total 
cells per colony exceeded approximately 50 cells at day 7 and 100 cells at day 14.  
The measure of inhibition by imatinib, or ‘index of response,’ was calculated as the mean 
response at 1 μM and 5μM imatinib at days 7 and 14 compared to the untreated control. 
The numbers of colonies for each level of imatinib exposure were averaged and divided 
by the average of the untreated control. An example of the calculations used to formulate 
the index of response is included in Appendix V. In this manner, the varying levels of 
inhibition by imatinib between different patients could be compared.  
Figure 4.1A shows the colony assay results from a case carrying ETV6-PDGFRB who 
showed a positive response to imatinib. Myeloid colony formation was inhibited markedly 
by exposure to imatinib, as shown by the colony numbers from the imatinib treated 1µM 
and 5µM dishes expressed relative to the untreated colony counts. The index of response 
for this case was 0.18. This contrasts to the weaker effect imatinib has on cells from a 
healthy normal control, shown in Figure 4.1B where the index of response was higher at 
0.45. Based on experiments performed by Dr. A. Chase using a series of normal controls 
and BCR-ABL positive CML patients 
302, an index of response of 0.2 or below determines a 
positive response to inhibition with imatinib.  
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A 
 
 
 
 
 
 
 
 
B 
 
Figure 4-1. The in vitro imatinib sensitivity colony assay. Example A shows an example of a positive 
response to imatinib from a case with ETV6-PDGFRB (index of response; 0.18), and example B 
shows a negative response to imatinib from a normal control (index of response; 0.45). Myeloid 
mononuclear cells were cultured in semi-solid medium and exposed to two concentrations of 
imatinib to measure the degree of inhibition on colony formation. Colonies were scored on days 7 
and 14, and colony numbers from the imatinib-treated dishes were expressed relative to the 
untreated colony counts.  
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4.2.2  The in vitro imatinib liquid culture assay 
To examine the effect of exposure to imatinib on the survival and proliferation of mature 
MPN cells, either granulocytes or MNCs were cultured in supplemented RPMI 1640 with 
0μM, 1μM and 5μM imatinib, for two weeks. The liquid culture assay was set up using a 
starting concentration of 1x10
6 to 5x10
6cells/ml in 24 well plates, in duplicate, and 
surrounding empty wells filled with sterile water to prevent evaporation. The plates were 
incubated at 37°C, 5% CO2 over a period of 2 to 3 weeks, and cells in each well were 
counted twice weekly, using trypan blue staining to discriminate alive from dead cells. 
Medium from each well was changed weekly. 
Similar to the in vitro colony assay, the liquid culture assay was first tested on cells from a 
series of normal controls and BCR-ABL positive CML patients to determine parameters for 
measuring the inhibition by imatinib (data provided by Dr A. Chase). An example of cell 
counts and the calculations from a liquid culture assay performed on granulocytes from 
an imatinib-sensitive MPN case are described in Appendix V. A positive response is shown 
by a reduction in growth and survival in the imatinib treated cultures compared to the 
untreated cultures (Figure 4.2). Although the judgement as to whether the treated 
cultures differed significantly from controls was subjective, the results of these assays 
clearly correlated with patient genotype as detailed below. 
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Figure 4-2. The in vitro liquid culture imatinib sensitivity assay. Liquid culture results for an 
imatinib-responsive BCR-ABL positive patient (A) and an unresponsive case (B), expressed as total 
cell number (i) and relative cell number (ii). The degree of sensitivity to imatinib was more easily 
interpreted by expressing the counts from the treated cultures relative to the untreated cultures 
for each time point. 
 
 
4.2.3  Measurement of JAK2 V617F in PV cases undergoing treatment with imatinib 
and rIFNα 
DNA was extracted from total leukocytes, granulocytes separated from PB samples or 
from pre-treatment, unstained BM slides.  JAK2 V617F was initially detected using AS-PCR 
PCR. The proportion of mutant allele (%V617F) was quantified using pyrosequencing 
using primers JAK2_pyro_V617F_F and JAK2_pyro_V617F_R and sequenced with primer 
JAK2_ pyro_V617F_seq. Comparison of the %V617F between control and treated patients 
was performed by the Mann-Whitney test. 
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4.3  Results 
4.3.1  Identification of candidate imatinib-sensitive MPN patients in vitro 
As outlined above, a minority of MPN patients carry oncogenic tyrosine kinase fusion 
proteins that can be effectively targeted by imatinib therapy in vivo 
102,220,296,301. Although 
most of these cases have rearrangements of PDGFRA or PDGFRB, occasional imatinib 
sensitive cases have been reported in the absence of any known molecular or cytogenetic 
marker. Here I investigated whether cells isolated from the PB or BM of 200 MPN patients 
could be cultured in vitro with imatinib to determine whether they are likely to be 
responsive to this inhibitor. Further investigation by other members of the group was 
then focused on finding acquired genetic abnormalities in imatinib-sensitive kinases.  
 
4.3.1.1  Results of the in vitro imatinib sensitivity assays on MPN cases 
The colony assay was performed on 157 MPN samples, of which 131 gave an evaluable 
response; 26 showed a positive response to imatinib as defined above, 17 were 
borderline responders and 88 did not respond to imatinib. The imatinib sensitivity status 
of the remaining 26 samples was not determined, either because the MNCs failed to 
divide in culture, or the colonies were uncountable due to over-proliferation.  
Of the 171 MPN samples subject to liquid culture assay, 145 gave an evaluable result, 
with 24 showing marked inhibition to imatinib, 16 samples were borderline responders 
and 105 did not show any significant inhibition to the inhibitor. Twenty six samples were 
not successfully evaluated by liquid culture as all cells died very early in culture.  
Figure 4.3 shows an example of one sample, E111, which displayed borderline inhibition 
to imatinib on liquid culture, and a tentative positive response on colony assay, with an 
index of 0.182. This case proved negative for all molecular tests. 
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Figure 4-3. Case E111 showed a borderline response to imatinib 
exposure in liquid culture and colony assay. For the liquid culture 
assay, line graphs depicting total cell number (A) and relative cell 
number (B) some evidence of inhibition. In the colony assay (C) 
the cells were inhibited by imatinib, but this effect was marginal 
(index = 0.182). 96 
There were 15 samples that did not give a result on either assay. In total 185 out of 200 
MPN samples tested yielded a result for one or both in vitro assays. Six cases responded 
to imatinib in both assays, whereas a significant number of samples (n=38) were inhibited 
by exposure to imatinib in one assay, but not the other. This is shown in more detail in 
Table 4.1, where the results for each sample in liquid culture and corresponding colony 
assay are listed as positive, borderline, negative, not done or not informative. A full table 
of results for each case alongside any molecular abnormality identified is listed in 
Appendix VI.   
 
 
   colony assay  
      positive  borderline  negative 
not 
done 
not 
informative  total 
liquid 
culture 
assay 
positive  6  3  12  2  1  24 
borderline  4  1  1  5  5  16 
negative  7  6  51  30  11  105 
not done  4  3  13  0  9  29 
not informative  5  4  11  6  0  26 
total  26  17  88  43  26  200 
Table 4-1. A summary of results from the in vitro liquid culture and colony assay. 
 
4.3.2  Molecular results of cases subject to imatinib sensitivity assay 
All samples tested negative for BCR-ABL by RT-PCR. Other fusions were tested for as 
indicated by karyotypic abnormalities. All samples were also screened for FIP1L1-PDGFRA 
by RT-PCR, and 15 were shown to harbour the fusion gene. Out of the 200 MPN samples 
set up for either in vitro assay, three had ETV6-PDGFRB translocations, two had rare 
PDGFRA translocations (BCR-PDGFRA and KIF5B-PDGFRA), and one sample had a BCR-
FGFR1 translocation. 146 out of the 200 samples were screened for JAK2 V617F by allele 
specific PCR and pyrosequencing and 11 tested positive. Of 18 samples with a confirmed 
or suspected diagnosis of SM, 9 were found to be positive for the KIT D816V mutation. 
The main findings are summarised in Table 4.2. 
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  Number of positive 
responders/number tested 
Tyrosine kinase 
mutation 
Number with tyrosine 
kinase mutation (out 
of 200 unless stated) 
Colony assay  Liquid culture assay 
PDGFRB translocations  2  2/2  1/2 
FIP1L1-PDGFRA  15/199  3/14  11/12 
PDGFRA translocations  2  0/2  0/2 
BCR-FGFR1  1  0/1  0/1 
KIT D816V  9  0/8  1/6 
JAK2 V617F  11/146  4/7  0/10 
Uncharacterised 
mutation 
161  16/118 (13.6%)  11/133 (8.3%) 
Table 4-2.  Results of in vitro imatinib sensitivity assays in MPN patients. One patient carried KIT 
D816V plus JAK2 V617F. 
 
Figure 4.4 shows results of the colony assay for all cases investigated in this study. 
Individual indeces of response are plotted vertically, and cases are grouped according to 
molecular abnormality status. Colony growth of healthy normal controls was not inhibited 
by imatinib, and all indices lie above 0.2. Conversely, the indeces for the BCR-ABL positive 
controls all fall below 0.2. MPN cases carrying PDGFRB translocations displayed very low 
indeces, however cases with FIP1L1-PDGFRA fusions showed a more varied level of 
imatinib sensitivity, with the majority proving unresponsive to the drug by this method.  
MPN cases with KIT D816V were not inhibited by imatinib in this assay, a finding 
compatible with the known resistance of this mutation to imatinib. JAK2 V617F positive 
cases displayed varied imatinib sensitivity, ranging from cases with acute sensitivity, to 
others that were unresponsive. Finally, uncharacterised MPN cases displayed a range of 
sensitivities, with some being classed as positive responders.  
The remaining samples proved negative for all PCR based tests, and 16/118 (13.6%) of 
these showed a response by colony assay and 11/133 (8.3%) were positive by liquid 
culture. These figures include three cases that significantly responded to imatinib on both 
assays. Overall, 24/161 (14.9%) of samples without known mutations responded to 
imatinib. If all borderline responders were included, this value rises to 29.8% (48/161) 
patients displaying some degree of imatinib sensitivity.  98 
It was not possible to actually treat any of these positive responders with imatinib in vivo, 
so whether these cases harbour true imatinib-sensitive tyrosine kinase mutations remains 
to be determined. However, it seems likely that at least some of them may harbour 
mutations of imatinib sensitive tyrosine kinases. 
 
 
Figure 4-4. In vitro imatinib sensitivity colony assay results (indeces) plotted for MPN cases for the 
controls and each mutation category. 
 
4.3.3  Deregulated tyrosine kinases may be identified in MPN patients that display 
sensitivity to imatinib in vitro  
Of the 185 cases who gave an evaluable response in either or both assays, a total of 44 
cases displayed sensitivity to imatinib in one or more assay. Of the 44 cases, 20 were 
found to carry tyrosine kinase mutations, whereas 24 proved negative for all molecular 
tests. There were a total of 39 cases identified with a tyrosine kinase mutation, 
confirming signalling from some deregulated tyrosine kinases is not inhibited by imatinib. 99 
Out of 15 FIP1L1-PDGFRA positive cases studied, 14 were examined for imatinib 
sensitivity by colony assay and only three displayed significant reductions in colony 
numbers. In contrast, out of the 12 FIP1L1-PDGFRA positive cases tested by liquid culture, 
11 were positive (an example of the liquid culture on a FIP1L1-PDGFRA case that 
responded is shown in Figure 4.5). Imatinib sensitivity was therefore much more obvious 
for this fusion in the liquid culture set up with granulocytes compared to the colony assay 
set up with MNCs. The two assays primarily assess two different biological processes: the 
colony assay measures proliferation of progenitor cells whilst the liquid culture assay 
primarily assesses survival of non-proliferating cells. Two possible explanations for these 
discrepant results are therefore that FIP1L1-PDGFRA may activate survival rather than 
proliferation pathways, or that CFU-GM may not be part of the malignant clone. Further 
work by Dr Andy Chase revealed that only a minority of CFU-GM from FIP1L1-PDGFRA 
positive cases harbour the fusion gene. This data, along with my results, contributed to a 
study reporting that FIP1L1-PDGFRA is found predominantly  in more advanced stage of 
differentiation compared to BCR-ABL which is present in both myeloid and lymphoid 
lineages, and the great majority of CD34+ cells as well as the great majority of CFU-GM 
302.   100 
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Figure 4-5. The liquid culture imatinib sensitivity assay results from a FIP1L1-PDGFRA positive case 
E107.The results are shown as total cell number (A) and relative cell number (B). Cell culture was 
stopped at day 9 after marked inhibition was observed. 
 
Samples from MPN patients found to harbour rarer tyrosine kinase translocations were 
investigated using both in vitro assays where possible. Two out of three patients carrying 
ETV6-PDGFRB were significantly inhibited by exposure to imatinib in liquid culture. The 
third case exhibited borderline sensitivity, but it subsequently emerged that this patient 
was undergoing imatinib therapy at the time the PB sample was taken. One ETV6-PDGFRB 
positive case also underwent colony assay and yielded a clear positive result.  A recently 
characterised PDGFRA translocation, KIF5B-PDGFRA 
105, was marginally inhibited by 
imatinib on colony assay, and did not display any sensitivity in liquid culture, however this 
patient did respond to imatinib when treated.  One patient carrying BCR-PDGFRA did not 
0
0.2
0.4
0.6
0.8
1
1.2
0 1 2 5 7 9
c
e
l
l
 
c
o
u
n
t
 
1
x
1
0
6
time (days)
0µM
1µM
5µM
0
0.2
0.4
0.6
0.8
1
1.2
0 1 2 5 7 9
r
e
l
a
t
i
v
e
 
c
e
l
l
 
n
u
m
b
e
r
time (days)
1µM
5µM101 
show imatinib sensitivity in either assay, moreover, this case did not respond to imatinib 
when administered in vivo, despite literature reports stating BCR-PDGFRA is responsive to 
imatinib 
104,303. 
Of the nine KIT D816V positive SM samples, eight were set up for colony assay and six 
were set up in liquid culture. Only one case was significantly inhibited by imatinib in liquid 
culture, and all cases were unresponsive by colony assay. Overall, this is consistent with 
previously reported resistance of this mutation to imatinib.  
Of the eleven MPN cases carrying JAK2 V617F set up in either liquid culture or colony 
assay, 4/7 displayed a significant sensitivity to imatinib on colony assay, but no JAK2 
V617F positive samples (0/10) clearly responded to imatinib in liquid culture.  Of note, all 
JAK2 V617F positive samples that responded by colony assay were homozygous for the 
mutation, plus a further two homozygous cases were also classed as borderline 
responders in liquid culture. One MPN case carried both KIT D816V and JAK2 V617F point 
mutations, but did not display any sensitivity to imatinib in either assay. The results for 
JAK2 V617F positive cases are at first sight inconsistent with the fact that JAK2 is not 
responsive to imatinib, but it is possible that the colony growth from these cases included 
EPO-independent BFU-Es as a consequence of JAK2 V617F rather than the expected CFU-
GMs. Growth of BFU-Es is known to be inhibited by imatinib, probably as a consequence 
of inhibition of normal KIT.  
Collectively these results indicate that the assays in their current form are far from 
perfect: they do not identify all genuine imatinib responders and several cases that most 
likely have imatinib resistant disease were identified as responders in one or both assays. 
Nevertheless, it is possible that some of the 24 cases with no known mutation that were 
responsive in one or both assays did genuinely have imatinib responsive disease. 
However due to the high cost of treatment none of these individuals actually received 
imatinib and so this remains speculative. Subsequent analysis of these cases by other 
members of the group have thus far failed to reveal any cryptic tyrosine kinase fusion 
genes or imatinib responsive point mutations in these cases and so the reasons for the in 
vitro responsiveness remains unclear. 102 
Certainly it would be highly desirable to have a simple assay that reliably predicted 
imatinib responsive MPNs. In addition to the problems I observed with false positive and 
false negative results, the assays were often difficult to interpret and were very time 
consuming to perform. Potentially some other techniques could be explored, e.g. total 
phosphotyrosine levels have been used to predict response to imatinib therapy in CML 
patients 
304, and measurement of expression levels of the tumour suppressor WT1 have 
been used with some success to predict imatinib sensitivity in CML 
305. More broadly, 
downstream signalling components that are targeted by ABL, PDGFRα and PDGFRβ, could 
perhaps be monitored and used to identify cases with activated tyrosine kinases. An 
example could be phosphorylation of STAT5, which is known to be downstream of many 
activated tyrosine kinases 
301,306 and can be rapidly assessed by flow cytometry 
307. 
However I did not develop any of these techniques or attempt to refine the culture assays 
any further as it became apparent that true imatinib responsive cases that were negative 
for known responsive fusions were in fact very rare. For example in the study that first 
identified FIP1L1-PDGFRA, Cools et al. analysed 16 imatinib responsive cases of which 
only 9 (56%) tested FIP1L1-PDGFRA positive. However in a more recent trial of imatinib in 
HES, Baccarani et al. (2007) found that some FIP1L1-PDGFRA negative cases did appear to 
respond haematologically to imatinib but the responses were transient and all relapsed 
within approximately one year, strongly suggesting that the responses were a 
consequence of non-specific myelosuppression. In previous studies these cases may well 
have been considered erroneously as true imatinib responders 
308. 
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4.4  The utility of JAK2 V617F as a molecular marker for predicting 
treatment response in PV  
The seminal discovery of JAK2 V617F furthered the understanding of the molecular basis 
of MPN, and its presence confirms the diagnosis of a clonal disorder instead of a reactive 
process. Here I describe one of the first studies to use V617F as a molecular marker of 
disease in PV as a means to gauge response to treatment. V617F is a very suitable 
candidate for this role, as nearly all PV cases are V617F positive. Furthermore, the level of 
V617F is also associated with more severe disease; specifically higher haematocrit, lower 
mean cell volume, higher white blood cell count, vascular complications and myelofibrosis 
273,275.  Measurement of JAK2 V617F levels is thus prognostically important throughout 
the clinical course of affected patients. 
Traditionally, many PV patients receive phlebotomy to reduce red cell mass. Because 
patients treated only by venesection are more likely to suffer thrombosis or haemorrhage 
which is frequently fatal, myelosuppressive therapy is also administered. Drugs such as 
chlorambucil and radioactive phosphorus are rarely used nowadays due to the potential 
for promoting leukaemic transformation 
309. Hydroxyurea (HU) is currently the 
cytoreductive treatment of choice, because of its effectiveness, convenience and low 
cost, but a potential for leukaemia may still exist 
310 
311 especially in patients who develop 
post-polycythaemic myelofibrosis and who have been treated with other agents 
312-314. 
Despite conventional treatment with phlebotomy and HU, many patients can experience 
night sweats, pruritus, and develop iron deficiency 
315. Anagrelide and rIFNα may be 
prescribed in certain cases. It has been reported that rIFNα may induce long term 
remission in PV but at the cost of appreciable side effects 
316-319. More recently, 
experimental trials have indicated that the majority of PV patients treated with imatinib 
achieved complete or partial haematological responses. Imatinib has been shown to be 
effective in reducing phlebotomy requirements in PV and often results in a reduction of 
spleen size, but it has not been reported to lower elevated platelet counts 
242,244,320. 
Occasional reports have shown that rIFNα or imatinib may induce cytogenetic responses 
in some PV cases 
316 however most individuals do not present with a chromosome 
abnormality 
265,295,321, and thus it has not been generally possible to gauge the depth of 104 
any treatment-related responses. Therefore, the isolation of JAK2 V617F in the majority 
of PV cases, together with the use of relatively sensitive methods of detection, makes 
monitoring treatment responses at the molecular level a real possibility.  
 
4.4.1.1  Study design 
To undertake this study, we collaborated with Dr R. Silver, a clinician based in New York, 
US, who provided the samples from PV patients undergoing treatment with imatinib and 
rIFNα. I established the JAK2 V617F status of each case, and samples from JAK2 V617F-
positive patients were then quantified before and during treatment by pyrosequencing.  
In total 111 patients were studied, of whom 21 had undergone treatment in two 
sequential phase II single institution studies. Seven cases received rIFNα in the first study, 
where IFNα was administered as an initial dose ranging from 1MU three times weekly to 
3MU daily. These patients had a median follow up of 60 months ranging from 13 to 132 
months. Fourteen cases received imatinib in the second study, where the initial dose 
administered ranged from 400 to 800mg daily, and these patients had a median follow up 
of 17 months, ranging from 5 to 31 months. The 90 remaining patients comprised the 
control group and were either untreated or treated by phlebotomy only, HU and/or 
anagrelide.  
Clinical responses were assessed by Dr R. Silver, who classified the haematological 
response as either complete haematological response (CR), partial haematological 
response (PR) or no haematological response (NR). The criteria used to determine 
response to treatment were based on that set by the Polycythemia Vera Study Group, 
and are listed in table 4.3.  
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(A) 
  CR  PR 
Phlebotomy   No requirement  No requirement 
Haematocrit  Sustained at <45% for men and 
<42% for women 
Sustained at <45% for men and 
<42% for women 
Platelet count  ≤ 600x10
9/L  600 to 1000x10
9/L 
 
(B) 
  CR  PR 
Phlebotomy   No requirement within first 18 
months of treatment 
No requirement within first 18 
months of treatment 
Haematocrit  Sustained at ≤45% for men and 
≤42% for women 
Sustained at ≤45% for men and 
≤42% for women 
Platelet count  ≤ 400x10
9/L  > 400x10
9/L 
Spleen size  Absent spleen, if initially 
palpable 
Spleen reduced to ≤50% 
original size, if initially palpable 
 
Table 4-3. Criteria used to measure haematological response of PV patients undergoing treatment 
with (A) rIFNα and (B) imatinib. 
 
4.4.1.2  Results 
AS-PCR detected JAK2 V617F in 82/90 (82%) of the control PV cases, and in all 21 cases 
undergoing treatment with imatinib and rIFNα indicating that neither therapy eradicated 
JAK2 V617F. To quantitate the level of disease I then used a pyrosequencing assay, which 
measures the proportion of alleles that have the V617F mutation. A description of the 
clinical details and V617F measurement for each patient who received imatinib and rIFNα 
is shown in table 4.4.  106 
 
(A) imatinib  Patient 
identifier 
sex  Age at diagnosis 
(years) 
Dose (mg/day)  F/U 
(months) 
Response  %V617F on 
treatment 
%V617F pre-
treatment 
  1  M  26  800  5  NR  44  nd 
  2  F  60  700  5  PR  41  34 
  3  M  49  800  9  NR  89  71 
  4  F  67  500  9  PR  91  88 
  5  M  58  400  10  PR  72  nd 
  6  M  48  800  15  PR  57  40 
  7  M  31  800  17  PR  76  63 
  8  F  48  500  17  CR  8  25 
  9  F  28  800  19  PR  83  82 
  10  M  72  400  21  NR  72  nd 
  11  M  54  300  24  CR  21  44 
  12  M  43  400  25  PR  60  40 
  13  M  30  600  25  PR  19  nd 
  14  M  53  700  31  PR  30  nd 107 
(B) rIFNα  Patient 
identifier 
sex  Age at diagnosis 
(years) 
Dose  F/U 
(months) 
Response  %V617F on 
treatment 
%V617F pre-
treatment 
  15  F  32  3MU three 
times/week 
13  CR  19  nd 
  16  F  39  3MU/5 
days/week 
45  CR  39  nd 
  17  M  53  3MU/day  50  CR  29  nd 
  18  F  48  4MU/alternate 
days 
60  PR  87  nd 
  19  M  42  2MU three 
times/week 
60  CR  27  nd 
  20  M  52  4.25MU three 
times/week 
108  CR  22  nd 
  21  M  39  3.5MU/day  132  CR  25  nd 
 
Table 4-4. Summary of patient characteristics and results for cases undergoing therapy with (A) imatinib and (B) rIFNα. Abbreviations: nd, not 
determined; NR, no response; PR, partial response; CR, complete response; MU, million units; F/U, follow up (equals time of sampling) after starting 
treatment with imatinib or rIFNα.108 
As shown in Figure 4.6, the results showed that the median percentage of mutated JAK2 
alleles (%V617F) did not differ significantly between the imatinib treated cases (median 
59%, range 8-91) and the V617F positive cases from the control group (median 53%, 
range 5-100). The %V617F was lower in the rIFNα treated cases (median 27%, range 19-
87) compared to controls (p=0.03). This apparent difference may simply reflect the high 
proportion of cases in this selected group who had achieved CR, and not necessarily any 
preferential inhibitory effect of rIFNα over imatinib. 
 
 
Figure 4-6. Levels of JAK2 V617F in treated and control PV cases. (A) Comparison of %V617F in 
control (n=82), mutation-positive PV cases who were not treated with imatinib or rIFNα and 
patients who were treated with imatinib (n=14) or rIFNα (n=7). Vertical lines indicate the range of 
results, open boxes indicate the interquartile range and thick horizontal lines indicate median 
values. 
%
 
V
6
1
7
F
 
100  
80 
60 
40 
20 
0 
control 
n=82 
imatinib 
n=14 
rIFNα 
n=7 
P=0.96 
P=0.03     109 
The results from molecular analysis on the imatinib treated patients revealed the median 
%V617F for individuals with NR, PR and CR were 72% (44-89; n=3), 60% (30-91; n=9) and 
15% (8 and 21; n=2), respectively. In the rIFNα treated group the single case with a PR had 
87% V617F compared to a median of 26% (19-39) for the six cases in CR. Individuals who 
achieved CR on imatinib or rIFNα (n=8) had a lower %V617F (median 24%, range 20-29) 
than those patients who did not achieve CR (n=13, median=72, range 19-91) and also the 
control group (P=0.001 and P=0.0007, respectively) (Figure 4.7).   
 
 
Figure 4-7.Comparison of %V617F levels in control PV cases (n=82) and patients who showed CR 
(n=8), PR (n=10) or NR (n=3) following therapy with imatinib or rIFNα.  
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To determine more precisely the magnitude of any change as a consequence of therapy, 
we compared %V617F levels in pre- and post-treatment samples for 9 of the imatinib 
treated cases. Pre-treatment samples (stored bone marrow slides) were obtained 
retrospectively and not available for the other cases. Of these nine cases, the seven who 
showed NR or PR on imatinib showed a marginal increase (median 1.2 fold, range 1.0-1.5) 
in the percentage of V617F alleles on treatment. In contrast, the two patients who 
achieved CR showed a two to three fold reduction in %V617F on treatment (Figure 4.8). 
Subsequent to the publication of this study we identified one patient who achieved CR on 
rIFNα for whom a pre-treatment sample was available. In this case there was also a 
fifteen-fold reduction (from 61% to 4.1%) in %V617F levels upon treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-8.Changes in %V617F on imatinib therapy. %V617F was measured before starting 
imatinib and at various times whilst on therapy for 7 patients who showed NR (blue line) or a PR 
(green line), and two cases who showed a CR (red line). 
 
To confirm that the changes observed in this study were not due to differences in %V617F 
between PB and BM, I compared the %V617F levels in contemporaneous PB and BM 
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specimens taken from 11 control PV patients. Very similar levels V617F mutant alleles 
were observed in blood and marrow in all cases, with an overall correlation coefficient of 
0.97 (Figure 4.9).  
 
 
 
Figure 4-9.Comparison of JAK2 V617F level in PB and BM from 11 control PV cases. 
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4.5  Discussion 
4.5.1  JAK2 V617F is a useful molecular marker for monitoring PV patients treated with 
imatinib and rIFNα  
The discovery of JAK2 V617F prompted a revision of the World Health Organisation 
classification of Hematopoietic and Lymphoid Neoplasms (2008) 
22 which now quotes 
V617F as a major diagnostic marker of myeloproliferative disease. Although the precise 
pathogenetic contribution of the mutation remains unclear, V617F is an attractive 
candidate with which to monitor minimal residual disease and evaluate treatment 
efficacy. Here I described the first attempts at using V617F to gauge the depth of 
response of PV patients treated with imatinib and rIFNα. Both these therapies have been 
reported to induce remission in PV patients, but the responses have not previously been 
investigated at the molecular level. I found all patients undergoing imatinib or rIFNα 
therapy remained strongly positive for JAK2 V617F, although there was a significant 
reduction in the median percentage of mutant alleles that correlated with haematological 
response. In addition, individuals who achieved complete haematological remission had 
lower levels of V617F than those who did not. Pre-treatment samples were available for 
nine imatinib-treated cases, and of these seven with no or partial haematological 
responses showed a marginal increase in the percentage of V617F alleles on treatment 
(median 1.2 fold, range 1.0 to 1.5), whereas the two patients who achieved complete 
haematological remission showed a 2 to 3 fold reduction. These results indicate that 
although PV patients may benefit from therapy with rIFNα and imatinib, patient 
responses at the molecular level are relatively modest.  
The magnitude of these responses contrasts strongly with CML, in which many individuals 
experience a 1000 fold or greater reduction in BCR-ABL levels, following treatment 
298,322. 
Imatinib is a selective inhibitor of ABL, PDGFR, KIT and FMS tyrosine kinases but is not 
active against JAK2. It is known that KIT signal transduction pathways are required for 
erythropoiesis 
323,324 and it is possible that the observed clinical benefits of imatinib in PV 
are a consequence of KIT inhibition.  113 
Similar findings were subsequently reported by the Nordic MPN study group who 
described a limited effect on V617F levels during two years of pegylated rIFNα therapy 
325. In this study, eight V617F-positive patients receiving pegylated rIFNα, achieved 
complete haematological remission after 24 months. Of these eight cases, only five 
demonstrated a 1.2 to 3.6 fold reduction in V617F burden.  
The results in both this study and my work were taken from a limited group of available 
patients investigated retrospectively and it cannot be excluded that other PV patients 
might exhibit more substantial molecular responses. Indeed, Kiladjian et al. (2006) 
326 
undertook a prospective evaluation of V617F as a molecular marker in a phase 2 study of 
pegylated rIFNα (peg-IFNα) in PV patients, with a median followed up time of  11 months. 
In 24 out of 27 PV patients, a mean average decrease from 49% to 27% V617F levels was 
observed following treatment, and in one case mutant JAK2 was no longer detectable 
after 12 months. Furthermore, the authors recently published results from a multicenter 
phase 2 trial of treatment of V617F-positive PV with peg-IFNα-2a, a modified form of 
rIFNα, with higher efficacy and better tolerance 
327. Out of 37 evaluable patients, all 
displayed a haematological response at 12 months follow up, including 94.6% who 
achieved a complete haematological response. V617F levels were monitored in sequential 
samples from 29 patients, and the level of V617F decreased progressively in 26 cases, 
from a median average of 45% V617F before peg-IFNα-2a, to 3% after 36 months. In 
seven cases, the levels of V617F were reduced below the limits of detection. The authors 
conclude peg-IFNα-2a is very effective at inducing high rates of haematological and 
molecular response in PV, and may even eliminate the JAK2 mutant clone in selected 
cases. However, the real-time PCR-based method of detecting JAK2 V617F employed in 
this study was sensitive to only approximately 1% mutant level, so the potential for a 
persisting low level of mutation-carrying cells that survive peg-IFNα-2a cannot be ruled 
out. Indeed, one patient with PV who achieved complete molecular response with peg-
IFNα-2a after two months treatment, discontinued treatment and V617F reappeared 
shortly afterwards 
328.  
Altogether, these preliminary data suggest that even in sustained haematological 
remission under rIFNα treatment, the malignant myeloproliferative clone remains present 
in the majority of JAK2 V617F positive cases, and treatment should continue even if 114 
molecular remission appears to be reached. IFNα is known to exert a general anti-
myeloproliferative effect by targeting cytokine and haematopoietic cells and exerting a 
non-specific influence on cell-mediated and humoural immune responses, but its precise 
mechanism of action remains to be understood.  
Measurement of JAK2 V617F has also been used to assess the molecular effect of V617F-
positive MPN following other therapeutic strategies. The efficacy of HU has been 
evaluated in a large series of V617F-positive ET cases. Campbell et al. (2005) reported a 
superior haematological response in V617F-positive ET patients compared to patients 
with wild-type JAK2 receiving HU treatment 
329. Furthermore, a recent study also 
describes a two-fold reduction in V617F levels in three quarters of V617F-positive PV and 
ET patients being treated with HU 
330. 
Similar studies have also provided insights into the correlations between JAK2 V617F 
mutant allele burden and disease phenotype. A significant decrease of BM JAK2 V617F 
allele burden was associated with haematologic improvement in three patients with post-
PV MF and a del(5)(q31) abnormality,  who underwent  treatment with lenalidomide 
331. 
However, a case with V617F-positive chronic eosinophilic leukaemia achieved a complete 
molecular response obtained after IFNα-2a treatment but did not display evidence of any 
significant haematological improvement 
332.  The effect of dose-reduced allogeneic stem 
cell transplantation for cases with JAK2 V617F-positive MF was also evaluated at the 
molecular level, using a real time PCR assay to detect V617F that claimed to have a 
sensitivity of down to 0.01%. A total of 21 JAK2 V617F positive cases underwent stem cell 
transplantation procedures, and 78% became negative for V617F suggesting complete 
molecular remission. Furthermore, in those patients who eventually relapsed, variation of 
V617F allele burden correlated with the clinical course 
333. 
Taken together therefore, these observations indicate that the clinical manifestation of 
MPN and changes in V617F allele burden are associated in most instances. However, it is 
premature to conclude that modest reductions in V617F allele burden indicate clinical 
benefit although some studies, including mine, demonstrate that molecular responses 
correlate with haematologic improvement following treatment. Some people have 
argued that since the majority of cases that have achieved haematological response 115 
remain V617F-positive, this suggests that alternative pathogenic mutations may co-exist 
with JAK2 V617F. Together with studies comparing clonality based on X chromosome 
inactivation patterns and co-existing cytogenetic abnormalities alongside the JAK2 
mutation, this implies V617F could be a secondary genetic event 
268,271,334. More recently, 
a variety of JAK2 inhibitors have been trialled in MPN. Early results indicate that patients 
with advanced disease may benefit from treatment, i.e. they feel better and experience 
reductions in spleen size, but disappointingly any reductions in the clone size as 
determined by the %V617F are very modest 
335-338. 
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5  Assessment of methods for detecting JAK2 exon 12 mutations 
5.1  Introduction 
Investigations into the molecular pathogenesis of the 5% of PV cases that are V617F 
negative revealed that a significant proportion carry mutations in exon 12 of the JAK2 
gene 
266. Mutations in exon 12 span nucleotides 1606 to 1635 and are significantly 
different to V617F in that typically more than one base is altered by insertion, deletion 
and substitution, or combinations of all three. The net effect appears to be either amino 
acid substitution, deletion of one or more residues, or duplication of a small number of 
residues, all of which conserve the reading frame of the protein. Exon 12 mutations affect 
residues lying approximately 80 amino acids before V617, a region which contributes to 
the SRC homology (SH2) domain and beginning of the JH2 domain. Although the structure 
of the JAK2 protein has yet to be fully elucidated 
149, homology-based molecular 
modelling suggests these regions are near the predicted loop that carries V617 in a 
theoretical model of the full-length JAK2 protein 
339. Furthermore, like V617F, in vitro 
analysis has shown that JAK2 exon 12 mutations activate pathways associated with 
erythropoietin signalling, and in a murine model expression of one of these exon 12 
mutations resulted in a MPN phenotype 
266. Data has emerged suggesting exon 12 
mutations are associated with a particular clinical phenotype, namely a relatively isolated 
erythrocytosis, with normal levels of leukocytes and platelets
340. This marked 
erythrocytosis is associated with low serum erythropoietin levels 
341,342, however these 
features are not sufficiently distinctive for individuals with exon 12 mutations to be 
recognised by clinical phenotype alone. Indeed, exon 12 mutations have also been found 
in cases of idiopathic erythrocytosis (IE) as well as PV.   
Subsequent to the initial report describing mutations in exon 12, further cases with novel 
sequence changes have been described, summarised in Figure 5.1. The significance of 
each particular sequence change is not yet known, but mutations F537_K539delinsL, 
H538QK539L, N542_E543del and K539L all induce IL3-independent growth of the factor 
dependent cell line Ba/F3/EPOR, with very similar proliferation kinetics to one another, 
and to V617F 
266. Interestingly, these experiments showed all exon 12 mutations were 117 
more strongly activating (i.e. higher phosphorylation levels of substrate proteins) than the 
V617F allele. This supports the hypothesis that stronger signalling induced by, for 
example, homozygous V617F and now exon 12 mutations, is associated with a more 
erythroid phenotype, whereas weaker signalling is associated with a phenotype with 
elevated platelets 
281,343.  118 
 
Figure 5-1. Different JAK2 exon 12 mutations identified to date. DNA, amino acid sequence and position, followed by a list of the different exon 12 
mutations identified, and the number of cases reported in the literature are indicated 
266,341,342,344,345. Nucleotide deletions are indicated by a dash, 
substitutions are in blue and nucleotide insertions are in red. Continuation of sequence to the line underneath is indicated by a comma. 119 
Exon 12 mutations were originally discovered by a sequencing screen of DNA extracted 
from EECs cultured from V617F negative PV patients, as this greatly enriches for mutant 
alleles that may not be detectable by normal sequencing 
266. The culturing of patient 
material prospectively to find exon 12 mutations is very time consuming and thus not 
widely applicable in a diagnostic setting. A more sensitive method, AS-PCR, was therefore 
developed to detect the four mutant alleles that were first identified (K539L, 
N542_E543del, F537_K539delinsL and H538QK539L) in order to screen more cases 
266. A 
number of subsequent publications used a combination of direct sequencing and AS-PCR 
to screen V617F negative PV cases for exon 12 mutations 
341,346,347. AS-PCR is a relatively 
sensitive method 
341, but four individual PCRs must be performed per sample and only 
pre-defined mutations are detected, precluding the isolation of most other sequence 
changes. Direct sequencing is potentially able to detect all mutations, but is a relatively 
insensitive technique that is not generally able to detect mutations when present in less 
than 20% of alleles. Since exon 12 mutation-positive cells are often present at low levels 
in PB compounded by the finding that, in contrast to V617F, cells carrying exon 12 
mutations are nearly always heterozygous 
266, alternative methods of detection are 
needed.  
 
5.1.1  Aims 
To help address the shortcomings of presently available methods, the aim of this part of 
the study was to develop and apply alternative sensitive and generally applicable PCR-
based techniques to identify exon 12 mutations in V617F negative PV and IE. To this end I 
developed and evaluated two methods: HRM analysis and wild-type blocker PCR. 
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5.2  Methods 
5.2.1  HRM reaction conditions 
A 126 bp amplicon was generated using primers located in JAK2 exon 12 and intron 12 
(JAK2_ex12_HRM_F and JAK2_ex12_HRM_R, primers sequences listed in Appendix III). 
Each 20µL PCR contained 20-40ng DNA or 1x10
6 plasmid copies, 0.5U Platinum Taq 
polymerase (Invitrogen, Paisley, UK), 2.5mM MgCl2, 1x Platinum Taq polymerase buffer 
(Invitrogen), 200µM dNTPs, 0.5µM of each primer, and 1x LC Green Plus (Idaho 
Technologies, Salt Lake City, UT, USA) as the intercalating dye. PCRs were performed in 
duplicate, and the cycling and HRM analysis conducted on a RotorGene 6000™ real-time 
analyser (Corbett Life Sciences, Mortlake, NSW, Australia). The PCR profile was as 
follows; an initial hold at 95°C for 10 minutes, 40 cycles of 95°C for 15s, 58°C for 30s, and 
72°C for 20s, followed by 50°C for 30s, then a melt from 70°C to 95°C rising at 0.1°C per 
second (the speed of data acquisition was up to 1000 data collection points per °C 
transition).  
Normalisation bars were between 72°C and 75°C for the leading range, and 92°C and 
93°C for the tailing range. The resulting data were analysed using the associated custom 
software (RotorGene Series Software V1.7.25). All samples and mutation-carrying 
plasmids were run alongside a series of at least six normal controls whose combined melt 
profile characteristics were used as a standard reference that the software used to 
distinguish normal from variant melt profiles, with a confidence of 90%. 
 
5.2.2  Wild-type blocking PCR (WTB-PCR) 
WTB-PCR was performed in duplicate on 25ng DNA or 1µl plasmid dilution (1x10
6 copies) 
using 0.5µM JAK2 exon 12 forward and reverse primers (JAK2_ex12_WTB_F and 
JAK2_ex12_WTB_R), 1U Amplitaq DNA polymerase Stoffel fragment (Applied Biosystems, 
Foster City, CA, USA), 10x Stoffel buffer (Applied Biosystems), 0.2mM dNTPs (Amersham), 
3.75mM magnesium chloride, 1µM JAK2 exon 12 LNA oligonucleotide 
(JAK2_ex12_wtLNA_oligo), made up to 25µl with sterile distilled water. WTB-PCR was 
conducted on a Tetrad thermocycler (MJ Research), under the following conditions; 95°C 121 
for 10 minutes, 30 cycles of 94°C for 1 minute, 57°C for 1 minute and 72°C for 1 minute, 
and a final extension of 72°C for 10 minutes. Ten microlitres of each PCR was run on a 
1.5% gel to check for amplification. PCR products were sequenced directly depending on 
band intensity. If the PCR product was weak or not visible, a second round of PCR was 
carried out by diluting the WTB-PCR product 1:50 in sterile distilled water, and nested 
into the second PCR. The second PCR conditions were 1µl diluted product from the first 
PCR, 0.5µM forward primer (JAK2_ex12_WTB_F2), 0.5µM reverse primer 
(JAK2_ex12_WTB_R2), 1U Amplitaq Gold (Applied Biosystems), 10x Amplitaq buffer 
(Applied Biosystems), 0.2mM dNTPs, 1.5mM MgCl2 and distilled water to a final volume 
of 25µl. PCR amplification was conducted as described above, except the melting 
temperature was 60°C.  
 
5.2.3  Sequencing HRM products 
HRM products were treated with ExoSAP, purified and sequenced. 
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5.3  Results 
5.3.1  Application of high resolution melt (HRM) analysis to JAK2 exon 12 
5.3.1.1  Rationale and background 
HRM analysis is an established method of detecting mutations in a short region of DNA, 
and involves the precise monitoring of the progressive change in fluorescence caused by 
the release of a saturating intercalating DNA dye from a DNA duplex as that duplex is 
denatured by increases in temperature 
348. DNA duplexes each have a characteristic 
melting behaviour that is subtly altered by nucleotide substitutions, deletions and 
insertions, and these melting differences are resolved by the release of an appropriate 
intercalating DNA dye, such as LC Green. This methodology has been successfully used to 
screen patient samples for JAK2 V617F 
349,350, plus other clinically relevant genes such as 
KIT 
258, BRAF, 
351, EGFR, HER2, 
352 RET 
353 and KRAS 
354. The HRM approach to mutation 
detection is advantageous in that it can theoretically detect any nucleotide changes 
within the amplicon being analysed. Furthermore, once established it is a simple and 
quick method whereby the melt analysis is performed immediately following PCR 
amplification. The PCR product can then be sequenced to confirm the presence of a 
mutation, and to identify the affected nucleotides. 
 
5.3.2  HRM analysis validation and determination of sensitivity level 
For optimal sensitivity, HRM amplicons must span the minimal region of interest using 
primers that amplify exponentially during PCR, whilst avoiding if possible any inherited 
polymorphisms that also affect the melt behaviour of the amplicon. In this study, PCR 
primers were designed to amplify a 126 bp region that spanned the entire coding region 
of exon 12.   
Initially HRM was evaluated on a series of 30 normal controls plus a patient carrying F537-
K539delinsL, at a level that was known to be detectable by sequencing and AS-PCR. The 
normal controls produced similar melt profiles whereas the case carrying a mutation 
produced a clearly variant melting profile. As only limited material from patients positive 
for exon 12 mutations was available, optimisation of the method was subsequently 123 
performed on plasmids encoding the various mutant alleles, and sensitivity levels were 
determined on dilution series of mutant plasmids into a plasmid carrying the wild-type 
allele. A series of pGEM-T plasmids containing cloned inserts for several exon 12 mutation 
were provided by Dr Linda Scott, Cambridge. For the dilution series to test assay 
sensitivity, I created a wild-type plasmid using primers JAK2_ex12_WTB_F and 
JAK2_ex12_WTB_R, to amplify normal human genomic DNA. The amplicon was cloned 
into PCR-4 for propagation. Plasmids were used at a concentration of 1x10
6 copies/µL 
diluted in 0.1X TE containing 50µg/ml tRNA.  
HRM analysis was first trialled on plasmids diluted 50:50 into wild-type, as at this 
concentration the test sample should contain the highest possible ratio of 
heteroduplexes. Mutant alleles tested were F537-K539delinsL, H538-K539delinsL, 
H538QK539L, K539L, R541-E543delinsK, N542-E543del or E543-D544del, and all produced 
variant melt profiles on HRM. HRM data is presented in two formats: the first is a 
normalised plot (Figure 5.2A), in which the amount of intercalating dye remaining at 
temperature point is expressed as a fraction of the amount prior to data acquisition. The 
second is a difference plot, where the average HRM profile of the control samples was 
used by the genotype function of the machine software as the standard wild-type profile 
for subsequent comparison to each of the test samples (Figure 5.2B). Analysis of these 
seven mutant samples demonstrated that each mutant allele has its own characteristic 
melting curve that was clearly distinct from those obtained when wild-type exon 12 
samples were analysed. The individual nature of the mutant melting curves became more 
apparent when the data were represented in a difference plot. Interestingly, those 
mutations that had in common a K539L substitution had similar difference plots, with the 
greatest divergence between mutant and wild-type profiles occurring at approximately 
79
oC. The difference plots for the R541-E543delinsK, N542-E543del and E543-D544del 
mutants had a different slope to those associated with a K539L substitution, and the 
greatest divergence between mutant and wild-type occurred at approximately 77.5
oC. 
These differences were seen consistently over multiple runs. 
The ability of HRM analysis to detect low levels of exon 12 mutations in a background of 
normal DNA was evaluated by titrating each of the mutant alleles with wild-type exon 12 
to produce using a range of mutant allele dilutions (100%, 50%, 20%, 10%, 5% and 1%). 124 
HRM was then applied to the dilution series made from each of the mutant alleles. An 
example of the difference plots obtained for the F537-K539delinsL and N542-E543del 
mutations are depicted in Figure 5.3. 
The lower limit for detecting the nucleotide changes in JAK2 exon 12 was calculated by 
the RotorGene Series Software (using a confidence interval of 90%) to be 5% for F537-
K539delinsL and N542-E543del alleles, 7% for the R541-E543delinsK and E543-D544del 
alleles, 10% for the K539L allele, and 20% for the H538-K539delinsL and H538QK539L 
alleles. These data were also used as a guide to estimate the mutation level for two 
patients with a F537-K539delinsL or a N542-E543del mutation. Patient 1 (PT1; labelled 
‘query’ in Figure 5.3A) appeared to have a mutant allele burden of approximately 50%, 
consistent with all granulocytes being heterozygous for the F537-K539delinsL mutation, 
whereas Patient 2 (PT2; labelled ‘query’ in Figure 5.3B) had a mutant allele burden 
greater than 20%, but less than 50%. The estimates obtained using HRM analysis 
accorded well with the estimates independently obtained from granulocyte DNA 
sequence traces (data not shown).   125 
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Figure 5-2. Development of a high-resolution melting-curve (HRM) assay to detect JAK2 exon 12 mutations. A) HRM analysis of six wild-type exon 12 
samples and 50:50 mixtures of wild-type and each exon 12 mutation. All mutant alleles have a melting curve profile that is distinct from that of the wild-
type allele. B) Difference plots demonstrate more clearly that each mutant allele has its own characteristic melting curve, with those alleles with 
deletions of residues that include E543 (red; E543_D544del, purple; R541_E543delinsK, orange: N542_E543del) having a similar curve that is distinct 
from those alleles containing a K539L substitution (blue; K539L, brown; H538QK539L, dark green; F537_K539delinsL and light green; H538_K539delinsL).  126 
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Figure 5-3. HRM assays detect mutant JAK2 alleles present at low frequency. HRM analysis of mixtures of wild-type and mutant JAK2 exon 12 alleles 
demonstrate that these assays can detect relatively low levels of mutant allele. Examples are shown for the F537_K539delinsL (A) and the N542_E543del 
mutations (B). Also included are the HRM traces of two granulocyte DNA samples from patients previously shown to carry the respective exon 12 
mutation (indicated on each figure as ‘query’). 127 
5.3.3  Development of a novel wild-type blocking PCR for the detection of existing and 
novel JAK2 exon 12 mutations  
 
The sensitivity with which some mutations could be detected by HRM was disappointingly 
low, e.g. only 20% for the H538-K539delinsL and H538QK539L alleles. For V617F it is 
generally considered that a sensitivity of 1-2% is required for routine analysis and 
presumably therefore it would be desirable for exon 12 mutation assays to have a similar 
sensitivity. An alternative method of detecting exon 12 mutations was therefore 
investigated, with a focus on improving the sensitivity of detection above that of the HRM 
methodology, whilst retaining the capacity to detect novel sequence changes. I 
investigated a wild-type blocker (WTB) assay, previously described to amplify BRAF 
mutations in DNA from melanoma samples containing a large proportion of wild-type 
DNA 
355. Central to the WTB-PCR method is a non-extendable oligonucleotide probe with 
locked nucleic acid (LNA)-substituted bases that binds a specific sequence (in this case the 
wild-type allele) with high affinity such that high temperatures do not melt the duplex 
during PCR cycling. The Stoffel fragment of Taq DNA polymerase is used for amplification, 
which lacks the 5’-3’ exonuclease activity of the parent enzyme and thus cannot degrade 
the blocker oligonucleotide. If mutations are present in the target sequence, the affinity 
of the LNA-oligonucleotide and target DNA heteroduplex is reduced sufficiently such that 
the LNA-oligonucleotide is displaced and amplification can proceed. Thus, the LNA-
oligonucleotide specifically blocks amplification of the wild-type sequence; any mutations 
are enriched in the PCR product and can be identified by sequencing. An overview of the 
WTB-PCR principle is outlined in Figure 5.4. 
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Figure 5-4. WTB-PCR strategy. The LNA-oligonucleotide probe anneals to wild-type sequence 
preventing amplification of wild-type DNA. Mismatches in the target sequence prevent the LNA-
oligonucleotide blocker binding and amplification by Stoffel-fragment polymerase can proceed. 
 
In this study, I adapted WTB-PCR for the detection of exon 12 mutations in PB total 
leukocyte or granulocyte DNA samples. An oligonucleotide that contains six LNA-modified 
nucleotides was designed to be complementary to wild-type JAK2 exon 12 sequence 
affected by mutations described in the original report by Scott et al. (2007) 
266. Six LNA-
modified bases were incorporated into the oligonucleotide as this provided optimal 
rigidity for binding target sequence with high affinity, whilst retaining a melting 
temperature so high that the resulting heteroduplex was not destabilised during thermal 
cycling. The position of this LNA-oligonucleotide probe is shown in Figure 5.11. New 
mutations in exon 12 have subsequently been identified after the LNA-oligonucleotide 
probe was designed, and all apart from the relatively rare large insertion mutations, 129 
V536_I546dup11, F537_I546dup10+F547L and 547insL+I540+F547dup8 
342, are covered 
by the LNA-oligonucleotide sequence.  
 
5.3.3.1   Determining WTB-PCR sensitivity in detecting JAK2 exon 12 mutations 
WTB-PCR was optimised on genomic DNA previously identified as positive for F537-
K539delinsL mutation by AS-PCR and by normal sequencing. A concentration of 1μM wild-
type JAK2 exon 12 LNA-oligonucleotide was found to optimally block amplification from 
25ng of wild-type DNA. WTB-PCR was also tested on DNA from 20 healthy normal 
controls, and did not result in the amplification of any false positive /erroneous sequence 
changes in any case. 
The ability of WTB-PCR to detect low levels of exon 12 mutation was evaluated using a 
series of plasmid-dilution experiments for seven different mutations. WTB-PCR was 
performed with and without the LNA-oligonucleotide, and the latter PCR served as a 
control for amplification by Stoffel-fragment polymerase. WTB-PCR products were 
visualised on a 1.5% agarose gel, and those that produced weak bands (those at the 
lowest dilutions of mutant plasmid) were re-amplified by nesting into a second PCR. 
Sequencing confirmed that the presence of the LNA-oligonucleotide enriched the 
proportion of mutant allele on the chromatogram for each exon 12 mutation tested, 
whether the mutation consisted of deletions, substitutions or both. An example of a gel 
picture following first step amplification with and without the LNA-oligonucleotide probe 
on a plasmid dilution series of the F537_K539delinsL allele into wild-type is shown in 
Figure 5.5. 
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Figure 5-5. Gel of WTB-PCR amplification (first step) on plasmid dilutions of wild-type JAK2 exon 
12 and the F537_K539delinsL mutation. PCR amplification with and without the LNA-
oligonucleotide blocker is shown. Without the LNA-oligonucleotide, mutant and wild-type 
sequences are amplified indiscriminately. In the presence of the LNA-oligonucleotide, 
amplification from wild-type exon 12 is blocked and only mutant alleles are replicated by Stoffel-
fragment polymerase.  
 
The LNA-oligonucleotide was shown to inhibit amplification of wild-type sequence thus 
enhancing mutant alleles even at dilutions containing relatively low levels of mutant 
plasmid. Mutant alleles were visible and discernable on the resulting sequencing 
chromatograms down to levels of 1% for all exon 12 mutant alleles tested.  An example of 
the sensitivity of WTB-PCR at detecting the F537_K539delinsL allele is shown in Figure 
5.6. 131 
 
 
Figure 5-6. Sequence traces of WTB-PCR products following amplification of different dilutions of F537_K539delinsL plasmid with and without the LNA-
oligonucleotide blocker. In the absence of the LNA-oligonucleotide blocker the mutation was not detectable below a 10% dilution of mutant into wild-
type plasmid. However, in the presence of the LNA-oligonucleotide, sequencing revealed the presence of the F537_K539delinsL mutation even at a 
dilution of 1%.132 
5.3.4  Screening JAK2 V617F negative PV and IE patients for mutations in exon 12 
The ability of both HRM analysis and WTB-PCR to detect exon 12 mutations was 
evaluated in a direct comparison with AS-PCR in three V617F negative patient cohorts: 37 
cases with IE (Group 1; supplied by Dr Melanie Percy, Belfast), 19 cases with PV (Group 2; 
supplied by Dr Richard Silver, New York) and a further 211 cases (Group 3) acquired 
locally, with a suspected or confirmed diagnosis of PV or IE. Most of these cases provided 
by Dr Percy and Dr Silver were known to have low erythropoietin levels. Due to lack of 
specific consent, detailed clinical information was not available for the local cases. 
The analysis also included positive control DNA from four cases with F537_K539delinsL, 
N542_E543del, and R541_E543delinsK (2 cases) kindly provided by Dr Linda Scott, plus 
plasmid dilution series described above (plasmids carrying F537-K539delinsL, H538-
K539delinsL, H538QK539L, K539L, R541-E543delinsK, N542-E543del and E543-D544del 
mutations). 
 
5.3.4.1  Preliminary screen for JAK2 exon 12 mutations by AS-PCR  
Control plus Group 1 and 2 samples were initially screened using four separate AS-PCRs 
that detect the F537_K539delinsL, K539L, H538QK539L and N542_E543del alleles, as 
described 
266. Of the Group 1 samples, 6 were positive by AS-PCR. Case M2 was positive 
using the H538QK539L allele-specific primer and case M29 was positive for K539L. Cases 
M18 and M39 were positive for both H538QK539L and K539L mutation detecting AS-
PCRs. Cases M42 and M44 were positive by the AS-PCR for F537_K539delinsL.  None of 
the Group 2 samples tested positive (results summarised in Table 5.1). 
 
5.3.4.2   HRM analysis of JAK2 exon 12 in V617F negative cases 
The HRM methodology established using cloned exon 12 alleles was then used to screen 
the PV and IE cases. Each case was run in duplicate, alongside a series of four normal 
controls and the four mutation positive controls. HRM analysis was successful in 
discriminating DNA samples wild-type for JAK2 exon 12 from those carrying an exon 12 133 
mutation. Figure 5.7 shows the results from an HRM screen on eight cases including the 
four positive controls, each of which produced clearly divergent melt profiles.  
Of the test cases in the three patient groups, just four (M7, M18, M40 and E2871) 
produced melt profiles that were consistently variant to that produced by the normal 
controls, suggesting the presence of a mutation (data not shown). Sequencing of the HRM 
product using the primers used for amplification revealed nucleotide changes in each 
case except M40 (results summarised in Table 5.1). 134 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-7. HRM analysis on JAK2 V617F negative patients with PV and IE. The difference plot shows the melting profile of exon 12 amplified from 4 
normal controls, 4 mutation-positive cases (patients A-D)and 4 cases with V617F negative IE (indicated as mutation-negative patients). Granulocyte DNA 
sequence chromatograms from the four mutation-positive cases are shown, with patients A and B having an R541-E543delinsK mutation, patient C 
having a N542-E543del mutation, and patient D having a F537-K539delinsL mutation.135 
5.3.4.3   JAK2 exon 12 mutations detected by WTB-PCR  
WTB-PCR was then conducted on all samples. Fourteen cases were confirmed to carry 
mutations in exon 12 on sequencing of the products. The results are summarised in Table 
5.1 and nucleotide sequence changes are listed in Figure 5.11. An agarose gel picture 
displaying the products following first step amplification by WTB-PCR with and without 
the oligonucleotide probe, on one normal control and six mutation-positive cases is 
shown in Figure 5.8. 
 
Lane identifier  Sample  JAK2 exon 12 mutation identified 
a  E2871  H538_K539delinsL 
b  M2  H538QK539L 
c  M7  I540_E543delinsKK 
d  E596  E543_D544del 
e  M18  K539L plus other clones 
f  M35  N542D_E543X 
 
 
 
Figure 5-8. Gel picture of WTB-PCR on six JAK2 exon 12 mutation positive cases. Gel 
electrophoresis of exon 12 PCR products from first step amplification with and without the LNA-
oligonucleotide blocker for two normal cases (N) and six mutation-positive cases (a to f), with 
corresponding mutation identified listed in Table 5.11. Mutations were identified in cases M2, 
M18 and M35 following sequencing the product from a second round of PCR amplification. 136 
Of the 14 mutation positive cases identified on sequencing of the WTB-PCR product, 
three had novel nucleotide changes that have not been reported elsewhere. Case E2871 
had an H538_K539delinsL change and case M7 had I540_E543delinsKK but for case M18, 
the sequencing trace following WTB-PCR was difficult to interpret (Figure 5.9).  
 
 
 
Figure 5-9. WTB-PCR sequence traces from cases carrying novel mutations in JAK2 exon 12. (A) 
Amino acid number and residue corresponding to the wild-type DNA sequence targeted by the 
blocking LNA-oligonucleotide (indicated by yellow line). The novel sequencing changes are easily 
identifiable as H538_K539delinsL in case E2871 (B) and I540_E543delinsKK in case M7 (C), 
however for case M18 (D), the trace was abnormal but uninterpretable. A comparison of mutant 
sequences to wild-type sequence produced by the Mutation Surveyor 3.1 software is indicated 
below the sequencing trace for each case. A flat central green line indicates sequence homology; 
deletions are deviation above this line and substitutions are indicated by a peak. 137 
 
I therefore cloned the PCR product from case M18 for further investigation. Sequencing 
of 24 individual colonies identified five different clones, each of which carried the AA to 
TT substitution that corresponds to the K539L allele. Additionally, four of these clones 
also carried deletions and/or insertions of one or two nucleotides immediately preceding 
the K539L, resulting in a frame shift that theoretically causes creation of STOP codons 
downstream (Figure 5.10 and 5.11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-10. Clones isolated from WTB-PCR product from case M18. Five different clones were 
identified (panels A to E), each carrying the AA to TT substitution that causes K539L.  
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5.3.4.4  Summary of JAK2 exon 12 mutations detected by AS-PCR, HRM analysis and 
WTB-PCR 
In total 267 cases were analysed for mutations in exon 12 of JAK2 by AS-PCR, HRM 
analysis and WTB-PCR, and 10 cases tested positive for a mutation (in addition to the four 
positive controls), of which 8 came from Group 1, 2 were from Group 2 and none were 
from Group 3. The results are summarised in Table 5.1 and the sequence changes for all 
cases found to carry exon 12 mutations in this study are shown in Figure 5.11. 
Overall, both HRM and WTB detected all four positive controls, whereas AS-PCR only 
picked up two of them. Of the ten mutant cases detected by WTB, six were detected by 
AS-PCR and only three by HRM. 
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group 
case 
identifier 
AS-PCR 
HRM 
analysis 
WTB-PCR 
JAK2 exon 12 
mutation identified 
Controls 
A  negative  variant 
mutation 
visible 
R541_E543delinsK 
B  negative  variant 
mutation 
visible 
R541_E543delinsK 
C  N542_E543del  variant 
mutation 
visible 
N542_E543del 
D  F537_K539delinsL  variant 
mutation 
visible 
F537_K539delinsL 
Group 1 
M2  H538QK539L  negative 
mutation 
visible 
H538QK539L 
M7  negative  variant 
mutation 
visible 
I540_E543delinsKK 
M18 
H538QK539L and 
K539L 
variant 
mutation 
visible 
K539L background, 
some clones with 
STOP codons 
M29  K539L  negative 
mutation 
visible 
K539L 
M38  negative  negative 
mutation 
visible 
F537_K539delinsL 
M39 
H538QK539L and 
K539L 
negative 
mutation 
visible 
H538_K539del 
M42  F537_K539delinsL  negative 
mutation 
visible 
F537_K539delinsL 
M44  F537_K539delinsL  negative 
mutation 
visible 
F537_K539delinsL 
Group 2 
E2871  negative  variant 
mutation 
visible 
H538_K539delinsL 
E596  negative  negative 
mutation 
visible 
E543-D544del 
Table 5-1. Summary of JAK2 exon 12 mutations found in JAK2 V617F negative PV and IE cases. 
Each case was screened by AS-PCR, HRM and WTB-PCR for sequence changes in exon 12.140 
 
 
Figure 5-11. Nucleotide sequence alterations in JAK2 exon 12 identified in this study. Wild-type exon 12 DNA and amino acid sequence are shown, with 
the mutation-positive cases underneath. Nucleotide deletions are indicated by a dash and substitutions are blue. The wild-type blocking LNA-
oligonucleotide target sequence (underlined).141 
5.4  Discussion 
5.4.1  Assessment of AS-PCR, HRM and WTB-PCR at detecting JAK2 exon 12 mutations  
Exon 12 mutations in the JAK2 gene are unusual in that they typically comprise a 
combination of small intragenic deletions, insertions, and substitutions that conserve the 
reading frame. Nevertheless, these diverse abnormalities result in altered growth factor 
responses in vitro and a myeloproliferative phenotype when expressed in a murine BM 
transplant model 
266. Compared with patients with JAK2 V617F-positive PV, patients with 
PV or IE carrying an exon 12 mutation have a clinical phenotype mainly characterised by 
isolated erythrocytosis and low serum EPO 
341,356. Analogous to V617F, the finding of an 
exon 12 mutation strongly indicates the presence of an MPN, so it is important to have 
robust methods of detection to aid diagnosis.  
Since the initial discovery of mutations in exon 12 of the JAK2 gene 
266, other mutations 
affecting the same region have been described. Some of these mutations, e.g. 
I540_E543delinsMK were discovered by enriching for the mutation-carrying cells by the 
expansion of EECs in vitro, then by sequencing across exon 12 
344. In other cases the 
mutations were visible by directly sequencing exon 12 amplified from PB granulocyte 
DNA, e.g. V536_I546dup11 and F537_I546dup10+F547L, indicating a relatively large 
proportion of mutant-allele in the specimen 
342. Application of the four AS-PCRs originally 
designed by Scott et al. (2007) 
266 has contributed to the identification of the majority of 
exon 12 mutation-positive cases described in the literature. Although AS-PCR is more 
sensitive than direct sequencing it targets specific mutations and will therefore miss most 
novel sequence changes. However due to the primer design, some novel variants may be 
detected, for example the E543_D544del mutation was originally identified by 
sequencing, but was also detected by AS-PCR for the N542_E543del mutation 
341. It is 
likely that other cases found to be positive by AS-PCR may carry subtly different 
mutations to those that the PCR was designed to detect. However the opposite may be 
true in some instances: in one case direct sequencing revealed an AAA to CTA substitution 
which caused a K539L mutation, but this was not detected by AS-PCR for K539L, as this 
PCR was specifically designed for the AA to TT substitution 
356.  142 
HRM analysis was used in this study to detect exon 12 mutations, based on the premise 
that this technique detects any possible sequence changes in the amplicon being studied, 
as detection is based on differences in melting behaviour. In theory, HRM analysis should 
be capable of detecting the V536_I546dup11 and F537_I546dup10+F547L mutant alleles, 
as these target bases within the amplicon region, but DNA was not available to assess 
this. I evaluated the sensitivity of HRM using plasmids carrying a series of exon 12 
mutations diluted into wild-type plasmid, and found that HRM was only capable of 
detecting mutation level down to 5% for some mutant alleles, but only 20% mutant level 
for other alleles. Furthermore, whist HRM analysis did detect mutations in all four 
positive controls plus three cases in the screen, there were seven that went undetected 
by this method.  
One likely explanation, as determined by the experiments with mutation-carrying 
plasmids, is the unexpectedly poor sensitivity of HRM, especially in the case of mutations 
affecting histidine 538. The case (M2) that carried a H538QK539L mutation was not 
detected by HRM, consistent with the fact that the detection level for this particular 
mutation is above 15%. Furthermore, the application of HRM as only a pre-screening 
method was demonstrated by the false identification of one case (M40). This case was 
later found to be negative for exon 12 sequence changes by WTB-PCR and sequencing, 
and the false-positive result was attributed to an abnormally high salt concentration in 
the DNA sample, which was later resolved by cleaning the DNA using a Microcon filter 
(following manufacturer’s instructions, Millipore, Watford, UK).  
Because of the low sensitivity of HRM, I sought to develop a PCR based method that 
reduced the amount of wild-type sequence whilst selectively amplifying any mutant 
alleles present. For this I designed a wild-type blocking (WTB) PCR based on an existing 
method published by Dominguez and Koloney (2005) 
355, where this technique was used 
to amplify BRAF mutations in DNA from melanoma samples containing a large proportion 
of wild-type DNA. I designed an oligonucleotide probe containing LNA substituted bases 
that selectively blocked amplification of wild-type exon 12 sequence whilst amplification 
of other regions can proceed. This increases the proportion of mutant alleles so they 
become more visible on a sequencing chromatogram. The sensitivity of WTB-PCR at 
detecting various exon 12 mutations was tested using plasmids carrying a series of exon 143 
12 mutations diluted into wild-type plasmid described above, and all different mutant 
alleles tested were detected readily at a level of 1% mutant. WTB-PCR was then used to 
screen all groups of JAK2 V617F negative PVs and ten cases were positive for an exon 12 
mutation, plus all four controls. Furthermore, WTB-PCR detected novel sequence changes 
in three cases (M7, M18 and E2871):  
•  WTB-PCR on case M7 revealed two small deletions in exon 12 that resulted in an 
I540_E543delinsKK mutation. This was detected by HRM but not by any AS-PCR. In 
addition, the nucleotide deletions are different to those that create the previously 
described I540_E543delinsMK (figure 5.9C).  
•  Case M18 was positive by AS-PCR for both H538QK539L and K539L mutations and 
had a variant melt profile on HRM. However, sequence analysis on the trace from 
WTB-PCR proved difficult to interpret so the WTB-PCR product was cloned for 
further investigation. Sequencing of individual clones revealed five different 
mutations (Figure 5.10). Each clone carries an AA to TT substitution that when 
translated individually corresponds to the K539L mutation, but additionally there 
were also insertions and/or substitutions of one or two T or C nucleotides that 
shift the reading frame introducing a STOP codon immediately downstream. It 
seems likely that the out-of-frame variants are non-functional since premature 
truncation of the JAK2 protein in the pseudokinase JH2 domain would result in 
loss of the entire catalytically active JH1 kinase domain. The presence of these 
multiple mutations, however, is highly unusual and suggests the possibility of 
underlying genetic instability.  
•  The mutation in case E2871 was readily visible upon sequencing the product 
following HRM analysis as H538_K539delinsL. This mutation was then confirmed 
by WTB-PCR. Despite being present at a relatively high level in PB, this mutation 
would not have been detected by an AS-PCR screen alone. In addition, the bases 
mutated to create H538_K539delinsL are different to those reported previously 
346. 
•  The WTB-PCR revealed an E543_D544del mutation in patient E596, plus five DNA 
samples from this patient taken over a period of approximately two years (data 144 
not shown). The mutation was not detected by HRM, nor by AS-PCR, suggesting a 
particularly low level of mutation.  
This last point raises the question what level of mutation is clinically significant? Although 
there is no definitive answer to this question, it is generally considered that assays 
designed to detect V617F should have a sensitivity approaching 1% and therefore it 
seems reasonable that exon 12 mutation assays should have a similar sensitivity. My 
study indicates that WTB-PCR is the most suitable method for detecting exon 12 
mutations since it can detect relatively low level mutations and identify novel sequence 
changes. However there are two important technical issues of the application of WTB-
PCR. Firstly, WTB-PCR works optimally on a low DNA concentration (below 20ng/µl per 
PCR), to avoid saturation of the LNA-oligonucleotide with a high wild-type DNA 
concentration and therefore it is important to accurately quantify test DNAs. Secondly, 
only exon 12 mutations within the region covered by the oligonucleotide blocker may be 
identified by this method. Subsequent to the initial design of WTB-PCR, other mutations 
have been reported in the literature and the wild-type DNA region of all apart from the 
two cases involving the 36 base pair duplications 
342 are covered (at least in part) by the 
oligonucleotide blocker. It is probable other mutations may be found in exon 12 that lie 
outside this region and will not be detected by my WTB-PCR but they could be covered by 
designing additional WTB oligonucleotides. A further weakness is that the test relies on 
the somewhat subjective judgement of visualising an amplification product on a gel after 
the WTB blocker PCR. A more robust approach may be to routinely perform nested PCR 
on all samples, and to sequence the products in each case. Obviously though this 
approach would be more time consuming and expensive. 
Although the identification an exon 12 mutation provides evidence of a clonal disorder 
and is therefore diagnostically and potentially clinically relevant, the significance of each 
particular sequence alteration remains unclear. When four exon 12 mutant alleles, K539L, 
N542_E543del, F537_K539delinsL and H538QK539L, were expressed in Ba/F3 cells in 
vitro, they induced similar levels of IL3-independent cell division and activated signalling 
pathways involved in erythrocytosis. Furthermore, expression of K539L in a murine model 
induced MPN associated with marked erythrocytosis 
266. It is likely that the other (in-
frame) mutations would behave in the same way, but this remains to be formally tested. 145 
Furthermore, it is possible that different sequence changes may be associated with 
clinical variability, however given the rarity of these changes it is unlikely that any 
consistent differences could be recognised.  
There is considerable discrepancy in the frequency of exon 12 mutations in patients with 
V617F negative PV reported in the literature. Some reports describe exon 12 mutations in 
virtually all patients studied 
266,340,344,347 whereas exon 12 mutations were much rarer in 
other studies 
346,356. Apart from clinical phenotype, an obvious reason for this discrepancy 
was the methods of detection used, where studies that relied only on direct sequencing 
detected fewer mutations. Moreover, the source of DNA used for screening affects the 
sensitivity of detection. It is suggested that exon 12 mutations preferentially cause 
expansion of erythroid progenitors within the bone marrow 
266. Screening of BM cells may 
be preferable to PB granulocytes, however this has not been proven. Analysis of EEC 
colonies may result in detection of further cases but it is impractical on a routine basis 
344. 
Treatment is likely to impact on the level of circulating neoplastic cells, so obtaining 
samples at diagnosis is also important in the detection of exon 12 mutations. 
One important conclusion drawn from my study was that the incidence of exon 12 
mutations in JAK2 V617F negative cases referred with unexplained erythrocytosis is very 
rare, even when using sensitive methods of detection. While it is conceivable there may 
be cases with extremely low levels of exon 12 mutation that remain undetected, WTB-
PCR, AS-PCR and HRM failed to isolate any examples of exon 12 mutations in the 211 local 
cases. Although detailed clinical information was not available for these cases, it is likely 
that the great majority did not have an MPN but rather had marginally abnormal blood 
counts that may have been caused by environmental factors such as excess drinking 
and/or smoking (Dr David Oscier, Bournemouth, personal communication). In contrast, 
the analysis of a clinically well-characterised cohort known to have low EPO levels (Group 
1) revealed mutations in 8/37 (22%) of cases, which suggests that mutation testing should 
be highly targeted towards individuals who fulfil the diagnostic criteria for PV, have low 
serum EPO levels and EECs, and do not carry V617F. The pick-up rate of exon 12 
mutations in Group 2 was somewhat lower at 2/19 (11%), however since several of these 
cases had been treated with interferon or imatinib it is possible that the clone size may 
have been reduced to below the sensitivity of detection. 146 
6  JAK2 haplotype is a major risk factor for the development of 
myeloproliferative neoplasms 
6.1  Introduction 
6.1.1  The genetics of JAK2 in MPN 
The presence of the JAK2 V617F mutation has proven to be a definitive pathogenetic 
marker for a subset of Philadelphia chromosome negative MPN. However unlike CML, 
where expression of BCR-ABL drives a largely uniform disease phenotype, V617F has been 
isolated in distinct MPN subtypes that share important features but have different clinical 
characteristics. Isolation of JAK2 V617F in over 90% of cases with PV, roughly half of cases 
with ET and MF 
197-201, plus other, rarer forms of atypical MPN 
252 was unexpected, but 
several lines of evidence have been proposed to account for the phenotypic diversity 
associated with V617F.  
 
(i) Levels of V617F expression. In many cases of PV and MF, the level of V617F is relatively 
high as a consequence of heterozygous cell undergoing mitotic recombination at 
chromosome 9p to become homozygous (acquired UPD), but this event is rare in ET 
198,199,252,281. Clinical studies have indicated that disease phenotype is correlated with 
dosage of the V617F mutant allele, where a higher mutation burden is associated with 
longer disease duration, splenomegaly, raised haematocrit, and the propensity to 
transform to AML 
275,357-359. Furthermore, when expressed retrovirally in transgenic mice, 
the ratio of JAK2 wild-type to mutant allele strongly affects the outcome of disease 
phenotype. Relatively low levels of JAK2 V617F induced thrombocythemia, characteristic 
of an ET-like phenotype, whereas polycythaemia was present in animals with high degree 
of transgene expression 
283.  
 
(ii) Additional acquired mutations. There are several lines of evidence that indicate other, 
largely uncharacterised, acquired abnormalities influence disease phenotype, either in 
combination with or independently of V617F 
360.  The observation that in some cases only 
a proportion of clonal PV cells are V617F positive 
271,361, and the demonstration of clonal 147 
haematopoiesis by X chromosome inactivation pattern (XCIP) analysis in informative 
females with JAK2V617F negative ET 
269,334, are both strong indicators for the presence of 
alternative mutations to JAK2 V617F. Furthermore, it has been shown in rare cases with 
JAK2 V617F-positive PV, that progression to AML is associated with expansion of a JAK2 
V617F negative clone 
262.   
 
(iii) Genetic background. Mouse models have provided evidence to show that the genetic 
background, i.e. the mouse strain may modify phenotype induced by JAK2 V617F.  When 
the JAK2 V617F transgene was expressed in the BM of C57Bl/6 mice, the animals 
displayed erythrocytosis with mild leukocytosis. However, when JAK2 V617F was 
expressed in Balb/c mice, a different genetic background, the mice displayed 
erythrocytosis with dramatically increased leukocyte count and bone marrow fibrosis 
282,362,363. In humans, both epidemiological data and familial MPN studies indicate that 
inherited factors may predispose to the development of MPNs. Familial MPN is 
characterised by a pattern of autosomal dominant inheritance with incomplete 
penetrance, variable presence of the three MPN entities PV, ET and MF in a single family, 
and with clinical and molecular features indistinguishable from sporadic MPN 
204. In all 
cases examined so far, JAK2 V617F and JAK2 exon 12 mutations were acquired 
somatically in the haematopoietic cells of some (but not all) affected familial cases, but 
these mutations were never inherited through the germ-line 
364,365. Therefore, in these 
families an unknown inherited mutation predisposes carriers to somatically acquire JAK2 
mutations and presumably other uncharacterised mutations. With regard to sporadic 
MPN, Landgren et al. (2008) showed, in a population-based approach, an increased risk of 
PV, ET and MF in first degree relatives of patients with known MPNs 
272. If the 
predisposing factor has low penetrance then it might be relatively common in the 
population. Recently, Pardanani et al. (2008) have suggested that inherited single 
nucleotide polymorphisms (SNPs) within JAK2 are associated with specific MPN subtypes, 
providing the first evidence in patients that constitutive host factors contribute to MPN 
phenotype 
366. In this study I aimed to examine these recent findings more closely, and 
further characterise the role of inherited factors in JAK2 V617F-positive MPN.  
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6.1.2  Genetic association studies 
In order to investigate variation within the JAK2 locus I used methods employed for the 
genetic mapping of somatically inherited traits and phenotypes. The smallest unit of 
variation is the SNP, a DNA sequence variant that occurs when a nucleotide differs 
between individuals. Almost all common SNPs have only two alleles, and within a given 
population, SNPs are assigned a minor allele frequency (maf), which is the lowest allele 
frequency at a locus observed in that particular population. SNPs are the most common 
type of genetic variation, and because they are often conserved across populations they 
are useful markers for use in association studies. Genetic association studies aim to test 
whether SNPs are associated with a disease, by comparing results from two different 
groups; disease-carrying subjects and healthy controls. SNPs found to have a significant 
association may themselves be in a biologically relevant locus or may be a marker of 
another nearby genetic change i.e. the association may be due to linkage disequilibrium 
(LD) with the true causal variant. LD describes the observation that alleles that are close 
together in the genome tend to be inherited together. A carefully selected group of these 
SNPs, called tag SNPs, can be used to capture all genetic variation in an LD block. When 
grouped together, SNPs are referred to collectively as a haplotype, and within haplotype 
blocks recombination is rare and LD is high. Therefore, the SNPs within a haplotype block 
are inherited together and the genotype of a single tag SNP can be used to infer the 
genotypes of other SNPs within the block. The strength of the correlation between tag 
SNPs is described using several statistics, but the most useful in association studies is the 
r
2 value. The Pearson correlation coefficient, r
2, is a measure of LD between two genetic 
markers, and values equalling 1 indicate the two SNPs have not been separated by 
recombination, whereas lower values indicate a lesser degree of LD. The size of LD blocks 
depends on the rate of recombination: in areas of low recombination LD blocks may 
extend for hundreds of kilobases whereas in regions of high recombination LD blocks may 
only be a few Kb or less. The definition of LD blocks, haplotypes and tag SNPs across the 
genome have enabled genome wide association studies (GWAS) to be performed. These 
studies have been very successful in detecting common, low penetrance predisposition 
alleles to a variety of disorders 
367. 
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In epidemiological studies it is possible to define statistically the degree of risk associated 
with a particular variant, calculated as a ratio of the probability of the event occurring in a 
group with the phenotype in question versus a control group. There are two expressions 
that define this risk, the Odds-Ratio (OR) and Relative Risk (RR), and the formulae used to 
determine these expressions are described below.  
 
6.1.3  Distortion of SNP ratios in cases with acquired UPD 
Quantification of SNP allele ratios in constitutional DNA samples usually results in a 
polymorphism being defined as homozygous, heterozygous, or nullizygous for a particular 
allelic variant. Haplotypes are typically determined by long range PCR, cloning and 
sequencing to genotype the SNPs, or by statistical inference 
368. However the JAK2 
mutation provided a unique opportunity to read haplotypes directly in cases with 
acquired UPD.  
The mitotic recombination that gives rise to acquired UPD in many patients with PV and 
MF typically involves all or a substantial region of chromosome 9p and thus SNPs within 
this region are also reduced to homozygosity 
199. V617F positive cases that have a high 
level of V617F mutation carry a large homozygous V617F clone, and it is this population of 
neoplastic cells that distorts SNP allele ratios away from the expected 50:50 value that is 
seen in normal and heterozygous V617F cells (Figure 6.1). It should be possible therefore 
to directly read JAK2 haplotypes in cases with homozygous V617F as a consequence of 
distorted SNP allele ratios (Figure 6.2). Haplotypes provide more power for genetic 
association studies since they more accurately describe the genetic variation in any region 
whereas tag SNPs are often strongly but not completely associated with any particular 
haplotype. 
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Figure 6-1. Acquired UPD duplicates JAK2 V617F and flanking heterozygous SNPs to homozygosity. 
Many heterozygous SNPs span chromosome 9 (heterozygosity is illustrated here as A:a, B:b, C:c at 
each locus).  V617F (indicated by an asterisk) arises on one chromosome (blue), without affecting 
the ratio of heterozygous SNP allele ratios close by. If the region carrying V617F undergoes mitotic 
recombination, the mutant allele becomes duplicated onto the other (green) chromosome and all 
flanking SNPs are also reduced to homozygosity. 151 
 
Figure 6-2. Heterozygous SNP allele ratios are skewed by high levels of acquired UPD. Many 
heterozygous SNPs span wild-type JAK2, but it is not possible to say which allelic variants are 
associated with one another, only that the ratio is 50:50. If JAK2 V617F (illustrated by the asterisk) 
is present at levels ranging from 50 to 90% (panel A), clonal expansion will skew heterozygous SNP 
ratios so that the all SNP alleles linked in cis to the mutation are selected for. By measuring SNP 
allele ratios quantitatively a combination of linked SNP alleles (haplotype) can be read from the 
distorted SNP allele ratios. In this example, the haplotype associated with V617F is abaab, and the 
residual wild-type haplotype can also be determined (babba). In some cases with a very high level 
of mutation (≥90% V617F) (panel B), all heterozygous SNP ratios are reduced to homozygosity by 
the mutant positive clone, so the normal background cannot be seen. 
 
6.1.4  Aims 
Initially, the aim of this study was to try and confirm or refute the association between 
particular JAK2 variants and certain MPN subtypes proposed by Pardanani et al. (2008). In 
doing this, it became apparent that there was a strong association between JAK2 V617F 
positive diseases and a particular constitutional haplotype of this gene. The study then 
focused on defining this association, specifically: 
1.  Characterising JAK2 haplotypes in more detail. 
2.  Evaluating the risk of developing MPN associated with JAK2 haplotype. 
3.  Preliminary investigations into the reasons for JAK2 haplotype skewing.  
4.  Investigating the impact of JAK2 haplotype in V617F negative MPN. 
5.  Investigating the impact of JAK2 haplotype in familial MPN. 152 
6.2  Materials and methods 
6.2.1  Patient samples 
G e n o m i c   D N A   o r   c D N A   w a s   e x t r a c t e d   f r o m   P B   o r   B M   s a m p l e s   f r o m   l o c a l   c a s e s   a n d   a l s o  
c a s e s   p r o v i d e d   b y   D r   R .   S i l v e r   ( N e w   Y o r k ,   U S A ) .   D N A   w a s   a l s o   p r o v i d e d   b y   D r   L .   W a n g  
(New York, USA), Dr A. Reiter (Mannheim, Germany), Dr K. Zoi (Athens, Greece) and Dr H. 
Cario (Ulm, Germany). 
A total of 775 cases with MPN were analysed. Of these, 592 were V617F positive (PV, 
n=203; ET, n= 224; MF, n=41; unclassified MPN, n=124), and 183 had V617F negative 
disease (locally obtained ET, n=47; Greek ET, n=136) as determined by AS-PCR and 
pyrosequencing. Individuals from a previously described MPN family were also analysed 
364. The controls included healthy individuals from the UK (n=188, first degree relatives of 
individuals referred for variety of genetic conditions) and Greece (n=108, provided by Dr 
K. Zoi). Data generated by the Welcome Trust Case Control Consortium (WTCCC) from the 
UK blood donor cohort (n=1500) 
369 was also used.  
 
6.2.2  Genotyping by pyrosequencing 
In this study all genetic variation at SNP loci and JAK2 V617F burden was measured in PB 
leukocyte DNA using pyrosequencing. Because the allelic ratio (i.e. the ratio of allele A to 
allele B at any SNP) for any heterozygous SNPs were distorted away from the value of 0.5 
in cases with a sizeable homozygous V617F clone, I adopted the following scoring criteria 
for all SNPs: (i) if one allele had an allelic ratio ≥0.9, the sample was scored as 
homozygous for that SNP, (ii) where allelic ratios were 0.11-0.89, samples were scored as 
heterozygous. These cut offs were at least 3 standard deviations more than background, 
(i.e. values read for allele B in healthy controls who were A/A homozygotes). Similarly, for 
homozygous V617F cases (V617F >50%), SNPs with allelic ratios ≥0.6 or ≤0.4 were 
considered to be derived from the V617F-mutated or residual wild-type alleles, 
respectively. For V617F homozygous cases in which the %V617F was ≥90%, no 
information could be obtained about the residual wild-type JAK2 allele and thus these 
cases were considered to contribute only one allele to the analysis (Figure 6.2). 
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6.2.3  Allele-specific PCR (AS-PCR) 
AS PCR was performed using forward primers that were specific for V617F 
(JAK2_rs867_T_F) or the corresponding wild-type sequence (JAK2_rs867_G_F) in 
combination with a common reverse primer (JAK2_i14.15_R3), producing a 565bp 
product that included the 46/1 tag SNP rs12343867.  The AS-PCR strategy to capture the 
46/1 haplotype is described in figure 6.3, alongside an example of the PCR products and 
sequencing traces for some heterozygous V617F-positive cases. PCR was optimised on 
DNA from the HEL cell line (100% V617F) and normal healthy controls, and tested on 
homozygous V617F-positive cases where the mutation was known to be in cis to the 46/1 
haplotype. Products were sequenced to determine whether V617F was on the 46/1 allele.  
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A 
 
 
B            JAK2 V617F level (% mutant allele)  
 
 
 
Wild-type specific PCR 
 
 
V617F-specific PCR 
 
C  
 
 
 
 
 
Figure 6-3. AS-PCR for tag SNP rs12343867 captures the 46/1 haplotype in heterozygous V617F-
positive cases. (Panel A) AS-PCR between V617F (yellow circle) located in JAK2 exon 14, captures 
the 46/1 tag SNP (green circle). The positions of the mutant specific and wild-type specific primers 
are indicated. (Panel B) Wild-type and mutant specific PCR products from AS-PCR performed on 
normal controls (0%), a 100% V617F positive cell line, and seven V617F positive cases with varying 
levels of mutation. (Panel C) Sequencing to identify the tag SNP (SNP nucleotide indicated by 
arrow) genotype of each PCR product confirms the wild-type is heterozygous (CT heterozygous 
tag SNP) for the 46/1 haplotype, whereas the V617F mutation has arisen on the 46/1 haplotype (C 
tag SNP allele only). 
Wild-type specific PCR indicates the case 
Is heterozygous for rs12343867 
 
JAK2 V617F specific PCR indicates V617F 
arose on C allele of rs12343867 
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6.2.4  Colony analysis 
Haemopoietic colonies from normal controls comprising a minimum of 100 cells were 
counted on day 14, and characterised based on morphology as either CFU-GM, CFU-
GEMM, CFU-E, or BFU-E. JAK2 haplotype status was determined after colonies were 
counted using DNA extracted from the MNC or granulocyte cell fractions. 
 
6.2.5  Expression analysis  
RNA was extracted from peripheral blood leukocytes of V617F negative MPN cases that 
were known to be heterozygous for rs10429491 and/or rs2230724 (JAK2 exonic SNPs) as 
well as heterozygous for 46/1, as determined by rs12340895 genotype. RNA was reverse 
transcribed with random hexamer primers and the ratio of the two alleles for each SNP in 
genomic DNA and cDNA was determined by specific pyrosequencing assays. 
 
6.2.6  Statistical analysis 
The proportion of 46/1 alleles for each patient subgroup was compared to controls using 
Fisher’s exact test (2-tailed). Colony numbers were compared to genotype using the 
Mann-Whitney U test.  
Odds ratios and relative risk were calculated as follows: 
A=number of 46/1 alleles in cases 
B=number of 46/1 alleles in controls 
C=number of non-46/1 alleles in cases 
D=number of non-46/1 alleles in controls 
 
The OR and RR can then be calculated as:  
OR= (A/B)/(C/D) 
RR = (A/(A+B)(C/(C+D))  
 
These values and 95% confidence intervals were calculated using a 2-way Contingency 
Table Analysis html applet supplied by Paul Strike, Salisbury Research & Development 
Support Unit. 156 
 
The population attributable risk level % (PAR%) was calculated as f(RR-1)/(1+f(RR-1) *100, 
where ‘f’ is the frequency of risk factor (46/1 allele in population of WTCCC controls) 
370. 157 
6.3  Results 
6.3.1  Defining genetic variation at the JAK2 gene locus 
Pardanani et al. identified three JAK2 SNPs (rs7046736, rs10815148, and rs12342421) 
that were significantly but reciprocally associated with PV and ET 
366. Three additional 
JAK2 SNPs (rs10758669, rs3808850, and rs10974947) were also significantly associated 
with PV compared to controls. However there were two obvious weaknesses in this 
study: (i) they had not taken into account the fact that acquired UPD in many PV cases 
will distort the ratios of JAK2 SNPs and (ii) the study used only HapMap samples as 
controls. I therefore set out to perform a more detailed analysis to determine if the 
associations could be replicated. 
In order to map the genetic variation of JAK2, Pardanani et al. (2008) genotyped a total of 
13 SNPs. Analysis of the resultant allele frequencies led the authors to define six major 
haplotypes, which accounted for 67.7% of JAK2 alleles in the MPN population. Table 6.1 
shows the haplotypes proposed by Pardanani et al. (2008), listed 1 to 6, alongside the tag 
SNPs studied and the frequency of each haplotype for the 179 MPN cases genotyped in 
their study. These haplotypes could be captured by just six SNPs as highlighted in blue in 
Table 6.1, and the reduced haplotype produced from these six SNPs is listed in the last 
column. 
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1  A  A  A  A  C  T  C  A  A  G  G  G  T  0.015  AAAGGG 
2  A  A  A  T  C  T  T  C  T  C  G  G  T  0.148  AACCGG 
3  A  A  C  A  C  T  C  A  A  G  G  G  T  0.192  ACAGGG 
4  G  A  A  A  C  T  T  C  T  C  A  G  G  0.014  GACCAG 
5  G  A  C  A  C  T  C  A  A  G  G  G  T  0.178  GCAGGG 
6  G  G  A  A  A  C  C  C  T  C  A  A  G  0.13  GACCAA 
 
Table 6-1. JAK2 haplotypes defined by Pardanani et al. (2008). Genotyping of 13 SNPs predicted 
six haplotypes that accounted for 67.7% JAK2 alleles. A minimal set of six tag SNPs that can 
capture these haplotypes are indicated in blue along with haplotype frequency and reduced 
haplotype genotypes. 
 
I first investigated the genetic diversity of JAK2 in our cohort of homozygous PV cases. I 
selected only homozygous cases with a mutant burden greater than 50% because skewing 
of heterozygous SNP allele ratios would aid the haplotyping of alleles that were either 
linked or not linked to V617F. Pyrosequencing assays were designed for the six SNPs that 
comprise the revised haplotype listed in table 6.1 (rs7864782, rs10758669, rs7046736, 
rs12342421, rs10974947, and rs2031904) and used to screen 73 homozygous PV cases. 
Whilst it was possible to read the haplotype associated with V617F in most cases with 60-
90% V617F, the residual haplotype (i.e. the haplotype on which V617F had not arisen) 
could also be read by the finding of heterozygous allele ratios in the range 0.1-0.4. In 
cases with ≥90% V617F, however, information about alleles on the non-V617F 
chromosome were lost (Figure 6.2). This was because it was not possible to determine 
whether a homozygous SNP allele pyrosequencing result was due to complete skewing 
from a heterozygous allele ratio, or the SNP was constitutionally homozygous. 
Table 6.2 shows an example of how high level V617F positive cases were haplotyped for 
these six SNPs by allele skewing. 159 
 
case   %V617F   rs7864782   rs10758669   rs7046736  rs1234241   rs10974947   rs2031904   V617F 
haplotype  
Wild-type 
haplotype  
  A     G     A     C     A    C   G    C     A     G     A     G  
E659   99   100    0    7    93   100    0   100    0    6    94     2    98   ACAGGG   ?  
E2433   80   14   86    4    96    82   18    85   15   0   100     0   100   GCAGGG   ACCCGG  
E2513   62   71   29   31    69    68   32    74   26   8   92     0   100   ACAGGG   GACCGG  
E1186   49   46   54    9    91    48   52    45  55  51   49    49   51   ?   ?  
 
Table 6-2. Examples of four JAK2 V617F positive PV cases quantified for six JAK2 tag SNPs using pyrosequencing. The V617F level (% mutation burden) is 
listed alongside the allele frequencies for each SNP (%allele) measured by pyrosequencing. The V617F associated haplotype and the wild-type haplotype 
is listed last in the row. In many cases that harboured a homozygous V617F clone it was possible to directly read the haplotype on which the mutation 
arose by the finding that one allele at each SNP predominated (allelic ratio ≥0.6, e.g. cases E659, E2433 and E2513). In cases with a homozygous clone 
and %V617F <90%, it was usually possible to read the residual haplotype (i.e. the haplotype of the chromosome that had not acquired V617F) by the 
finding of allelic ratios between 0.1-0.4 (e.g. cases E2433 and E2513). Where the homozygous clone was small or nonexistent (most cases with %V617F 
<60%), neither the V617F nor wild-type haplotype could be read (e.g. case 1186). 160 
The results for 73 V617F positive cases with a homozygous V617F burden (>50%) are 
listed in table 6.3. It was possible to identify each of the six haplotypes predicted by 
Pardanani et al. (2008) in many cases, plus I was able to identify nine further haplotypes 
that were designated 7 to 15. In 27 cases the allele skewing due to a high mutation 
burden was such that residual wild-type haplotype could not be determined. In total 
therefore I was able to read 73 V617F associated haplotypes and 45 residual wild-type 
haplotypes. 
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number 
(n=45)  f 
1  A  A  A  G  G  G  2  0.03  2  0.04 
2  A  A  C  C  G  G  1  0.01  11  0.24 
3  A  C  A  G  G  G  26  0.36  4  0.09 
4  G  A  C  C  A  G  2  0.03  2  0.04 
5  G  C  A  G  G  G  29  0.40  0  0.00 
6  G  A  C  C  A  A  2  0.03  5  0.11 
7  A  C  C  C  G  G  2  0.03  7  0.16 
8  G  A  C  C  G  G  3  0.04  7  0.16 
9  A  C  A  C  G  G  2  0.03  1  0.02 
10  A  A  A  C  G  G  0  0.00  2  0.04 
11  A  A  C  C  A  A  0  0.00  1  0.02 
12  A  C  C  C  A  G  1  0.01  0  0.00 
13  G  C  C  C  G  G  0  0.00  3  0.07 
14  A  C  C  C  A  A  0  0.00  1  0.02 
15  G  A  A  G  G  G  3  0.04  0  0.00 
undefined                    0  0.00  27  0.60 
 
Table 6-3. JAK2 haplotypes found in homozygous (>50% V617F) cases. Haplotypes were 
determined from the genotype status of 6 JAK2 SNPs. Haplotype numbers 1-6 were defined by 
Pardanani et al; haplotypes 7-15 were identified in this study. The number and frequencies (f) of 
each haplotype carrying the V617F allele and the background wild-type allele are indicated. 
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The genotyping data reveals a striking difference between the V617F and residual wild-
type haplotypes: 55 of the 73 V617F alleles (75%) were accounted for by just two 
haplotypes, numbers 3 and 5. In contrast only 4 (9%) of the wild-type alleles were 
haplotype 3 and none were haplotype 5. This striking difference is highly significant 
(P=7x10
-13; Fishers exact test). Haplotypes 3 and 5 are highly related and only differ by 
rs7864782 genotype. This SNP lies just 5’ of the JAK2 gene, and is in a separate LD block 
according to HapMap data (Figure 6.4).  
 
 
 
Figure 6-4. Genetic variation spanning the JAK2 gene. The r
2 values, a measure of marker to 
marker LD, are plotted pairwise as boxes, and dark shading indicates high LD. This plot was 
generated using genotype data from the CEU population (diagram taken from the HapMap 
website, www.hapmap.org). The relative position of the six tag SNPs used to define variation 
across the JAK2 gene are indicated. 
 
 
In summary therefore, these results indicated that homozygosity for V617F was not seen 
randomly, but rather occurred preferentially when this mutation was present on the 
related JAK2 haplotypes 3 and 5.  162 
6.3.2  JAK2 haplotypes predicted by SNP data from the WTCCC 
To explore this observation in more detail,  a more accurate haplotype structure of JAK2 
was determined using 14 SNPs genotyped by the Wellcome Trust Case Control 
Consortium (WTCCC) in 1500 UK healthy blood donors 
369. The allele frequency data was 
subject to analysis using a computer programme called PHASE. PHASE implements a 
Bayesian statistical method for reconstructing haplotypes from population genotype data 
368. The programme inferred a total of 92 haplotypes, of which nine accounted for 94% of 
JAK2 alleles (Figure 6.5).  
 
 
Figure 6-5.  The nine most common JAK2 haplotypes in the UK population. The 14 SNPs in bold 
were analysed by the WTCCC in 1500 blood donors from which the frequencies were determined; 
asterisks indicate SNPs that tag 46/1. Rs78644782, rs10124001 and rs10758669 are immediately 
upstream of JAK2; all other SNPs are within JAK2 introns. 
 
I was then able to match up the six haplotypes predicted by Pardanani et al. (2008) 
366 
with the WTCCC haplotypes using SNPs genotyped in both studies where an allelic variant 
was unique to one particular haplotype. To aid the matching process, I designed 
pyrosequencing assays to genotype four additional SNPs, (rs6476934, rs2149556, 
rs10815160 and rs17425819). These SNPs were genotyped in homozygous V617F positive 
cases who displayed evidence of allele skewing following previous genotyping, and who 163 
carried a haplotype (defined by Pardanani et al., 2008) other than haplotypes 3 or 5. This 
analysis revealed that WTCCC haplotype numbers 46 and 1 were identical to haplotypes 3 
and 5 defined in Pardanani et al. (2008). As previously mentioned, this haplotype is 
identical within the region of the LD block that includes the JAK2 gene (Figure 6.4) and are 
therefore henceforth referred together as ‘46/1.’ Haplotype 46/1 has a combined 
frequency of 0.24 in the WTCCC population. Figure 6.5 shows that rs12343867 and 
rs12340895 both tag 46/1, i.e. the genotype for these SNPs is different for 46/1 compared 
to other haplotypes. Genotyping either of these SNPs can therefore be used as a 
surrogate to determine 46/1 status. SNP rs12340895 was chosen for this purpose as it 
performed better in pyrosequencing assays. For any individual, a G/G genotype for this 
SNP indicates homozygosity for 46/1; G/C indicates heterozygosity for 46/1 and C/C 
indicates that neither allele is 46/1. 
 
6.3.3  Confirmation that homozygous V617F-positive MPN cases are reciprocally 
associated with the 46/1 haplotype 
As described above, the association of the 46/1 haplotype with V617F positive disease 
was first determined in 73 PV cases with a homozygous level of mutation. These cases, 
plus an additional 69 cases of homozygous V617F-positive MPN (mutation burden >50%), 
were genotyped for the tag SNP rs12340895 to confirm the association of 46/1 with 
V617F. It was found that out of the 142 alleles that harboured V617F, 109 (77%) were 
46/1 haplotype whereas this haplotype was seen for only 9 of the 74 (12%) residual wild-
type alleles that could be read (P =1.4x10
-20, Fisher’s exact test, 2-tailed). The frequency 
of 46/1 was significantly greater for V617F alleles compared to that seen in normal 
WTCCC controls (P=1.4x10
-34), and the frequency of residual 46/1 wild-type alleles was 
significantly less than WTCCC controls (P=0.007). These data confirm a huge excess of 
46/1 alleles in homozygous V617F mutated MPNs, and that the JAK2 mutation in these 
cases is usually on the 46/1 allele. 
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6.3.4  Genotyping of rs12340895 in healthy normal controls  
In genetic studies it is important to compare genotypes between ethnically matched 
cases and controls. All patients in the MPN disease categories PV, MF, ET and unclassified 
MPN analysed in this study were drawn from the UK or US, and thus were assumed to be 
predominantly Caucasian. The WTCCC controls are therefore likely to be sufficient, 
however it was important to check that these data were representative and therefore a 
local cohort for 188 healthy controls (anonymised first degree relatives of individuals 
referred for a variety of non-malignant conditions) were genotyped for rs12340895.  As 
described below, some MPNs were from Greece and so it was also necessary to 
determine allele frequencies in healthy normal cases from this country. The results (Table 
6.4) show that there is no significant difference between the frequency of 46/1 in local 
controls and the WTCCC and that there is no difference between the UK and Greece. 
 
 
  number 
of cases 
genotype  alleles 
allele 
frequency 
  CC  CG  GG  C  G  C  G 
HapMap CEU European 
population 
            0.742  0.258 
local healthy normal 
controls 
188  103  78  7  284  92  0.755  0.245 
WTCCC  1500        2280  720  0.760  0.240 
Greek normal controls  108  60  41  7  161  55  0.745  0.255 
 
Table 6-4.  Allele genotypes and frequency of the JAK2 SNP rs12340895 in healthy normal controls 
used in this study. 
 
6.3.5  Heterozygous V617F-positive MPNs are also associated with the 46/1 haplotype 
The 46/1 haplotype status was then determined in further cases carrying a lower level of 
V617F (<50% V617F). Heterozygous V617F-positive cases with a confirmed diagnosis of 
PV, ET and MF, plus other cases with an unclassified MPN, were subject to 
pyrosequencing for rs12340895. In some cases with PV and MF carrying a heterozygous 
level of V617F (i.e. %V617F ≤50%), it was possible to see the effect of a small homozygous 165 
V617F positive clone, manifested as an allele distortion of the tag SNP, if the tag SNP was 
originally heterozygous. For these cases it was possible to infer the presence of the 46/1 
haplotype by skewing of the allele ratio to the G allele of the tag SNP. The results from 
cases that showed allele skewing are shown in Table 6.5. Again, there is a marked excess 
of 46/1 associated with the V617F allele compared to the wild-type allele (P=3.1x10
-17 for 
all 163 cases). 
 
  
  
V617F allele  WT allele 
46/1  not 46/1  46/1  not 46/1 
PV  67  32  17  82 
MF  10  10  1  19 
Unclassified MPN  25  19  10  34 
total  102  61  28  135 
 
Table 6-5. Determining the haplotype associated with V617F in cases heterozygous (<50%) JAK2 
V617F-positive MPN disease entities, by tag SNP (rs12340895) genotyping. Allele frequencies that 
were either homozygous or skewed were used to determine the haplotype associated with 
V617F.  
 
In total, analysis of 177 heterozygous V617F positive MPNs showed that the 46/1 
haplotype was more frequent (135/354 alleles, 38%) compared to that seen in 188 locally 
sourced healthy controls (92/376 alleles, 24%; P = 0.0001) as well as the WTCCC cohort (P 
=3.3x10
-8). This confirmed that 46/1 is enriched in V617F positive MPNs irrespective of 
whether they harbour a homozygous or heterozygous mutant clone. 
Table 6.6 shows the total allele frequencies of the 46/1 haplotype in the V617F-positive 
MPN disease subtypes and normal controls. Haplotype 46/1 was more frequent in all 
V617F positive disease entities regardless of origin (UK or USA) and the excess of 46/1 
was highly significant for all disease subtypes. The allele frequencies seen in PV, ET and 
MF were very similar and the fact that the P value is higher in PV and lower in MF just 
reflects the number of cases that underwent analysis. There was no difference between 
allele frequencies seen in controls and cases with idiopathic erythrocytosis (n=76), a 
disorder characterised by marked erythrocytosis with a reactive origin. 166 
 
total 
cases 
genotypes 
allele 
frequencies 
(i) 
minus 
cases 
>90% 
allele frequencies (ii) 
F of 
46/1 
P value 
(versus 
local 
controls) 
OR (95% CI) 
P value 
(versus 
WTCCC 
controls) 
OR (95% CI) 
  CC  CG  GG  C  G  C  G 
N non 
46/1 
alleles 
N  46/1 
alleles 
PV
a (UK)  192  36  100  56  172  212  1  15  171  197  0.54  2.88E-16  3.6 (2.6-4.8)  7.56E-30  3.6 (2.9-4.6) 
ET (UK)  78  18  41  19  77  79  0  0  77  79  0.51  8.24E-09  3.2 (2.1-4.7)  4.27E-13  3.2 (2.4-4.5) 
MF
a (UK)  41  10  21  10  41  41  1  4  37  40  0.48  8.00E-05  2.9 (1.7-4.7)  6.12E-06  2.9 (1.9-4.6) 
unclassified 
MPN
a (UK) 
124  23  62  39  108  140  2  5  106  135  0.56  3.33E-15  3.9 (2.8-5.6)  3.40E-24  4.0 (3.1-5.3) 
V617F positive 
ET (GR) 
143  42  78  23  162  124  n/a  n/a  162  124  0.43  4.51E-07
b  2.4 (1.7-3.3)
b  9.18E-12  2.4 (1.9-3.1) 
Idiopathic 
erythrocytosis 
76  40  31  5  111  41  n/a  n/a  111  41  0.27  0.58  1.1 (0.7-1.7)  0.437  1.2 (0.8-1.7) 
UK controls  188  103  78  7  284  92  n/a  n/a  284  92  0.24  -  -  8.48E-01  1.0 (0.8-1.3) 
WTCCC controls  1500  -  -  -  2280  720  n/a  n/a  2280  720  0.24  8.48E-01  1.0 (0.8-1.3)  -  - 
GR controls  108  60  41  7  161  55  n/a  n/a  161  55  0.25  8.43E-01  1.1 (0.7-1.6)  6.22E-01  1.1 (0.8-1.5) 167 
Table 6-6. (Previous page) Summary of genotyping results. Genotypes and allele frequencies (i) for 
SNP rs12340895 (G allele tags the 46/1 haplotype, C allele tags all other haplotypes) shown for 
each JAK2 V617F-positive MPN disease category; PV, MF, ET and unclassified MPN. Groups 
marked 
a  contain some cases with ≥90% V617F and thus the residual wild-type allele could not be 
assigned as 46/1 or not 46/1. Number (N) of the allele frequencies (ii) of V617F arising on the 46/1 
haplotype and V617F arising on all other backgrounds are indicated, alongside levels of 
significance achieved in comparison to the UK local controls and the WTCCC controls, and the 
respective OR of these comparisons. Frequency (F) of 46/1 for each group is indicated. P values 
were calculated using Fisher’s exact test, 2-tailed. GR, Greek samples; UK, United Kingdom 
samples; 
b values versus healthy Greek controls.  
 
 
To illustrate the association of V617F with the 46/1 haplotype, Figure 6.6 depicts allele 
distributions of the tag SNP rs12340895 for controls and the V617F positive cases. In the 
188 local normal controls, the SNP allele frequency is plotted in a ranked fashion, and this 
plot shows the common allelic variant is the C, with very few cases homozygous for the G 
allele (Figure 6.6A). When the allele frequencies for the 192 PV cases are plotted against 
level of V617F, it is apparent that the normal distribution is not observed, but there is an 
asymmetrical distortion towards the G allele, the allele that tags the 46/1 haplotype 
(Figure 6.6B). Indeed, this bias for the G allele is emphasised by the observation that 
many V617F positive cases were homozygous for the G allele, in stark contrast to the 
matched population of normal controls. There was also an over-representation of the G 
allele in ET (Figure 6.6 C), and MF (Figure 6.6 D). Allele skewing resulting from reduction 
to homozygosity is a rare event in ET, indicated by the relatively lower level of V617F in 
this disease.168 
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Figure 6-6. Scatter plots showing the allele distribution of the JAK2 46/1 tag SNP rs12340895. The 
graphs show genotype of the SNP (% C) in ranked order for 188 local normal controls (A), and 
against level of the JAK2 mutation (% mutant allele) for V617F positive PV cases (B), V617F 
positive ET (C) and V617F positive MF (D).  170 
6.3.6  Determining the risk of developing MPN conferred by the 46/1 JAK2 haplotype  
The fact that 46/1 is more frequent in V617F positive MPNs compared to controls 
indicates that this haplotype predisposes to these diseases. The magnitude of this 
predisposition is indicated by the OR and RR. The ORs for each disease entity are shown in 
table 6.6 and the data for all V617F positive disease is summarised in table 6.7. Based on 
the results from these analyses, it was determined that JAK2 46/1 confers an OR of 3.7 
(95% CI 3.1-4.3), and a RR of 2.6 (95% CI 2.3-2.9), indicating that 46/1 is a strong 
predisposition factor for development of V617F associated MPNs.  
 
  G   C  total 
V617F positive cases  465   405   870  
WTCCC  720   2280   3000  
totals  1185   2685   3870 
 
Table 6-7. 2 X 2 contingency table showing the allele frequencies for the tag SNP rs12340895 from 
435 cases with JAK2 V617F positive MPN and 1500 normal controls from the WTCCC. The risk 
allele G tags the 46/1 haplotype. 
 
The counts of 46/1 alleles in cases together with corresponding counts in WTCCC controls 
and the population frequency of 46/1 from the WTCCC data were then used to determine 
the population attributable risk (PAR). Put simply, PAR measures the reduction in 
incidence that would be observed if the population had no 46/1 alleles, compared with its 
actual haplotype distribution. When compared to the frequency of the risk factor (46/1 
allele; 53.4%) in the general population (WTCCC; 24%), the PAR for the 46/1 allele was 
calculated to be 27.8% 
370. Recently results from a Swedish epidemiological study have 
demonstrated that there is a 5.7 to 7.5 fold elevated risk of MPN among first degree 
relatives of MPN patients, suggesting there are common, strong, shared susceptibility 
genes predisposing to PV, ET and MF 
272. Data provided by Landgren et al. (2008) (RR 5.7 
to 7.5) shows the range of PAR in their study was 53% to 61%. Assuming no difference 
between the UK and Swedish populations, the 46/1 haplotype thus accounts for 50% of 
the increased risk in first degree relatives. 171 
6.3.7  Allele-specific PCR capturing a second tag SNP to determine if V617F arose on 
the 46/1 haplotype 
The results so far have shown that both homozygous and heterozygous JAK2 V617F 
positive MPNs are linked to an excess of the 46/1 haplotype. In homozygous V617F cases 
it was clear that V617F was generally on the 46/1 allele in cases that were heterozygous 
for 46/1, however in cases without any allele distortion it was not clear if V617F was on 
the 46/1 or non-46/1 allele.  
To determine if V617F was generally in cis or trans to the 46/1 allele, cases were selected 
that were heterozygous for both the mutation and the haplotype for analysis. The SNP 
rs12343867 C allele tags the presence of the 46/1 haplotype (Figure 6.5) and lies just 410 
bp from the JAK2 V617 codon. An AS-PCR could therefore be designed which detected 
both the tag SNP and V617F (Figure 6.3). 
In total AS-PCR was performed on 66 informative heterozygous V617F positive cases and 
the results are shown in table 6.8. Sequencing the products revealed that 49 (74%) V617F 
alleles arose on a 46/1 allele whereas only 17 (26%) residual wild-type alleles were 46/1 
(P=2.1x10
-8). In both heterozygous and homozygous V617F cases, it is clear therefore that 
the V617F mutation tends to be on the 46/1 allele. 
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V617F allele  WT allele 
46/1  not 46/1  46/1  not 46/1 
PV  17  6  6  17 
ET  16  2  2  16 
MF  4  3  3  4 
Unclassified MPN  12  6  6  12 
totals  49  17  17  49 
 
Table 6-8. Results from AS-PCR for tag SNP rs12343867 on informative V617F heterozygotes 
without allele distortions. 
 
 
6.3.8  Does the 46/1 haplotype affect expression of JAK2? 
One possible reason for the observed association might be that JAK2 on the 46/1 
haplotype is expressed at a different level to JAK2 on other haplotypes. To explore this 
possibility, pyrosequencing primers were designed to quantify the allele ratios of two 
JAK2 exonic SNPs (rs10429491 and rs2230724) in matched cDNA and genomic DNA from 
control V617F negative MPN cases that were heterozygous for at least one of the exonic 
SNPs, as well as being heterozygous for 46/1.  
In total 46 cases were studied; 29 cases heterozygous for rs2230724, and 40 cases 
heterozygous for rs10429491 (some cases were heterozygous for both SNPs). The cDNA 
specific primers were designed with one amplification primer crossing over an exon-exon 
boundary and were confirmed to be cDNA-specific by testing on genomic DNA. In DNA 
the allele ratio is expected to be normally distributed around 50%, whereas in cDNA any 
expression difference associated with 46/1 compared to other haplotypes would be 
expected to result in deviations from 50%, e.g. if JAK2 on 46/1 was expressed 1.5 fold 
higher than JAK2 on other haplotypes then the cDNA allele ratio would be 60%, if 2 fold 
higher then 67% etc. 
A comparison of the variances (F-test) or means of the allele ratios (t-test) between cDNA 
and genomic DNA for each individual with either SNP did not reveal any significant 
differences (rs2230724, p=0.16; rs10429491, p=0.98). This indicates that 46/1 is not 173 
associated with either increased or decreased JAK2 expression, at least in peripheral 
blood leukocytes from individuals with JAK2 V617F negative MPN (Figure 6.7). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-7. No expression differences between JAK2 on 46/1 compared to other alleles. Box plots 
showing allele ratios in V617F negative, 46/1 heterozygous controls (n=46) that were also 
heterozygous for rs2230724 (n=29, top panel) and/or rs10429491 (n=40, bottom panel). There 
was no difference between the allele ratio variances (F-test, P values shown) or means (t-test) 
between cDNA and DNA for either SNP indicating no detectable expression differences associated 
with 46/1. 
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It may be postulated any functional variant which predisposes to V617F positive MPN 
may exist only on a subset of 46/1 alleles, and perhaps any discernable JAK2 expression 
differences would be missed by examining V617F negative cases. However as the 
frequency of 46/1 is 0.24 in normal controls, and approximately 0.5 in V617F positive 
MPNs, this means an excess of 0.26 in MPNs which may carry the 46/1 allele with the 
predisposing factor. Based on this, this subset is more likely to be enriched in V617F 
positive cases. JAK2 expression differences were then investigated in V617F positive 
MPNs, and only heterozygous mutation positive cases with no evidence of a homozygous 
clone were selected for analysis. As above, the variances (F-test) or means of the allele 
ratios (two sample t-test) between cDNA and DNA for 14 cases were compared, for 
exonic SNPs rs10429491 and rs2230724. Interestingly, the difference between DNA and 
cDNA mean allele ratios for SNP rs10429491 was just significant (t-test p=0.04), but not 
significant for rs2230724 (t-test p=0.191) (Figure 6.8). This statistical test assumes a 
normal distribution of data; if the non-parametric Mann-Whitney test is used the 
difference for rs10429491 falls just below the level of significance (p=0.065). 
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Figure 6-8. Expression differences between DNA and cDNA for two exonic JAK2 SNPs in MPN cases 
with JAK2 V617F on 46/1. Boxplots showing the mean allele variances between DNA and cDNA 
were compared in JAK2 V617F positive cases carrying one or more copies of 46/1, for rs2230724 
and rs10429491. A small difference between DNA and cDNA was observed for rs10429491, but 
not rs2230724 (t-test p values are shown). 
 
 
The finding of a significant difference between DNA and cDNA for rs10429491 could 
allude to subtle functional differences conferred by 46/1 in only a subset of V617F 
positive cases carrying 46/1. The rs10429491 mean allele ratios for DNA and cDNA were 
52.4 and 55.8, respectively, indicating a difference of only 3.4%. However, this was not 
the case for rs2230724, and it would be expected both SNPs would show a difference if 
there was a real effect of 46/1 on expression. The rs10429491 expression increase is very 
marginal, and although the data is far from convincing, it does provide the rationale for 
examining further cases.  
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6.3.9  Is the sequence of JAK2 on 46/1 the same as that on other haplotypes? 
To determine if the primary sequence of JAK2 on 46/1 was the same as other haplotypes 
all 25 exons were sequenced, including those encoding the 5’ and 3’ untranslated regions, 
in eight MPN cases with V617F on the 46/1 allele and eight healthy controls that were 
negative for 46/1. No sequence variants were detected, except for the two previously 
described silent polymorphisms rs10429491 and/or rs2230724 in exons 6 and 19, 
respectively. To determine if these exonic SNPs or other unknown intronic variants might 
affect splicing overlapping RT-PCRs were performed to cover all exon-exon junctions. 
Sequencing of the products did not reveal any differences between JAK2 mRNA in MPNs 
with V617F on 46/1 (n=8) and controls without 46/1 (n=8) (primers listed in Appendix III). 
 
 
 
 
Figure 6-9. Illustration of overlapping RT-PCR products covering the JAK2 transcript. JAK2 contains 
25 exons and all exon-exon boundaries were amplified by a series of RT-PCRs (horizontal lines) 
designed to detect any alternative splice variants. Location of V617, and coding SNPs rs10429491 
and rs2230724 are shown. 
 
 
6.3.10 Does JAK2 haplotype status influence myeloid colony formation in 
haematopoietically normal individuals? 
To investigate the possibility that JAK2 on the 46/1 haplotype is different functionally 
from other JAK2 alleles, a preliminary experiment was performed to determine if its 
effect was visible in vitro. JAK2 is required for signaling downstream of a variety of 
receptors for cytokines that are critical for myelopoiesis (e.g. IL-3, G-CSF, GM-CSF, EPO) as 
well as other receptors that are active in lymphoid and non-haemopoietic cells 
371.  It is 177 
widely known that myeloid colony formation varies widely between individuals, so I 
investigated whether JAK2 haplotype status had a measurable effect on myeloid colony 
formation in haematologically normal individuals. In a prospective analysis, PB samples 
were obtained that were less than 4 days old from 104 anonymised haematologically 
normal controls. MNCs were plated in semi-solid medium containing myeloid cytokines 
and EPO and after 14 days the number of colonies were counted and characterised based 
on morphology as CFU-GM or BFU-E. The JAK2 haplotype status was determined after 
colonies were counted using DNA extracted from the MNC or granulocyte cell fractions by 
genotyping the 46/1 tag SNP rs12340895.  
Out of 104 cases studied, 102 successfully grew myeloid colonies and were included in 
the analysis.  Table 6.9 shows a summary of the results from this investigation.  The allele 
frequency for the tag SNP was C: 0.72, G: 0.27 which was not significantly different to the 
normal controls. 
 
  CFU-GM  BFU-E  total colony number 
range  0-146  3-489  7-602 
median   30.0  102.0  122.5 
mean   36.2  129.4  162.4 
 
Table 6-9. Summary of myeloid colony type and number from 102 haematopoietically normal 
individuals. 
 
The colony number and type were then grouped according to JAK2 haplotype status. The 
numbers of CFU-GM and BFU-E colonies without the 46/1 haplotype was compared to 
the colony numbers from those that carried either one or two copies of the 46/1 
haplotype (the number of cases that were homozygous for 46/1 was too small to analyse 
as a single entity). The median colony numbers of CFU-GM, BFU-E and total colony count 
for the two genotype groups were compared using the Mann-Whitney U test (Table 6.10 
and Figure 6.10).  
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  not 46/1 (54)  one or two copies of 46/1 (48)   
  range  mean  median  range  mean  median  P value 
CFU-GM  1-137  39.9  37.0  0-146  32.0  26.0  0.03 
BFU-E  3-489  132.8  111.5  4-378  125.6  98.5  0.947 
total colony number  7-602  172.6  138.0  7-484  157.5  121.0  0.594 
 
Table 6-10. Myeloid colonies grown in semi-solid media from PB from haematopoietically normal 
individuals, grouped according to 46/1 JAK2 haplotype status. The table shows the number 
(range), mean and median CFU-GM and BFU-E colonies counted after 14 days incubation, for 
cases nullizygous or heterozygous/homozygous for the 46/1 allele. Number of cases for each 
category is shown in brackets. 
 
 
Despite a wide range of values, this data showed that individuals who carried at least one 
46/1 allele grew significantly fewer CFU-GM than those who did not (p=0.03, Mann 
Whitney U test). There was no effect, however, on BFU-E growth (Figure 6.10). Although 
it is not obvious why this should be, this result is consistent with the hypothesis that JAK2 
on 46/1 is indeed functionally different from other JAK2 alleles.  179 
 
Figure 6-10. Boxplots displaying the distribution of total 
myeloid (A), CFU-GM (B) and BFU-E (C) colony numbers 
against JAK2 haplotype status. Cases without the 46/1 
JAK2 haplotype are labelled ‘not 46/1’ and cases carrying 
one or two copies of the 46/1 haplotype are labelled 
‘46/1.’ The significance levels for comparisons A, B and C 
were 0.594, 0.03, and 0.947 respectively.  
P=0.03  P= 0.594 180 
6.3.11 The relevance of the 46/1 haplotype in JAK2 V617F negative MPN 
The possibility that a functional variant might also be relevant to the pathogenesis of 
V617F negative MPNs was explored. I genotyped tag SNP rs12340895 in V617F negative 
ET and MF cases from the UK (n=47) and found 37/94 alleles were 46/1, which was 
significantly greater than the frequency observed in locally sourced controls (P=0.009) as 
well as the WTCCC cohort (P=0.002) (Table 6.11).  
This apparent association was then investigated in a larger group of V617F negative ETs, 
provided by Dr K. Zoi (Athens, Greece). Rs12340895 allele frequencies of 136 V617F 
negative ETs were compared to matched controls (n=108) from Greece.  This analysis 
failed to confirm a significant association between 46/1 and V617F negative MPN, 
however the low P value (P=0.09) suggests that the relevance of 46/1 to V617F negative 
cases warrants further investigation. 
The JAK2 46/1 haplotype was also investigated using tag SNP genotyping in further V617F 
negative MPN entities (n=497); HES, FIP1L1-PDGFRA positive CEL, KIT D816V-positive and 
negative SM and BCR-ABL-positive CML cases sampled at chronic phase. As shown in 
Table 6.11 there was no significant association between 46/1 and any of these diseases.  
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         SNP genotypes 
SNP allele 
frequencies  
 P value  
(versus  
matched 
controls)       
Number 
of  cases  CC  CG  GG  C  G 
V617F negative MPN (UK)  47  17  23  7  57  37  0.009 
V617F negative ET (GR)  136  58  67  11  183  89  0.09 
HES  88  46  38  4  130  46  0.67 
FIP1L1-PDGFRA positive CEL  32  17  11  4  45  19  0.44 
SM  88  49  34  5  132  44  0.92 
KIT D816V positive SM  42  21  19  2  61  23  0.58 
BCR-ABL positive CML  247   70  53  7  193  67  0.09 
UK controls  188  103  78  7  284  92  - 
WTCCC controls  1500        2280  720  - 
Greek controls   108  60  41  7  161  55  - 
 
Table 6-11. Distribution of the 46/1 haplotype in JAK2 V617F negative MPN. Genotype and allele 
frequencies for rs12340895 (G allele tags the 46/1 haplotype, C allele tags all other haplotypes) 
shown for each JAK2 V617F negative MPN disease category. All MPN cases were obtained from 
local centres and the levels of significance achieved in comparison to UK controls are indicated, 
except the Greek JAK2 V617F negative ETs were compared to matched controls from Greece. P 
values were calculated using Fisher’s exact test, 2-tailed.  
 
 
6.3.12 Investigating JAK2 haplotype status in familial MPN 
It has been previously shown that JAK2 V617F is not inherited in affected individuals from 
families with MPN, but that an unknown factor predisposing to acquiring the mutation 
must be responsible instead 
204,364,372. Through collaboration with Dr Holger Cario and Dr 
Heike Pahl, I was able to investigate the JAK2 haplotype status of a PV pedigree in which 
V617F arose independently in two affected individuals 
373. Family members were 
analyzed for the 46/1 haplotype tag SNP rs12340895 and, as shown on Figure 6.11, one 
affected individual (UPN 534) was heterozygous for 46/1, but the second (UPN 533) was 
negative for this haplotype. Allele-specific PCR for UPN 534 revealed that V617F had 
arisen on the 46/1 allele, confirming the association between this haplotype and the 182 
mutation. This shows that 46/1 is not solely responsible, at least in this family, for 
predisposition to PV. 
 
 
 
Figure 6-11. Familial PV pedigree genotyped for the JAK2 46/1 haplotype. The two affected 
individuals (UPNs 534 and 533) are shown as green circles. The genotype for rs12340895 is shown 
(G = 46/1 allele; C = non-46/1 allele), plus the %V617F in affected cases. Allele-specific PCR for 
UPN 534 showed that V617F arose on the 46/1 allele. All other cases were negative for V617F, 
PRV1 expression, endogenous erythroid colony growth and had normal blood counts 
373. 183 
6.4  Discussion 
6.4.1  Estimation of homozygous clone size using flanking SNPs 
Many blood samples from MPN cases will comprise a mixture of three types of cell: 
normal JAK2, heterozygous V617F and homozygous V617F. The %V617F measures the 
total proportions of mutant and wild-type alleles but gives limited information with 
regard to the relative proportions of heterozygous and homozygous cells. The maximum 
%V617F for a heterozygous clone is 50% and so levels higher than this must indicate that 
a homozygous clone is present. For %V617F levels <50%, however, the situation is less 
clear. As illustrated in Figure 6.12A and B, the %V617F may be identical in cases with a 
large heterozygous clone and those with a small homozygous clone. These two situations 
may be distinguished by an analysis of flanking SNPs. Pyrosequencing is readily able to 
distinguish differences in allele ratio of 10% and thus analysis of flanking SNPs can detect 
homozygous clones that constitute only 20% of the total cell population (Figure 6.12C). 
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Figure 6-12. Detection of small homozygous clones using flanking SNPs. Panels A and B illustrate a 
large heterozygous clone and small homozygous clone, respectively. Fifteen cells with two 
chromosomes (wild-type, black; V617F, grey) each are shown for each clone. The proportion of 
mutant chromosomes (%V617F) is identical in both scenarios. Measurement of the allele ratios of 
flanking SNPs, however, clearly distinguishes the two. C. Graph illustrating the relationship 
between homozygous clone size and skewed allele ratios of heterozygous flanking SNPs. 
Pyrosequencing can reliably detect differences in allelic ratios of 10% and therefore a 
homozygous clone that comprises at 20% or more of the total cell population can be detected. 
The percentage of mutant alleles depends on the size of both the homozygous and the 
heterozygous mutated clones, but in the extreme situation of 80% normal cells, 20% homozygous 
and 0% heterozygous mutated cells the total percentage of mutated alleles is only 20%. Thus, 
measurement of flanking SNPs can detect a small homozygous clone in cases with only 20% 
V617F. 185 
The time scale of the progression from heterozygosity to homozygosity is not well 
defined, but there are two theoretical extremes, outlined in figure 6.13. Firstly evolution 
to homozygosity may occur slowly so that a heterozygous clone expands steadily and 
achieves a large size before the homozygous clone begins to grow out and eventually 
predominate. In the second situation, the transition to homozygosity occurs rapidly, 
without the significant expansion of the heterozygous clone.  
 
 
 
 
 
 
 
 
 
 
Figure 6-13. Clonal cell populations in JAK2 V617F positive PV and MF. The JAK2 mutation arises in 
one cell, (red) and confers a selective advantage, driving clonal expansion. If a heterozygous 
V617F-positive cell then acquires a second hit (acquired UPD at 9p), the new homozygous clone 
may expand at a faster rate than the heterozygous clone. The transition to may occur slowly (A) 
giving time for a heterozygous clone to expand, or rapidly (B) with minimal chance of a 
heterozygous clone building before the homozygous clone takes over. 
 
The theoretical effect of progression of V617F from a heterozygous to homozygous state 
on flanking SNPs is illustrated in Figure 6.13. Considering the situation B in Figure 6.13 
where transition to homozygosity occurs early in the evolution of the disease, the allele 
ratio of heterozygous SNPs in the region affected by acquired UPD would be expected to 
steadily change from 50% to either 100% or 0% over time depending on which 
chromosome V617F arose (lines ‘N + Homozygous V617F’ on Figure 6.14). For situation A 
in Figure 6.13, the heterozygous clone increases is size until it reaches a maximum of 50% 186 
V617F when all cells in the sample are heterozygous for the mutation. During this time 
there is no change in flanking SNP ratios (line ‘N + Heterozygous V617F’ on Figure 6.14). A 
homozygous clone then begins to grow out and the flanking SNP ratios change steadily to 
100% or 0% (lines ‘Heterozygous + Homozygous V617F on Figure 6.14). For any given 
sample, therefore, it is expected that that flanking heterozygous SNP ratios will fall 
somewhere in the blue arrowhead. This theoretical scenario accords very well with that 
actually seen in patients (Figure 6.6), although due to the preference for V617F to arise 
on 46/1, one half of the arrowhead predominates (seen most clearly for PV in Figure 
6.6b). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-14. Homozygous JAK2 V617F distorts heterozygous SNP allele ratios. See text for details.  
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6.4.2  V617F-associated disease is preferentially associated with the 46/1 JAK2 
haplotype 
This study describes the molecular characterisation of an inherited predisposition to 
myeloproliferative disease, specifically the finding that the risk of developing an MPN 
positive for the JAK2 V617F point mutation is associated with a particular constitutional 
JAK2 haplotype. Moreover, this association is comparatively strong, in comparison to 
other predisposition alleles identified in genome-wide association studies. Overall there 
was a three- to fourfold greater chance of developing V617F-positive MPN in individuals 
that carry the haplotype compared to those that did not (OR of 3.7 [95% CI 3.1-4.3] and 
RR of 2.6 [95% CI 2.3-2.9; n=435]), both calculated using cases versus WTCCC controls. 
Initially the analysis focused on homozygous V617F cases, exploiting the fact that 
distorted flanking SNP allele ratios could be used to directly read the haplotype on which 
V617F resided as well as the residual haplotype that did not acquire V617F. Seventy seven 
percent of homozygous V617F-positive cases carried V617F on the 46/1 haplotype and 
using tag SNPs it was subsequently shown that this haplotype was also overrepresented 
in heterozygous V617F positive cases. This result was highly significant, and contrasted 
strongly with results initially published by Pardanani et al. (2008) who did not see this 
association 
366. There are two principal factors that may account for this difference. First, 
although JAK2 V617F status was considered as an independent variable for the statistical 
analysis in the Pardanani study, the V617F mutation burden and the SNP allele skewing 
brought about by acquired UPD in homozygous cases was not considered. Second, the 
results from SNP allele frequencies for each test group were compared statistically to the 
relatively small Caucasian population defined by HapMap, not a matched group of 
controls with a similar ethnicity. A 46/1 tag SNP (rs10758669) was reported by Pardanani 
et al. to be significantly associated with PV but not with ET or MF compared to haplotype 
controls. This result is presumably explained by the relatively high prevalence of V617F in 
PV compared to the other two subtypes. 
Far from providing evidence for phenotypic pleiotropy in MPN as first suggested by 
Pardanani et al. (2008), the findings in this study provide the first evidence of a 
constitutional factor predisposing to acquisition of a specific mutation. Furthermore, the 
counts of 46/1 alleles in cases, along with corresponding counts in WTCCC controls and 188 
the population frequency of 46/1 from the WTCCC data, suggest that 46/1 accounts for 
approximately 28% of the population attributable risk 
370. A recent study from Sweden 
has demonstrated a RR of 5.7-7.5 in first degree relatives of MPN patients corresponding 
to an attributable risk of 53-61% 
272. Assuming no difference between the UK and Swedish 
populations, the 46/1 haplotype thus accounts for 50% of the increased risk in first 
degree relatives, indicating that additional factors predisposing to these diseases remain 
to be identified. As the association of the 46/1 haplotype with V617F-positive disease 
may account for only half of this risk of sporadic MPN, these finding provide a good basis 
for undertaking a wider investigation to identify other common low penetrance 
predisposition alleles, particularly for V617F negative disease. This could be accomplished 
in a genome-wide association study.  
The finding that certain SNPs and haplotypes are associated with common disease has 
been well defined in the literature. Many publications report the localisation of common 
SNPs associated with a wide range of malignant and non-malignant diseases and diverse 
clinical conditions, such as type 1 and type 2 diabetes, obesity, colorectal and breast 
cancer 
374-378. Some associations with leukaemia have also been described such as a 
particular haplotype of the pro-apoptotic gene BCL2 was linked to increased susceptibility 
of developing CML 
379, and polymorphisms in apoptosis- and immunoregulation-related 
genes have been shown to be associated with the risk of CLL 
380-382. Characterisation of 
disease-associated loci may lead to the identification of causal variants that are in LD with 
the significant SNPs.  
In some instances the causal mechanism behind the association between trait and a 
particular SNP has been elucidated. Polymorphisms in the promoter regions of a gene 
may affect expression, whereas polymorphisms in the gene may alter mRNA stability or 
protein structure. For example, functional polymorphic loci are well characterised in 
cytokine and cytokine receptor SNPs 
383. Additionally, the functional consequence of a 
common polymorphism in the complement factor B gene was recently found to confer a 
disease-protective effect against age-related macular degeneration 
384. 
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6.4.3  How is the 46/1 haplotype associated with JAK2 V617F disease? 
These results show that the 46/1 haplotype predisposes to V617F-positive disease, but 
underlying mechanism is unclear. There are two hypotheses that may account for the 
association of V617F disease with 46/1:  
1.  V617F may arise randomly on all haplotypes but 46/1 is in LD with an unknown 
constitutional functional variant that interacts with V617F in a manner that makes 
the development of clinically manifest disease more likely compared to V617F on 
a non-46/1 haplotype (fertile ground hypothesis). 
2.  There is a specific mutational mechanism by which V617F preferentially arises on 
a 46/1 haplotype (hypermutability hypothesis). 
These hypotheses are not necessarily mutually exclusive and are considered below. 
 
Inspection of the HapMap data (www.hapmap.org; Figure 6.4) indicates that the entire 
JAK2 gene is contained within a 280kb LD block that includes two other genes located at 
the 3’ end; INSL4 and INSL6. In principle, 46/1 would be linked to a functional SNP that 
affects any of these three genes. The expression of both INSL4 and INSL6 was investigated 
by RT-PCR performed on cDNA from PB granulocytes from two V617F-positive PV cases 
and two normal controls. No product was amplified, strongly suggesting that both genes 
are not expressed in haemopoietic cells. Indeed, a search using the Gene Expression 
Omnibus website managed by NCBI (http://www.ncbi.nlm.nih.gov/geo/) revealed both 
genes are not expressed in haematopoietic tissue. It is highly likely therefore, that any 
functional variant within 46/1 directly affects JAK2. 
 
6.4.4  Evidence for a functional variant linked to the JAK2 46/1 haplotype 
The first hypothesis suggests that V617F arises at the same rate on different JAK2 
haplotypes, but if the mutation is on 46/1, the cell gains a stronger selective advantage 
compared to V617F on other haplotypes. Alternatively it is possible that the selective 
advantage is the same but there is a greater chance of abnormal blood counts developing 
if V617F is on 46/1. Either scenario might be explained by a functional difference of JAK2 
on 46/1, e.g. altered gene expression or protein function.  190 
To look for a possible functional difference, myeloid colonies were cultured from 102 
haematopoietically normal individuals and grouped according to JAK2 haplotype status in 
a prospective investigation.  Surprisingly, I did see a difference with regards to haplotype 
status; normal cases with one or two copies of the 46/1 allele grew significantly fewer 
CFU-GM, that those who did not carry any 46/1 alleles. There was no impact, however on 
BFU-E colony formation. Whilst this result supports the notion that the 46/1 haplotype is 
functionally different to other backgrounds, exactly how this result fits with the 
phenotype of V617F-positive disease is not immediately obvious. Marked erythrocytosis 
with variable amplification of other myeloid cell lineages 
385, and hypersensitivity to 
myeloid cytokines 
386 characterise the majority of cases with JAK2 V617F. Indeed it has 
been shown in vitro that the level of V617F expression correlates with greater 
hypersensitivity to EPO 
197. It could be hypothesised that the 46/1 JAK2 variant, through 
altered binding affinity to one or more myeloid cytokine receptors, indirectly subverts 
signalling to reduce granulocyte progenitor numbers, leaving the signalling pathway 
stimulated by the EPO receptor unaffected, so that the numbers of erythroid progenitors 
remains unchanged, but expand via an autocrine or paracrine mechanism. 
Further evidence for a functional variant comes from the finding that SNP rs10758669, 
which also tags 46/1, was identified as being significantly associated with Crohn’s disease 
and ulcerative colitis in a recent genome wide association study 
387-389. Crohn’s disease 
and ulcerative colitis are believed to result from aberrant inflammatory responses, and it 
has been suggested that JAK2 may be relevant due to its role in IL23 signalling in T-cell 
subsets 
388. The finding that JAK2 46/1 (and also variants of STAT3 and IL23) are 
associated with these diseases strongly suggests that constitutional signalling differences 
in this pathway influence susceptibility to Crohn’s. 
In this study, experiments were undertaken initially to detect expression differences in 
JAK2, using V617F negative cases that were heterozygous for one of two JAK2 exonic 
SNPs as well as being heterozygous for the 46/1 haplotype. By quantifying the allele ratios 
for both SNPs in matched DNA and cDNA it should have been possible to detect 
deviations in the level of JAK2 transcripts between haplotypes. Since pyrosequencing can 
reliably detect differences in allele ratios of 10%, expression differences of only 1.5 fold 
between 46/1 and non 46/1 haplotypes should be detectable. My data showed there was 
an apparent difference for one exonic SNP but not the second, but the difference of 3.4% 191 
was very minor. The discordant results between the two SNPs analyses suggest more 
cases should be examined to see if there is a real difference. Although it is possible that 
expression differences less than 1.5 fold might be relevant, this seems unlikely. Moreover, 
as this experiment was conducted on DNA and cDNA from total leukocytes, it is possible 
that relevant expression differences that are confined to early stages of myeloid cell 
development might be missed. Expression differences may be better analysed in a 
detailed investigation of flow-sorted myeloid progenitors from V617F positive cases 
carrying one or two copies of 46/1.  
Sequence analysis of all JAK2 exons failed to identify any sequence differences between 
this gene on 46/1 and non 46/1 haplotypes. Since it is possible that intronic variants could 
lead to altered splicing, overlapping RT-PCRs to cover all exon-exon junctions were 
performed but again no differences were detected. These findings suggest that if there is 
any functional difference of JAK2 on 46/1, it must be very subtle. This is perhaps not 
surprising since roughly a quarter of V617F positive cases are negative for 46/1, and so 
this haplotype is clearly not required for disease development. 
 
6.4.5  Evidence for a mutational mechanism linked to the JAK2 46/1 haplotype 
The alternative hypothesis is that the 46/1 haplotype could confer a hypermutable 
property on the JAK2 locus. Carriers of the ‘genetically unstable’ haplotype would more 
frequently acquire mutations in JAK2, and those mutations confer a selective advantage 
that results in a clonal disorder.  
Evidence for this theory was proposed by Olcaydu  et al. (2009) 
390, who also discovered 
the association of V617F-positive MPN with the 46/1 JAK2 haplotype (which they termed 
‘GGCC’ haplotype). In this study, haematopoietic myeloid colonies were cultured from 
three individuals with MPNs who carried clones of V617F-positive cells plus other 
cytogenetically visible abnormalities, del(20q) and del(13q). Analysis of individual colonies 
revealed patterns that indicated V617F must have originated at least twice. Further 
analysis was performed on a larger series of cases using an allele specific PCR plus 
genotyping for the nearby SNP rs12343867 (which happens to tag 46/1). Of 109 cases 
analysed, three had V617F on both alleles suggesting that the mutation had arisen twice. 
A case of PV positive for both JAK2 V617F and an exon 12 mutation was also recently 192 
described, where the mutations defined separate clonal populations 
259. Since the 
acquisition of V617F is a rare event and the probability of an exon 12 mutation is 
considerably less, the chance of acquiring two completely independent JAK2 mutations is 
miniscule. Olcaydu et al. conclude there must be a DNA sequence variant present on the 
risk allele that confers susceptibility to DNA damage or unfaithful replication or repair. A 
recent study by Plo et al. (2008) 
391 reported that JAK2 V617F expression in vitro 
stimulates homologous recombination (HR) and thus genetic instability, but also wild-type 
JAK2 was also capable of inducing HR, but to a lesser extent. Mutations preceding 
acquisition of V617F may also account for, or contribute to the genetic instability 
observed in MPN 
268.  
Exactly how the JAK2 46/1 allele might create this ‘mutator phenotype’ is unclear. If the 
46/1 haplotype is more predisposed to acquiring mutations, the mechanism responsible 
must presumably be able to confer hypermutability from a distant location since analysis 
of the exons revealed no sequence differences. One area worthy of investigation 
described recently is that insertion-deletion polymorphisms present in heterozygous form 
increase the mutation rate in regions located in close proximity 
392. This could perhaps be 
tested by undertaking deep resequencing experiments 
393 to determine whether there 
are any differences in spontaneous mutation rates close to JAK2 between normal 
individuals carrying the risk haplotype, and those with other haplotypes. Results from this 
may provide an explanation as to why a minority of healthy normal individuals were 
found to apparently carry a low level of the JAK2 V617F mutation 
394. 
In addition to the specific association described here for MPN, the finding that 46/1 
predisposes to a somatic mutation may have wider relevance. Genome-wide association 
studies are identifying increasing numbers of loci that predispose to diverse malignancies. 
The findings in this study suggest that such loci should be considered as candidates for 
the acquisition of somatic mutations. At least two other relevant examples are present in 
the literature. First, the APC polymorphism I1307K, found in 6.1% of people of Ashkenazi-
Jewish origin, accounts for an approximate 2-fold increased risk of colorectal cancer. This 
rare allele creates an unstable sequence that is hypermutable, leading to somatic, 
truncating mutations occurring in adjacent sequence which predispose to cancer 
395. 
More recently, research into common genetic variation that modifies susceptibility to 
lung cancer has revealed particular polymorphisms and haplotypes within the TP53 gene 193 
that are associated with adverse prognosis and an increased risk (OR 2.32) of developing 
lung cancer in African-Americans, but not Caucasians 
396. Whether this is a result of a 
functional interaction or propensity to acquire mutations is unclear. 
 
6.4.6  The JAK2 46/1 does not explain V617F-positive familial MPN  
Examples of MPN segregating in families has provided firm evidence that that JAK2 V617F 
is an acquired somatic mutation, and not passed through the germ-line. Firstly, V617F 
was shown to be absent in T lymphocytes of familial patients carrying the mutation in 
granulocytes 
372. Furthermore, a different mutation burden was reported in affected 
relatives, whereas if the mutation was transmitted in the germ-line then V617F should be 
found in 50% of alleles 
365. 
My study included an investigation of the 46/1 haplotype in one family with MPN, 
previously characterised by Cario et al. (2005)
364. This family included two JAK2 V617F-
positive relatives with PV, but the obligate carrier was healthy with wild-type JAK2. 
Genotyping of this family revealed only one affected individual carried V617F on the 46/1 
haplotype. This indicates that 46/1 does not provide a genetic predisposition to acquiring 
V617F, at least in this family. Indeed, linkage of disease to 9p has not been described in 
any MPN family to date 
204. Further characterisation of JAK2 haplotypes in other families 
with members with V617F-positive MPN will clarify the influence of the 46/1 allele, 
however it seems likely that these are different situations. To be seen as a familial trait, 
any genetic variant must be highly penetrant, i.e. the chance of developing an MPN is 
high if the variant is inherited. The 46/1 haplotype on the other hand is very common: a 
gene frequency of 0.24 predicts that 5.8% of normal individuals will be homozygous for 
46/1 and 36.5% will be heterozygous (p
2 and 2pq in the Hardy-Weinberg equation, 
respectively). Although very common and associated with an increased risk of developing 
an MPN, the absolute risk is still very low because of the very low penetrance. If the 
incidence of a V617F positive MPN is roughly 4 per 100,000 per annum 
23, and the risk of 
developing an MPN is three fold higher for individuals with at least one copy of 46/1, then 
it would be expected that the incidence of V617F positive MPN would be 3 per 100,000 
per annum for individuals with 46/1 and 1 per 100,000 per annum for individuals without 194 
46/1. The contribution of 46/1 to understanding genetic predisposition to MPN is 
illustrated in Figure 6.15. 
 
 
 
Figure 6-15. Genetic predisposition to MPNs. This illustration shows the two ends of the genetic 
spectrum. On the top left side are rare examples of families with members with MPN displaying 
Mendelian inheritance, where the penetrance is high. Conversely, in the bottom right hand side 
there are the common alleles, like the JAK2 46/1 haplotype, where the effects on risk of disease 
contributed by each gene locus may be modest, but when combined they may substantially 
increase the risk of disease. 
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7  Conclusions and discussion 
 
Much of the discussion of the work in this thesis is presented in the preceding chapters. 
This chapter discusses my work in a wider context, with reference to some of the work I 
have undertaken subsequently and areas for future research. 
The original aim of this study was to investigate how deregulated tyrosine kinases 
contribute to the molecular pathogenesis of MPNs. Shortly after starting my investigation, 
JAK2 V617F was discovered, and my research then focused on characterising this very 
interesting mutation. Since starting this project, understanding of the molecular biology 
of MPN has been furthered substantially, and recent findings will be discussed alongside 
my results where relevant. 
 
7.1  Detection and characterisation of JAK2 V617F 
In 2005, the finding of JAK2 V617F was a highly significant step forward in the 
understanding of the pathogenesis of MPN, and this mutation became a new disease 
marker when the WHO revised the diagnostic criteria for PV, ET and MF 
397. Research 
presented in this thesis described the first evidence that V617F was not restricted to 
cases with classical MPN, but may also be  in atypical MPNs, specifically MPN-U, aCML, 
and rare cases with CNL and HES 
252. Other studies confirmed my findings, and wider 
screens isolated V617F in 1% MDS and 18% megakaryocytic AML. However, V617F was 
not found in patients with BCR-ABL positive CML (except for rare cases that appear to 
have co-incident CML and MPN), AML, or ALL 
261,262. More intensive investigations for 
V617F in de novo AML isolated the mutation in 3% of patients with M1 and M2 subtypes, 
suggesting a correlation of V617F with less differentiated leukaemias with a normal 
karyotype 
398. V617F was also identified in approximately 6% of AMLs carrying a t(8;21) 
translocation, suggesting oncogenic co-operation between the translocation product 
RUNX1-CBFA2T1 and JAK2 V617F, analogous to that proposed for FLT3 ITD mutations in 
this subtype of AML 
399.There have also been extensive investigations looking for V617F in 196 
non-haematological cancers and lymphoid malignancies, but V617F was entirely absent 
280.  
At the beginning of my investigations into JAK2 V617F, it was quickly determined that 
standard sequencing techniques would miss a significant proportion of V617F positive 
cases due to an inadequate level of sensitivity. To circumvent this, I used two alternative 
methods of detection; AS-PCR and pyrosequencing, which attained sensitivity levels of 2% 
and 5%, respectively. Although AS-PCR was semi-quantitative, accurate quantification of 
the mutation level was achieved using pyrosequencing. After validation in my hands, both 
methods were then used by the Wessex Regional Genetics Laboratory to test for JAK2 
V617F as part of a diagnostic service to confirm a diagnosis of MPN. Over 3500 cases have 
now been screened for V617F. A very small minority of samples carry low levels of 
mutation detected by AS-PCR, but not by pyrosequencing due to its slightly higher 
detection threshold. In these circumstances a provisional report is issued with a request 
for a new sample in six months time to see whether the mutation becomes more readily 
detected. During routine screening, it was observed that one individual was strongly 
positive for V617F on AS-PCR but then apparently negative by pyrosequencing. Following 
direct sequencing, it transpired the patient carried V617F plus a C618R mutation, a very 
rare change reported previously in only two individuals 
400. The C618R mutation is 
thought to have destabilised the pyrosequencing sequencing primer oriented in the 
reverse direction, whereas in the AS-PCR the mutation-detecting primer is in the forward 
orientation so could detect V617F. There are now a range of methods published in the 
literature claiming accurate detection of JAK2 V617F 
401, and some semi-quantitative real-
time PCR assays report sensitivity levels of down to 0.01% mutation level 
402. However, 
the clinical significance of a such a low mutation burden in patients at diagnosis remains 
to be determined, especially given recent anecdotal reports that nearly 1% of 
haematologically normal individuals apparently tested positive for V617F 
394. Such 
sensitive techniques, however, may be important for monitoring therapeutic responses as 
discussed below. 
One issue with using JAK2 V617F diagnostically is that in the context of myeloid 
neoplasms, V617F cannot be used to distinguish one MPN from another. The presence of 
V617F does complement laboratory and clinical markers, including histology in the 197 
diagnosis of both ET and MF, by excluding the possibility of reactive thrombocytosis or 
myelofibrosis. Where a diagnosis of PV is suspected, clinicians now generally choose to 
screen for V617F in PB rather than measure red cell mass in the patient, which is an 
unpleasant and expensive procedure 
22. However V617F or exon 12 mutations are not 
detected in occasional PV cases, either because they are wholly absent, or are present 
beneath the limits of detection 
347. These observations together with the fact that only 
half of ET and MF cases are positive for JAK2 V617F have led to V617F being only one of a 
series of criteria in the diagnostic algorithms defined by the WHO 
22. 
The finding of one single mutation in several phenotypically related, but clearly distinct 
diseases was unexpected. Explanations for this are far from confirmed, but do provide 
tentative evidence for how V617F can be associated with different neoplasms. One 
hypothesis relates to the level of JAK2 V617F the patient carries, that is the disease 
phenotype is correlated with V617F mutant allele burden. In vitro evidence for this comes 
from experiments expressing variable levels of mutation in mouse models. Low levels of 
V617F induce an ET-like phenotype dominated by thrombocytosis, whereas a higher level 
of mutant allele leads to a PV-like phenotype, characterised by erythrocytosis and 
eventually myelofibrosis 
282,283,363,403. As I have shown in this thesis, JAK2 V617F allele 
burden is a measurable variable being determined by the frequency of mitotic 
recombination events and the expansion of mutant positive clones. In humans the 
average V617F mutation burden of ET cases is statistically lower than that seen in PV and 
MF, consistent with the fact that acquired UPD is an infrequent event in ET 
198,199,252. This 
was later explored at the progenitor level by Scott et al. (2006), who grew EECs from 
patients with ET, PV and MF and investigated the presence of V617F in each colony. Even 
in cases with <50% V617F in total granulocytes, a mixture of heterozygous and 
homozygous V617F erythroid colonies was present in most PV and MF cases, but only 
heterozygous V617F positive colonies were found in the vast majority of ET cases 
281. It 
has been speculated that as PV cases have a lower serum EPO level than ET cases, 
homozygous V617F positive erythroid colonies have a stronger selective advantage in a 
low-EPO environment. Alternatively, PV cases may have a longer subclinical prediagnosis 
phase of disease than ET cases, allowing more time for homozygosity to occur. Mitotic 
recombination at the JAK2 locus may be more frequent in PV perhaps due to a 198 
haematopoietic microenvironment that is more genetically damaging, or the presence of 
other mutations or inherited differences that influence genetic stability. Whatever the 
reason, it is highly likely that JAK2 V617F alone cannot account for the MPN phenotypes 
seen clinically.  
A recent study correlated JAK2 V617F allele burden in cases with MPN with gender, and 
showed women had significantly lower allele burdens than men at diagnosis. 
Furthermore, on follow up the increase in allele burden per year was significantly less in 
females compared to males, and women were 4.5 times more likely to evolve from ET to 
PV. This suggests sex is an independent factor that may go some way to account for the 
variability in V617F allele burden, and that females have a lower frequency of mitotic 
recombination events compared to males 
404.   
Another highly plausible explanation for why JAK2 V617F is linked to more than one 
neoplasm is that V617F may not be the disease-initiating lesion. Other undiscovered 
mutations may precede the acquisition of V617F, and directly influence the neoplastic 
phenotype 
360,405. Evidence for preceding mutations comes from studies focusing on 
markers of clonal proliferation. For example, it has been shown that in patients with a 
V617F mutation burden of <25%, the granulocytes that did not carry V617F were often 
clonal, as determined by the X chromosome inactivation pattern in female cases, or by 
the presence of deletions on chromosome 20q 
268. Furthermore, when the level of clonal 
granulocytes was measured and compared against the level of the V617F allele, a direct 
correlation was observed for PV, but not ET or MF 
269. Another study showed that V617F-
positive MPN cases carry a small number of EECs which were wild-type for JAK2, 
alongside other V617F-positive colonies 
271.  Subsequently, other mutations have been 
shown to be acquired in MPN, but as yet not one has been strictly associated with a 
particular phenotype. 
Mutations in the thrombopoietin receptor gene, MPL, are associated with a more 
distinctive clinical picture; having been isolated only in a small proportion of MF and ET 
cases 
406. MPL W515L mutations constitutionally activate JAK-STAT signalling, induce 
ligand independent proliferation in cell lines and reproduce many phenotypic 
characteristics of MF when expressed in mouse models, e.g. atypical megakaryocytic 199 
hyperplasia, splenomegaly due to extramedullary haematopoiesis and thrombocytosis. 
Inactivating mutations of the E3 ubiquitin ligase, CBL, have been isolated in a small 
minority of cases with MF, CMML and aCML and are thought to act by a general increase 
in the level of signalling from tyrosine kinases 
407,408. Other mutations have been 
identified for which the mechanism of transformation is currently less clear. Acquired 
mutations of TET2 have been isolated in approximately 15% of patients with various 
forms of myeloid disease; 19% of MDS, 12% MPN (JAK2 V617F positive and negative 
cases), 22% CMML and 24% of cases with secondary AML 
409. Likewise, 11% of MDS and 
43% of cases with CMML carry mutations in ASXL1 
410. The very newly indentified IDH1 
and IDH2 mutations have, as yet, only been isolated in 31% of JAK2 V617F positive MPNs 
that have evolved to acute leukaemia 
411, and not in PV or ET cases that were in chronic 
phase.  
 
7.2  MPN cases may have more than one clonal proliferation 
There is mounting evidence to suggest an increasing degree of clonal heterogeneity in 
patients with MPN.  It has been shown previously that the clonal burden is not accounted 
for by burden of JAK2 V617F alone, and in some cases the disparity is made up by other 
markers of clonal proliferation, like del(20q) or other unidentified mutations 
268. More 
detailed study of progenitor colonies has shown that del(20q) 
288, and mutations in TET2 
409 may follow or precede acquisition of a JAK2 mutation.  In this thesis I studied myeloid 
progenitors from a patient carrying both JAK2 V617F and KIT D816V in vitro. The 
mutations were found to be mutually exclusive, an observation mirrored in a larger series 
of similar MPNs with biclonal mutations or cytogenetic abnormalities 
287. It is currently 
hypothesised that (i) either the different clonal populations are phylogenetically related, 
having risen from a shared founder clone, or (ii) the different clones are unrelated, and 
reflect transformation of independent stem cells. Although transformation of 
independent stem cells might at first sight seem implausible, it is worth pointing out that 
the molecular basis for disease predisposition in MPN families has not been elucidated 
and it is possible that these individuals have inherited a genetic variant that increases the 
probability of acquiring mutations in haemopoietic cells. 200 
This issue of biclonality is elegantly illustrated in those cases with MPN that transform to 
acute leukaemia. It was observed that in those cases that transform from V617F positive 
MPN to acute phase, the level of V617F frequently drops and even disappears as 
transformation progresses 
265,270. This suggests a clonal V617F negative cell carries the 
potential to acquire various leukaemogenic mutations and proliferate independently of 
V617F. It was recently observed that the majority of cases that transformed to JAK2 
V617F positive AML were preceded by primary MF or myelofibrotic transformation, 
implying that JAK2 V617F AML is preceded by mutations that give rise to a ‘myelofibrosis-
like’ phenotype 
412. In contrast, other cases with additional mutations in TP53, CBL, TET2, 
and now IDH mutations 
411, were present in JAK2 wild-type leukaemic blasts but absent 
from JAK2 V617F positive MPN. This implies different pathogenetic mechanisms may 
underlie transformation to JAK2 wild-type and JAK2 mutant AML.  
There have been speculations that the cell in which JAK2 V617F arises may go some way 
to explain some of the phenotypic pleiotropy of MPN.  It has been shown, at least in PV 
cases that JAK2 V617F arises in multipotent HSCs and their myeloid-restricted progeny, 
and predisposes towards erythroid differentiation 
413,414. The observation that V617F was 
absent in T cells from PV patients first suggested V617F was a myeloid-specific mutation 
197,199. However more investigations have isolated V617F in T and B cells in small groups of 
MPN patients 
415 
416, and some individuals with MF have a mutation burden in 
lymphocytes that equals that measured in granulocytes 
417,418. Moreover, the notion that 
V617F may favour different cellular targets, and that this may define the clinical 
phenotype of MPN remains a weak hypothesis, given the observation that CD34+ cells 
carry V617F at very similar levels to that found in granulocytes 
418. Conversely, enforced 
expression of JAK2 V617F in human HSCs and myeloid progenitors directed differentiation 
towards the erythroid lineage, along with increased expression and phosphorylation of 
GATA-1 and PU.1 transcription factors 
419-421. Altogether this suggests that V617F arises in 
a stem cell and directs myeloid proliferation, rather than being restricted to myeloid cells. 
Recently a very interesting, novel role of JAK2 was identified; JAK2 may directly regulate 
gene expression by the phosphorylation of histones in the nucleus 
422. It is well 
characterised how JAK2 functions in the cytoplasm as a critical signalling component for 
diverse receptors at the cell surface 
371. This new nuclear function of JAK2 revealed a 201 
novel epigenetic mechanism by which JAK2 may function in an altogether different 
setting. Both wild-type and constitutively active (V617F positive) JAK2 were shown to 
phosphorylate histone H3 at position Y41. Phosphorylation prevents binding of 
heterochromatin protein 1 alpha (HP1α), the effect of which is likely to include increased 
mitotic recombination and increased expression of heterochromatic genes. Whether this 
has any relevance to MPN is currently unclear, but these findings indicate that the cellular 
consequences of deregulated JAK2 are likely to be complex. 
 
7.3  Acquired uniparental disomy  
One recurrent theme of this thesis has been acquired UPD for chromosome 9, observed 
in a significant proportion of cases with JAK2 V617F positive MPN. Brought about by 
somatic recombination at mitosis, this mechanism ultimately results in duplication of one 
chromosome or chromosomal region and concurrent loss of the other allele. In this thesis 
I used a PCR-based method, MLPA, to show MPN cases with a high V617F burden carried 
two copies of JAK2. This complemented microsatellite analysis to show that the observed 
stretches of homozygosity had arisen by mitotic recombination and not by deletion or 
duplication of chromosome 9. Furthermore, the observation that acquired UPD not only 
reduces one mutation, but also all the heterozygous SNP alleles linked in cis, to 
homozygosity, provided a key tool in identifying a particular constitutional JAK2 
haplotype associated with the acquisition of V617F.  
Acquired UPD has been best described in solid tumours, usually with the effect of 
inactivating tumour suppressor genes 
423-425. As with JAK2 V617F 
197, acquired UPD allows 
malignant cells to multiply gene mutations and to dispose of wild-type alleles, thus 
obtaining a selective growth advantage over cells without acquired UPD. The advent of 
high-density SNP genotype arrays has shown that approximately 17% of cases with AML 
have evidence of acquired UPD 
426. Moreover, homozygously mutated genes CEBPA, WT1, 
FLT3 and RUNX1 are all associated with acquired UPD in AML 
129 
427, suggesting that 
acquired UPD is a relatively common mechanism of disease progression. More recently, 
mutations of MPL 
406, CBL 
407, and TET2 
409,428 have been discovered in MPN, and all are 202 
associated with varying levels of acquired UPD.  It is unclear why loss of heterozygosity of 
mutations at some loci tend to occur by acquired UPD and others by deletion of the wild-
type allele. LOH for JAK2 and MPL mutations is almost always associated with acquired 
UPD whereas LOH of TP53 and RB mutations are usually a consequence of deletion of the 
wild-type allele. One reason for a preference for acquired UPD might be the presence of 
one or more neighbouring dosage sensitive genes, deletion of which would confer a 
proliferative disadvantage or even lethality to the cell. It is also possible that the 
expression of imprinted genes may either be silenced or enhanced by acquired UPD, 
depending on which allele is methylated and which one is duplicated. Alternatively, 
acquired UPD may serve to duplicate a minor disease-prone allele present in the germ-
line, which may have a deleterious effect. Most likely, the acquisition of an additional 
copy of the mutant allele results in increased levels of a protein with pathogenetic 
potential. This might be of relevance for the activity of oncogenes such as JAK2 V617F but 
not for tumour suppressor genes such as TP53. 
The molecular basis of a significant proportion of MPN cases still remains to be 
determined. Identifying recurrent regions of acquired UPD has proven very useful in the 
past for selecting candidate genes, but as the regions of homozygosity are often greater 
than 10 megabases in size, this is still an arduous task. Alternatively, new acquired 
mutations are likely to be identified as a result of ‘next-generation’ sequencing, which is 
set to become cheaper and easier to use. 
 
7.4  JAK2 V617F is a suitable molecular marker of clonal disease and 
response to treatment 
Following the successful application of imatinib as a BCR-ABL tyrosine kinase inhibitor for 
the treatment of CML, the identification of JAK2 mutations in MPNs has generated 
extensive interest in developing JAK2-specific inhibitors to treat these diseases. Although 
it may or may not be the disease-initiating lesion 
265,268-271, expression of JAK2 V617F in 
murine models is singularly sufficient to cause a myeloproliferative phenotype, where the 
mice recapitulate many clinicopathologic features observed in human PV, ET and MF 203 
282,283. Therefore, mutant JAK2 remains a valid target for therapeutic intervention in 
MPNs. As I have investigated in this thesis, JAK2 V617F is a reliable and sensitive marker 
of disease, and may be used to monitor response to therapy. Other groups have reported 
the use of %V617F as a molecular marker, and the majority correlate a fall in %V617F with 
haematological improvement 
277,279,326-328,330-333.  
Numerous JAK2 inhibitors have been identified, based on the experience gained from the 
development of tyrosine kinase inhibitors in CML. Although no single small-molecule JAK2 
inhibitor is available yet for broad clinical use, there are already a number compounds 
reported to have significant activity against JAK2 V617F in vitro 
429-431 and some have 
been tested in animal models 
432 and in vitro cultures of JAK2 V617F positive patient cells 
433. A small number are under evaluation in phase I and II studies in patients with primary 
and secondary MF. Some V617F positive patients with MF and post PV/ET MF treated 
with compounds INCBO18424 and XL019 displayed significant reduction of spleen size, 
reduced leukocytes and improvement of symptoms 
434. However, there was very limited 
reduction in proportion of V617F in PB granulocytes indicating minimal impact on the size 
of the malignant clone. 
Exactly how these compounds exert their effects in not understood, but it is possible 
there may be significant off-target effects, e.g. on other JAK family members or possibly 
as a consequence of inhibiting normal JAK2. Unlike BCR-ABL, the V617F mutation is 
localised in a region outside of the ATP-binding pocket of the JAK2 enzyme. Therefore 
ATP-competitive inhibitors are not likely to distinguish between wild-type and mutant 
JAK2 proteins. The JAK family play an important role in coordinating haematopoiesis, 
making it pertinent to specifically target JAK2 to avoid undesirable long-term effects. 
JAK3, like JAK2, is expressed in haematopoietic cells, and plays a vital role in immunity, so 
any unwarranted inhibition may be damaging, especially as JAK3-deficient mice are viable 
but display severe combined immunodeficiency 
435. Despite the failure to reduce the size 
of the mutant clone, it has been suggested JAK inhibitors do have significant therapeutic 
benefit by controlling debilitating symptoms of disease, like splenomegaly or the effects 
of high levels of circulating cytokines, e.g. pruitus 
434.  204 
There is mounting clinical evidence correlating JAK2 V617F allele burden to disease 
phenotype, complications and evolution to myelofibrosis. As mentioned above, ET cases 
tend to have a low allele burden, those with PV and MF carry an intermediate level, and it 
has been shown elsewhere those with post-PV MF have a very high level of V617F 
278,279,405. To investigate the clinical relevance of JAK2 mutation status, a large series of ET 
cases entered into the Primary Thrombocythaemia (PT-1) trial were screened 
retrospectively for V617F, and status was correlated to various clinical, laboratory and 
diagnostic parameters 
329. Roughly half of the ET cases were positive, and those that 
carried V617F were more likely to have a PV-like phenotype characterised by increased 
haemoglobin, elevated neutrophils and erythrocytes, more venous thrombosis, and 
higher rate of polycythaemic transformation. V617F-positive ET cases also had a low 
serum EPO level, and were significantly more sensitive to hydroxyurea compared to 
anagrelide. Furthermore, due to the numerous shared features, it has been proposed that 
JAK2 V617F positive PV and JAK2 V617F positive ET could be better viewed as a 
continuum, with each neoplasm at either ends of the model, with the difference being 
accounted for by transition to V617F homozygosity, acquired or inherited genetic 
modifiers, gender, and constraints of physiology, like suppression of EPO production and 
depletion of iron stores. There are now numerous clinical studies correlating %V617F to 
disease characteristics, and the majority agree that there is a linear relationship between 
mutation burden and severity of disease 
273-279,436. However the differences are relatively 
subtle and are probably of limited value for the assessment of individual patients. 
 
7.5  JAK2 exon 12 mutations are very rare in MPN 
A small proportion of cases with PV (some with an initial diagnosis of IE) acquire 
mutations in exon 12 of JAK2, and these mutations are thought to have a similar 
pathogenic effect as V617F by inducing a myeloproliferative phenotype, characterised by 
marked erythrocytosis 
266. However, unlike V617F, exon 12 mutations may be found 
almost anywhere in the exon, exist as nucleotide insertions, deletions, substitutions or a 
mix of all three changes. These features together with the observation that exon 12 
mutations predominantly exist in heterozygous form only, and positive cells are relatively 205 
infrequent in PB and BM, make detecting them technically challenging. Having been 
unable to find an exon 12 mutation in a large series of local V167F negative cases with a 
tentative referral of MPN using existing methods of standard sequencing and AS-PCR, I 
developed and applied two alternative PCR-based methods for detecting mutations in 
exon 12. These were HRM analysis and WTB PCR. Both methods proved more sensitive 
than standard sequencing, were capable of detecting novel mutations, but the WTB PCR 
was the most sensitive at uncovering low level mutations. Despite these improved 
methods, no exon 12 mutations were detected in our local group, suggesting the 
incidence of this particular mutation is extremely low, and screening should only be 
undertaken after careful clinical characterisation.  
To date mutations in exon 12 and V617F of JAK2 have only ever been isolated in patients 
with a myeloid disease 
197,266. Recently, mutations at JAK2 residue R683 have been 
identified in 18% of patients with Down’s syndrome (DS)-associated ALL 
373,437. Further 
investigation revealed JAK mutations in a small minority of paediatric ALL cases, where 
mutations in JAK2 mainly targeted R683 
438. The finding that mutations affecting R683 
have been identified almost exclusively in DS and non-DS high-risk ALL, and mutations in 
exon 12 and exon 14 are entirely myeloid-associated, suggests the nature of the JAK2 
mutation may play a direct role in establishing the disease phenotype. Additionally, a 
T875N JAK2 mutation was identified at in an AMKL cell line 
439, and a deletion of five 
amino acids starting at residue I682 (IREED deletion) was found in a single case of DS-ALL 
440. The reasons for why different mutations within the JAK2 gene are linked to different 
phenotypes are unclear, but this does suggest there is something functionally different 
about JAK2 in each biological setting. As mentioned previously, V617F has been isolated 
at varying levels in both myeloid and lymphoid cell types, so it would be interesting to 
determine what other lineages carry these other JAK2 mutations.  
One study has investigated the question of why valine at position 617 mutates to 
phenylalanine in MPN and not another amino acid. In an in vitro system, several other 
mutations at position 617 could, to varying extents, induce constitutive signalling but only 
V617W was comparable to V617F in stimulating STAT5 activation. However, the codon 
that codes for tryptophan (TGG) could only be obtained by three nucleotide substitutions 
from the wild-type valine (GTC), whereas phenylalanine (TTC) only required one 206 
nucleotide substitution 
441. Consequently V617W is expected to be very uncommon in 
patients. 
As discussed above, patients with MPN may carry more than one activating mutation, and 
the combination of these could influence disease phenotype. There is already some 
precedence for the idea of cooperating mutation(s) contributing to pathogenesis in 
relation to JAK2. In cases with paediatric ALL carrying the JAK2 R683 mutations, there 
were also often concomitant alterations in genes involved in lymphoid development 
(IKZNF1) and tumour suppression (CDKN2A/B), suggesting that co-occurrence of these 
lesions is important for pathogenesis of this particular disease, or that these other 
abnormalities are lineage-specific secondary mutations 
438. A minority of V617F positive 
MPNs have also been shown to carry mutations in genes with myeloid growth factor 
signalling roles, e.g. KIT D816 
114, MPL W515 
406,  and CBL 
407,408 however in most of these 
that have been analysed the JAK2 and other mutations occur in separate clones. A new 
set of mutations have been identified in MPN which may disrupt chromatin remodelling 
with consequent effects on the regulation of gene expression. These include mutations in 
TET2 
409 and ASXL1 
410 but it is not yet clear if these co-operate in any way with 
deregulated JAK2 signalling.  
Interestingly, the phenotype and clinical course of JAK2 activated by mutation (MPN 
being a relatively indolent, chronic disease), is distinctly different to disease associated 
with JAK2 fusion genes (e.g. ETV6-JAK2, PCM1-JAK2), which more closely resembles 
leukaemias associated with ABL1 fusion genes (aggressive CML and ALL). This observation 
highlights the phenotypic importance of the mechanism leading to kinase activation. 
Moreover, both JAK2 fusions above have been isolated in both myeloid and lymphoid 
proliferative phenotypes, suggesting that they do themselves not specify either myeloid 
or lymphoid differentiation.  
 
7.6  Inherited predisposition to acquiring MPN 
In this thesis I describe the finding that JAK2 V617F is not acquired randomly, but instead 
preferentially arises on a specific constitutional JAK2 haplotype which was termed ‘46/1.’ 207 
At least one allele of 46/1 is found in approximately 50% of normal individuals, and so this 
haplotype is a common low penetrance predisposition allele, similar to those typically 
identified by GWAS. The association between V617F and 46/1 is relatively strong, with 
the odds of developing an MPN three to four fold higher in individuals carrying the 
haplotype than those who did not. Furthermore, it was possible to determine that the 
46/1 haplotype accounts for 50% of the MPN risk attributable to genetic factors. The 46/1 
haplotype is associated with homozygous and heterozygous levels of V617F. The 46/1 
haplotype block has a tag SNP in close proximity to the V617F mutation, so it was possible 
to determine in cases heterozygous for 46/1 and V617F that the mutation was 
significantly more likely to arise on the 46/1 chromosome.  
46/1 was seen at comparable frequencies in different MPN subtypes, so does not explain 
the phenotypic diversity associated with JAK2 V617F. Nor does 46/1 account for familial 
MPNs, which are expected to be caused by rare, highly penetrant variants in genes that 
remain to be identified. It is not clear why an acquired mutation as prevalent as JAK2 
V617F is associated with a particular inherited background. The first hypothesis considers 
46/1 is inherently more genetically unstable, acquiring V617F at a faster rate than other 
haplotypes (hypermutability hypothesis). The second hypothesis proposes V617F may 
arise on all haplotypes at equal rates but 46/1 may carry an additional factor that either 
provides a selective advantage to the V617F positive clone, or interacts in some way to 
increase the likelihood of abnormal blood counts (fertile ground hypothesis). These 
hypotheses are not necessarily mutually exclusive, and there is evidence to support each 
theory. 
The hypermutability hypothesis is favoured by Olcaydu et al. (2009) 
390, who observed 
that V617F was seen in cis to both alleles of a nearby heterozygous SNP in 3 out of 109 
(3%) MPNs. In a recent screen of 46/1 in 207 ET cases, I found 2 (1%) carried V617F on 
46/1 plus a different JAK2 haplotype, thus confirming the findings of Olcaydu et al. 
Additionally, rare cases with both JAK2 V617F and JAK2 exon 12 mutations have been 
recorded 
259. The finding of double mutated cases might therefore in theory be explained 
by hypermutability of JAK2 on 46/1, but other factors could account for this. For example, 
other acquired or inherited genetic variants may predispose to the acquisition of JAK2 
mutations, thus greatly increasing the probability of two separate mutations in the same 208 
individual. This enhanced propensity to acquire JAK2 mutations is already accepted in the 
context of familial MPNs, where multiple affected family members acquire V617F or an 
exon 12 mutation as a result of inheriting an as yet uncharacterised, highly penetrant 
genetic variant 
364,372. Although documented MPN families are relatively uncommon, a 
study recently published estimated that as many as 8% of cases have a family history of 
MPN 
442, and thus a substantial minority of affected individuals may have an elevated, 
inherited propensity to acquire multiple JAK2 mutations. The JAK2 V617F mutation itself 
was recently reported to increase the rate of homologous recombination as well as 
mutation rate 
391 and thus JAK2 mutant cells may be intrinsically more likely to acquire 
additional JAK2 mutations. There may be acquired or inherited weaknesses of various 
components of DNA repair or mitotic spindle machinery, or telomere shortening. The 
incidence of acquired UPD increases with age in MPN, and also MDS and AML, so perhaps 
cumulative acquisition of genetic and epigenetic lesions may contribute to development 
of disease 
443.  
If there is a specific mutational mechanism by which V617F preferentially arises on the 
46/1 haplotype, then other mutations in JAK2 may also be associated with this allele. An 
association between 46/1 and JAK2 exon 12 mutations was described recently 
444, a 
finding I replicated recently in 69 cases (p=0.002, manuscript submitted). Similar to my 
findings for V617F, in 31 cases heterozygous for 46/1, 71% of exon 12 mutations were 
acquired in cis to 46/1. Nevertheless, an association of different JAK2 mutations with 46/1 
is equally compatible with the alternative hypothesis, fertile ground.  
Our group marginally prefer the fertile ground hypothesis, based on the observations 
presented in this thesis that 46/1 is associated with lower numbers of myeloid colony 
forming units in normal individuals. Furthermore, a 46/1 tag SNP showed robust 
association with Crohn’s disease and ulcerative colitis, non-malignant disorders believed 
to result from a perturbed inflammatory response 
387-389. GWAS studies in Crohn’s disease 
also detected significant associations with genes encoding the IL-23 receptor and STAT3, 
thereby strongly implicating functional differences in the IL23/JAK2/STAT3 pathway in the 
pathogenesis of this disorder. Moreover, it has subsequently been shown that there is a 
20% increased incidence of MPN in individuals that have had a preceding history of an 
autoimmune disorder, and for Crohn’s disease this risk is 2 to 3 fold 
445. These findings 209 
strengthen the hypothesis that common functional genetic variants impacting on JAK2 
signalling predispose to these clinically very diverse conditions. With this in mind, I 
recently investigated whether the STAT3 SNP rs744166, identified in Crohn’s GWAS 
studies also predisposes to MPN. Using pyrosequencing, I genotyped PB DNA from our 
cases with JAK2 V617F positive PV (n=136) and JAK2 V617F negative ET (n=338), and 
compared the results to control data obtained from the WTCCC blood cohort. No 
significant differences were observed between cases and controls, and we concluded 
therefore that there was no evidence to indicate that this particular variant of STAT3 
predisposes to MPN. 
Since finishing the work for this thesis I have focused mainly on trying to distinguish 
between the fertile ground and hypermutability hypotheses. If, according to the fertile 
ground hypothesis, the 46/1 haplotype is functionally different to JAK2 on other 
haplotypes, it might be expected to influence the clinical phenotype or be associated with 
specific features of disease. To explore this possibility I genotyped a 46/1 tag SNP in 
patients entered into the Primary Thrombocythaemia 1 (PT-1; n=751) study, a clinical trial 
that included newly diagnosed and previously treated patients aged 18 years or over who 
met the Polycythaemia Vera Study Group (PVSG) criteria for ET 
446. Results were then 
compared to clinical, laboratory and demographic data by the trial statistician, Dr Peter 
Campbell (Cambridge, UK) for both V617F-positive and V617F negative cases. No 
significant associations were seen with any clinical or laboratory feature (for example, age 
at diagnosis, blood counts, haemoglobin, erythropoietin and spleen size). Furthermore, 
there was no association with survival, arterial thrombosis, major haemorrhage, or 
transformation to MF or acute leukaemia (manuscript submitted). Similar findings were 
recently published by Pardanani et al. (2009) 
447. By contrast absence of 46/1 has been 
associated with inferior survival in MF 
448. 
Analysis of the PT-1 cohort indicated that the JAK2 46/1 haplotype was more prevalent in 
cases with an exon 10 MPL mutation, although this did not achieve statistical significance 
(P=0.06). This observation was explored further in an additional 176 cases recruited from 
the UK, Greece, Italy and Germany, all proven to be negative for V617F. After controlling 
for population stratification by using controls from each of the four countries, the 210 
association between 46/1 and MPL exon 10 positive cases achieved significance (p=0.004, 
manuscript submitted).  
MPL requires JAK2 for signalling and thus the finding of an excess of 46/1 alleles in MPL 
mutated cases suggests a functional difference of JAK2 on 46/1 compared to other alleles, 
rather than the 46/1 allele being more genetically unstable. There is already some 
precedence for a functional SNP variant in AML pathogenesis. Investigations into patients 
with AML and a complex karyotype revealed an association between a SNP variant 
located in an enhancer region of the PU.1 transcription factor, which through altered 
binding of a transcriptional regulatory protein (SATB1), was shown to reduce PU.1 
expression significantly in specific myeloid progenitor subtypes 
449. Regarding 46/1, 
however, I have not found evidence of any expression differences between 46/1 and non 
46/1 alleles, nor have I found any variants after sequencing all coding regions and 
untranslated regions of JAK2 in eight homozygous V617F positive MPNs with 46/1.  
I conclude that if a functional difference is present on 46/1, then its effect is relatively 
subtle. For example, a difference in expression of JAK2 may only be evident in a 
haematopoietic precursor cell (similar to the PU.1 SNP above), and not apparent in my 
experiments on total leukocytes isolated from PB. Alternatively, 46/1 may impact on cell 
cycle progression. A subtle functional difference would also be consistent with the 
observation that 46/1 is not present in approximately 25% of JAK2 V617F positive MPNs, 
and thus the haplotype is clearly not required for disease development.   
46/1 has great potential for further experimental investigation. My preliminary results 
using myeloid progenitors isolated from the PB of healthy normal controls provided 
tentative evidence that 46/1 was functionally different to other JAK2 alleles. However, to 
define exactly how 46/1 influences cell proliferation, differentiation, and other 
parameters, a more detailed approach will be required. If the effects of 46/1 are 
restricted to a particular lineage or stage of differentiation, then this requires comparison 
of highly purified cell subtypes isolated from the PB, and probably BM, of both normal 
and V617F positive cases. Obtaining these samples is likely to prove difficult, plus the 
numbers of each cell type may limit what experiment can be performed. In vitro 
experiments into 46/1 are confounded by the fact that JAK2 V617F positive cases carry 211 
variable levels of mutant allele making direct comparison difficult. Since the causal variant 
linked to 46/1, whether fertile ground or hypermutability, is unknown it is not possible to 
use cell lines or mouse models to further understand the underlying mechanism. One 
experimental alternative might be the creation of immortal B cell lines from JAK2 V617F 
positive cases by transfection with Epstein-Barr virus. By selection of those positive for 
V617F and homozygous for 46/1, then it could be assumed that the functional variant 
may be present in the cell line. The growth factor IL-6 receptor signals via JAK2, so it could 
be hypothesised that stimulation of this pathway could reveal measurable differences 
attributed to the 46/1 allele. If a more phenotypically similar renewable cell source is 
required then one possibility is the use of human induced pluripotent stem (iPS) cells 
derived from JAK2 V617F positive patients 
450. These human iPS cells exhibit 
characteristics similar to human ES cells and can be expanded in culture. The cells can be 
induced to differentiate into CD34+ progenitors that recapitulate features of JAK2 V617F 
positive progenitors, e.g. increased erythropoiesis, and a characteristic gene expression 
profile.  
It is not known whether the association of JAK2 and MPL mutations with the 46/1 
haplotype reflects something unique about the JAK2 locus, or whether other acquired 
driver mutations in cancer also arise on specific inherited haplotypes. In a preliminary 
investigation I found no relationship between MPL mutations and MPL haplotype 
(manuscript submitted). Whilst this does not preclude the possibility that somatic 
mutations in other genes might occur preferentially on particular haplotypes, it does 
suggest that this is not a general phenomenon. I am currently looking at relationship 
between acquired mutations in AML and their respective haplotypes. 
As previously mentioned, the 46/1 haplotype accounts for 50% of the population 
attributable risk of developing MPN, but it only explains a very minor component of 
V617F negative disease. A small GWAS performed on V617F-positive MPNs by Kilpivaara 
et al. (2009) 
451 was able to detect 46/1, plus the frequency of three SNPs at 3q21, 4q31 
and 7p11 were reported to differ between PV and ET, suggesting a potential role in 
phenotypic diversity. However, I failed to replicate these findings in a larger series of 
cases suggesting these findings were either spurious or much weaker than originally 
proposed. Nevertheless, it is highly likely that there are other common, low penetrance 212 
predisposition alleles to be identified and MPNs, particularly V617F negative cases, seem 
ripe for a comprehensive GWAS analysis. 
 
Before 2005 the study of MPN was generally considered to be rather a scientific 
backwater. I consider myself fortunate to have started my studies at the time of the JAK2 
revolution and participate in a field that is now at the cutting edge of molecular 
haematology. 
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Appendix I 
Solutions  
Freezing mix: 4ml RPMI supplemented with 10% foetal calf serum, L-glutamine and 
penicillin-streptomycin, 4ml DMSO and 12ml foetal calf serum. 
Guanidium thiocyanate (GTC): 4M guanidium thiocyanate, 5mM EDTA, 25mM sodium 
citrate pH 7.0, 0.5% sarcosyl. 7µl β-mercaptoethanol per 1ml of GTC was added fresh 
prior to use. 
LB broth: 25g LB broth per litre of distilled water, and autoclaved before use. 
LB agar: 3g agar per 200ml LB broth, and autoclaved before use. 
Loading buffer (for DNA gel electrophoresis): 0.05% bromophenol blue, 40% sucrose, 
0.5% sodium dodecyl sulphate, 0.1M EDTA, pH8.0. 
Lysis buffer (for removing red cells from PB and BM samples): 7M urea, 0.3M NaCl, 10mM 
EDTA, 10mM Tris-Cl, pH 7.5. 
Phosphate buffered saline (PBS): PBS was prepared as instructed by the manufacturer 
(Oxoid, Basingstoke, UK). One tablet of PBS was dissolved in 100ml water and autoclaved. 
Red cell lysis buffer: 155mM KHCO3, 0.1mM EDTA, pH 7.4 at 4°C. 
Resuspension buffer (RSB): 4.38g NaCl, 48ml EDTA made up to 1 L with sterile water. 
Thawing Solution for cryopreserved cells: 20mls HBSS (Invitrogen), 100,000U DNase I 
(Invitrogen) and 200U sodium heparin (CP Pharmaceuticals, Wrexham, UK). 
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Appendix II 
PCR programmes  
High fidelity PCR programme 
Step  Temp (°C)  duration 
1  95  2 min 
2  94  20 sec 
3  64  2 min 
4  68  14 min 
5  10 times to step 2 
6  94  20 sec 
7  64  40 sec 
8  68  14 min 
9  22 times to step 6 
10  72  9 min 
11  15  forever 
 
Pyrosequencing PCR 
Step  Temp (°C)  duration 
1  94  7 min 
2  94  30 sec 
3  58  30 sec 
4  72  45 sec 
5  39 times to step 2 
6  72  7 min 
7  15  forever 
 
Sequencing programme 
Step  Temp (°C)  duration 
1  96  1 min 
2  96  10 sec 
3  50  30 sec 
4  60  2 min 
5  25 times to step 2 
6  4  forever 
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Appendix III 
Primers sequences 
JAK2 V617F AS-PCR primers 
Primer name  Sequence (5’-3’) 
Forward outer (FO)  TCCTCAGAACGTTGATGGCAG 
Reverse outer (RO)  ATTGCTTTCCTTTTTCACAAGAT 
Forward wild-type specific (Fwt)  GCATTTGGTTTTAAATTATGGAGTATaTG 
Reverse mutant specific (Rms)  GTTTTACTTACTCTCGTCTCCACAaAA 
 
Pyrosequencing primers 
F = forward primer, R = reverse primer, SEQ = sequencing primer, BIO = biotinylated 
 Primer name  Sequence (5’-3’) 
JAK2_pyro_V617F_F  5’BIO-GAAGCAGCAAGTATGATGAGCA 
JAK2_pyro_V617F_R   TGCTCTGAGAAAGGCATTAGAA 
JAK2_pyro_V617F_seq  TCTCGTCTCCACAGA 
KIT_pyro_D816V_F  5’BIO -CCTTACTCATGGTCGGATCAC 
KIT_pyro_D816V_R  GCAGAGAATGGGTACTCACGT 
KIT_pyro_D816V_seq  CACATAATTAGAATCATTCTTG 
JAK2_RS7864782_F   5'BIO-TTGTAATTATGCATGTCGGCTTCC 
JAK2_RS7864782_R  TAAGAGCTCAAGACAGGGCTGTTT  
JAK2_RS7864782_SEQ   GCTGTTTGTGGCTCAGT  
JAK2_RS10758669_F  5'BIO-GGTTTTCAAGCACCAAAGTTTAAT 
JAK2_RS10758669_R  GGTTGGCTATGGCAAAGAAA  
JAK2_RS10758669_SEQ  AAATTTTCCAATACCTCC   
JAK2_RS6476934_F  ACTCTTTCCTCCCCTAAGCTCTGT 
JAK2_RS6476934_R  5'BIO-CAAATAAAAAGGGCCTCAGAGCA 
JAK2_RS6476934_SEQ  TTCGTCTGAAAGGATCTA 
JAK2_RS7046736_F   5'BIO-AAAAAGCCAATTCGAGTCACTTA 
JAK2_RS7046736_R  AACTGGAAATCACACTGCCTTAAA 
JAK2_RS7046736_SEQ  AAAATGCATTGATGCTT 
JAK2_RS2149556_F  5'BIO-CATTCCTTTTTATTGCTGGGTAGT 
JAK2_RS2149556_R  AAGTGAAAGCAACCCAAATGTCC 
JAK2_RS2149556_SEQ  GAATACATTTAAAATTTGAG 
JAK2_RS12342421_R  TTTTCCCTTTGCTCGAGTTATTC 
JAK2_RS12342421_F  5'BIO-AACTATCACATTGGCTCACACAG 
JAK2_RS12342421_SEQ  TGTCAACATAAACCACATC 
JAK2_RS10974947_F  5'BIO-AATTACAGGGTTTGAAAATTACCG  
JAK2_RS10974947_R  TCTTTGGCTTGAACTTTTCACA  
JAK2_RS10974947_SEQ  CAGAAATGTAATAACACTCC  216 
JAK2_RS10119004_F  5'BIO-TTGTCATTTTTAACTGCGCTTCT  
JAK2_RS10119004_R  CAATGCTTTTATCTGTGGGAATTA  
JAK2_RS10119004_SEQ  GAGACTCCTTTTCCTCAC 
JAK2_RS12343867_F  TGGCAGGTTCAACATAACATTGG  
JAK2_RS12343867_R  5-BIO-TGCCGTAAACCTTCAATATGTAAA 
JAK2_RS12343867_SEQ  GGAACTGACAGAAATGATT  
JAK2_RS12340895_F  TGGTAATATCTTCGAGGTATGCC  
JAK2_RS12340895_R  5'BIO-CCAAACCACTGCTTTTGAGAAGA  
JAK2_RS12340895_SEQ  GGTATGCCTTTATTTTAG  
JAK2_RS2031904_F  5'BIO-GTACGGGAACAATACAACTTAGCA 
JAK2_RS2031904_R  TGCAGCGTGAGAACAGACTAATA  
JAK2_RS2031904_SEQ  GAGTCATAAGTGCCTAACC  
JAK2_RS17425819_F  GGCTCTGGCGTCTTAGTCTTCA 
JAK2_RS17425819_R  5'BIO-AGCCCTTCCCACCACACA 
JAK2_RS17425819_SEQ  CGACTGGCTCACAGAC 
JAK2_RS10815160_F  CCCCAGTGATACATGAATTTAAT 
JAK2_RS10815160_R  5'BIO-TTTGGAGCACAGTAGAGTCTTAAT 
JAK2_RS10815160_SEQ  TATGAAGATTCAGAGATTTG 
JAK2_rs2230724_DNA_F  5'BIO-ACTCACGATTATTTTGGTCAACTT  
JAK2_rs2230724_DNA_R  AACTGTGTAGGATCCCGGTCT  
JAK2_rs2230724_DNA_seq  GGCACCAGAAAACCC  
JAK2_rs2230724_cDNA_F  5'BIO-CCTTCTTTCAGAGCCATCATACGA  
JAK2_rs2230724_cDNA_R  GCACATCTCCACACTCCCAAAAT 
JAK2_rs2230724_cDNA_seq  GGCACCAGAAAACCC  
JAK2_rs10429491_DNA_F  AGCCTGGCCAATTTGTATCTTGTA  
JAK2_rs10429491_DNA_R  5'BIO-CCATCCCAAGACATTCTTCCT 
JAK2_rs10429491_DNA_seq  GGCATGATTTTGTGCA  
JAK2_rs10429491_cDNA_F  GAAGCTCCTCTTCTTGATGACTTT 
JAK2_rs10429491_cDNA_R  5'BIO-TTTGGTAAGAATGTCTTGTAGCTGATAGAG 
JAK2_rs10429491_cDNA_seq  GGCATGATTTTGTGCA 
EPOR_rs318699_F  5'BIO-AGCACATCTCATTCCCCTGAA 
EPOR_rs318699_R  CAGCTCCAGCAAAAAGTCCC 
EPOR_rs318699_seq  TGTGTCATGTGTCCACC 
 
JAK2 MLPA primers 
Primer name  Sequence (5’-3’) 
JAK2_exon3_MLPA_A  GGGTTCCCTAAGGGTTGGATGAAGCAAATAGATCC 
AGTTCTTC 
JAK2_exon3_MLPA_B  5’Phosphate-
AGGTGTATCTTTACCATTCCCTTGAAGGGCTCAGAATGAGCCGC
TCAGTTCCCTTCTAGATTGGATCTTGCTGGCAC 
JAK2_exon9_MLPA_A  GGGTTCCCTAAGGGTTGGAATAGATTAACTGCAGATGCACATC 
JAK2_exon9_MLPA_B  5’Phosphate-217 
ATTACCTCTGTAAAGAAGTAGCACTCTTGATTACATCCAGGGGC
GCGTGTCTAGATTGGATCTTGCTGGCAC 
JAK2_exon16_MLPA_A  GGGTTCCCTAAGGGTTGGATCTGCTTATCAGAGAAGAAGACAG 
JAK2_exon16_MLPA_B  5’Phosphate-
GAAGACAGGAAATCCTCCTTTCATTGGGTCCGACAGCTTTCTAG
ATTGGATCTTGCTGGCAC 
JAK2_exon20_MLPA_A  GGGTTCCCTAAGGGTTGGAACTTGGGTAATTTTGGTGTG 
JAK2_exon20_MLPA_B  5’Phosphate- 
GAGATGTGCCGTGGTCGCTGTAAAGGATCCTGATGCG 
AGGGCCAGGGCTTCAGGGCTTCTAGATTGGATCTTGCT 
GGCAC 
 
MLPA primers used to determine JAK2 copy number 
Gene name, GenBank 
Accession number and 
size of PCR product  
Primer name  Sequence (5’-3’) 
FES 
NM_002005 
90bp 
FES_Exon 2 _F  GGGTTCCCTAAGGGTTGGACTGGAGGGC
ATGAGAAAGTGGATG  
FES_Exon 2 _R  5’Phosphate-
GCCCAGCGGGTCAAGAGTGACAGGTCTA
GATTGGATCTTGCTGGCAC 
JAK2  
NM_004972 
109bp 
JAK2_Exon 1_F  GGGTTCCCTAAGGGTTGGAGCTAGCTGC
ACGGTGATATTTCTGAAATGCCAATT 
JAK2_Exon 1_R  5’Phosphate-
CTATGAAGCAAATAGATCCAGTTCCAGCT
TCTAGATTGGATCTTGCTGGCAC 
SOAT1 
NM_003101 
112 bp 
 
SOAT1_Exon 4_F  GGGTTCCCTAAGGGTTGGAGACGCATTG
CAGGTCAGCATCATTAGATAATGGTGG 
SOAT1_Exon 4_R  5’Phosphate-
GTGCGCTCTCACAACCTTTTCTGTGTCAA
GCAGCTCTAGATTGGATCTTGCTGGCAC 
BTK  
NM_000061 
115bp 
 
BTK_Exon 2_F  GGGTTCCCTAAGGGTTGGACTTCAAGAA
GCGCCTGTTTCTCTT 
BTK_Exon 2_R  5’Phosphate-
GACCGTGCACAAACTCTCCTACGTCAGGT
TAAACGCTGTGCGTGATCATTCTAGATTG
GATCTTGCTGGCAC 
TYK2 
NM_003331 
118bp 
TYK2_Exon1_F  GGGTTCCCTAAGGGTTGGAGCATAACGT
ATCAGCAGTGAGTCATCGCTGACAGCT 
TYK2_Exon1_R  5’Phosphate-
GAGGAAGTCTGCATCCACATTGCACTGC
AACTAGGATCCGTCTAGATTGGATCTTGC
TGGCAC 218 
RON  
NM_002447 
124bp 
 
RON_Exon1_F  GGGTTCCCTAAGGGTTGGAGTCAATGAT
GTCCAGTCCGCAATCGCCTGCATGTGCTT
GGGC 
RON_Exon1_R  5’Phosphate-
CTGACCTGAAGTCTGTCCAGAGCCGTCAT
CCAGTACGGCGTCTAGATTGGATCTTGCT
GGCAC 
 
JAK2 exon 12 HRM and WTB-PCR primers 
Primer name  Sequence (5’-3’) 
JAK2_ex12_HRM_F  AATGGTGTTTCTGATGTACC 
JAK2_ex12_HRM_R  AGACAGTAATGAGTATCTAATGAC 
JAK2_ex12_WTB_F  CTCCTCTTTGGAGCAATTCA 
JAK2_ex12_WTB_R  GAGAACTTGGGAGTTGCGATA 
JAK2_ex12_wtLNA_oligo*  TTCA+C+A+AAATCAGAA+A+T+GAAG 
JAK2_ex12_WTB_F2  GGAGCAATTCATACTTTCAGTGT 
JAK2_ex12_WTB_R2  AACAGATGTTGTTTTAAAAGGAC 
*LNA modified nucleotides are preceded with an ‘+’ 
 
AS-PCR primers to detect JAK2 SNP rs12343867 
 
Primer name  Sequence (5’-3’) 
JAK2_rs867_T_F  TGGTTTTAAATTATGGAGTATATT 
JAK2_rs867_G_F  TGGTTTTAAATTATGGAGTATATG 
JAK2_i14.15_R3  GCAAGGTGCAATAAAATGAGG 219 
JAK2 cDNA specific primers  
Transcript position (bp)  Primer name  Forward sequence (5’-3’)  Primer name  Reverse sequence (5’-3’) 
9-475  JAK2_ex1_F  GGAGAGAGGAAGAGGAGCAGA  Jak2_ex2.3_R  CAGAACATTTGCCGTCGCG 
465 -2210  JAK2_ex2_F4  GGCAACAGGAACAAGATGTGAACTG  JAK2_ex13.14_R4  ACTTGCTGCTTCAAAGAAAGACTCTGAAT 
557 - 2205  JAK2_ex2.3_F4  CGACGGCAAATGTTCTGAAAAAGA  JAK2_ex13.14_R4  ACTTGCTGCTTCAAAGAAAGACTCTGAAT 
771-1438  JAK2_ex4_F  TCTGGTATCCACCCAACCAT  JAK2_ex7.8_R  AAATCCTGTTCTGTCAGTGTCTCA 
771-3075  JAK2_ex4_F  TCTGGTATCCACCCAACCAT  JAK2_ex19.20_R  TACCCTTGCCAAGTTGCTGT  
885-1438  JAK2_ex5_F2  GAGCCTATCGGCATGGAATA  JAK2_ex7.8_R  AAATCCTGTTCTGTCAGTGTCTCA 
1023-1721  JAK2_ex6_F  GAATGTCTTGGGATGGCAGT  JAK2_ex9.10_R  AATGGCAAAATCCATCGAAA 
1023-2270  JAK2_ex6_F  GAATGTCTTGGGATGGCAGT  JAK2_ex11.12_R  TTTGATTTATCTTTTGGCTTTGG 
1485-3561  JAK2_ex8_F  GCAAACCAAGAGGGTTCAAA  JAK2_ex22.23_R  TCTGGAGCATACCAGAATATG 
1536-3832  JAK2_ex8.9_F3  GGTAAAAATCTGGAAATTGAACTTA  JAK2_ex25_R  AAGGAGGGGCGTTGATTTAC 
1866-2370  JAK2_ex11_F  GAGAATGAAGAGTACAACCTC  JAK2_ex14.15_R  AAGGGTGTTTTCTTCTAGAAAAT 
2033 - 3190  JAK2_ex11_F4  TTACCAGATGGAAACTGTTCGCTCA  JAK2_ex25.3UTR_R4  GGTCATTTCTTTCATCCAGCCATGT 
1731-2498  JAK2_ex10_F  AGAAAGCAGGTAATCAGACTGGA  JAK2_exon15/16_R  TGTAGCTTTCTTTGAGAATCCAGA 
1731 -2725  JAK2_ex10_F  AGAAAGCAGGTAATCAGACTGGA  JAK2_exon16/17_R  TAGATTACGCCGACCAGCA 
2685-3561  JAK2_ex17_F  TTTGGCAACAGACAAATGGA  JAK2_ex22.23_R  TCTGGAGCATACCAGAATATG 
3247-3689  JAK2_20.21_F  CAGTGCTGGTCGGCGTAAT  JAK2_ex24_R  TTGTTTGTCATTGCCAATCATACGC 220 
3543-3832  JAK2_ex22.23_F  CCCATATTCTGGTATGCTCCA  JAK2_ex25_R  AAGGAGGGGCGTTGATTTAC 
3661-4778  JAK2_ex23.24_F2  CCAGCGGAATTTATGCGTATGAT  JAK2_ex25_R2  TTATTGGCAGTCAGCAGCTC 
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Appendix IV 
Calculations performed on MLPA data to determine JAK2 copy number of homozygous 
V617F positive MPNs 
Peak areas from each patient were exported to an Excel spreadsheet, which was designed 
to assess the ratio of each peak relative to all other peaks for that individual, plus 
equivalent peak areas obtained from other V617F positive cases or normal controls run 
alongside each other in the assay. As illustrated below, values for each peak area were 
entered into the corresponding control or test column in the spreadsheet, which then 
applied a series of calculations to normalise each test peak area against one other peak 
area from the same run and the equivalent values derived from the control sample. The 
tables below show examples of data derived from two female homozygous JAK2 V617F 
case normalised together (Table A1), a male homozygous JAK2 V617F case normalised 
against a female equivalent, with one copy of X-linked gene BTK (Table A2), and a female 
case carrying a constitutional del(9p) normalised to a different normal female sample, 
showing only one copy of JAK2 (Table A3). An example of the calculations used to 
normalise test peaks in example A to the control, and determine the dosage quotient for 
JAK2, is: 
JAK2 copy number = (test FES peak area/test JAK2 peak area)/ (control FES peak 
area/control JAK2 peak area) 
or (9559/9018)/ (7795/8320) = 1.1314 
If the resulting dosage quotient falls between the range 0.8 to 1.2 this denotes the 
presence of two copies of the target region (MLPA copy number ranges defined 
previously by Bunyan et al. 
251). A deletion was scored if the dosage quotient was less 
than 0.7 (coloured red by the spreadsheet), and a duplication was scored if the quotient 
was 1.3 or greater (coloured green). Thus a full row of dosage quotients all below 0.6 
highlighted red by the spreadsheet indicates a deletion of one copy of that gene, and a 
row of dosage quotients all above 1.3 and highlighted green indicates a copy number 
increase. Any red-coloured differences should be consistent across different markers, as 
shown in Tables A2 and A3. 222 
   peak area  Exons 
Exons  Control  Test  FES  JAK2  SOATIA  BTK  TYK2  RON  HCKA 
FES  7795  9559  1.0000  1.1314  0.8663  0.9547  1.0427  1.0736  1.1429 
JAK2  8320  9018  0.8839  1.0000  0.7657  0.8438  0.9216  0.9489  1.0102 
SOATIA  5094  7211  1.1544  1.3060  1.0000  1.1020  1.2037  1.2393  1.3193 
BTK  14576  18723  1.0475  1.1851  0.9074  1.0000  1.0922  1.1246  1.1972 
TYK2  10815  12719  0.9590  1.0850  0.8308  0.9156  1.0000  1.0296  1.0961 
RON  8521  9733  0.9315  1.0538  0.8069  0.8892  0.9712  1.0000  1.0646 
HCKA  8511  9132  0.8750  0.9899  0.7580  0.8353  0.9123  0.9394  1.0000 
Table A1.  
 
   peak area  Exons 
Exons  Control  Test  FES  JAK2  SOATIA  BTK  TYK2  RON  HCKA 
FES  7034  18648  1.0000  1.0738  0.8457  1.6653  0.9691  0.9559  0.8215 
JAK2  5906  14582  0.9313  1.0000  0.7876  1.5510  0.9026  0.8902  0.7651 
SOATIA  4486  14063  1.1825  1.2697  1.0000  1.9692  1.1460  1.1303  0.9714 
BTK  12346  19654  0.6005  0.6448  0.5078  1.0000  0.5819  0.5740  0.4933 
TYK2  9228  25244  1.0319  1.1080  0.8726  1.7184  1.0000  0.9863  0.8477 
RON  7021  19473  1.0462  1.1233  0.8847  1.7422  1.0139  1.0000  0.8594 
HCKA  6262  20209  1.2173  1.3071  1.0295  2.0272  1.1797  1.1636  1.0000 
Table A2. 
 
   peak area  Exons 
Exons  G1654  Test  FES  JAK2  SOATIA  BTK  TYK2  RON  HCKA 
FES  4300  9479  1.0000  2.0773  1.2782  1.2463  0.9995  1.2667  1.0154 
JAK2  4494  4769  0.4814  1.0000  0.6153  0.6000  0.4811  0.6098  0.4888 
SOATIA  3214  5543  0.7824  1.6252  1.0000  0.9751  0.7820  0.9910  0.7944 
BTK  6517  11527  0.8024  1.6668  1.0256  1.0000  0.8020  1.0164  0.8147 
TYK2  5984  13198  1.0005  2.0784  1.2788  1.2469  1.0000  1.2674  1.0159 
RON  6310  10981  0.7894  1.6399  1.0091  0.9839  0.7890  1.0000  0.8016 
HCKA  3754  8150  0.9848  2.0458  1.2588  1.2274  0.9843  1.2475  1.0000 
Table A3. 
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Appendix V 
In vitro colony assay calculations to determine response to imatinib 
Shown here is an example of the myeloid colony counts and calculations used to assess 
the response to imatinib exposure for one patient with MPN. Colonies from each 
triplicate dish a, b and c were counted at days 7 and 14, and the values for each triplicate 
were averaged (table B1).  
 
  
0µM  1µM  5µM 
a  b  c  av  a  b  c  av  a  b  c  av 
day 7  7  9  11  9.00  3  1  0  1.33  2  1  1  1.33 
day 14  10  10  8  9.33  3  1  4  2.67  1  2  1  1.33 
Table B1. In vitro colony assay colony numbers measured in triplicate at day 7 and day 
14, exposed to 0, 1 and 5 µM imatinib.  
 
The 1µM and 5µM values were then expressed relative to the 0µM value (table B2): 
 
  No of colonies 
  0µM  1µM  5µM 
Day 7  1  0.15  0.15 
Day 14  1  0.29  0.14 
Table B2. In vitro colony assay colony number expressed as a fraction of the value of the 
unexposed measurement. 
 
The index of response was then calculated as the average of the relative 1µM and 5µM 
values at days 7 and 14: 
0.15+0.15+0.29+0.14  = 0.18 
       4 
In this instance the result would be considered as borderline as it is only marginally below 
the response threshold (0.2) defined by the analysis of CML cases and normal controls. 224 
In vitro liquid culture assay calculations to determine response to imatinib 
In this example of the in vitro imatinib liquid culture assay, PB granulocytes from a patient 
carrying an imatinib-sensitive lesion (BCR-ABL) were exposed to 0µM, 1μM and 5μM 
imatinib and viable cells were counted over a period of 22 days. Each culture was set up 
in duplicate (dishes a and b), and the total cell numbers (recorded here in table B3 as 
multiples of 1x10
6) were averaged. 
Day  0µM  1µM  5µM 
a  b  average  a  b  average  a  b  average 
0  5  5  5.00  5  5  5.00  5  5  5.00 
4  2.45  2.5  2.48  1.98  2.05  2.02  1.78  1.98  1.88 
8  1.3  1.3  1.30  0.98  1.16  1.07  0.83  1  0.92 
12  0.8  0.65  0.73  0.33  0.29  0.31  0.1  0.15  0.13 
15  0.37  0.15  0.26  0.09  0.06  0.08  0.02  0.03  0.03 
19  0.12  0.2  0.16  0.03  0.01  0.02  0.04  0.01  0.03 
22  0.08  0.1  0.09  0.01  0.02  0.02  0.05  0.01  0.03 
Table B3. In vitro liquid culture assay cell numbers (1x10
6cells) counted in duplicate over 
time (days) in response to 0, 1, and 5 µM imatinib.  
 
The results were then expressed relative to the count at day 0, which is given a value of 1 
(table B4). 
Day  0µM  1µM  5µM 
0  1  1  1 
4  0.495  0.403  0.376 
8  0.26  0.214  0.183 
12  0.145  0.062  0.025 
15  0.052  0.015  0.005 
19  0.032  0.004  0.005 
22  0.018  0.003  0.006 
Table B4. In vitro liquid culture assay cell counts normalised to the cell counts of the 
untreated control.  
These values were then plotted on a line graph. The response, determined by visual 
inspection, is defined as a reduction in cell survival in the imatinib treated cultures, 
compared to the untreated culture (Figure 4.2). Inhibition of cell growth and survival by 225 
imatinib exposure was also determined by expressing the counts from the treated 
cultures relative to the untreated cultures for each time point (table B5).  
 
Day  1µM  5µM 
0  1  1 
4  0.81  0.75 
8  0.82  0.70 
12  0.42  0.17 
15  0.28  0.09 
19  0.12  0.15 
22  0.16  0.33 
Table B5. In vitro liquid culture assay cell counts of the imatinib-exposed cultures, 
normalised to the untreated control. 
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Appendix VI 
In vitro imatinib sensitivity liquid culture and colony assay results alongside molecular 
abnormality where identified. 
Sample 
identifier  referral 
Colony assay 
result 
Liquid culture 
assay result 
mutation 
identified 
E199  ?HES  negative  negative  JAK2V617F 
E300  aMPN  negative  negative  BCR-FGFR1 
E367  AML with SM  negative  negative  KIT D816V 
E464  MPN  negative  negative  JAK2V617F 
E662  SM  negative  negative  KIT D816V 
E673  MPN   negative  negative  JAK2V617F 
E726  SM  negative  negative  KIT D816V 
E784  SM  negative  negative  KIT D816V 
E177  aCML  not informative  negative  JAK2V617F 
E213  HES  not informative  negative  JAK2V617F 
E610  MPN  not informative  negative  JAK2V617F 
E640  SM  not informative  negative  KIT D816V 
E664  MDS/MPN  not informative  negative  JAK2V617F 
E513  T cell lymphoma  negative  not done  FIP1L1-PDGFRA 
E683  MPN  borderline  not informative  KIF-PDGFRA 
E251  SM  negative  not informative  KIT D816V 
E386  MPN  negative  not informative  BCR-PDGFRA 
E685  SM  negative  not informative  KIT D816V 
E776  SM  negative  not informative  KIT D816V 
E359  HES  borderline  positive  FIP1L1-PDGFRA 
E614  SM  borderline  positive  FIP1L1-PDGFRA 
E630  ?MPN  borderline  positive  FIP1L1-PDGFRA 
E176  HES  negative  positive  FIP1L1-PDGFRA 
E44  HES  negative  positive  FIP1L1-PDGFRA 
E458  HES  negative  positive  FIP1L1-PDGFRA 
E566  HES  negative  positive  FIP1L1-PDGFRA 
E606  HES  negative  positive  FIP1L1-PDGFRA 
E758  SM  negative  positive  KIT D816V 
E817  HES  negative  positive  FIP1L1-PDGFRA 
E156  MPN  positive  borderline  JAK2V617F 
E350  MPN  positive  borderline  JAK2V617F 
E521  MPN  positive  borderline  ETV6-PDGFRB 
E583  MPN  positive  negative  JAK2V617F 
E536  HES  positive  not informative  FIP1L1-PDGFRA 
E537  HES  positive  not informative  JAK2V617F 
E688  HES  positive  not informative  FIP1L1-PDGFRA 
E107  MPN  positive  positive  FIP1L1-PDGFRA 227 
E273 
AML with 
t(5;12)  positive  positive  ETV6-PDGFRB 
E905  ?MPN  positive  positive  FIP1L1-PDGFRA 
E194  CNL  negative   positive  none identified 
E552  HES  negative   positive  none identified 
E950  HES  negative   positive  none identified 
E219  HES  negative   positive  none identified 
E57  HES  negative   positive  none identified 
E117 
AML with 
eosinophilia  not done  positive  none identified 
E250  MDS/MPN  not done  positive  none identified 
E667  MPN  not informative  positive  none identified 
E649  HES  positive  positive  none identified 
E111  MPN  positive  borderline  none identified 
E402  HES  positive  negative  none identified 
E595  HES  positive  negative  none identified 
E650  HES  positive  negative  none identified 
E897  MPN  positive  negative  none identified 
E1009  MPN  positive  negative  none identified 
E74  SM  positive  negative  none identified 
E492  HES  positive  not done  none identified 
E495  HES  positive  not done  none identified 
E988  HES  positive  not done  none identified 
E1045  HES  positive  not done  none identified 
E281  MPN  positive  not informative  none identified 
E508  HES  positive  not informative  none identified 
E689  HES  positive  positive  none identified 
E61  aCML  positive  positive  none identified 
E504  HES  borderline  borderline  none identified 
E531  HES  negative  borderline  none identified 
E106  MPN  not done  borderline  none identified 
E173  MPN  not done  borderline  none identified 
E180  aCML  not done  borderline  none identified 
E201  MPN  not done  borderline  none identified 
E245  HES  not done  borderline  none identified 
E68 
AML with 
eosinophilia  not informative  borderline  none identified 
E178  SM  not informative  borderline  none identified 
E210  HES  not informative  borderline  none identified 
E228  MPN  not informative  borderline  none identified 
E378  CMML  not informative  borderline  none identified 
E316  HES  borderline  negative  none identified 
E317  HES  borderline  negative  none identified 
E394  HES  borderline  negative  none identified 
E608  HES  borderline  negative  none identified 228 
E721  MPN  borderline  negative  none identified 
E970  HES  borderline  negative  none identified 
E568  HES  borderline  not done  none identified 
E580  IMF  borderline  not done  none identified 
E989  HES  borderline  not done  none identified 
E682  HES  borderline  not informative  none identified 
E777  MPN  borderline  not informative  none identified 
E862  HES  borderline  not informative  none identified 
E42  HES  not done  negative  none identified 
E62  HES  not done  negative  none identified 
E63  HES  not done  negative  none identified 
E70  MPN  not done  negative  none identified 
E71  MPN  not done  negative  none identified 
E72  aCML  not done  negative  none identified 
E85  MPN  not done  negative  none identified 
E99  aCML  not done  negative  none identified 
E101  HES  negative  negative  none identified 
E103  aCML  not done  negative  none identified 
E110  CMML  not done  negative  none identified 
E115  MPN  not informative  negative  none identified 
E116  HES  not done  negative  none identified 
E158  aCML  not done  negative  none identified 
E160  aCML  not done  negative  none identified 
E163  CMML  not done  negative  none identified 
E167  CMML  not done  negative  none identified 
E195  HES  not done  negative  none identified 
E203  HES  not done  negative  none identified 
E258  HES  not done  negative  none identified 
E282  MPN  not informative  negative  none identified 
E284  HES  negative  not informative  none identified 
E287  HES  negative  negative  none identified 
E288  HES  not done  negative  none identified 
E290  MDS  negative  negative  none identified 
E305  MPN  not done  negative  none identified 
E310  aCML  negative  negative  none identified 
E311  HES  negative  negative  none identified 
E332  HES  negative  negative  none identified 
E333  HES  negative  not done  none identified 
E337  HES  negative  negative  none identified 
E347  aCML  negative  negative  none identified 
E351  HES  negative  negative  none identified 
E353  HES  negative  negative  none identified 
E372  HES  negative  negative  none identified 
E373  SM  not informative  negative  none identified 
E374  HES  not informative  negative  none identified 229 
E393  HES  negative  negative  none identified 
E416  HES  negative  negative  none identified 
E417  HES  not informative  negative  none identified 
E430  HES  negative  not informative  none identified 
E435  MPN  negative  negative  none identified 
E443  MPN  negative  not done  none identified 
E467  MPN  negative  negative  none identified 
E469  HES  negative  negative  none identified 
E471  HES  negative  negative  none identified 
E472  aCML  not done  negative  none identified 
E480  MPN  negative  negative  none identified 
E484  aCML  negative  negative  none identified 
E487  HES  negative  negative  none identified 
E491  HES  negative  negative  none identified 
E497  HES  negative  not done  none identified 
E512  HES  negative  negative  none identified 
E514  CMML  negative  negative  none identified 
E518  MDS/MPN  negative  not done  none identified 
E520  HES  negative  negative  none identified 
E523  HES  not done  negative  none identified 
E532  MPN  negative  negative  none identified 
E542  HES  negative  negative  none identified 
E543  MPN  negative  negative  none identified 
E560  HES  negative  not done  none identified 
E567  HES  negative  not informative  none identified 
E587  HES  negative  negative  none identified 
E597  HES  negative  negative  none identified 
E605  MDS  negative  not informative  none identified 
E607  MPN  not done  negative  none identified 
E609  HES  negative  negative  none identified 
E622  HES  negative  not informative  none identified 
E626  MPN  negative  negative  none identified 
E628  HES  not done  negative  none identified 
E634  HES  negative  negative  none identified 
E636  HES  negative  negative  none identified 
E641 
ET transforming 
to MF  negative  not done  none identified 
E643 
AML with 
eosinophilia  not done  negative  none identified 
E651  HES  negative  not done  none identified 
E660  SM  negative  not done  none identified 
E663  MPN  negative  negative  none identified 
E697  MPN   negative  negative  none identified 
E709  HES  negative  not done  none identified 
E720  HES  negative  negative  none identified 230 
E728  HES  not done  negative  none identified 
E730  HES  negative  negative  none identified 
E748  MDS/MPN  negative  not done  none identified 
E755  HES  negative  not informative  none identified 
E781  HES  negative  negative  none identified 
E793  SM  negative  not done  none identified 
E795  M  not done  negative  none identified 
E816  HES  negative  negative  none identified 
E818  MPN  negative  not informative  none identified 
E831  aCML  negative  negative  none identified 
E899  aCML  negative  negative  none identified 
E920  JMML/MPN  negative  negative  none identified 
E1010  HES  negative  negative  none identified 
E1031  HES  not done  negative  none identified 
E1044  HES  negative  not done  none identified 
E1072  HES  not done  negative  none identified 
E67  HES  not done  negative  none identified 
NP99  MPN  not informative  negative  none identified 
E74  SM  not informative  not done  none identified 
E81  MPN  not informative  not done  none identified 
E205  MPN  not informative  not done  none identified 
E207  HES  not informative  not done  none identified 
E209  HES  not informative  not done  none identified 
E240  SM  not done  not informative  none identified 
E241  SM  not done  not informative  none identified 
E242  HES  not done  not informative  none identified 
E257  HES  not informative  not done  none identified 
E267  HES  not informative  not done  none identified 
E118  aCML  not done  not informative  none identified 
E121  HES  not done  not informative  none identified 
E168  MPN  not informative  not done  none identified 
E170  HES  not informative  not done  none identified 
E185  HES  not done  not informative  none identified 
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 JAK2 haplotype is a major risk factor for the development
of myeloproliferative neoplasms
Amy V Jones1,2, Andrew Chase1,2, Richard T Silver3, David Oscier4, Katerina Zoi5, Y Lynn Wang3,
Holger Cario6, Heike L Pahl7, Andrew Collins2, Andreas Reiter8, Francis Grand1,2 & Nicholas C P Cross1,2
Chronic myeloproliferative neoplasms (MPNs) are a group of
related conditions characterized by the overproduction of
cells from one or more myeloid lineages. More than 95% of
cases of polycythemia vera, and roughly half of essential
thrombocythemia and primary myeloﬁbrosis acquire a unique
somatic 1849G4T JAK2 mutation (encoding V617F) that is
believed to be a critical driver of excess proliferation1–4.
We report here that JAK2V617F-associated disease is strongly
associated with a speciﬁc constitutional JAK2 haplotype,
designated 46/1, in all three disease entities compared to
healthy controls (polycythemia vera, n ¼ 192, P ¼ 2.9  
10 16; essential thrombocythemia, n ¼ 78, P ¼ 8.2   10 9
and myeloﬁbrosis, n ¼ 41, P ¼ 8.0   10 5). Furthermore,
JAK2V617F speciﬁcally arises on the 46/1 allele in most cases.
The 46/1 JAK2 haplotype thus predisposes to the development
of JAK2V617F-associated MPNs (OR ¼ 3.7; 95% CI ¼ 3.1–4.3)
and provides a model whereby a constitutional genetic factor
is associated with an increased risk of acquiring a speciﬁc
somatic mutation.
The ﬁnding of JAK2V617F was a major step forward in understanding
the pathogenesis of MPNs, but it remains unclear how this single
abnormality gives rise to distinct clinical entities. Clinical phenotype is
clearly associated with JAK2V617F dosage: in many PV and MF cases
JAK2V617F is reduced to homozygosity as a consequence of acquired
isodisomy (generally referred to as acquired uniparental disomy;
a U P D )a tc h r o m o s o m e9 p ,b u tt h i si sr a r ei nE T 2,5,6. Several lines of
evidence indicate that other, largely uncharacterized, acquired
abnormalities also have a role in specifying disease phenotype either
in combination with or independently of JAK2V617F (refs. 7,8).
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Figure 1 Allele distortions due to aUPD enable direct reading of JAK2
haplotypes. (a)T h eJAK2V617F mutation (indicated by an asterisk) and
ﬂanking SNPs are reduced to homozygosity in a proportion of cells following
mitotic recombination. (b)S N P sa n dJAK2V617F were quantiﬁed by
pyrosequencing. In many cases that harbored a homozygous JAK2V617F
clone, it was possible to directly read the haplotype on which the mutation
arose by the ﬁnding that one allele at each SNP predominated (allelic ratio
Z0.6, for example, cases E659, E2433 and E2513). In cases with a
homozygous clone and %V617F o90%, it was usually possible to read the
residual haplotype (that is, the haplotype of the chromosome that had not
acquired JAK2V617F) by the ﬁnding of allelic ratios between 0.1–0.4 (for
example, cases E2433 and E2513). Where the homozygous clone was small
or nonexistent (most cases with %V617F o60%), neither the JAK2V617F
nor wild-type haplotype could be read (for example, case E1186).
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LETTERSFurthermore, both epidemiological data and family studies indicate
that inherited factors may predispose to MPNs9,10 and it has also been
suggested that inherited SNPs within JAK2 are associated with speciﬁc
MPN subtypes11.
To determine the role of inherited factors, we initially analyzed six
JAK2-spanning SNPs (rs7864782, rs10758669, rs7046736, rs12342421,
rs10974947, rs2031904) in MPN cases with a homozygous JAK2V617F
clone (%V617F allele 450%; n ¼ 142) using pyrosequencing, which
provides a quantitative readout of allele ratios. The mitotic recombi-
nation that gives rise to aUPD typically involves most of chromosome
9p2,6 and thus SNPs within this region are also reduced to homo-
zygosity; consequently, the haplotype on which JAK2V617F arose could
be read directly from allele ratios that were signiﬁcantly greater than
the expected value of 0.5. In most cases with 60–90% V617F, the
residual haplotype (that is, the haplotype on which V617F had not
arisen) could also be read by the ﬁnding of heterozygous allele ratios
in the range 0.1–0.4. In cases with Z90% V617F, however, informa-
tion about alleles on the non-V617F chromosome was lost (Fig. 1 and
Methods). Notably, of the 142 alleles that harbored V617F, 109 (77%)
had an identical haplotype (subsequently designated 46/1) within the
JAK2 gene, whereas this haplotype was seen for only 9 of the 74 (12%)
residual wild-type alleles that could be read (P ¼ 1.4   10 20,F i s h e r ’ s
exact test, two-tailed). These results indicated that homozygosity for
JAK2V617F was not random, but rather occurred preferentially when
this mutation was present on a speciﬁc JAK2 haplotype.
To explore this observation in more detail, we ﬁrst determined the
haplotype structure of JAK2 using 14 SNPs genotyped by the Well-
come Trust Case Control Consortium (WTCCC) in 1,500 healthy
blood donors from the UK12. PHASE analysis13 inferred 92 haplo-
types, of which nine accounted for 94% of JAK2 alleles (Fig. 2). Two
haplotypes (numbers 46 and 1; referred to henceforth together as 46/
1) were identical except for rs7864782 and had a combined frequency
of 0.24. A tagged SNP (rs12340895) that was in complete linkage
disequilibrium (LD) with 46/1 was then used to screen for this
haplotype in further cases. In an initial analysis of 177 heterozygous
JAK2V617F-positive MPNs, 46/1 occurred more frequently (135/354
alleles) than in 188 locally sourced healthy controls (92/376 alleles; P ¼
0.0001) as well as the WTCCC cohort (P ¼ 3.3   10 8). The 46/1
haplotype was more frequent in all JAK2V617F-positive disease entities
regardless of origin (UK or United States); however, there was no
difference in the frequency of 46/1 between controls and cases with
idiopathic erythrocytosis (Table 1). To determine whether JAK2V617F
was in cis or trans to the 46/1 allele in cases that were heterozygous for
both the mutation and the haplotype, we carried out allele-speciﬁc
PCRs for JAK2V617F to amplify products that included a second 46/1
tag SNP (rs12343867) in intron 14. Sequencing of the products in 66
informative cases showed that 49 (74%) JAK2V617F alleles arose on a
46/1 allele, whereas only 17 (26%) residual wild-type alleles were 46/1
(P ¼ 2.1   10 8).
We have previously described a polycythemia vera pedigree in
which JAK2V617F was not inherited but arose independently in two
affected individuals14. Family members were analyzed for rs12340895:
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Figure 2 SNPs, haplotypes and LD around JAK2.( a) The nine most
common JAK2 haplotypes in the UK population. The 14 SNPs in bold were
analyzed by the WTCCC in 1,500 blood donors from which the frequencies
were determined; asterisks indicate SNPs that tag 46/1, which are
highlighted in gray. rs78644782, rs10124001 and rs10758669 are
immediately upstream of JAK2; all other SNPs are within JAK2 introns.
(b)L Di nt h eJAK2 region (HapMap data release 23a/phase II March 2008).
Table 1 Summary of genotyping results
Category
Number
of cases
Number of
46/1 alleles
Number of
non-46/1 alleles
Frequency
46/1
P value (versus
UK local controls) OR (95% CI)
P value (versus
WTCCC controls) OR (95% CI)
JAK2V617F-positive PV 192a 197 171 0.54 2.88E 16 3.6 (2.6–4.9) 7.56E 30 3.6 (2.9–4.6)
JAK2V617F-positive ET 78 79 77 0.51 8.24E 09 3.2 (2.1–4.7) 4.27E 12 3.2 (2.4–4.5)
JAK2V617F-positive MF 41a 37 40 0.48 8.00E 05 2.9 (1.7–4.7) 6.12E 06 2.9 (1.9–4.6)
JAK2V617F-positive unclassiﬁed MPN 124a 135 106 0.56 3.33E 15 3.9 (2.8–5.6) 3.40E 24 4.0 (3.1–5.3)
Idiopathic erythrocytosis 76 41 111 0.27 5.80E 01 1.1 (0.7–1.7) 4.37E 01 1.2 (0.8–1.7)
JAK2V617F-negative MPN (UK) 47 36 58 0.38 9.00E 03 1.9 (1.2–3.1) 2.00E 03 2.0 (1.3–3.0)
JAK2V617F-positive ET (GR) 143 124 162 0.43 4.51E 07b 2.4 (1.7–3.3)b 9.18E 12 2.4 (1.9–3.1)
JAK2V617F-negative ET (GR) 136 89 183 0.33 9.00E 02b 1.5 (1.1–2.1)b 2.00E 03 1.5 (1.2–2.0)
UK controls 188 92 284 0.24 – – 8.48E 01 1.0 (0.8–1.3)
WTCCC controls 1,500 720 2,280 0.24 8.48E 01 1.0 (0.8–1.3) – –
GR controls 108 55 161 0.25 8.43E 01 1.1 (0.7–1.6) 6.22E 01 1.1 (0.8–1.5)
PV, polycythemia vera; ET, essential thrombocythaemia; MF, myeloﬁbrosis; MPN, myeloproliferative neoplasm (all samples from the ﬁrst six categories were from the UK and United States). GR,
Greek samples; UK, UK samples; WTCCC, Wellcome Trust Case Control Consortium analysis of 1,500 UK blood donors.
aThese groups included some cases with Z90% V617F and thus the residual wild-type allele could not be assigned as 46/1 or not 46/1. bValues versus healthy Greek controls. All P values were
calculated using Fisher’s exact test, two-tailed.
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LETTERSone affected individual (UPN 534) was heterozygous for 46/1 but the
second (UPN 533) was negative for this haplotype (Fig. 3). Allele-
speciﬁc PCR for UPN 534 showed that JAK2V617F had arisen on the
46/1 allele, conﬁrming the association between this haplotype and the
mutation. However, this pedigree illustrates that 46/1 is not solely
responsible, at least in this family, for predisposition to polycythemia
vera. Indeed, linkage of disease to 9p has not been described in any
family with MPN.
We suggest two hypotheses to account for the association of MPNs
with 46/1: (i) JAK2V617F may arise randomly on all haplotypes but
46/1 is in LD with an unknown constitutional functional variant that
interacts with JAK2V617F in a manner that makes the development of
clinically manifest disease more likely compared to JAK2V617F on a
non-46/1 haplotype, or (ii) there is a speciﬁc mutational mechanism
by which JAK2V617F preferentially arises on a 46/1 haplotype. These
hypotheses are not necessarily mutually exclusive. Inspection of the
HapMap data (Fig. 2) indicates that the entire JAK2 gene is contained
within a 280-kb LD block that includes two other genes (INSL4 and
INSL6) that are not expressed in hemopoietic cells, as veriﬁed by RT-
PCR analysis. It is highly likely therefore that any functional variant
within 46/1 directly affects JAK2. Notably, rs10758669, a SNP that also
tags 46/1, was identiﬁed as signiﬁcant in a recent genome-wide
association study of Crohn’s disease15, thus supporting the hypothesis
of a functional JAK2 variant on that allele. This SNP was also reported
to be signiﬁcantly associated with polycythemia vera but not with
essential thrombocythemia or myeloﬁbrosis11, a result that is pre-
sumably explained by the relatively high prevalence of JAK2V617F in
polycythemia vera compared to the other two subtypes.
JAK2 is required for signaling by diverse myeloid cytokine receptors
(for example, IL-3, G-CSF, GM-CSF, EPO) as well as other receptors
in lymphoid and nonhemopoietic cells16. To investigate the possibility
that JAK2 on the 46/1 haplotype is different functionally from other
JAK2 alleles, we tested whether 46/1 inﬂuences myeloid colony
formation in hematologically normal individuals (n ¼ 56). In a
prospective analysis, we counted the numbers of granulocyte-
macrophage colony-forming units (CFU-GM) and erythroid burst-
forming units (BFU-E) in peripheral blood and compared the results
to JAK2 haplotype. Individuals that carried at least one 46/1 allele grew
signiﬁcantly fewer CFU-GM, consistent with the hypothesis that JAK2
on 46/1 is indeed functionally different from other JAK2 alleles. There
was no effect, however, on BFU-E growth (Fig. 4).
One possible reason for the observed association might be that
JAK2 on 46/1 is expressed more or less than JAK2 on other haplotypes.
To explore this possibility, we used pyrosequencing to quantify the
allele ratios of two JAK2 exonic SNPs (rs10429491 and rs2230724) in
matched cDNA and genomic DNA from control JAK2V617F-negative
cases that were heterozygous for at least one of the exonic SNPs as well
as heterozygous for 46/1 (n ¼ 46). We found no differences in allele
ratios in cDNA and genomic DNA with either SNP, indicating that
46/1 is not associated with either increased or decreased JAK2
expression, at least in peripheral blood leukocytes (Supplementary
Fig. 1 online).
Finally, we explored the possibility that a functional variant might
also be relevant to the pathogenesis of JAK2V617F-negative MPNs. We
genotyped rs12340895 in JAK2V617F-negative essential thrombocythe-
mia and myeloﬁbrosis cases (n ¼ 47) from the UK and found that
36 or 94 alleles were 46/1, signiﬁcantly higher than the frequency in
locally sourced controls and the WTCCC cohort (P ¼ 0.009 and P ¼
0.002, respectively). However, we failed to conﬁrm this association in
an additional series of JAK2V617F-negative essential thrombocythemia
cases (n ¼ 136) and controls (n ¼ 108) from Greece, although the
P value of 0.09 and slightly elevated odds ratio suggests that the
relevance of 46/1 to JAK2V617F-negative cases warrants further inves-
tigation (Table 1).
Our data thus demonstrate that both homozygous and heterozy-
gous JAK2V617F-associated disease is preferentially associated with
46/1, and that this haplotype seems to be in LD with an as-yet-
uncharacterized functional variant. However, this does not exclude the
possibility that JAK2 on 46/1 allele might be also be hypermutable.
Whatever the mechanism, our data indicate that 46/1 is a strong
predisposition factor for development of JAK2V617F-associated MPNs
(OR ¼ 3.7; 95% CI ¼ 3.1–4.3; relative risk ¼ 2.6; 95% CI ¼ 2.3–2.9;
n ¼ 435 cases versus WTCCC controls). The counts of 46/1 alleles in
cases and WTCCC controls and the population frequency from the
WTCCC data (Table 1), suggest that 46/1 accounts for 28% of the
population attributable risk17. A recent Swedish study demonstrated a
relative risk of 5.7 in ﬁrst-degree relatives of individuals with poly-
cythemia vera10, corresponding to an attributable risk of 53%.
Assuming no difference between the UK and Swedish popu-
lations, 46/1 thus accounts for slightly over 50% of the increased
risk in ﬁrst-degree relatives. For essential thrombocythemia and
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Figure 4 Association between JAK2 haplotype and numbers of hemopoietic
colonies. CFU-GM and BFU-E colony growth per 4   105 peripheral blood
mononuclear cells from 56 healthy controls that were 46/1 nullizygous (C/C
at rs12340895, n ¼ 30) or had at least one 46/1 allele (G/C, n ¼ 21; or
G/G, n ¼ 5). Box plots illustrate the 95% range (vertical lines), median
(horizontal lines) and interquartile range (boxes). Colony numbers were
compared by the Mann-Whitney U test.
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Figure 3 Familial polycythemia vera pedigree. The two affected individuals
(UPNs 534 and 533) are shown as black circles. The genotype for
rs12340895 is shown (G ¼ 46/1 allele; C ¼ non-46/1 allele), as is the
%V617F in affected cases. Allele-speciﬁc PCR for UPN 534 showed that
JAK2V617F arose on the 46/1 allele. All other individuals had normal blood
counts and were negative for JAK2V617F, PRV1 overexpression and
endogenous erythroid colony growth14.
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LETTERSmyeloﬁbrosis, the contribution of 46/1 is less clear, as it is unknown
what proportion of the risk in ﬁrst-degree relatives10 is attributable to
cases that are JAK2V617F positive and those that are JAK2V617F negative.
In addition to the speciﬁc association we describe here in MPNs,
our ﬁndings may have wider relevance. Genome-wide association
studies are identifying increasing numbers of loci that predispose to
diverse malignancies18–20; our ﬁndings suggest that these loci should
be considered as candidates for the acquisition of somatic mutations.
METHODS
Subjects. We analyzed a total of 775 subjects with MPN, of whom 183 had
JAK2V617F-negative disease and 592 were JAK2V617F positive (PV, n ¼ 203; ET,
n ¼ 224; MF, n ¼ 41; unclassiﬁed MPN, n ¼ 124). Subjects were recruited from
clinics in the UK, United States and Greece. We also analyzed a previously
d e s c r i b e df a m i l yw i t hM P Nf r o mG e r m a n y 14. For controls we analyzed healthy
individuals from the UK (n ¼ 188) and Greece (n ¼ 108), and we also used data
generated by the WTCCC from the UK blood donor cohort (n ¼ 1,500)12.T h e
study was approved by the relevant internal review boards and ethics committees
and informed consent was provided according to the Declaration of Helsinki.
Genotyping. Total peripheral blood leukocyte DNA was analyzed by pyrose-
quencing for SNPs and JAK2V617F as described21. Primer sequences are
provided in Supplementary Table 1 online. Because the allelic ratios (the ratio
of allele A to allele B at any SNP) for any heterozygous SNPs were distorted
away from the expected value of 0.5 in cases with a sizeable homozygous
JAK2V617F clone, we adopted the following scoring criteria for all SNPs: (i) if
one allele had an allelic ratio Z0.9, the sample was scored as homozygous for
that SNP; (ii) where allelic ratios were 0.11–0.89, samples were scored as
heterozygous. These cutoffs were at least 3 s.d. more than background (that is,
values read for allele B in healthy controls who were A/A homozygotes).
Similarly, for homozygous JAK2V617F cases with V617F 450%, SNPs with
allelic ratios Z0.6 or r0.4 were considered to be derived from the V617F-
mutated or residual wild-type alleles, respectively. For JAK2V617F homozygous
cases in which the V617F was Z90%, no information could be obtained about
the residual wild-type JAK2 allele and thus these cases were considered to
contribute only one allele to the analysis.
Allele-speciﬁc PCR. Allele-speciﬁc PCR was performed using forward primers
that were speciﬁc for JAK2V617F (VF-ASF) or the corresponding wild-type
sequence (WT-ASF) in combination with a common reverse primer (ASR),
producing a 565-bp product that included the 46/1 tag SNP rs12343867.
Ampliﬁcation conditions were optimized on DNA from the HEL cell line
(100% V617F) and normal healthy controls. Products were sequenced to
determine whether JAK2V617F was on the 46/1 allele or not.
Colony analysis. Mononuclear cells (MNCs) from peripheral blood of hema-
topoietically normal controls were isolated by centrifugation over lymphoprep
(Axis-Shield) and cultured in methylcellulose medium (H4434; Stem Cell
Technologies) at a density of 4   105 cells per 30-mm plate (in a ﬁnal volume
of 1 ml), in triplicate, following the manufacturer’s instructions. Colonies
comprising a minimum of 100 cells were counted on day 14, and characterized
on the basis of morphology as either CFU-GM, CFU-GEMM, CFU-E or BFU-
E, as described by StemCell Technologies. JAK2 haplotype status was deter-
mined after colonies were counted using DNA extracted from the MNC or
granulocyte cell fractions.
Expression analysis. RNA was extracted from peripheral blood leukocytes of
JAK2V617F-negative MPD cases that were known to be heterozygous for
rs10429491 and/or rs2230724 (JAK2 exonic SNPs) as well as heterozygous for
46/1, as determined by rs12340895 genotype. RNAwas reverse transcribed with
random hexamer primers and the ratio of the two alleles for each SNP in
genomic DNA and cDNA was determined by speciﬁc Pyrosequencing assays
(Supplementary Table 1).
Statistical analysis. The proportion of 46/1 alleles for each case subgroup was
compared to controls using Fisher’s exact test (two-tailed). Colony numbers
were compared to genotype using the Mann-Whitney Utest. For the expression
analysis, the mean and variance of SNP allelic rations were compared by t and
F tests, respectively. Odds ratios (OR) were calculated as (number of 46/1 alleles
in cases/number of 46/1 alleles in controls)/(number of non-46/1 alleles in
cases/number of non-46/1 alleles in controls). Relative risk (RR) was calculated
as (number of 46/1 alleles in cases/number of 46/1 alleles in cases plus
controls)/(number of non-46/1 alleles in cases/number of non-46/1 alleles in
cases plus controls). Population attributable risks were calculated as (f(RR  
1)/1 + f(RR   1))100, where f is allele frequency17.
Note: Supplementary information is available on the Nature Genetics website.
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4 ADVANCE ONLINE PUBLICATION NATURE GENETICS
LETTERSClonal diversity in the myeloproliferative neoplasms:
independent origins of genetically distinct clones
Neoplasia is thought to be initiated in a single cell, with step-
wise accumulation of genetic lesions leading to a malignant
phenotype. However, divergent clones bearing dissimilar
patterns of somatic mutation have been observed in both
multifocal and premalignant epithelial tumours. In some cases,
an overlap in somatic mutation pattern was observed,
indicating that divergent clones were the phylogenetically
related progeny of a shared founder clone (Sidransky et al,
1992). In other cases, no such overlap could be identiﬁed,
raising the possibility that some tumours are comprised of
more than one genetically unrelated clone (Leedham et al,
2008).
The human myeloproliferative neoplasms (MPNs) are
premalignant clonal stem cell disorders often driven by
activated tyrosine kinases, including BCR-ABL1 in chronic
myeloid leukaemia and JAK2 mutations in polycythaemia vera
and essential thrombocythaemia. Recurrent genetic alterations,
other than those activating a tyrosine kinase, are uncommon in
early disease, but genetic events accumulate with progression
through an accelerated phase of disease to acute leukaemia
(Campbell & Green, 2006; Melo & Barnes, 2007). As such,
MPNs serve as an experimentally tractable paradigm for the
study of early stage tumorigenesis. Circumstantial evidence
suggests that some MPN patients harbour genetically
dissimilar clones: cytogenetically abnormal but BCR-ABL1
negative clones have been reported following imatinib therapy
(Deininger et al, 2007); patients with a JAK2 mutant MPN can
progress to a JAK2 wild-type acute leukaemia (Campbell et al,
2006); and two different tyrosine kinase mutations may be
found in the same patient (Bocchia et al, 2007; Li et al, 2008).
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Summary
This study looked for clonal diversity in patients with a myeloproliferative
neoplasm associated with more than one acquired genetic lesion. A tyrosine
kinase mutation and a cytogenetic lesion were present in the same clone in six
of seven patients. By contrast, the genetic lesions were present in separate
clones in all six patients with two tyrosine kinase pathway mutations.
Moreover, in two patients the clones were genetically unrelated by
X-chromosome inactivation studies. These data demonstrated clonal
diversity in a subset of patients with early stage haematopoietic malignancy
and showed, for the ﬁrst time, that such clones may arise independently.
Keywords: myeloproliferative disorder, cytogenetics, clonality, leukaemia,
tyrosine kinases.
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progenitor colonies has been reported in only two cases, and
although one case suggested the presence of biclonal disease,
evolution from a shared founder clone could not be excluded
(Bocchia et al, 2007; Li et al, 2008). We have therefore studied
MPN patients with more than one acquired genetic lesion to
look for the presence of clonal diversity and to assess the
genetic relationship of such clones.
Materials and methods
Patients met the Polycythemia Vera Study Group criteria for
essential thrombocythaemia or polycythaemia vera or the
World Health Organisation criteria for primary myeloﬁbrosis
or systemic mastocytosis and were recruited from MPN clinics
in Cambridge, Belfast, London, Birmingham and Salisbury.
Institutional and Multi-Region Ethics Committee approval
was obtained and the study was carried out in accordance with
the principals of the Declaration of Helsinki.
For culture of progenitor colonies, peripheral blood mono-
nuclear cells were plated in Methocult (Stem Cell Technolo-
gies, Vancouver, Canada) and incubated for 14 days at 37 C
and 5% CO2. Individual colonies were placed either in water
and heated to 98 C for DNA extraction or into RLT buffer for
RNA extraction according to the manufacturer’s protocol
(Qiagen, Hilden, Germany).
Results and discussion
Haematopoietic colonies were grown from peripheral blood
obtained from 13 MPN patients with two or more acquired
genetic lesions (Table I). Individual colonies, each derived
from a single progenitor, were genotyped for the relevant
genetic lesions. Using quantitative pyrosequencing, all three
JAK2 V617FF-positive patients with trisomy 9 harboured
colonies with a 1:2 ratio of wild-type to mutant allele (Fig S1A
and B), indicating (i) the JAK2 mutation and trisomy 9 were in
the same clone; (ii) trisomy 9 reﬂected duplication of the
chromosome carrying the mutant JAK2 allele; and (iii) loss of
wild-type JAK2 is not essential for the development of
polycythaemia vera (Scott et al, 2006). Quantitative pyrose-
quencing also demonstrated that in two patients trisomy 8 and
JAK2 V617F were present within the same clone (Fig S1C
and D). Loss of heterozygosity analysis was used to study three
patients with a 20q deletion (Fig S2A and B). In Patient 5, the
20q deletion preceded acquisition of the BCR-ABL1 fusion.
Although 20q deletions have been reported in chronic myeloid
leukaemia, to our knowledge this is the ﬁrst report of a 20q
deletion preceding acquisition of BCR-ABL1. In Patient 6, the
20q deletion coexisted with the JAK2 mutation in all colonies,
but in Patient 7 the two lesions were present in separate clones.
Taken together, our results demonstrate that cytogenetic
lesions frequently reﬂect evolution within the clone carrying
an oncogenic tyrosine kinase. However in one of seven cases
the cytogenetic abnormality reﬂected the presence of a separate
clone (Fig 1A).
We also studied six patients carrying JAK2 V617F together
with a second tyrosine kinase pathway mutation (four MPL
W515L, one KIT D816V and one JAK2 E543-D544del;
patients 8–13, Table I). In all six cases, analysis of individual
colonies demonstrated that JAK2 V617F and the second
mutation were mutually exclusive, indicating that the two
lesions were present in separate clones (Figs 1B and S2C).
This could result from the two genetic lesions occurring as
Table I. Clinical features of patients with two or more acquired genetic lesions.
Patient MPN Sex
At diagnosis
Prior Therapy
Disease duration
(years) Lesion 1 Lesion 2 Age years Hb g/l WCC ·10
9/l Plts ·10
9/l
1 PV F 61 158* 20Æ2 671 HC 3 JAK2 V617F Trisomy 9
2 PV F 65 198* 7Æ2 542 HC 8 JAK2 V617F Trisomy 9 Trisomy 8
3 PV M 71 182 10Æ4 977 HC 1 JAK2 V617F Trisomy 9
4 PV M 66 177* 10Æ6 553 HC 4 JAK2 V617F Trisomy 8
5 CML M 52 134 26Æ8 167 IM 9 BCR-ABL del(20q)
6 PMF M 59 94 3Æ3 68 None 9 BCR-ABL1 del(20q)
7 ET M 69 135 7Æ9 1016 HC 12 JAK2 V617F del(20q)
8 ET F 92 134 10Æ8 1240 HC 2 JAK2 V617F MPL W515L
9 ET F 28 140 12Æ8 1221 HC, AN 20 JAK2 V617F MPL W515L
10 ET M 72 128 6Æ7 1258 HC 1Æ5 JAK2 V617F MPL W515L
11 ET M 74 140 6Æ6 979 None 0 JAK2 V617F MPL W515L
12 SM M 43 147 10Æ1 306 NL, PK, HC 3Æ5 JAK2 V617F KIT D816V
13 PV F 73 172* 5Æ3 314 Ven 8 JAK2 V617F JAK2 E543-D544del
MPN, myeloproliferative neoplasm; Hb, haemoglobin; WCC, white cell count; Plts, platelet count; PV, polycythaemia vera; CML, chronic myeloid
leukaemia; PMF, primary myeloﬁbrosis; ET, essential thrombocythaemia; SM, systemic mastocytosis; HC, hydroxycarbamide; IM, imatinib; AN,
anagrelide; NL, nilotinib; PK, PKC412; Ven, venesection alone.
*Increased red cell mass conﬁrmed by radio-isotope studies.
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Fig 1. Analysis of progenitor colonies from myeloproliferative neoplasm (MPN) patients with two acquired genetic lesions. (A) Summary of
individual colony analysis from seven patients (1–7) with a tyrosine kinase pathway mutation and an additional cytogenetic abnormality, showing the
number of individual colonies bearing each genotype and illustrating the relationship of the two clones in each patient. (B) Summary of individual
colony analysis from six patients (8–13) with two tyrosine kinase pathway mutations, showing the number of individual colonies bearing each
genotype and illustrating the relationship of the two clones. (C) Models to explain the coexistence of two separate mutation-bearing clones: either the
mutation bearing clones are clonally related, having arisen from a shared founder clone, or the mutation-bearing clones are clonally unrelated, having
arisen in independent haematopoietic stem cells. (D) X-chromosome inactivation patterns in the mutation-bearing clones from female patients (8, 9
and 13). cDNA prepared from single erythroid colonies was ampliﬁed by reverse-transcription polymerase chain reaction followed by direct
sequencing of an informative expressed single nucleotide polymorphism (SNP) in a gene known to undergo X-inactivation (rs12009345 in LANCL3,
rs11549009 in IDS and rs2071932 in MAGED2). In Patients 9 and 13 the mutation-bearing clones expressed different alleles of the X-linked SNP,
indicating that the two mutations had arisen in unrelated haematopoietic stem cells.
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tively the two genetic lesions may represent independent
clonal expansions (Fig 1C). To distinguish between these
possibilities, X-chromosome inactivation patterns (XCIP)
were studied in the three female patients (Fig 1D). In Patient
8, both MPL-mutant and JAK2-mutant colonies expressed the
same allele of the X-linked LANCL3 gene, a result consistent
with either model in Fig 1C. By contrast, in Patient 9, the
MPL-mutant and JAK2-mutant colonies expressed different
alleles of the X-linked IDS gene. Furthermore, in Patient 13
the JAK2 V617F-positive and JAK2 E543-D544del-positive
colonies expressed different alleles of the MAGED2 gene.
These data provide formal proof that Patients 9 and 13 both
harboured two clones that arose independently and not from
a shared founder clone.
Three aspects of our data are worth emphasising. Firstly,
whereas cytogenetic abnormalities tended to occur in the same
clone as a tyrosine kinase mutation, detection of a second
tyrosine kinase pathway mutation reﬂected the presence of a
separate clonal expansion in all six cases studied. It is possible
that additional activated tyrosine kinases within the same clone
would not confer any further selective advantage, consistent
with the observation that tyrosine kinase pathway mutations
are generally mutually exclusive in myeloid leukaemias (Kelly
& Gilliland, 2002). Secondly, we have identiﬁed seven patients
with biclonal disease from around 1 000 MPN patients
screened. Although the precise denominator is unclear, this
seems much greater than expected given the prevalence of each
individual MPN (McNally et al, 1997). Thirdly, our data
demonstrated that patients may harbour diverse clones that
have arisen independently and not from a shared founder
clone. This phenomenon has been observed in multifocal
thyroid carcinoma (Shattuck et al, 2005), but to our knowl-
edge this is the ﬁrst demonstration in haematological malig-
nancies. These data suggest a role for either an inherited allele
or an environmental mutagen in promoting the acquisition or
survival of such clones. A familial association with MPN has
been reported (Landgren et al, 2008), often showing incom-
plete penetrance (Bellanne-Chantelot et al, 2006), and a recent
report implicated environmental exposure in MPN pathogen-
esis (Hoffman et al, 2007). In conclusion, our data indicate
that patients with early stage haematological malignancy may
harbour distinct clones, and that such clones may arise
independently.
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Brief Report
ABSTRACT
Diverse JAK2 exon 12 mutations have been described in patients with V617F-negative polycythemia vera. Development of a sensitive
detection assay capable of identifying any of these mutations is required for medium-throughput diagnostic screens. Non-mutated and
mutant JAK2 exon 12 alleles were amplified from patient samples and cloned into plasmid vectors, then used to determine the sensi-
tivity of a novel high-resolution melting-curve assay designed to detect all mutant JAK2 exon 12 alleles tested. High resolution melting
analysis was more sensitive than direct sequencing and capable of detecting exon 12 mutations in granulocytes at moderate levels. In
a blinded analysis of DNAs from V617F-negative erythrocytosis patients,with direct sequencing and allele-specific PCR used in one lab-
oratory and high resolution melting analysis in another, high resolution melting successfully identified JAK2 exon 12 mutations in all 4
mutation-positive patients.High resolution melting analysis is a rapid,sensitive and high-throughput technique that is suitable for screen-
ing for JAK2 exon 12 mutations.
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Introduction
The presence of an acquired V617F JAK2 mutation has been
reported in the majority of patients with a myeloproliferative
disorder (MPD);
1-5 the mutant allele can be detected in 95% of
patients with polycythemia vera (PV), and in half of those with
essential thrombocythemia (ET) or primary myelofibrosis
(PMF).
1,6,7 The molecular pathogenesis of the disorder in most
MPD patients lacking the V617F mutation remains largely
unclear. Alternate mutations are absent in the JAK or STAT
gene family members in patients with V617F-negative ET or
PMF,
8 although acquired mutations in JAK2 exon 12 have been
identified in cases of V617F-negative PV.
9 In contrast to patients
with V617F-positive PV, patients with a JAK2 exon 12 muta-
tion present with erythrocytosis, but have white cell and
platelet counts within the normal range. These mutations may
also be detected in patients with erythrocytosis that fail to ful-
fill the Polycythemia Vera Study Group (PVSG) diagnostic cri-
teria for PV,
10 and are instead classified as having idiopathic
erythrocytosis (IE).
9,11
Individual allele-specific PCR reactions have been developed
to detect the first four exon 12 mutations to be described.
9
However, additional mutations have subsequently been identi-
fied,
11-16 including duplications that might not easily be identi-
fied using an allele-specific PCR strategy.
14 It is possible that
additional mutant alleles exist. There is, therefore, a need to
develop more generally applicable, sensitive assays to detect
JAK2 exon 12 mutations for use in a diagnostic setting.
Design and Methods
Patients
DNA samples from 50 erythrocytosis patients attending the
Johns Hopkins Medical Institutes (Baltimore, MD, USA) and
from exon 12 mutation-positive patients attending Adden-
brooke’s Hospital (Cambridge, UK) were used. Institutional
Ethics Committee approval was obtained at both institutions,
written informed consent obtained from each patient, and the
study was carried out in accordance with the principals of the
Declaration of Helsinki. Clinical features of the Baltimore
patients have been published elsewhere.
13
Mutant and wildtype JAK2 exon 12 alleles
Patient genomic DNA was prepared from density gradient-
purified granulocytes using the Puregene Cell kit (Gentra
Systems, Minneapolis, MN, USA). Presence of the V617F
JAK2 mutation was excluded by sequencing and allele-specif-
ic PCR
1 (data not shown). DNA was amplified using primers
flanking  JAK2  exon 12 (forward: 5’-CTCCTCTTTGGAG-CAATTCA-3’; reverse: 5’-GAGAACTTGGGAGTTGC-
GATA-3’). PCR products were treated with ExoSAP-IT
(GE Healthcare, Amersham, UK), then cloned into
pGEM-T (Promega, Southampton, UK).
HRM reaction conditions
A 126bp amplicon was generated using primers in JAK2
exon 12 (5’-AATGGTGTTTCTGATGTACC-3’) and
intron 12 (5’-AGACAGTAATGAGTATCTAATGAC-3’).
Each PCR contained 20-40 ng DNA or 1×10
6 plasmid
copies, 2.5 mM MgCl2, 200 µM dNTPs, 0.5 µM of each
primer, 1× Platinum  Taq polymerase buffer and 0.5U
Platinum Taq polymerase (Invitrogen, Paisley, UK), and
1× LC-Green Plus (Idaho Technologies, Salt Lake City,
UT, USA). Duplicate PCRs and the HRM analysis were
conducted on a RotorGene 6000™ real-time analyzer
(Corbett Life Sciences, Mortlake, Australia). The PCR pro-
file was: an initial hold at 95°C for 10 mins., 40 cycles of
95°C for 15 secs., 58°C for 30 secs., and 72°C for 20 secs.,
followed by 50°C for 30 secs., then a melt from 70°C to
95°C rising at 0.1°C/second (data acquisition was up to
1,000 data collection points per °C transition).
Normalization bars were between 72-75°C for the lead-
ing range, and 92-93°C for the tailing range. 
Sequencing HRM products
HRM product was treated with ExoSAP-IT, then used
as the template for sequencing with the Big Dye
Terminator kit (Applied Biosystems, Warrington, UK).
Each 10 µL reaction mix consisted of 10 ng primer, 0.5 µL
of Big Dye Terminator premix and 1.5 µL 5x sequencing
buffer. Sequencing reactions were performed using 24
cycles of 96° C for 30 secs., 50° C for 15 secs., and 60° C
for 2 mins. on a MJ Research Tetrad thermocycler (Biorad,
Hemel Hempstead, UK). The Montage SEQ96 sequencing
reaction clean-up kit (Millipore, Watford, UK) was used to
purify sequencing reactions, and the resultant DNA resus-
pended in deionised formamide and loaded onto an ABI-
3100 sequencer (Applied Biosystems). Sequences were
analyzed using Mutation Surveyor 3.1 software
(SoftGenetics, State College, PA, USA).
Results and Discussion 
High-resolution melt-curve analysis assay validation
and sensitivity
One drawback to employing allele-specific PCR
assays to screen large numbers of DNAs has been that
multiple individual PCR reactions would be needed for
each sample. Moreover, novel mutations would escape
detection. Given these concerns, we sought to establish
a single sensitive screening method capable of detecting
all possible JAK2 exon 12 mutations; one candidate
approach is high-resolution melt-curve analysis (HRM),
which has been successfully applied to the detection of
the V617F mutation within JAK2 exon 14 in patients
diagnosed with an MPD.
17-20 PCR primers were
redesigned to generate an amplicon suitable for HRM
analysis of JAK2 exon 12. HRM involves precise moni-
toring of the progressive fluorescence change caused by
the release of an intercalating DNA dye from a DNA
duplex as that duplex is denatured by increasing temper-
ature.
21 Base substitutions, deletions and insertions pro-
duce subtle differences in the melting behavior of indi-
vidual DNA duplexes, which can be detected by the use
of an appropriate fluorescent dye, such as LC-Green.
21
Since this methodology will be affected by the presence
of inheritable polymorphisms, a candidate region con-
taining  JAK2 exon 12 and intron 12 (chromosome 9:
5,059,925-5,060,831; genome build 2006) was selected
on the basis of an absence of polymorphisms in the
NCBI database (http://www.ncbi.nlm.nih.gov/sites/entrez/).
However, we subsequently identified a previously unre-
ported polymorphism within this region in 85 out of 128
tested individuals; this variation involves the presence or
absence of a pentanucleotide sequence (position
5,060,231-5,060,235) that would significantly affect any
HRM profile. Accordingly, this region was excluded from
High resolution melting analysis for JAK2 mutations
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Figure 1. Development of a high-resolution melting-curve (HRM)
assay to distinguish between the various JAK2 exon 12 mutated
alleles. (A) Analysis of six wildtype exon 12 samples (black line)
and 50:50 mixtures of wildtype and F537-K539delinsL (green),
H538-K539delinsL (lime), H538QK539L (brown), K539L (cyan),
R541-E543delinsK (purple), N542-E543del (orange) or E543-
D544del (red) alleles reveal that all mutant alleles had a melting
curve profile distinct from that of the wildtype allele, and each
with its own characteristic profile. (B) Difference plots demon-
strate more clearly that each mutant allele has a characteristic
melting curve, with those alleles with deletions of residues includ-
ing E543 (purple, orange, red lines) having a curve distinct from
those alleles with a K539L substitution (green, blue, brown lines). 
A
B
wildtype
F537-K539delinsL
F538-K539delinsL
H538QK539L
K539L
R541-E543delinsK
N542-E543del
N543-E544del
100
90
80
70
60
50
40
30
20
10
0
+4
+3
+2
+1
0
-1
-2
-3
-4
-5
-6
-7
-8
-9
-10
-11
-12
-13
-14
F
l
u
o
r
e
s
c
e
n
c
e
 
(
n
o
r
m
a
l
i
s
e
d
)
F
l
u
o
r
e
s
c
e
n
c
e
 
d
i
f
f
e
r
e
n
c
e
 
(
t
e
s
t
 
m
i
n
u
s
 
c
o
n
t
r
o
l
)
temperature (degrees celsius)
72 73 74 75 76 77 78 79 80 81 82 83 84 85
temperature (degrees celsius)
72 73 74 75 76 77 78 79 80 81 82 83 84 85the final amplicon. HRM analysis was performed on a
RotorGene 6000™ real-time analyzer, and the resulting
data analyzed using the associated RotorGene Series
Software (V1.7.25). Figure 1 shows typical results
obtained when equal amounts of wildtype and mutation-
carrying plasmid were used. The data are presented in
two formats: a normalized plot (Figure 1A), in which the
amount of intercalating dye remaining at any temperature
point is expressed as a fraction of the amount prior to data
acquisition; and a difference plot, where the average
HRM profile of the control samples was used by the
genotype function of the machine software as the stan-
dard wildtype profile for subsequent comparison to each
of the test samples (Figure 1B). Analysis of six control and
seven mutant samples demonstrated that each mutant
allele had its own characteristic melting curve that was
distinct from those obtained when wildtype exon 12 sam-
ples were analyzed (Figure 1A). The individual nature of
the mutant melting curves became more apparent when
the data were represented in a difference plot (Figure 1B).
Mutations that had in common a K539L substitution had
similar difference plots, with the greatest divergence
between mutant and wildtype profiles occurring at 79° C.
Difference plots for the R541-E543delinsK, N542-E543del
and E543-D544del mutants had slopes different to those
associated with a K539L substitution, and the greatest
divergence between mutant and wildtype occurred at
77.5° C.
The ability to detect low levels of a JAK2 exon 12 muta-
tion in a background of non-mutated DNA was evaluated
by titrating each of the mutant alleles with wildtype exon
12 to produce a range of mutant allele dilutions. The
lower limit for detecting nucleotide changes in exon 12
was calculated by the RotorGene software to be 5% for
F537-K539delinsL (Figure 2) and N542-E543del alleles,
7% for the R541-E543delinsK and E543-D544del alleles,
10% for the K539L allele, and 20% for the H538-
K539delinsL and H538QK539L alleles (data not shown).
Titration data were also used to estimate the level of
mutant allele in the granulocyte DNA sample of a F537-
K539delinsL-positive PV patient (PT1; Figure 2).
9
Estimates obtained using HRM analysis agreed closely
with those independently obtained from granulocyte
DNA sequence traces.
JAK2 exon 12 mutation detection in V617F-negative
patients with erythrocytosis
The HRM methodology established using cloned
exon 12 alleles was next assessed using a set of granu-
locyte DNA samples obtained from 50 V167F-negative
erythrocytosis patients,
13 only 10 of whom fulfilled
PVSG diagnostic criteria.
10 Since exon 12 mutation-
positive patients often present with an isolated ery-
throcytosis and might not fulfil these criteria,
9,11 this
patient cohort was selected for analysis as it was con-
sidered to be similar to sample populations being
assessed for the presence of an exon 12 mutation in a
A.V. Jones et al. 
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Figure 2. High resolution melting assays detect mutant JAK2 alle-
les present at a low frequency. High resolution melting analysis of
mixtures of wildtype and F537-K539delinsL JAK2 exon 12 alleles
(0% mutant, black line; 1%, cyan; 5%, brown; 10%, lime; 20%,
orange; 50%, purple; 100%, blue) demonstrates that these assays
can detect relatively low levels of mutant allele. Also included is
the  high resolution melting trace (red) and sequence chro-
matogram of a granulocyte sample from a patient previously
shown to carry an exon 12 mutation.
Figure 3. Screening of 50 V617F-negative patients with erythrocy-
tosis by high resolution melting assays and sequencing independ-
ently identifies 4 mutation-positive cases. Sequencing, allele-spe-
cific PCR, and high resolution melting analysis was independently
used to screen granulocyte DNAs from 50 V617F-negative erythro-
cytosis cases. Difference plots are shown for 4 of the 8 samples
from healthy controls (black traces), 4 samples from mutation-
negative patients within this cohort (cyan traces), and for the 4
samples suggestive of a JAK2 exon 12 mutation (Patients A to D:
lime, orange, purple and red lines respectively). Granulocyte DNA
sequence chromatograms from each of these mutation-positive
cases are also shown, with Patients A and B having an R541-
E543delinsK mutation, Patient C having a N542-E543del muta-
tion, and Patient D having a F537-K539delinsL mutation. 
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patient Ddiagnostic laboratory setting. Allele-specific PCR and
sequence analysis of each sample (data not shown) had
been performed 1-2 months earlier by an investigator
not involved with the HRM analysis, and four samples
were found to be positive for a JAK2 exon 12 mutation
by each method. Subsequent HRM was successful in
discriminating DNA samples with a wildtype JAK2
exon 12 genotype from those including an exon 12
mutation (Figure 3), and correctly identified all positive
samples in this group with no false-positive results.
Direct sequencing of HRM products confirmed the
presence of an exon 12 mutation in these cases. When
compared with the titration experiment results (Figure
2), these data suggested mutant allele burdens of 20%,
25%, 35% and 50% respectively. All 4 patients had
mild splenomegaly, and serum erythropoietin levels
below the normal range, consistent with previous
observations.
9,11 Two patients had not fulfilled the
PVSG criteria at diagnosis; however, subsequent iden-
tification of JAK2 exon 12 mutations permits reclassi-
fication of these cases as PV using the recently modi-
fied WHO criteria.
22 None of the 5 patients with a first-
or second-degree relative with an MPD was mutation-
positive.
Several mutation screening methods have been used
so far to detect JAK2 exon 12 mutations, each with its
particular disadvantages. Dideoxy sequencing is rarely
sensitive below a 10% mutant allele frequency, corre-
sponding to a threshold of 20% granulocytes het-
erozygous for an exon 12 mutation. Allele-specific
PCR requires performing multiple amplification reac-
tions in order to ensure that all potential mutations can
be excluded. A PCR-based technique with sensitivity
comparable to that of allele-specific PCR has been
recently described,
15 although this relies upon the pres-
ence of a deletion within exon 12, thereby precluding
detection of the duplication mutations or the
nucleotide substitution mutants present in some indi-
viduals. Single-strand conformation polymorphism,
denaturing high performance liquid chromatography
or HRM methodologies might prove useful, as they
make the detection process more cost effective by
reducing the amount of sequencing ultimately
required. However, the HRM approach described here
has the added advantage of increased simplicity and
rapid turn-around time, being an in-tube method in
which the melting analysis is performed immediately
after PCR amplification. 
Mutation analysis of granulocyte DNA samples
from V617F-negative erythrocytosis patients using
sequencing, allele-specific PCR and HRM allowed us
to assess the sensitivity and positive predictive value
of the HRM methodology. Mutations were not detect-
ed by allele-specific PCR or sequencing in samples
scored as wildtype by HRM, resulting in 100% sensi-
tivity and 100% positive predictive value for this
methodology in the patient sample set tested. Four
samples had aberrant melting profiles that suggested
the presence of an exon 12 mutation; independently-
obtained allele-specific PCR and sequencing data con-
firmed the presence of these alterations (Figure 3, and
data not shown). In instances of patients with a low
clonal burden, however, exon 12 mutations identified
by HRM may not be confirmable by dideoxy sequenc-
ing; allele-specific PCR may be required for mutation
confirmation in these instances. Alternatively, as all
patients positive for JAK2 exon 12 mutation have ery-
thropoietin-independent erythroid colonies (EECs),
9,11
individual colonies could be analyzed by dideoxy
sequencing to confirm the mutation suspected.
We observed two limitations to this HRM methodol-
ogy: one was its inability to identify the H538QK539L
and H538-K539delinsL JAK2 alleles when their abun-
dance was less than 20%. However, these are both rel-
atively rare mutant alleles, occurring in only 4 of the 50
cases reported in the literature.
9,11-14,16,23 In contrast, the
most common exon 12 mutations (F537-K539delinsL,
N542-E543del, E543-D544del) were all detectable at a
relative abundance of 7% or less. Secondly, patient
samples with purely mutant DNA may pose a problem
due to an absence of heteroduplex formation.
However, homozygous exon 12 mutations are relative-
ly rare in patients, with only 2 cases reported.
11,14 In
both instances, non-mutated exon 12 sequence was
apparent within the granulocyte DNA sequence trace,
and we would predict that HRM analysis of these
DNAs would provide a melting curve significantly dif-
ferent from that of a control sample.
In conclusion, we successfully used HRM to identify
somatic mutations in JAK2 exon 12 in 4 of 50 erythro-
cytosis patients lacking the V617F JAK2 mutation.
These results correlated exactly with allele-specific
PCR and sequencing results obtained independently. 
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FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid
leukemia affect different leukemic cells
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We investigated genetically affected leukemic cells in FIP1L1-
PDGFRAþ chronic eosinophilic leukemia (CEL) and in BCR-
ABL1þ chronic myeloid leukemia (CML), two myeloprolifera-
tive disorders responsive to imatinib. Fluorescence in situ
hybridization speciﬁc for BCR-ABL1 and for FIP1L1-PDGFRA
was combined with cytomorphology or with lineage-restricted
monoclonal antibodies and applied in CML and CEL, respec-
tively. In CEL the amount of FIP1L1-PDGFRAþ cells among
CD34þ and CD133þ cells, B and T lymphocytes, and
megakaryocytes were within normal ranges. Positivity was
found in eosinophils, granulo-monocytes and varying percen-
tages of erythrocytes. In vitro assays with imatinib showed
reduced survival of peripheral blood mononuclear cells but no
reduction in colony-forming unit growth medium (CFU-GM)
growth. In CML the BCR-ABL1 fusion gene was detected in
CD34þ/CD133þ cells, granulo-monocytes, eosinophils, ery-
throcytes, megakaryocytes and B-lymphocytes. Growth of both
peripheral blood mononuclear cells and CFU-GM was inhibited
by imatinib. This study provided evidence for marked differ-
ences in the leukemic masses which are targeted by imatinib in
CEL or CML, as harboring FIP1L1-PDGFRA or BCR-ABL1.
Leukemia (2007) 21, 397–402. doi:10.1038/sj.leu.2404510;
published online 11 January 2007
Keywords: lineage afﬁliation; FIP1L1-PDGFRAþCEL; BCR-
ABL1þCML
Introduction
BCR-ABL1þ chronic myeloid leukemia (CML) is a paradigm for
the multilineage involvement of an imatinib-sensitive chronic
myeloproliferative disorder in which an affected stem cell
ordinately differentiates toward both myeloid and lymphoid
hematopoietic pathways.
Chronic eosinophilic leukemia (CEL), is a chronic myelopro-
liferative disorder whose diagnosis is based on persistent
eosinophilia (41.5 10
9/l), organ involvement and increased
blast cells in peripheral blood or bone marrow and/or clonality,
as shown by cytogenetics and X-inactivation.
1–4 Cools et al.
5
ﬁrst described a genetic clonal hallmark for a speciﬁc CEL
subgroup. The CHIC2 gene deletion at 4q12 results in a fusion
between the FIP1L1 and PDGFRA genes. As a consequence the
PDGFRA tyrosine kinase is activated. Interestingly, imatinib
mesylate, a tyrosine kinase inhibitor, rapidly induces remission
in the majority of patients, although disease is not fully
eradicated.
In order to compare the hematopoietic cell lineages affected
by FIP1L1-PDGFRA in CEL and by BCR-ABL1 in CML, we
combined ﬂuorescence in situ hybridisation (FISH) with
cytomorphology (MISH), as well as with immunostaining
ﬂuorescence immunophenotyping and interphase cytogentics
as a tool for the investigation of neoplasms (FICTION).
Furthermore, we tested in vitro imatinib sensitivity both on
peripheral blood mononuclear cells and in colony-forming unit
growth medium (CFU-GM) from patients with CEL and CML.
Results showed that FIP1L1-PDGFRAþ cells are limited to
advanced stages of myeloid cell differentiation, whereas BCR-
ABL1 is present in both myeloid and lymphoid lineages.
Accordingly, imatinib inhibited peripheral blood mononuclear
cells and CFU-GM in BCR-ABL1 þCML, but only peripheral
blood mononuclear cells in FIP1L1-PDGFRAþ CEL. In this
study, we assessed a restricted lineage afﬁliation of hemato-
poietic cells labeled by FIP1L1-PDGFRA in CEL.
Materials and methods
Patients and controls
A total of 16 FIP1L1-PDGFRA-positive CEL cases were included
in this study. Bone marrow aspirates were used to investigate
lineage afﬁliation in eight patients. In eight additional cases,
peripheral blood was used for in vitro studies on imatinib
sensitivity. Patients were selected from the Hematology Depart-
ments of the Universities of Perugia and Bari (Italy), from the
Hematology Department and Centre for Human Genetics of the
University of Leuven (Belgium) and from the Wessex Regional
Genetics Laboratory of the Salisbury District Hospital, Salisbury
(UK). Four cases of CML were selected from patients referred to
the Hematology Department of the University of Perugia (Italy).
Twelve healthy donors were used as controls. The study was
approved by the Hematology Department IRB (Reg. no.
00003450; FWA 00005268) of University of Perugia, Italy.
Genomic probes and monoclonal antibodies
The FIP1L1-PDGFRA/4q12 was studied with clone RP11-3H20
labeled with biotin alone or in combination with clone RP11-
120K16 labeled with digoxigenin (RP11 belongs to the Roswell
Park Cancer Institute (RPCI)11 library, http://bacpac.chori.org/).
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BCR-ABL dual-color/dual-fusion translocation probe (BCR clone
in green and ABL1 clone in orange) (Vysis, Olympus, Milan,
Italy).The following monoclonal antibodies were used: anti-
CD13, anti-CD14, anti-CD33, anti-CD3, anti-CD7, anti-CD19,
anti-CD20, anti-glycophorin C, anti-glycophorin A (Dako,
Milan, Italy), anti-CD34 (Becton-Dickinson, Milan, Italy), anti-
CD133 (Miltenyi Biotec S.r.l., Bologna, Italy).
FICTION and MISH
A FICTION published methodology
6 was slightly modiﬁed.
Brieﬂy, cytospins were prepared from bone marrow mono-
nuclear cells after centrifugation on Lymphoprep (AXIS-SHIELD,
Norway) using 100ml from a cell suspension of 1 10
6/ml.
Slides were air-dried at room temperature for 24h ﬁxed in
acetone for 10min and incubated with monoclonal antibodies
for 30min at room temperature. The three-step staining
technique used the following Cy3-conjugated polyclonal anti-
bodies: goat anti-mouse, rabbit anti-goat and donkey anti-rabbit
(Jackson Immunoresearch/Li StarFISH, Milano, Italy). After
immunostaining, slides were ﬁxed in Carnoy’s ﬁxative (meta-
nol:acetic acid, 3:1) for 1min and in 1% paraformaldehyde for
10min, washed in distilled water and dehydrated in an ethanol
series. For MISH investigations, bone marrow smears were air-
dried and ﬁxed in methanol:acetic acid (3:1) for 5min. Slides
and probes were co-denaturated on a hot plate at 761C and
incubated overnight at 371C in a humidiﬁed chamber. To detect
biotinylated DNA, slides were incubated three times: with
ﬂuorescein isothiocyanate (FITC)-conjugated avidin, with bioti-
nylated goat anti-avidin antibody and with FITC-conjugated
avidin (Vector Laboratories, DBA Italia, Milan, Italy).
Immunophenotype and hybridization signals were simulta-
neously identiﬁed and counted under an Olympus ﬂuorescence
microscope with ﬁlter sets for Cy-3 and FITC equipped with a
CCD camera (Sensys-Photometrics, Tucson, AZ, USA) run from
image analysis software (Vysis, SmartCapture, Olympus, Milan,
Italy). For each antibody, at least 13 (range 13–94) cells were
checked in CEL and CML patients and at least 145 cells in
normal controls (range 145–375).
MISH on eosinophils, and on megakaryocytes was carried out
after morphological identiﬁcation of single cells on bone
marrow smears applying a set of DNA clones described
previously (Figures 1 and 2). All the experiments were evaluated
by two independent observers.
CD34
þ cell selection
CD34
þ stem cells were labeled with CliniMACS CD34
microbeads (Miltenyi Biotec S.r.l., Bologna, Italy) and passed
through the magnetic ﬁeld of a Mini MACS separator (CD 34
Progenitor Cell Isolation Kit, Miltenyi Biotec S.r.l., Bologna,
Italy). Purity was analyzed on a FACscan (Cytomics FC 500,
Beckman Coulter, Milan, Italy) using a monoclonal antibody
speciﬁc for CD34 conjugated with FITC (Becton Dickinson,
Milan, Italy). After suspension in phosphate-buffered saline, cell
cytospins were prepared and ﬁxed: (1) 5min in 30% ﬁxative (3:1
methanol:acetic acid) diluted with 0.075 M KCl, (2) 10min in
20% ethanol diluted with 0.075 M KCl and (3) 10min in ﬁxative
(3:1 methanol:acetic acid). After ﬁxation interphase FISH was
performed using clone RP11-3H20 and clone RP11-120K16, as
described previously.
7
Progenitor cell colony assay
Thawed bone marrow mononuclear cells were washed in
Iscove-modiﬁed Dulbecco’s medium (IMDM; StemCell Tecnol-
ogies, Vancouver, Canada). Cells were counted and 1 10
5
were plated in 1ml aliquots in 30mm Petri dishes in a semisolid
assay. At least six Petri dishes were prepared for each patient.
Figure 1 Fluorescence in situ hybridization on intact cells in FIP1L1-
PDGFRAþ CEL. (a) FICTION with monoclonal antibodies against
CD34, CD133, CD33, CD13, CD14, CD3, CD7, CD20, glycophorin A
(top three lines). Red staining detects positive intact cells expressing
the speciﬁc antigen. Green spots indicate FISH signals in the nuclei
using a FITC-labeled genomic probe (RP11-3H20) for CHIC2. Two
green signals indicate normal disomic cells; one shows CHIC2
deletion, that is, FIP1L1-PDGFRA fusion (original magniﬁcation
 1000). Bottom line MISH (FISH on morphologically identiﬁed
cells). Left: autoﬂuorescent eosinophils without counterstain; in each
nucleus, one green signal indicates CHIC2 deletion. Right: one
megakaryocyte with polyploid nucleus with DAPI (blue) counter-
staining. Green signals indicate 3H20 probe (CHIC2 gene); red signals
indicate 120K16 probe (internal control). Eight overlapping red–green
signals (arrows) show no CHIC2 deletion (original magniﬁcation
 1000). (b) Histogram with FICTION results from eight CEL cases
(orange) and eight healthy controls (black). In CEL, CD33þ, CD13þ,
CD14þ, glycophorin Cþ and Aþ cells bearing CHIC2 deletion were
signiﬁcantly greater (Po0.05 vs controls). Non-parametric t-test,
Mann–Whitney test.
CEL and CML leukemic cells
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LeukemiaThe medium contained 30% FCS (HyClone, Logan, UT, USA),
3U/ml rhuEpo, 50ng/ml stem cell factor, 10ng/ml GM-CSF,
10ng/ml IL-3 (all from PeproTech, UK), 0.9% methylcellulose
(StemCell Inc., Canada) and IMDM. Cultures were incubated for
14 days, at 371C, 5% CO2, in a humidiﬁed incubator. CFU-GM
colonies were scored under an inverted microscope according
to standard criteria.
8 Colonies (40–50) were transferred singly
into a microtiter well containing 40ml hypotonic solution
(0.075 M KCL) for each cytospin. Cytospins were ﬁxed following
the same protocol described before for FISH on CD34þ cells.
After ﬁxation interphase FISH was carried out applying a set of
DNA clones described previously in the genomic probe section.
All the experiments were evaluated by two independent
observers.
Clonality by X-chromosome inactivation
Both peripheral blood and buccal epithelial samples were
obtained from the single CEL woman included in the study.
Mononuclear cells were isolated by Ficoll–Hypaque density
gradient centrifugation (Lympholyte-H, CEDARLANE, HORN-
BY, Canada). T lymphocytes were puriﬁed from the mono-
nuclear cell fraction using magnetic immunobeads coated with
an anti-CD3 antibody (Miltenyi Biotech GmbH, Bergish
Gladbach, Germany). Polymorphonuclear leukocytes (PMN)
were isolated from the red cell pellet following erythrocytes
removal by hypotonic lysis.
The X-chromosome inactivation patterns were established by
polymerase chain reaction (PCR) analysis of DNA methylation at
the human androgen receptor locus (HUMARA) as previously
published.
9
In vitro imatinib sensitivity
Test 1: Liquid culture assay. Peripheral blood mono-
nuclear cells or granulocytes from CEL, CML and normal
controls were cultured in 24-well plates in 1ml aliquots of
2–5 10
6 cells in Roswell Park Memorial Institute medium
1640 medium supplemented with 10% serum. Duplicate wells
were treated with 1 and 5mM imatinib. Cells were counted with
a hemocytometer twice weekly for 3 weeks. The medium was
supplemented on days 7 and 14. A decrease in cell numbers in
imatinib-treated wells compared with untreated control wells
indicated a positive response.
Test 2: CFU-GM assay. Peripheral blood mononuclear cells
from CEL, CML and normal control were separated using
lymphoprep (Axis-Shield, Oslo, Norway) and cultured in
methylcellulose supplemented with growth factors (Stem Cell
Technologies Ltd, Vancouver, Canada) at a cell density of
2 10
5 cells/ml in 3cm Petri dishes. Imatinib (Novartis, Basel,
Switzerland) was added to ﬁnal concentrations of 1 and 5mM.
Colony numbers were scored on days 7 and 14 from triplicate
plates. The response index was calculated as the mean
reduction in colony numbers in 1 and 5mM treated dishes on
days 7 and 14 compared with untreated dishes. After control
experiments using normal individuals and patients with BCR-
ABL1-positive CML, an index below 0.2 was established as
indicating positive response.
Results
The outcomes of FICTION and MISH studies on CEL patients
were summarized in Table 1 (see also Figure 1a and b). CD34
was investigated in 5/8 cases (patients 1, 2, 4, 5, 6, Table 1). In
all of them the percentage of CHIC2 deletion was equal to or
below the cutoff (13%) established at the upper limit on normal
control (Table 1). In patient 8, puriﬁed CD34þ cells were
Figure 2 Fluorescence in situ hybridization on intact cells in BCR-
ABL1þ CML. (a) FICTION with monoclonal antibodies against CD34,
CD133, CD33, CD13, CD14, CD3, CD7, CD20, glycophorin A (top
three lines). Red staining detects positive intact cells expressing the
speciﬁc antigen. Green spots indicate FISH signals in the nuclei using
a Spectrum Green-labeled genomic probe (Vysis, Olympus, Milan,
Italy) for BCR. Two green signals indicate normal disomic cells; three
show BCR split because of Philadelphia translocation (original
magniﬁcation  1000). Bottom line MISH (FISH on morphologically
identiﬁed cells). Left: autoﬂuorescent eosinophil without counterstain;
three green signals indicate Philadelphia translocation. Right: one
megakaryocyte with polyploid nucleus with DAPI (blue) counter-
staining. ABL1 gene is indicated by red signals and BCR gene by green.
Four overlapping red–green signals (arrows) indicate Philadelphia
BCR-ABL1 fusion. (b) Histogram with FICTION results from four CML
cases (blue) and four healthy controls (black). In CML, the numbers of
CD34þ, CD133þ, CD33þ, CD13þ, CD14þ, CD19þ, CD20þ,
glycophorin Cþ and Aþ cells bearing BCR-ABL1 fusion signals were
signiﬁcantly greater (Po0.05 vs controls). Non-parametric t-test,
Mann–Whitney test.
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Leukemiainvestigated with microbeads conjugated to an anti-CD34
monoclonal antibody. FISH analysis showed one signal in 15/
400 cells (4%) of the enriched CD34þ population (normal
experiment control 5%, i.e., 18/400). We used the anti-CD133
monoclonal antibody as an additional marker for a totipotent
stem cell. This antibody was studied in patients 2 and 6 and the
percentage of deletion was 9 and 7%, respectively (Table 1). For
this antibody, the cutoff was set at 10%.
CD33 was investigated in 6/8 patients. The percentage of cells
bearing CHIC2 deletion ranged from 84 to 95%. CD13 was
evaluated in 7/8 patients showing a percentage of deletion
between 80 and 98%. The anti-CD14 antibody also showed that
88–97% cells were affected by the CHIC2 deletion in the ﬁve
patients studied (Table 1).
Glycophorin C was investigated in 5/8 (no. 1, 2, 3, 4, 6,
Table 1) patients in whom CHIC2 deletion was detected in 37–
88% of cells (normal cutoff 11%). As glycophorin C may
crossreact with some granulocytes, glycophorin A was also
tested. Positivity conﬁrmed that erythroid cells were affected by
CHIC2 deletion. However, CHIC2 deletion in glycophorin A-
positive cells was 48% (38/79), 46% (43/93) and 15% (14/94),
respectively in patient 1, 2 and 6, suggesting inter-individual
variance in the malignant erythrocyte component of CEL.
Interphase ﬂuorescence in situ hybridization (I-FISH) on
megakaryocytes from healthy controls showed colocalization
of green and red signals as expected in the absence of 4q12
deletion. Results in 30 megakaryocytes in patient 2 showed
between 6 and 26 copies of colocalized red–green signals
(Table 1 and Figure 1a).
Eosinophils were identiﬁed by autoﬂuorescence granules. In
all patients, the positivity ranged between 88 and 98% of
elements (Table 1).
Results on both T and B lymphocytes were within the cutoff
limits established in normal controls (Figure 1a and b, and
Table 1).
In four cases of BCR-ABL1þ CML, the BCR-ABL1 rearrange-
ment was observed on totipotent CD34þ and CD133þ
stem cells and in committed lineages downstream, that is,
granulo-monocytes, erythrocytes, megakaryocytes and B
lymphoid cells (Table 2 and Figure 2a and 2b). In patient 2,
80% of eosinophils were positive for BCR-ABL1 rearrangement
(Table 2).
Table 1 FICTION and MISH experiments for CHIC 2 deletion in eight CEL cases
Patient
Antibody 1 2 3 45678 Controls cu offs
a
CD34 3/30 (10) 2/40 (5) F 4/30 (13) 3/25 (12) 0/30 (0) FF 13
CD133 F 2/22 (9) FF F 2/28 (7) FF 10
CD33 40/42 (95) 40/42 (95) 27/32 (84) 35/38 (92) F 40/43 (93) 40/42 (95) F 9
CD13 49/50 (98) 40/49 (82) 40/42 (95) 30/32 (94) 20/25 (80) 30/36 (83) 38/40 (95) F 11
CD14 30/33 (91) 32/33 (97) F 28/31 (90) F 37/42 (88) 34/35 (97) F 9
CD3 1/41 (2) 0/40 (0) 1/40 (2) 1/31 (3) 2/30 (7) 1/32 (3) 0/14 (0) F 9
CD7 2/26 (8) 3/28 (11) F 0/35 (0) F 2/32 (6) 1/31 (3) F 12
CD19 2/29 (7) FFFF 1/35 (3) FF 11
CD20 F 2/28 (7) 0/16 (0) 2/26 (8) F 2/32 (6) 1/31 (3) F 9
Glyc C 42/52 (81) 30/42 (71) 15/17 (88) 11/13 (85) F 18/48 (37) FF 11
Glyc A 38/79 (48) 43/93 (46) FFF 14/94 (15) FF 14
Megak F 0/30 (0) FFF F FF 0
Eos 50/54 (93) 40/44 (91) 45/51 (88) 35/39 (90) 30/32 (94) 41/42 (98) 40/42 (95) 40/43 (93) F
Abbreviations: CEL, chronic eosinophilic leukemia; Eos, eosinophils; Glyc A, glycophorin A; Glyc C, glycophorin C; Megak, megakaryocytes.
In each case, the number of positive cells/total cells (with percentage in parenthesis) is show.
aHighest percentage of normal cells with one CHIC 2 signal.
Table 2 FICTION and MISH experiments for BCR/ABL1 fusion gene in four CML cases
Patient
Antibody 1 2 3 4 Controls cutoffs
a
CD34 33/35 (94) 30/36 (83) 40/42 (95) 30/32 (94) 5
CD133 28/30 (93) 45/50 (90) 19/20 (95) 19/21 (90) 5
CD33 30/34 (88) 26/32 (81) 40/43 (93) 36/39 (92) 5
CD13 25/25 (100) 30/30 (100) FF 5
CD14 24/24 (100) 30/32 (93) FF 5
CD3 0/30 (0) 2/32 (6) FF 5
CD7 0/26 (0) 0/13 (0) FF 3
CD19 14/28 (50) 21/33 (64) 27/40 (67) 21/35(60) 6
CD20 26/42 (62) 16/31 (52) FF 5
Glyc C 22/26 (85) 30/32 (93) FF 4
Glyc A F 27/30 (90) FF 3
Megak 20/20 (100) FF F F
Eos F 12/15 (80) FF F
Abbreviations: CML, chronic myeloid leukemia; Eos, eosinophils; Glyc A, glycophorin A; Glyc C, glycophorin C; Megak, megakaryocytes.
In each case, the number of positive cells/total cells (with percentage in parenthesis) is shown.
aHighest percentage of normal cells with three BCR signals.
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recovered at day 14 in methylcellulose, and was carried out in
CEL (no. 1, 2, 6, Table 1) and in CML (no. 2 and 3 Table 2).
Results showed no CHIC2 deletion in CEL cases (the percentage
of CHIC2 deletion was equal to or above the cutoff of 5%) and
positivity for BCR-ABL1 in CML cases (respectively 100% in one
case, and 50% in the other).
Clonal analysis in the CEL female patient (case no. 2, Table 1)
showed skewed X-chromosome inactivation patterns in both
granulocytes and T lymphocytes. To distinguish between the
monoclonal nature of these cells and skewed Lyonization, we
examined the clonality pattern of buccal mucosa cells as non-
hematological control for the myeloid stem cell disorder. The
band pattern was opposite to that of PMN and T lymphocyte in
keeping with a true clonal hematopoiesis affecting both
granulocytes and T cells.
In vitro tests for sensitivity to imatinib in CEL showed that
peripheral blood mononuclear cells in liquid cultures were
inhibited (Figure 3, bottom left), but no signiﬁcant response was
seen in CFU-GM (median response index: 0.33 vs 0.43 in
controls) (Figure 3, bottom right). By contrast, three newly
diagnosed BCR-ABL1þ CML patients showed a signiﬁcant
response in both liquid cultures (Figure 3, left) and CFU-GM
assay (median response index¼0.05) (Figure 3, right).
Discussion
This study provided us with new insights on the characterization
of leukemic populations from two imatinib-sensitive myelopro-
liferative disorders, namely BCR-ABL1þ CML and FIP1L1-
PDGFRAþ CEL.
As expected, in CML the BCR-ABL1 rearrangement consis-
tently labeled multipotential stem cells expressing CD34 and
CD133 antigens. Moreover, both myeloid and lymphoid cells
were affected, mirroring a predicted cascade of hematopoietic
differentiation.
10 These ﬁndings concur with results of conven-
tional cytogenetics, G6PDH enzymatic activity, X-inactivation
and detection of the BCR-ABL1 transcript
11–14 and validate our
FISH approach for the assignment of a typical leukemic genetic
lesion to different hematopoietic lineages.
From this study, in CEL the CD34þ stem cells were not
affected, although in one case (patient 4, Table 1) with a high
value of CHIC2 deletion we cannot exclude the presence of
FIP1L1-PDGFRA in some CD34þ cells. Moreover, as a low
amount of positive nuclei from CD34þ sorted cells were
reported by Robyn et al.,
15 we also checked FIP1L1-PDGFRA in
CD34þ enriched cells after microbeads in patient 8 conﬁrming
our FICTION results. Furthermore, in two additional cases
(patients 2 and 6, Table 1), CHIC2 deletion was also absent in
CD133-positive cells. Thus, in contrast with BCR-ABL1 in CML,
CD34þ and CD133þ stem cells are virtually spared by the
FIP1L1-PDGFRA genetic lesion in CEL.
B and T lymphocytes were not affected by FIP1L1-PDGFRA,
as shown by identical results in CEL and normal samples
(Table 1 and Figure 1). However, in our female CEL patient in
whom X-inactivation could be performed (patient 2, Table 1),
we found that clonality included T lymphocytes, despite the
absence of FIP1L1-PDGFRA fusion, suggesting that, at least in
some cases, FIP1L1-PDGFRA recombination occurs after a still
unknown clonal mutation in a multipotential stem cell. Similar
results have been recently shown in a subset of chronic
myeloproliferative disorders in which clonality included cells
with and without the typical JAK2
V617F mutation.
16 Interestingly,
as far as it concerns lymphocyte cells, analogies are emerging
between FIP1L1-PDGFRA in CEL and PDGFRB recombinations
in other Ph-negative chronic myeloproliferations. In a previous
publication on a case of atypical CML, we showed that the H4-
PDGFRB fusion affected myeloid progenitors but neither CD3þ
nor CD19þ lymphocytes.
17 More recently we obtained similar
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Leukemiaresults in a case of ETV6-PDGFRBþ chronic myelomonocytic
leukemia in which both CD3þ and CD19þ cells were normal
(Crescenzi B and Mecucci C, unpublished). Whether PDGFRA
and PDGFRB recombinations affect a myeloid committed
progenitor, or if an affected multipotential stem cell undergoes
only restricted and disparate myeloid maturation, when targeted
by PDGFRA or PDGFRB recombinations, remains to be
determined. With respect to PDGFRB, the last hypothesis is
supported by Shigematsu et al.( Blood 2004; 104, abstract no.
387), who reported that an ETV6-PDGFRB fusion gene was able
to address only myeloid lineage differentiation when transfected
in lymphoid progenitors.
In this study we found that, in addition to eosinophils, the
leukemic mass in FIP1L1-PDGFRAþ CEL was limited to
erythrocytes and granulomonocytes. Strikingly, CFU-GM
growth was inhibited by imatinib in CML, but not in CEL
(Figure 3) and, accordingly, FISH on CFU-GM from CML was
positive for BCR-ABL1, whereas FISH on CFU-GM from three
CEL cases was negative for FIP1L1-PDGFRA. Whether FIP1L1-
PDGFRA behaves as a genetic lesion able to impart self-renewal
properties to mature precursors remains to be investigated.
Alternatively, the restricted FIP1L1-PDGFRAþ hematopoiesis
in CEL might be supported by microenvironmental conditions,
such as overexpression of speciﬁc cytokines. Interestingly, a
critical role of extrinsic factors in the pathogenesis of a full CEL
phenotype has been recently emphasized in a murine model
published by Yamada et al.
18 who showed that FIP1L1-PDGFRA
was not able to generate organ inﬁltration by eosinophils in the
absence of overexpression of interleukin 5.
In conclusion, for the ﬁrst time we identiﬁed major differences
between BCR-ABL1þ cells in CML and FIP1L1-PDGFRAþ
cells in CEL. Altogether our results show that the BCR-ABL1þ
model of affected CD34þ and CD133þ stem cell ordinately
undergoing multilineage differentiation does not apply to CEL
whose leukemic mass, labeled by FIP1L1-PDGFRA fusion and
targeted by imatinib is restricted to advanced stages of myeloid
hematopoiesis.
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JAK2-V617F mutation in a patient with Philadelphia-
chromosome-positive chronic myeloid leukaemia
Alwin Krämer, Andreas Reiter, Jens Kruth, Philipp Erben, Andreas Hochhaus, Martin Müller, Nicholas C P Cross, Amy V Jones, Anthony D Ho, 
Manfred Hensel
In July, 2000, a 50-year-old man presented with leuko-
cytosis and splenomegaly (21 cm). Leucocyte concen-
tration was 93×10
9/L, haemoglobin 150 g/L, and platelets 
345×10
9/L (ﬁ  gure 1). A diﬀ  erential blood count showed 
54% neutrophils, 2% lymphocytes, 13% myelocytes, 7% 
metamyelocytes, 2% promyelocytes, 1% blasts, and 
7% basophils. Lactate dehydrogenase (LDH) concen-
tration was increased at 484 U/L. 17 months previously, 
the blood count had been in the normal range. Bone-
marrow aspiration was dry and bone-marrow biopsy 
showed marked myeloid hyperplasia, increased mega-
karyopoiesis, and the beginning of ﬁ  brosis. Cytogenetic 
analysis revealed a chromosome translocation 
(t[9;22][q34;q11]) in all ten metaphases examined. Expres-
sion of B3A2 BCR-ABL mRNA was detected by reverse 
transcriptase polymerase chain reaction (RT-PCR) in 
peripheral-blood leucocytes. A diagnosis of BCR-ABL-
positive chronic myeloid leukaemia (CML) was made 
and treatment with hydroxycarbamide was started, 
resulting in rapid normalisation of peripheral-blood 
leucocytes. After 3 weeks, treatment was changed to 
imatinib (400 mg/day). Within 1 month, a complete 
haem  atological response was recorded. Cytogenetic and 
interphase ﬂ   uorescence in-situ hybridisation at 
6 months after the start of imatinib showed a complete 
cytogenetic response. The BCR-ABL:ABL ratio dropped 
from 90% at diagnosis to 0·021% after 6 months. 
16 months after starting imatinib, BCR-ABL transcripts 
became undetectable by real-time and nested RT-PCR 
(ﬁ  gure 2).
1 Repeated cytogenetic and quantitative BCR-
ABL RT-PCR analyses showed a continuing complete 
cytogenetic and molecular response, as shown in 
ﬁ  gure 2. However, in 2003, an unexpected decrease in 
platelet count and a continuous increase in serum LDH 
concentration was noted (ﬁ  gure 1). In 2004, immature 
myeloid cells began to appear in the peripheral blood 
and a bone-marrow biopsy in May, 2004, revealed 
advanced ﬁ   brosis. In 2005, leucocyte concentration 
continually rose above the upper normal limit. The 
spleen was enlarged to 18 cm. Cytogenetic analysis 
identiﬁ  ed a normal karyotype and BCR-ABL transcripts 
were still undetectable. Therefore, a JAK2-V617F muta-
tional analysis was done, which highlighted the presence 
of a heterozygous JAK2-V617F mutation, leading to the 
diagnosis of idiopathic myeloﬁ  brosis (IMF) according 
to the WHO diagnostic criteria. For JAK2 genotyping, 
DNA was ampliﬁ  ed and PCR products were directly 
sequenced using the PCR primers JAK2-1F 
(5’-TGCTGAAAGTAGGAGAAAGTGCAT-3’) and JAK2-
1R (5’-TCCTACAGTGTTTTCAGTTTCAA-3’).
The proportion of mutant JAK2-V617F alleles was 
quantiﬁ   ed using pyrosequencing as described.
2 Addi-
tionally, the allelic ratio of JAK2-V617F was conﬁ  rmed by 
a newly established quantitative real-time (RQ) PCR 
assay based on LightCycler technology (Roche Diagn-
ostics, Mannheim, Germany). DNA was extracted from 
peripheral blood leucocytes after red-cell lysis by stan-
dard procedures. Total JAK2  was established using a 
forward primer, 5’-AGGCTACATCCATCTACCTCAG-3’, 
a reverse primer, 5’-CCTAGCTGTGATCCTGAAACTG-3’ 
(MWG Biotech, Ebersberg, Germany), and the 
hybridisation probes 5’-ACAGGCTTGA  CCCATAA-
CACCT  GAAATA GAG-3’ and 5’-GAGTGGTACAGGAA-
TCATGAATAATGCCAGTCA-3’ (Tib Molbiol, Berlin, 
Germany). Mutant JAK2-V617F alleles were quantiﬁ  ed 
using the same forward primer and probes in 
combination with a mutation-speciﬁ   c reverse primer, 
5’-TTTTACTTACTCTCGTCTCCACAGAA-3’ (MWG Bio -
tech, Ebersberg, Germany). The allele copy number was 
identiﬁ  ed using a plasmid standard curve. JAK2-V617F 
positivity was expressed as the ratio between mutant 
JAK2-V617F  and total JAK2. Dilution experiments 
showed an assay sensitivity of 1%.
Retrospective analysis of frozen samples of peripheral-
blood leucocytes showed that the JAK2-V617F mutation 
was already present at initial diagnosis of BCR-ABL-
positive CML (ﬁ  gure 3). Consistent with the presence of 
an acquired somatic mutation, the JAK2-V617F mutation 
was absent in puriﬁ  ed CD3+ T lymphocytes (ﬁ  gure 3) 
Lancet Oncol 2007; 8: 658–60
Department of Internal 
Medicine V, University of 
Heidelberg, Heidelberg 
Germany (Prof A Krämer MD, 
Prof AD Ho MD, M Hensel MD); 
Department of Internal 
Medicine III, Faculty of Clinical 
Medicine Mannheim, University 
of Heidelberg, Mannheim, 
Germany (Prof A Reiter MD, 
J Kruth MD, P Erben MD, 
Prof A Hochhaus MD, 
M Müller MD); Wessex Regional 
Genetics Laboratory, Salisbury, 
UK (Prof NCP Cross PhD, 
AV Jones PhD)
Correspondence to: 
Prof Alwin Krämer, Clinical 
Cooperation Unit Molecular 
Haematology/Oncology, German 
Cancer Research Centre and 
Department of Internal Medicine 
V, University of Heidelberg, 
69120 Heidelberg, Germany 
a.kraemer@dkfz-heidelberg.de
L
e
u
c
o
c
y
t
e
s
 
(
/
n
L
)
 
a
n
d
 
m
e
t
a
m
y
e
l
o
c
y
t
e
s
 
i
n
 
p
e
r
i
p
h
e
r
a
l
 
b
l
o
o
d
 
(
%
)
 
P
l
a
t
e
l
e
t
s
 
(
/
n
L
)
 
a
n
d
 
l
a
c
t
a
t
e
 
d
e
h
y
d
r
o
g
e
n
a
s
e
 
(
U
/
L
)
 
0 
20 
40 
60 
80 
100 
0 
200 
400 
600 
800 
Spleen 21·3 cm  Spleen 17·7 cm 
Leucocytes 
Metamyelocytes and myelocytes  
in peripheral blood 
Platelets 
Lactate dehydrogenase 
Time (month/year) 
7/00 8/00  3/04  12/03  6/02  7/01  10/00  8/06  5/06  11/05  8/05 
Figure 1: Course of peripheral-blood parameters during treatment with imatinib in a patient with BCR-ABL-
positive chronic myeloid leukaemiahttp://oncology.thelancet.com   Vol 8   July 2007  659
Case Report
and buccal cells (data not shown). As demonstrated by 
two independent methods—JAK2-V617F pyrosequencing 
and PCR—the proportion of the mutant allele stayed 
roughly constant from diagnosis of CML in July, 2000, to 
February, 2006 (ﬁ  gure 2). Repeated cytogenetic analysis 
in May, 2006 again showed a normal karyotype.
JAK2 is a tyrosine kinase that has an important role in 
the signalling pathways of many haemopoietic growth-
factor receptors. The single acquired point mutation 
V617F (1849G>T) in JAK2 occurs in 50–97% of patients 
with IMF, essential thrombocytosis, and polycythemia 
vera.
2–6 By contrast, the JAK2-V617F mutation has never 
been identiﬁ   ed in a patient with BCR-ABL-positive 
CML.
7 This is the ﬁ  rst description of a patient, to our 
knowledge, in whom the BCR-ABL fusion gene and an 
acquired somatic JAK2-V617F mutation could be 
detected contemporaneously, with IMF becoming 
clinically relevant after successful treatment of CML by 
imatinib.
Several conclusions can be drawn from these data. 
First, bone-marrow ﬁ  brosis was not a consequence of 
progressive CML. Rather, myeloﬁ  brosis developed as a 
second myeloproliferative disorder (MPD) during 
complete cytogenetic and molecular remission of CML. 
Although the BCR-ABL fusion gene might represent the 
initiating lesion in most cases of CML, clinical 
manifestations of the disease can be variable. Speciﬁ  cally, 
bone-marrow ﬁ   brosis can occur, sometimes varying 
greatly during the course of the disease, and has been 
used to categorise patients into diﬀ  erent groups with 
distinctive survival caracter  istics.
8 Fibrogenesis in MPD 
is generally assumed to be mediated by the abnormal 
release of transforming growth factor-β and platelet-
derived growth factor (PDGF). Imatinib, a selective 
inhibitor of ABL, KIT, and PDGF receptor tyrosine 
kinases, and which is not active against JAK2, has been 
seen to reduce the content of bone-marrow ﬁ  bre  in 
patients with CML.
9 Regression of myeloﬁ  brosis  by 
imatinib is thought to be caused either by a direct PDGF-
antagonistic eﬀ  ect or by normalisation of megakaryo-
poiesis from which abnormal concentrations of PDGF 
are released. How  ever, expression of JAK2-V617F in 
murine haematopoietic cells leads to MPD associated 
with myeloﬁ  brosis.
10 Moreover, expression of a BCR-JAK2 
fusion gene has been described in a patient with atypical 
CML and bone-marrow ﬁ  brosis,
11 and the PCM1-JAK2 
fusion is associated with the development of myeloﬁ  brosis 
in patients with chronic and acute leukaemias.
12 These 
ﬁ   ndings suggest that JAK2-V617F contributes to the 
development of myeloﬁ  brosis in MPD,
3,10 and might have 
been responsible for the induction of myeloﬁ  brosis in 
our patient which, consequently, was independent of the 
presence of BCR-ABL and did not respond to imatinib 
treatment. This assumption is supported by the absence 
of clinical and molecular responses of patients with IMF 
and polycythemia vera treated with imatinib.
13,14 If 
treatment with imatinib had not been initiated, the 
clinical course of the patient could only have been 
speculated upon. Treatment and response to imatinib 
might have accelerated the outgrowth of the IMF.
Second, our data suggest that in our patient, the JAK2-
V617F mutation had occurred before the acquisition of 
the Philadelphia (Ph)-chromosome. Development of a 
Ph-positive CML has rarely been reported in patients 
with MPD.
15 In the few cases that have been reported, 
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there is a debate as to whether MPD and CML arise 
separately from each other, representing independent 
transformation of a normal stem cell, or whether the Ph-
chromosome arises in a stem cell that was part of the 
MPD clone. In our patient, JAK2-V617F was detectable at 
an almost constant allele frequency in all peripheral-
blood samples examined (ﬁ   gure 2). The most likely 
explanation for this ﬁ   nding is the presence of a 
heterozygous  JAK2-V617F mutation in most of the 
peripheral-blood leucocytes, implicating the simultaneous 
presence of the BCR-ABL fusion gene and the JAK2-
V617F mutation in white blood cells. Because BCR-ABL 
became undetectable after treatment with imatinib, but 
the  JAK2-V617F allele frequency remained virtually 
unchanged, the conclusion can be drawn that the Ph-
chromosome was acquired from a haematopoietic cell 
carrying the JAK2-V617F mutation. Several ﬁ  ndings 
suggest that MPD are caused by a mutation in an, as yet, 
unknown gene that precedes the acquisition of either a 
JAK2-V617F mutation or a BCR-ABL fusion gene.
3,16 The 
most reasonable explanation for the ﬁ  ndings presented 
here is that BCR-ABL can, in rare cases, occur on the 
background of the JAK2-V617F mutation, possibly 
augmented by an elusive initial mutation predisposing to 
the acquisition of both a JAK2-V617F mutation and a 
BCR-ABL translocation.
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Brief report
Minimal molecular response in polycythemia vera patients treated with imatinib
or interferon alpha
Amy V. Jones, Richard T. Silver, Katherine Waghorn, Claire Curtis, Sebastian Kreil, Katerina Zoi, Andreas Hochhaus, David Oscier,
Georgia Metzgeroth, Eva Lengfelder, Andreas Reiter, Andrew J. Chase, and Nicholas C. P. Cross
Imatinib and recombinant interferon
alpha (rIFN) can induce remission in
polycythemia vera (PV) patients, but
gauging the depth of responses has not
been possible due to lack of a speciﬁc
disease marker. We found that patients
undergoing imatinib (n  14) or rIFN
(n  7) therapy remained strongly pos-
itive for V617F JAK2, although there
was a signiﬁcant reduction in the
median percentage of mutant alleles
that correlated with hematologic re-
sponse (P  .001). Furthermore, indi-
viduals who achieved complete hema-
tologic remission had lower levels of
V617F than those who did not
(P  .001). Of 9 imatinib-treated cases
for whom pretreatment samples were
available, 7 with no or partial hemato-
logic responses showed a marginal in-
crease (median, 1.2-fold; range, 1.0-1.5)
in the percentage of V617F alleles on
treatment, whereas the 2 patients who
achieved complete hematologic remis-
sion showed a 2- to 3-fold reduction.
Our data indicate that, although PV pa-
tients may beneﬁt from imatinib or
rIFN, molecular responses are rela-
tively modest. (Blood. 2006;107:
3339-3341)
© 2006 by TheAmerican Society of Hematology
Introduction
Polycythemia vera (PV) is a myeloproliferative disease charac-
terized by an increased red-cell mass and usually an increase in
megakaryocytes in the bone marrow and platelets in the
peripheral blood. Untreated, the disease leads to thrombo-
hemorrhagic complications and in most cases to progressive
marrow myeloﬁbrosis, anemia, and splenomegaly.1 Long-term
remission has been reported with recombinant interferon alpha
(rIFN),2-7 and, more recently, a number of patients have
achieved complete or partial responses after treatment with
imatinib mesylate.8-11
rIFN has been reported to induce cytogenetic remission in
occasional patients and/or result in conversion of monoclonal to
polyclonal hematopoiesis.3 Such events have not been reported as
yet following imatinib treatment. However, since only 20% of
patients present with a chromosomal abnormality, it has not been
possible, in general, to gauge the depth of responses to treatment.
Here, we have exploited the recently described V617F JAK2
mutation12-18 as a disease marker to measure the response of PV
patients to rIFN or imatinib.
Study design
Patients
We studied 111 PV patients, of whom 21 had undergone treatment in 2
larger sequential phase 2 single-institution studies. Seven patients received
rIFN in the ﬁrst study (initial doses 1 MU 3 times weekly to 3 MU daily;
median follow-up, 60 months; range, 13-132), and 14 received imatinib in
the second study (initial doses 400 to 800 mg daily; median follow-up, 17
months; range, 5-31). The 90 remaining patients, constituting the control
group, were either untreated or treated by phlebotomy only, hydroxyurea,
and/or anagrelide. For rIFN-treated cases, complete hematologic response
(CR) was deﬁned as no need for phlebotomy, a sustained hematocrit level of
less than .45 (45%) for men and less than .42 (42%) for women, and platelet
count of 600  109/L or less. Partial hematologic response (PR) was the
aforementioned but platelet count ranged between 600 and 1000  109/L
(Polycythemia Vera Study Group criteria). For imatinib-treated patients,
CR was deﬁned as phlebotomy-free within the ﬁrst 18 months of treatment,
hematocrit level of .45 (45%) or less for men and .42 (42%) or less for
women, platelet count of 400  109/Lor less, and absence of splenomegaly
if spleen was initially palpable. PR was deﬁned as phlebotomy-free within
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3339 BLOOD, 15APRIL 2006 VOLUME 107, NUMBER 8the ﬁrst 18 months, hematocrit level of .45 (45%) or less for men and .42
(42%) or less for women, platelet count more than 400  109/L, and spleen
reduced to 50% or less of the original size, if initially palpable. All
responses were thus considered quantitative, not qualitative. The studies
had been approved by the internal review boards from participating
institutions and informed consent was provided according to the Declara-
tion of Helsinki.
Molecular studies
DNA was extracted from peripheral-blood samples (n  111) by standard
procedures after isolation of total leukocytes or granulocytes following
red-cell lysis or by density gradient centrifugation over Histopaque 1077
(Sigma-Aldrich,Ayrshire, United Kingdom). DNAwas also extracted from
pretreatment, unstained bone marrow slides (n  9). V617F was detected
initially using an ampliﬁcation refractory mutation system (ARMS) assay
as described.17 The proportion of mutant alleles (%V617F) was quantiﬁed
using pyrosequencing as detailed,17 except that samples were ampliﬁed
using primers 5-TCTTTGAAGCAGCAAGTATGA-3 and 5-biotin-
GCCTGTAGTTTTACTTACTCTCG-3 and sequenced with primer 5-
TTTTAAATTATGGAGTATGT-3. Comparison of the %V617F between
control and treated patients was performed using the Mann-Whitney test.
Results and discussion
Using ARMS, V617F was detected in 82 (91%) of the control PV
cases and in all 21 cases undergoing treatment with imatinib or
rIFN. The sensitivity of the assay is approximately 5%,17
indicating that neither therapy had reduced the percentage of
mutant cells below this level. Patient details and results are
summarized in Table 1.
To quantify the level of disease, we used pyrosequencing, which
measures the proportion of mutant alleles.17 As shown in Figure
1A, we found that the median percentage of mutated JAK2 alleles
(%V617F) did not differ signiﬁcantly between the imatinib-treated
cases (median, 59%; range, 8%-91%) and the V617F-positive
cases from the control group (median, 53%; range, 5%-100%). The
%V617F was lower in the rIFN-treated cases (median, 27%;
range, 19%-87%) compared with controls (P  .03), which prob-
ably reﬂects the high proportion of cases in this selected group who
had achieved CR rather than any preferential inhibitory effect of
rIFN over imatinib.
For imatinib-treated patients, the median %V617F for individu-
als with NR, PR, and CR were 72% (range, 44%-89%; n  3), 60%
(range, 30%-91%; n  9), and 15% (range, 8%-21%; n  2),
respectively. In the rIFN-treated group, the single case with a PR
had 87% V617F compared with a median of 26% (range, 19%-
39%) for the 6 cases in CR. Individuals who achieved CR on
imatinib or rIFN (n  8) had a lower %V617F (median, 24%;
range, 20%-29%) than those patients who did not achieve CR
(n  13; median, 72%; range, 19%-91%) and also the control
group (P  .001). There was a signiﬁcant trend in reduction of
%V617F values on comparison of patients who showed NR, PR, or
CR to therapy (P  .001, Figure 1B).
To determine the magnitude of any change that occurred as a
consequence of therapy, we compared %V617F levels in pretreat-
ment bone marrow and posttreatment peripheral-blood samples for
9 of the imatinib-treated cases (pretreatment samples were not
available for the other cases). Of these 9 cases, the 7 with NR or PR
showed a marginal increase (median, 1.2-fold; range, 1.0- to
1.5-fold) in the percentage of V617F alleles on treatment. In
contrast, the 2 patients who achieved CR showed a 2- to 3-fold
reduction in %V617F on treatment (Figure 1C). To conﬁrm that
these changes were not distorted by differences in the size of the
V617F clone between bone marrow and peripheral blood, we
compared the %V617F in contemporaneous specimens taken from
11 control PV patients. As shown on Figure 1D, similar %V617F
levels are seen in blood and marrow.
Interferon- exerts a general antimyeloproliferative effect,
although its precise mechanism of action is not understood. Since
pretreatment samples were not available for the rIFN-treated
cases in our study group, we cannot be certain that this therapy
resulted in a reduction of %V617F levels. However, this seems
likely to be the case since the rIFN-treated patients (all but one of
Table 1. Summary of patient characteristics and results for cases undergoing therapy with imatinib or rIFN
Patient
no. Sex
Age at diagnosis,
y Rx Dose F/U, mo Response
% V617F on
treatment
% V617F before
treatment
1 M 26 Imatinib 800 mg/d 5 NR 44 ND
2 F 60 Imatinib 700 mg/d 5 PR 41 34
3 M 49 Imatinib 800 mg/d 9 NR 89 71
4 F 67 Imatinib 500 mg/d 9 PR 91 88
5 M 58 Imatinib 400 mg/d 10 PR 72 ND
6 M 48 Imatinib 800 mg/d 15 PR 57 40
7 M 31 Imatinib 800 mg/d 17 PR 76 63
8 F 48 Imatinib 500 mg/d 17 CR 8 25
9 F 28 Imatinib 800 mg/d 19 PR 83 82
10 M 72 Imatinib 400 mg/d 21 NR 72 ND
11 M 54 Imatinib 300 mg/d 24 CR 21 44
12 M 43 Imatinib 400 mg/d 25 PR 60 40
13 M 30 Imatinib 600 mg/d 25 PR 19 ND
14 M 53 Imatinib 700 mg/d 31 PR 30 ND
15 F 32 rIFN 3 MU 3 times/wk 13 CR 19 ND
16 F 39 rIFN 3 MU 5 days/wk 45 CR 39 ND
17 M 53 rIFN 3 MU/day 50 CR 29 ND
18 F 48 rIFN 4 MU, alternate d 60 PR 87 ND
19 M 42 rIFN 2 MU 3 times/wk 60 CR 27 ND
20 M 52 rIFN 4.25 MU 3 times/wk 108 CR 22 ND
21 M 39 rIFN 3.5 MU/d 132 CR 25 ND
Rx indicates treatment; F/U, follow-up ( time of sampling) after starting rIFN or imatinib; NR, no response; ND, not determined; PR, partial response; CR, complete
response; and MU, million units.
3340 JONES et al BLOOD, 15APRIL 2006 VOLUME 107, NUMBER 8whom were in CR) had signiﬁcantly lower %V617F levels than
controls,and,furthermore,theselevelswerecomparablewiththose
seen in CR cases on imatinib. Indeed, subsequent to this study, we
have identiﬁed a further PV patient who showed a reduction in the
%V617F from a pretreatment level of 70% to 35% in CR on rIFN.
Imatinib is a selective inhibitor of ABL, PDGFR, KIT, and
FMS tyrosine kinases but is not active against JAK2. It is known
that KIT signal transduction pathways are required for erythropoi-
esis,19,20 and it is possible that the observed clinical beneﬁts of
imatinib in PV are a consequence of KIT inhibition. Although our
study demonstrates that molecular responses can be discerned in
PV patients that correlate with hematologic improvement, the
magnitude of these responses contrasts starkly with chronic
myeloid leukemia, wherein many individuals experience a 1000-
fold or greater reduction in BCR-ABL levels.21,22 While we cannot
exclude the possibility that occasional PV patients might exhibit
more substantial molecular responses, we conclude that the re-
sponse of PV to imatinib or rIFN is relatively modest.
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Figure 1. Levels of JAK2 V617F in treated and control
PV cases. (A) Comparison of %V617F in control, muta-
tion-positive PV cases who were either treated or not
treatedwithimatiniborrIFN.(B)Comparisonof%V617F
in control PV cases and patients who showed CR, PR, or
NR following therapy with imatinib or rIFN. Vertical lines
indicate the range of results; boxes, the interquartile
range; and thick horizontal lines, median values. (C)
Changes in %V617F on imatinib therapy. The %V617F
was measured before starting imatinib and at various
times while on therapy for 7 patients who showed no
response (NR) or a partial response (PR), and 2 patients
who showed a complete response (CR). (D) Comparison
of %V617F level in peripheral blood and bone marrow
from 11 control PV cases.
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BCR ABL that is
normally found in Ph
þ ALL, CML associated p210
BCR ABL by
virtue of its unique Dbl/Plecstrin-homology domain, can bind to
small GTPases of the Rho family both in vitro and in vivo.
3 This
in turn gives rise to Rho activation, which might be responsible
for promoting cellular motility. Taken together, it need to be
substantiated whether or not these events do indeed contribute
to malignant transformation; however, considering BCR-ABL-
induced abundant pool of p27 in the CML cytoplasm, one can at
least speculate the involvement of BCR-ABL-p27-RhoGTPase
axis in CML blast transformation (Figure 1).
Past few decades have witnessed considerable advancement
in identifying putative phosphorylation hotspots in p27 that are
important for cell cycle regulation. The N-terminus portion of
p27 is recruited to cyclin–cdk complexes and results in cell
cycle arrest and it is the C-terminus portion that can promote
cellular motility and thus metastatic potential. Intriguingly, these
two functions are virtually partitioned by a single parameter: the
address of p27 at a given point of time. Future studies could be
directed to unravel the individual domain contribution by using
respective knockout animal models, and it would be important
to look upon whether tampering p27 in such a manner can have
any consequences on cancer predisposition. Furthermore,
different CDKIs control diverse array of functions for HSC
maintenance. However, we know very little about how these
different CDKIs differentially regulate quiescence, self-renewal
and homing, three important aspects of regenerative medicine,
of normal and malignant HSCs. To conclude, we are only
beginning to appreciate the underlying importance of p27 and
other cell cycle inhibitors in the context of LSCs. Indeed, how
such an intrinsically unstructured p27 protein governs CML
biology need to be explored further.
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No evidence for ampliﬁcation of V617F JAK2 in myeloproliferative disorders
Leukemia (2007) 21, 2561–2563; doi:10.1038/sj.leu.2404845;
published online 5 July 2007
Acquired uniparental disomy following mitotic recombination
results in homozygosity for the V617F JAK2 mutation in a
proportion of patients with myeloproliferative disorders (MPD),
particularly polycythemia vera (PV) and myeloﬁbrosis (MF).
1
Recently, Hammond et al.
2 in a letter in Leukemia indicated that
a proportion of MPDs harbor more than two copies of V617F
JAK2 and suggested that disease evolution may involve further
gene duplication associated with genetic instability. In a follow-
up study, the same group found that this phenomenon was most
prevalent in PV, with more than one-third of mutation-positive
cases apparently having more than two V617F copies/cell.
3
Increased V617F copy number has been described in cell lines,
4
but has not thus far been veriﬁed in patients.
To determine if elevated JAK2 copy number could be detected
with an alternative methodology, we developed a test based on
multiplex ligation-dependent probe ampliﬁcation (MLPA), an
established technique for detecting DNA copy number
changes.
5–7 Four MLPA probe pairs targeting JAK2 exons 3, 9,
16 and 20 were designed, so that they could be combined with
the commercially available telomere MLPA probe mix (P036B
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adjacent 50 and 30 oligonucleotides which, when ampliﬁed by
universal primers following the hybridization and ligation steps,
generated products in the size range 98–126bp. The 30
oligonucleotides for each probe pair were modiﬁed with a
phosphate group at their 50 end, and each oligonucleotide pair
contained a tag sequence recognized by the MLPA Salsa
primers, so that the JAK2 probes were ampliﬁed alongside the
telomere probes in one reaction. MLPA was performed and
results were analyzed as described.
7,8 Ratios of test peaks to
control peaks and control peaks to other control peaks in each
patient sample were compared to the same ratios obtained for
two normal individuals that were included in each run. The four
JAK2 peak area ratios per sample were averaged to give a
relative dosage quotient for JAK2 as a representation of copy
number per cell. For normal sequences, a dosage quotient of 1.0
is expected; if a deletion or duplication is present, the dosage
quotient should be 0.5 and 1.5, respectively.
To validate the assay, we initially analyzed a series of control
samples. Twenty-one hematologically normal individuals gave a
median JAK2 dosage quotient of 1.01 (range 0.71–1.28). The
dosage quotient for a ﬁbroblast cell line carrying a der(9)t(6;9)
was 0.50, corresponding to deletion of one copy of JAK2, which
was further supported by deletion of one copy of the 9p
telomere probe. To control for increased copy number of the
JAK2 locus, the V617F-positive cell lines SET-2 and HEL were
analyzed. SET-2 has approximately 75% V617F, as determined
by pyrosequencing,
8 while MLPA revealed approximately ﬁve
copies of the 9p telomere (dosage quotient¼2.47) and ﬁve
copies of JAK2 per cell (dosage quotient¼2.50). HEL has 100%
mutant allele by pyrosequencing and MLPA indicated 9–10
copies of JAK2 (dosage quotient¼4.72), plus total deletion of
the 9p telomere and other abnormalities. These results are
illustrated in Figure 1, and accord well with previous estimates
of JAK2 copy number in these cell lines determined by
ﬂuorescence in situ hybridization.
4
Next, we investigated peripheral blood leukocyte DNA from
63 MPDs (PV, n¼45; MF, n¼5; other MPD, n¼13) that were
homozygous for V617F as determined by pyrosequencing
(median %V617F¼87%; range 63–99%). The JAK2 dosage
quotients (median 0.99; range 0.67–1.25) ascertained by MLPA
were no different from the normal control group and no case
was above the previously deﬁned cut-off required to deﬁne a
duplication.
6,7 Analysis of a further 16 heterozygous V617F
cases (median %V617F¼31%) yielded similar results with
again no evidence for increased JAK2 copy number. Although
Hammond et al. suggested that their results could be caused by
an internal tandem duplication of the V617F region rather than a
complete duplication of JAK2, such abnormalities have never
been reported on ampliﬁcation of JAK2 exon 14 from genomic
DNA and, in addition, we have not detected any aberrant size
bands using cDNA-speciﬁc primers to exons 13 and 15 in 15
homozygous V617F-positive cases analyzed by RT-PCR. We
conclude therefore that ampliﬁcation of the mutant JAK2 allele
is not a common factor in the evolution of JAK2 V617F-positive
disease.
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Figure 1 Representative MLPA genotyper traces for measuring JAK2 copy number per cell. The JAK2 probes for exons 9, 20, 16 and 3 result in
smaller bands than those from MRC-Holland telomere probe mix, of which 1p–12p are shown here. The JAK2 dosage quotient and estimated copy
numbers are shown. The der(9)t(6;9) cell line, which harbors only one copy of JAK2, shows reduced JAK2 and 9p subtelomere peaks relative to the
other peaks. HEL and SET-2 show an increase in the relative size of these peaks, while no JAK2 copy number alterations were detected in four
illustrative patient samples with a high %V617F.
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Rituximab with chemotherapy improves survival of non-germinal center type untreated
diffuse large B-cell lymphoma
Leukemia (2007) 21, 2563–2566; doi:10.1038/sj.leu.2404844;
published online 28 June 2007
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous
disorder that can be subdivided into several subtypes based on
DNA microarray-based gene expression proﬁling: germinal
center B-cell-like (GC) DLBCL and activated B-cell-like (ABC)
DLBCL. Patients with GC DLBCL have been shown to exhibit a
more favorable clinical outcome than patients with non-GC
DLBCL.
1 As with cDNA microarray, immunohistochemistry can
also be used to distinguish the GC/non-GC subtype of DLBCL
and to predict survival,
2 but there have been few reports
comparing clinical outcomes in cases of GC DLBCL and non-
GC DLBCL treated with rituximab.
3,4 We retrospectively
analyzed the treatment effect of rituximab with conventional
chemotherapy on these two DLBCL subtypes by means of
immunohistochemistry.
We analyzed patients with untreated DLBCL who were
diagnosed according to the WHO classiﬁcation.
5 Patients who
were diagnosed in our hospital between 2001 and 2005 were
treated with rituximab plus TCOP (R-TCOP) (cyclophos-
phamide, therarubicin, vincristine and prednisolone), and those
who were diagnosed in our hospital between 1997 and 2002
were treated with TCOP alone. R-TCOP consisted of a
combination of rituximab (375mg/m
2 administered on day 1
of each chemotherapy cycle) and TCOP (cyclophosphamide
750, therarubicin 50 and vincristine 1.4mg/m
2 administered on
day 2 and prednisolone 100mg/m
2 administered on days 2–6).
TCOP consisted of TCOP alone. We reduced the chemothera-
peutic dosage to two out of three patients who were more than
65 years of age. Tumor response was assessed at the end of
treatment according to the International Workshop criteria.
6
Immunohistochemical staining was performed using heat-
induced antigen retrieval, as described previously.
7,8 Details of
the immunohistochemical staining are provided in Table 1. The
scoring was based on the algorithm described by Hans et al.
2
Bcl-6, CD10 and melanoma associated antigen (mutated) 1
(MUM1) were considered positive if 30% or more of tumor cells
were stained with the respective antibody, and bcl-2 was
considered positive if 30% or more tumor cells were stained.
Given that bcl-6 and CD10 are markers of GC B cells, a case
was considered to be a case of GC DLBCL if CD10 alone was
positive or if both bcl-6 and CD10 were positive. If both bcl-6
and CD10 were negative, the case was considered to be a case
of non-GC DLBCL. If bcl-6 was positive and CD10 was
negative, the expression of MUM1 was used to determine the
group, that is if MUM1 was negative, the case was considered to
be a case of GC DLBCL, and if MUM1 was positive, the case
was considered to be a case of non-GC DLBCL.
The results of immunohistochemical staining and response
rates were compared between groups using w
2 test and Fisher’s
exact test. Event-free survival (EFS) was calculated from the time
of diagnosis to the date of disease progression, death or last
contact. Overall survival (OS) was calculated as the time from
diagnosis to the date of death or last contact. Survival curves
were constructed using the Kaplan–Meier method and com-
pared by log-rank test. Differences were considered signiﬁcant
at Po0.05. A general-purpose statistical software package,
StatFlex Version 5.0 (Artech Co., Osaka, Japan), which provides
results compatible with SPSS, was used for the data analyses.
The R-TCOP group comprises 38 patients. The median
follow-up time for surviving patients in this group was 13
months. The TCOP group comprises 31 patients. The median
follow-up time for surviving patients in this group was 25
months. Of the 69 cases in total, 26 (38%) and 43 (62%) were
considered cases of GC DLBCL and non-GC DLBCL, respec-
tively, on the basis of immunohistochemical analysis. In the R-
TCOP group, 18 (48%) and 20 (52%) cases were classiﬁed as
cases of GC DLBCL and non-GC DLBCL, respectively. In the
TCOP group, eight (26%) and 23 (74%) cases were classiﬁed as
cases of GC DLBCL and non-GC DLBCL, respectively. Bcl-2
was expressed in 63% of cases in the R-TCOP group, that is in
61% of GC DLBCL and 65% of non-GC DLBCL. Bcl-2 was
expressed in 53% of cases treated with TCOP alone, that is in
50% of GC DLBCLs and in 70% of non-GC-DLBCLs. The patient
characteristics (age, sex, performance status, Ann Arbor clinical
stage, B symptoms, bone marrow involvement, extranodal
disease, International Prognostic Index (IPI) and lactate de-
hydrogenase (LDH)) did not differ signiﬁcantly between groups
(that is, between patients grouped by treatment or by DLBCL
subtype) (Table 2).
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Myeloproliferative Disorders
Chronic neutrophilic leukemia with an associated
V617F JAK2 tyrosine kinase mutation
Chronic neutrophilic leukemia (CNL) is a rare
disease and can cause considerable diagnostic dif-
ficulty. Although the V617F JAK2 mutation has
been described by several groups to be associated
with classical myeloproliferative disorders (MPD),
this same mutation has been detected with a low
incidence in atypical MPD, such as CNL. Here we
report the presence of the V617F mutation in a
CNL patient, who is unusual for having survived
for more than 96 months, with little disease pro-
gression. It remains to be established what role this
mutation, which gives cells a proliferative advan-
tage, might play in the pathogenesis and prognosis
of rare atypical MPD.
haematologica 2005; 90:1696-1697
(http://www.haematologica.org/journal/2005/12/1696.html)
Chronic neutrophilic leukemia (CNL) is a rare disease
categorized under the World Health Organization
(WHO) classification
1 as a chronic myeloproliferative dis-
ease. In essence it is a diagnosis of exclusion, in a patient
presenting with neutrophilia and splenomegaly with no
evidence of chronic myeloid leukemia or a reactive neu-
trophilia. Diagnostic difficulties are not uncommon and it
is likely that many previous cases considered to be CNL
were misclassified. The stated figures for prognosis vary
widely. Reilly
2 performed a survival analysis of 33 cases
of patients felt to have ‘true chronic neutrophilic leukemia’
and suggested an overall median survival of 30 months
and a 5-year survival of 28%. Treatment approaches to
individuals with this disorder appear to be heteroge-
neous.
It is unusual for CNL individuals to survive for long,
although it has been described,
3 and we have one such
individual attending our clinic. This patient presented at
the age of 61 years with a 2- month history of fatigue and
an influenza-like illness. Examination revealed only mod-
erate hepatosplenomegaly. Hematologic findings were a
hemoglobin of 14.8 g/dL, total white cell count of
54×10
9/L (with neutrophils 48×10
9/L), and a platelet
count of 316×10
9/L. Examination of blood films revealed
a large population of segmented neutrophils with few
immature granulocytes and no circulating myeloblasts.
Bone marrow aspirate demonstrated a hypercellular mar-
row secondary to granulocytic proliferation with neither
overt dysplastic features nor an increase in the blast per-
centage. The trephine biopsy did not indicate any fibro-
sis, increase in plasma cells or megakaryocytic prolifera-
tion. Conventional cytogenetic analysis demonstrated a
normal male karyotype and the patient was negative for
the  BCR/ABL transcript by polymerase chain reaction
analysis. Since no cause was established for a secondary
neutrophilia he fulfilled the WHO
6 diagnostic criteria for
CNL and the management strategy at this stage was one
of observation only. Recently published data
4-8 have
shown the acquired V617F Janus Kinase (JAK) 2 mutation
is widespread amongst classical myeloproliferative (MPD)
disorders, albeit in a heterogeneous manner. JAK2 is a
member of the JAK non-receptor protein tyrosine kinase
family and this mutation is located in the highly con-
served JAK homology 2 (JH2) pseudokinase region. Loss
of valine at position 617 in this region would result in
constitutive tyrosine kinase phosphorylation activity by
disruption of the intrinsic auto-inhibitory activity of the
JH2 domain.
9 Consequently, cells possessing the V617F
JAK2 mutation would exhibit cytokine hypersensitivity
and possess a proliferative advantage.
Intriguingly, the V617F JAK2 mutation has also been
described in both atypical MPD and myelodysplastic syn-
dromes,
5,10 albeit at a low the incidence. Steensma et al.
10
analyzed six CNL patients and only one was found to
possess a homozygous V617F JAK2 mutation. Of partic-
ular interest, this patient also had a history of B-cell lym-
phoma. This was not the case in our patient. Another
study
5 indicated that 20% of atypical or unclassified MPD
were also positive for the V617F JAK2 mutation. 
We wanted to establish whether our patient possessed
the V617F JAK2 mutation we, therefore collected a blood
sample, after gaining informed consent according to the
Declaration of Helsinki. The sample was fractionated and
genomic DNA isolated using a Nucleon BACC 1 DNA
extraction kit (Nucleon Biosciences, Manchester, UK).
The 2343 ‘G to T’ JAK2 mutation (V617F) was by detect-
ed byan amplification refractory mutation system
(ARMS) as described elsewhere
4 except Thermo-Start
DNA Polymerase (ABene, Epson, Surrey) was used.
ARMS PCR allows the detection of both the wild type
JAK2 allele and the mutant V617F allele, as indicated by
the presence of 229bp and 279bp bands on a 3% agarose
gel (Figure 1). Our patient proved homozygous for the
mutation in the granulocytes and macrophages.
Sequencing data is shown in Figure 2. 
At present, our patient remains symptomatically well
and is maintained on hydroxycarbamide (also known as
hydroxyurea) 500 mg daily which was commenced
because his absolute neutrophil count continued to rise
Figure 1. ARMS assay for the detection of the JAK2 2343 G→T
base change. The wild type allele JAK2 allele and the mutant
V617F allele are indicated by the presence of 229bp and 279bp
bands. The PCR amplification control band is located at 463bp.
The CNL patient, (Lane 4) strongly exhibited the 279bp band and
was thus scored as homozygous. Lane 1: homozygous wild type
control; Lane 2: heterozygous control; Lane 3: 2343 G→T homozy-
gous control; Lane 5: PCR negative control; M: 1kb DNA ladder
(ABgene, Epson, Surrey, UK).
control
mutant
normal
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above 100×10
9/L. His neutrophil count now averages
around 30-45×10
9/L. A trial of imatanib mesylate, 400 mg
daily, produced no hematologic response. 
As mentioned previously, this patient with CNL has
had an unusually long survival (now 96+ months).
Interestingly, it appears that in other MPD the V617F
JAK2 mutation is associated with a longer median disease
duration.
7
An analysis of all cohorts of patients with CNL will
enable an evaluation of the prevalence and prognostic
relevance of the V617F JAK2 mutation in this disease.
However, it remains to be established how the presence
of a JAK mutation, which provides a proliferative advan-
tage, affects the pathogenesis of an atypical MPD. 
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Figure 2. Detection of the G1849T mutation in the JAK2 gene.
Sequencing of exon 12 of the JAK2 gene detected a base change
of G to T at nucleotide 1849 in unfractionated blood (B), macro-
phages/granulocytes (C) as compared to wild type sequence (D).
Bases are as follows:  G: black; A: green; T: red; C:  blue.
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Widespread occurrence of the JAK2 V617F mutation in chronic
myeloproliferative disorders
Amy V. Jones, Sebastian Kreil, Katerina Zoi, Katherine Waghorn, Claire Curtis, Lingyan Zhang, Joannah Score, Rachel Seear,
Andrew J. Chase, Francis H. Grand, Helen White, Christine Zoi, Dimitris Loukopoulos, Evangelos Terpos, Elisavet-Christine Vervessou,
Beate Schultheis, Michael Emig, Thomas Ernst, Eva Lengfelder, Ru ¨diger Hehlmann, Andreas Hochhaus, David Oscier, Richard T. Silver,
Andreas Reiter, and Nicholas C. P. Cross
Theanalysisofrarechromosomaltransloca-
tions in myeloproliferative disorders has
highlighted the importance of aberrant ty-
rosine kinase signaling in the pathogenesis
of these diseases. Here we have investi-
gated samples from 679 patients and con-
trols for the nonreceptor tyrosine kinase
JAK2 V617F mutation. Of the 480 myelopro-
liferative disorder (MPD) samples, the pro-
portion of positive cases per disease sub-
type was 30 (20%) of 152 for atypical or
unclassiﬁed MPD, 2 of 134 (2%) for idio-
pathic hypereosinophilic syndrome, 58 of
72 (81%) for polycythemia vera, 24 of 59
(41%) essential thrombocythemia (ET), and
15 of 35 (43%) for idiopathic myeloﬁbrosis.
V617F was not identiﬁed in patients with
systemic mastocytosis (n  28), chronic or
acute myeloid leukemia (n  35), secondary
erythrocytosis (n  4), or healthy controls
(n  160).HomozygosityforV617Fwasseen
in 43% of mutant samples and was closely
correlated with chromosome 9p uniparental
disomy.Homozygositywassigniﬁcantlyless
common in ET compared with other MPD
subtypes. In 53 cases analyzed, the median
level of PRV1 expression was signiﬁcantly
higher in V617F-positive cases compared
with cases without the mutation. We con-
clude that V617F is widespread in MPDs.
Detection of this acquired mutation is likely
to have a major impact on the way patients
with MPD are diagnosed, as well as serving
as an obvious target for signal transduction
therapy. (Blood. 2005;106:2162-2168)
© 2005 by TheAmerican Society of Hematology
Introduction
Chronic myeloproliferative diseases (CMPDs) are clonal hemato-
poietic stem cell disorders characterized by proliferation of one or
more myeloid cell lineages in the bone marrow and increased
numbers of mature and immature cells in the peripheral blood.
CMPDs include polycythemia vera (PV), essential thrombocythe-
mia (ET), idiopathic myeloﬁbrosis (IMF) and chronic myeloid
leukemia (CML), plus rarer subtypes such as chronic neutrophilic
leukemia (CNL), hypereosinophilic syndrome (HES), and chronic
eosinophilic leukemia (CEL). These diseases overlap with myelo-
dysplastic/myeloproliferative diseases (MDS/MPDs) such as atypi-
calCML(aCML)andchronicmyelomonocyticleukemia(CMML),
in which proliferation is accompanied by dysplastic features or
ineffective hematopoiesis in other lineages.1 We refer here broadly
to all these groups as myeloproliferative disorders (MPDs).
Although there are strict diagnostic criteria for MPD subtypes,
precise categorization remains a subject of debate2 and further-
more, it can be difﬁcult to differentiate some cases from reactive
disorders. Only CMLis characterized by a pathognomonic molecu-
lar marker, the BCR-ABL fusion, and the primary abnormalities
driving excess proliferation in most other cases have been obscure.
However, several lines of evidence have implicated aberrant
tyrosine kinase signaling as the root cause of MPDs. Breakpoint
cluster region–abelson (BCR-ABL) itself is a constitutively active
tyrosine kinase that is believed to be the primary, and probably the
only, driving force behind chronic-phase CML.3 Other gene fusions
have been identiﬁed in rare cases of aCML, CMML, and HES/CEL
that involve the tyrosine kinases PDGFRA, PDGFRB, FGFR1, and
JAK2.4,5 In addition, the KIT receptor is activated by point mutation
in the majority of cases of systemic mastocytosis, a disease that is
classiﬁed separately by the World Health Organisation but which is
clearly myeloproliferative in nature.1,6
Observations in other MPD subtypes have also implicated
aberrant signaling in their pathogenesis, albeit indirectly. Myeloid
cells from patients are hypersensitive to a number of growth factors
and cytokines, with PV and IMF in particular being characterized
by the presence of erythroid and megakaryocytic precursor cells,
respectively, that grow spontaneously in culture.7-10 This factor-
independent growth and/or terminal differentiation can be blocked
by a range of signal transduction inhibitors.11,12 Finally, some
patients show increased expression of the antiapoptotic factor
B-cell leukemia–XL (Bcl-XL) and activation of signal transducer
activator of transcription (STAT) 3 or STAT5,11,13,14 all of which are
downstream elements of tyrosine kinase signaling. To investigate
the molecular pathogenesis of MPDs we therefore initiated a
mutation screen for genes encoding tyrosine kinases and down-
stream signaling components.
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Patients
We studied samples from a total of 679 individuals. Of these, 480 were
patients with a known or suspected diagnosis of an MPD (268 males, 212
females) referred for analysis in Athens, Mannheim or Salisbury. Patients
were referred for PV (n  72, including one case who also had systemic
mastocytosis), ET (n  59), IMF (n  35), idiopathic HES (n  134),
systemic mastocytosis (n  28), CML-like diseases (aCML, CMML and
related atypical MPDs, n  99) or atypical, unclassiﬁed MPD (n  53).All
HES, systemic mastocytosis, CML-like diseases, and atypical, unclassiﬁed
MPD cases were tested for BCR-ABL, FIP1L1-PDGFRA, KIT D816V
(mastocytosis cases only), and other gene fusions as indicated by karyotype.
None were BCR-ABL–positive, but 24 had rare tyrosine kinase fusion genes
involving PDGFRA, PDGFRB, FGFR1,o rJAK2, and 8 had the KIT
D816V mutation. We also studied samples from patients with AML
(n  17), BCR-ABL–positive CML (n  18) plus controls from healthy
individuals (n  160) or individuals with secondary erythrocytosis (n  4).
The study was approved by the Internal Review Boards from participating
institutions and informed consent was provided according to the Declara-
tion of Helsinki.
Mutation screening
Initially, we studied a set of 40 atypical, CML-like MPD patients by
heteroduplex analysis (either denaturing high-performance liquid chroma-
tography or conformation-sensitive capillary electrophoresis) to screen
candidate genes encoding tyrosine kinase and downstream signaling
components for mutations. We focused on known mutational hotspots seen
in other malignancies or regions that were homologous to mutational
hotspots in other genes. We screened KIT (exons 10, 11 and 17), PDGFRA
(exons 12 and 18), PDGFRB (exons 12, 17 and 18), FMS (exons 7, 9, 12,
13, 18, 21 and 22), JAK2 (exon 20), CSK (exon 11), FES (exon 17), SYK
(exon 11), STYK1 (exon 8), TIE1 (exons 18 and 19), PTPN11 (exons 3 and
13), and BRAF (exons 11-14), but no abnormalities were detected apart
from known polymorphisms. All exons of HRAS, KRAS, and NRAS were
also screened and 5 (12.5%) cases were found to have activating mutations
of N-Ras (G12S, n  2; G12D, n  1; G12C, n  1; and G13S, n  1).
Polymerase chain reaction (PCR) primer sequences and assay conditions
are available on request. Following the recent report of the JAK2 V617F
mutation (2343G  T; JAK2 exon 12; RefSeq ID NM_00497215)i n
patients with PV, ET, and IMF,16-19 we focused speciﬁcally on this
abnormality.
V617F genotyping by ampliﬁcation refractory mutation
system (ARMS)
DNA was extracted by standard procedures after isolation of total leukocytes
from peripheral blood following red cell lysis or mononuclear cells by density
gradient centrifugation over Histopaque 1077 (Sigma-Aldrich, Ayrshire, United
Kingdom). Patients and controls were genotyped initially by a DNAtetra-primer
ARMSassay,amethodthatuses2primerpairstospeciﬁcallyamplifythenormal
and mutant sequences plus a positive control band in a single reaction. Primers
were designed using a ARMS design program20 and include mismatches to
maximize discrimination of the 2 alleles (shown in lowercase) and mutant/wild-
type–speciﬁc bases (underlined). PCR primers were: forward outer (FO),
5-TCCTCAGAACGTTGATGGCAG-3;reverseouter(RO),5-ATTGCTTTC-
CTTTTTCACAAGAT-3; forward wild-type–speciﬁc (Fwt), 5-GCATTTG-
GTTTTAAATTATGGAGTATaTG-3; reverse-mutant–speciﬁc (Rmt), 5-
GTTTTACTTACTCTCGTCTCCACAaAA-3.Ampliﬁcations were performed
for 30 cycles with HotStarTaq polymerase (Qiagen, Crawley, United Kingdom),
an annealing temperature of 60°C, 25 ng genomic DNA, and standard ampliﬁca-
tion conditions, except that the ﬁnal concentrations of the outer primers and the
mutant/wild-type–speciﬁc inner primers were 1 M and 0.5 M, respectively.
Products were resolved on 3% agarose gels and visualized after staining with
ethidiumbromide.Controlexperiments(notshown)indicatedthattheassaygave
identical results using 20 to 200 ng input DNA.
V617F genotyping and allele quantitation by Pyrosequencing
DNA samples were ampliﬁed using primers 5-biotin-GAAGCAGCAAG-
TATGATGAGCA-3 (forward; JAK2 exon 12) and 5-TGCTCT-
GAGAAAGGCATTAGAA-3 (reverse; JAK2 intron 12). Amplicons were
generated in a 50 L reaction volume with 15 pmol of forward and reverse
PCR primers, 0.2mM dNTPs (deoxyribonucleoside triphosphates; Pro-
mega, Southampton, United Kingdom), 1.5 mM MgCl2,1 Buffer II
(Applied Biosystems, Warrington, Cheshire, United Kingdom), 1 unit
AmpliTaq Gold (Applied Biosystems) using 10 ng genomic DNA. PCR
conditions were 94°C for 7 minutes; 50 cycles with denaturation at 94°C for
30 seconds, annealing at 58°C for 30 seconds, and elongation at 72°C for 30
seconds; 1 cycle at 72°C for 7 minutes; and a ﬁnal hold at 15°C.
Single-stranded biotinylated PCR products were prepared for sequencing
using the Pyrosequencing Vacuum Prep Tool (Biotage, Uppsala, Sweden).
Three microliters Streptavidin Sepharose HP (Amersham Biosciences,
Chalfont St Giles, United Kingdom) was added to 37 LBinding buffer (10
mM Tris [tris(hydroxymethyl)aminomethane]–HCl, pH 7.6; 2 M NaCl; 1
mM EDTA [ethylenediaminetetraacetic acid]; 0.1% Tween 20) and mixed
with 20 L PCR product and 20 L high-purity water for 10 minutes at
room temperature using a Variomag Monoshaker (Camlab, Over, United
Kingdom). The beads containing the immobilized templates were captured
onto the ﬁlter probes after applying the vacuum and then washed with 70%
ethanol for 5 seconds, denaturation solution (0.2 M NaOH) for 5 seconds,
and washing buffer (10 mM Tris-acetate, pH 7.6) for 5 seconds. The
vacuum was then released and the beads released into a PSQ 96 Plate Low
(Biotage) containing 45 L annealing buffer (20 mM Tris-acetate, 2 mM
magnesium acetate, pH 7.6), 0.3 M sequencing primer (5-TCTCGTCTC-
CACAGA-3; JAK2 exon 12, reverse orientation).The samples were heated
to 80°C for 2 minutes and then allowed to cool to room temperature.
Pyrosequencing reactions were performed according to the manufacturer’s
instructions using the PSQ 96 single nucleotide polymorphism (SNP)
Reagent Kit (Biotage), which contained the enzyme and substrate mixture
and nucleotides. The sample genotypes were determined using the Allele
Frequency Quantiﬁcation function in the SNP Software (Biotage, Uppsala,
Sweden). Samples were scored as homozygous if the proportion of the mutant
allele was greater than 50%, the maximum expected if a heterozygous mutant
clone had expanded to include all cells in the sample. In practice this is likely to
underestimate the number of homozygotes since our samples included lympho-
cytes (a proportion of which are probably not part of the mutant clone).
Quantiﬁcation of PRV1 mRNA
Mononuclear cell RNA was extracted and reverse transcribed into cDNA with
random hexamer primers using standard procedures. Real-time quantitative
(RQ)–PCR was performed in 12.5 L mastermix (TaqMan Universal PCR
Master Mix,Applied Biosystems); using 0.25 M PRV1-TM probe (5-FAM[6-
carboxy ﬂuorescein]–TTGTCTGGTGTGGT*TCAACAAGAAGCT-3, where
*6-carboxy-tetramethylrhodamine [TAMRA]), 0.5 M of each 3 and 5
oligonucleotide primers (PRV1-se 5-CTCTCAGGAGGTGGGCTGT-3 and
PRV1-as 5-GCGCAGAGAAGATCCCGA-3 respectively), 5 L cDNA in a
ﬁnal volume of 25 L. Ampliﬁcation was performed in a 2-step cycle
(denaturation, 95°C for 15 seconds, annealing/extension at 62°C for 60 seconds)
for 50 cycles. Ampliﬁcation and postprocessing calculations were performed
using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems).
The values obtained were normalized using the ABL gene as endogenous
control21 using the deltadeltaCt method.22
Microsatellite analysis
DNA samples were ampliﬁed with a series of ﬂuorescently labeled primer
pairs ﬂanking highly polymorphic microsatellite markers on chromosome
9p (D9S1779, D9S1858, D9S288, D9S1813, D9S286, D9S254, D9S157,
D9S171). Standard conditions were used with 25 to 50 ng input genomic
DNA, a ﬁnal volume of 10 L, 32 ampliﬁcation cycles, and 55°C annealing
temperature. Products were analyzed on an ABI 3100 genetic analyser
using the Genotyper 2.0 program (Applied Biosystems, Foster City, CA).
Peak heights were compared with controls and scored as heterozygous for
each marker if there were 2 clear peaks of similar intensity, or the ratio of
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homozygous if only one peak was visible or, to allow for the presence of
background normal cells, if one peak was one third or smaller than the
expected size compared with controls. Uniparental disomy (UPD) was
scored if 4 or more consecutive markers abutting or encompassing JAK2
were homozgygous (P  .05 of this occurring in the absence of UPD based
on published rates of heterozygosity23).
Copy number determination by multiplex ligation probe
ampliﬁcation (MLPA)
MLPA primers were designed to nonpolymorphic exons of FES (15q26),
JAK2 (9p24), SOAT1 (1q25), BTK (Xq22), TYK2 (19p13), MST1R/RON
(3p21), and HCK (20q11), and obtained from Biomers (Ulm, Germany).
Primers were between 43 and 69 bases in length and consisted of M13 tags,
a random stuffer sequence of variable length in order to generate
gene-speciﬁc products of different sizes and 20 bases homologous to the
target of interest (primer sequences available on request). Primers were
designed in pairs that would abut each other when hybridized to genomic
DNA, and the right-hand primer in each pair was synthesised with a
5phosphate group to enable ligation to the left oligonucleotide. Hybridiza-
tion of probe pairs to genomic DNA, ligation, and ampliﬁcation was
performed as described,24 with the PCR products being separated on anABI
3100 genetic analyzer. Peak areas were exported to an Excel spreadsheet
(Microsoft, Redmond,WA), which was designed to assess the ratios of each
test peak relative to all other peaks for that individual. Ratios of the JAK2
peak to other peaks in each patient sample were compared with the same
ratios obtained for 2 healthy individuals, which were included in each run.
For normal sequences a dosage quotient of 1.0 is expected; if a deletion or
duplication is present the dosage quotient should be 0.5 and 1.5, respec-
tively.25 BTK is on the X-chromosome and therefore provided an internal
control that the assay was working (dosage quotient of 0.5 in males and 1.0
in females).
Statistical analysis
Observed and expected frequencies were compared by 2 analysis.
Mutation status was compared with PRV1 mRNA levels using the
Mann-Whitney test.
Results
Incidence of V617F JAK2
Of the 480 samples with a known or suspected diagnosis of an
MPD, 129 (27%) were positive for the V617F JAK2 mutation by
the ARMS assay and 351 (73%) were negative. Representative
results are shown on Figure 1A. Sequence analysis of selected
cases (n  51) was fully concordant with theARMS results (Figure
2A), although in some cases the proportion of the mutant allele
was low and would have been difﬁcult or impossible to detect by
sequence analysis alone. Analysis of a dilution series indicated
the sensitivity of the ARMS assay to be 1% to 2% (Figure 1B),
whereas sequencing is generally accepted to have a sensitivity
of only 20% to 30%, depending on the sequence context.
Using theARMS assay, we found that the proportion of positive
cases per disease subtype ranged from 58 (81%) of 72 for PV to 0
(0%) of 28 for mastocytosis (Table 1). Strikingly, V617F was
detected in a substantial proportion of patients with CML-like
diseases and atypical, unclassiﬁed MPD. V617F was not detected
in any of the 480 MPD cases with rare tyrosine kinase fusion genes
(n  24),norinanyindividualwithCML(n  18),AML(n  17),
or in healthy controls (n  160). V617F and KIT D816V were
found in one individual who had both PV and systemic
mastocytosis, but not in any of the other 7 D816V-positive
cases. Of the 14 V617F mutation–negative patients with PV, 13
were male (P  .005, 2) but no other signiﬁcant associations
between sex and mutation status were identiﬁed. Mutation
analysis of JAK2 exon 12 in V617F-negative cases did not
reveal any additional sequence variants.
Relative ratios of V617F and normal JAK2 alleles
The ARMS and sequencing results for several patients showed
mutant bands much stronger than the wild-type bands (Figures 1A
and 2A) and in some cases the wild-type band was not visible at all,
suggesting that the mutation may be homozygous in the mutant
clone. SinceARMS and sequencing results are not always quantita-
tive, we designed a Pyrosequencing assay for the V617F mutation,
as this method is capable of providing robust allele ratios.26
Pyrosequencing was performed on the 90 mutant samples for
which DNAwas available, and conﬁrmed homozygosity in most of
the samples with a stronger mutant band byARMS analysis (Figure
2B). Samples analyzed by ARMS only were therefore scored as
homozygous if the ratio of mutant to wild-type bands was at least as
strong as that seen in the 50% dilution control (Figure 1B, 50%
track), as determined by visual inspection. Overall, homozygosity
was seen in 55 (43%) of 129 mutant samples and results for each
patient subgroup are summarized on Table 1. The frequency of
homozygotes relative to heterozygotes was not signiﬁcantly differ-
ent from the average of all cases in any of the subgroups apart from
ET, in which the proportion of homozygous mutants was signiﬁ-
cantly lower than average (P  .009, 2). We found evidence of a
residual wild-type signal in all but 2 homozygous cases by
Pyrosequencing, with dilution experiments (not shown) indicating
that the sensitivity of the assay was approximately 5%. Pyrose-
quence analysis of 23 cases that were normal genotype by the
ARMS test yielded normal (100% wild-type allele) in all cases.
Figure 1. ARMS assay to detect the JAK2 2343G > T in genomic DNA. (A)
Representative results. Tracks 5 and 6 show a normal genotype; tracks 1 and 3 show
a mutant band that is weaker or similar intensity to the normal band and were
therefore scored as heterozygous for the 2343G  T mutation; tracks 2, 4, 7, and 8
show a mutant band that is stronger than the normal band and were therefore scored
as homozygous for the mutation. Tracks 9 and 10 are negative controls and M is the
1-kilobase (kb) DNAladder (Invitrogen, Paisley, United Kingdom). (B) Sensitivity of
the ARMS assay. DNA from a homozygous patient with minimal residual wild-type
allele was diluted with normal DNA and ampliﬁed. The ARMS assay is routinely
capable of detecting V617F at a dilution of 1% to 2%. (C) Schematic outline of the
assay. Primers FO and RO ﬂank JAK2 exon 12 and should generate a control 463-bp
band in all cases. Primers Fwt and RO generate a 229-bp wild-type (2343G)–speciﬁc
product and primers FO and Rmt generate a 279-bp mutant (2343T)–speciﬁc
product.
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A homozygous V617F clone was seen in 24 (33%) of 72 cases of
PV, 4 (7%) of 59 cases of ET, and 10 (29%) of 35 cases of IMF.
This is strikingly similar to the frequencies of acquired chromo-
some 9p UPD (autosomal regions for which both copies are derived
from a single parent) that has been described in these diseases.
Furthermore, the minimal disomic region contains JAK2.27,28 To
determine if UPD9 was associated with homozygosity for V617F,
we initially performed microsatellite analysis on 57 MPD cases
(wild type, n  30; V617F homozygous, n  27). Microsatellites
were scored as homozygous or heterozygous and the results are
summarized on Figure 3. In wild type individuals, most microsatel-
lites are expected to be heterozygous. Consecutive tracts of
homozygousmarkersusuallyindicatelossofheterozygosity(LOH)
due to complete or partial chromosome loss, or UPD. We found
signiﬁcant tracts of homozygosity in the vicinity of JAK2 in 4
(13%) of the wild type cases and 25 (93%) of the V617F
homozygotes (P  .001). To determine whether this homozygosity
arose through LOH or UPD, we measured the number of copies of
the JAK2 gene relative to control genes by MLPA. One copy of
JAK2 would indicate LOH, whereas 2 copies would indicate UPD.
All 7 cases analyzed that were homozygous for both V617F and at
least 3 consecutive 9p markers had 2 copies of JAK2, consistent
with UPD9 (Figure 4A).
Correlation between the presence of V617F
and overexpression of PRV1
Overexpression of the PRV1 gene has been reported in the great
majority of patients with PV and a subset of patients with ET and
IMF.29-32Although the mechanism of overexpression is not known,
many groups consider quantiﬁcation of PRV1 mRNAto be a useful
supplementary test in the diagnosis of MPDs.To determine if PRV1
expression is associated with abnormalities of JAK2, we compared
mRNA levels to mutational status in 53 cases (PV, n  15; ET,
n  32; IMF, n  6). Although there was considerable overlap
between the range of PRV1 levels in normal JAK2 (n  30,
median  293, range  6-17 500) and V617F cases (n  23, me-
dian  2700, range  59-208 000), the difference between the 2
groups was signiﬁcant (P  .001, Mann-Whitney test). The me-
dian PRV1 level for homozygous V617F cases (median  4940,
n  11) was greater than the median for heterozygous cases
(median  1650, n  12), but the difference was not signiﬁcant
(P  .1, Mann-Whitney). Results are summarized in Figure 4B.
Table 1. Patient details and summary of results
Disease subtype
No.
patients
V617F-positive V617F-negative
V617F
homozygotes no.
(% of mutants)
No. patients
(%)
No. male/no.
female
Median age, y
(range)
No. patients
(%)
No. male/no.
female
Median age, y
(range)
PV 72* 58 (81) 31/27 57 (26-76) 14 (19) 13/1 57 (33-78) 24 (41)
ET 59 24 (41) 15/9 65 (5-88) 35 (59) 23/12 56 (24-88) 4 (17)
IMF 35 15 (43) 10/5 65 (44-78) 20 (57) 15/5 62 (41-92) 10 (67)
Idiopathic HES 134† 2 (1.5) 1/1 64 (63-65) 132 (99) 51/81 54 (3-89) 2 (100)
Mastocytosis 28‡ 0 (0) NA NA 28 (100) 16/12 53 (4-90) NA
CML-like MPDs 99§ 17 (17) 13/4 62 (17-76) 82 (83) 60/22 66 (2-95) 8 (47)
Unclassiﬁed MPD 53 13 (25) 7/6 63 (17-77) 40 (75) 17/23 61 (21-87) 7 (54)
Total 480 129 (27) 77/52 58 (2-95) 351 (73) 195/156 62 (5-88) 55 (43)
NAindicates not applicable.
*Includes one case with PV plus systemic mastocytosis who was positive for V617F and KIT D816V.
†Includes 7 FIP1L1-PDGFRA-positive CELcases, all of whom were negative for V617F.
‡Includes 7 KIT D816V-positive cases, all of whom were negative for V617F.
§Includes 17 cases with rare tyrosine kinase fusions (ETV6-PDGFRB, n  9; ZNF198-FGFR1, n  2; BCR-FGFR1, n  2; PCM1-JAK2, n  2; BCR-PDGFRA, n  1;
TP53BP1-PDGFRB, n  1), all of whom were negative for V617F.
Figure 2. Detection of the JAK2 by sequence analysis, and Pyrosequencing.
(A) Sequence traces of 3 individuals found to be wild-type, heterozygous, and
homozygous by the ARMS assay. (B) Representative pyrograms for one wild-type,
one heterozygous, and 2 homozygous individuals. The sequencing primer is in
reverse orientation (immediately abutting the site of the mutation) and the dispensa-
tion order GCAGCATAC was used (the 2 Gs are internal controls that should give no
peak; E and S indicate enzyme and substrate, respectively). In a wild-type individual
(sequence CACATAC) the peak heights of the ﬁrst C and A are similar. In a
heterozygous individual (sequence (C/A)ACATAC) the C peak is reduced in height
and theApeak increased above all other peaks as both the mutantAand followingA
are being read in the same reaction. In a homozygous individual (sequence
AACATAC) the ﬁrst C peak is either much lower than the A peak (third trace) or,
occasionally, absent (fourth trace). The ratio of the healthy (C) and mutant (A) alleles
is calculated by the Pyrosequencing SNP analysis software. Values are log10
delta-delta CtPRV1/ABL.
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We have identiﬁed the JAK2 V617F mutation in approximately
one-ﬁfth of patients with an atypical MPD, as well as conﬁrming
the presence of this mutation in the great majority of patients
with PV and nearly half of cases with ET or IMF. The ﬁnding of
an identical mutation in such clinically diverse (although clearly
related) cases is quite remarkable. There is nothing in the
sequence context to suggest that position 2343G might be
particularly mutable and, since no other mutations were found in
JAK2 exon 12, it seems likely that the V617F substitution must
have very speciﬁc functional consequences. The mutation
occurs in a highly conserved region of the pseudokinase (JH2)
domain, a region that is homologous to the true tyrosine kinase
domain but lacks key catalytic residues, and has been shown to
constitutively activate JAK2.16,17,19 The pseudokinase domain is
Figure 3. Microsatellite analysis to identify regions of homozygosity. The V617F
genotypeofthepatientsisindicatedaseitherhomozygousnormal(WT/WT;patients1-30)or
homozygous mutant (M/M; patients 31-57). Microsatellite markers on chromosome 9p are
shown in order from the most telomeric (D9S1779) to the most centromeric (D9S171) and
are scored as homozygous (black), heterozygous (white), or not done (gray). Based on
published rates of heterozygosity,23 signiﬁcant tracts of chromosome 9p homozygosity
(LOH/UPD) were scored if 4 consecutive markers above or below JAK2 were homozygous.
Figure 4. JAK2 copy number and correlation of status with PRV1 expression.
(A) Representative results of MLPA analysis to measure JAK2 copy number. The
relative peak areas for JAK2 are the same for 2 homozygous V617F cases with 9p
LOH (M/M) and 2 healthy controls (WT/WT), indicating the presence of 2 copies of
JAK2. The second case is male and shows a reduced peak height for the X-linked
gene BTK compared with the 3 other cases, all of which were female. (B) PRV1
mRNA levels (log10deltadeltaCtPRV1/ABL) determined by real-time PCR in 30 MPD
patients with normal JAK2 (WT) and 23 MPD patients with the V617F mutation.
These 23 patients are also shown split into the 12 heterozygous (HET) and 11
homozygous (HOM) cases. Vertical lines indicate the range of results, open boxes
indicate the interquartile range, and thick horizontal lines indicate median values.
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interaction with the kinase domain.33 Structural modeling has
suggested that residues V617 to E621 form a loop connecting 2
	-strands of the N-terminal lobe of the pseudokinase domain,
with C618 contacting the kinase activation loop. It has been
postulated that V617, C618, and other local residues inhibit
movement of the activation loop from its inactive to its active
conformation (ie, the V617 region plays a direct role in
negatively regulating JAK2 signaling).34 The substitution of
V617 by the large aromatic amino acid phenylalanine is likely to
disrupt this negative regulation, although this remains to be
proven biochemically. However, evidence that amino acid
substitutions in the pseudokinase domain can activate JAK2
comes from the Drosophilia mutation hopscotch, in which a
mutation corresponding to E695K in the human protein results
in hematopoietic hyperplasia.35 In addition, JAK2 has been
directly implicated in human malignancy, ﬁrst by fusion to
TEL/ETV6 and PCM1 as a consequence of chromosome translo-
cations in leukemia36-38 and, second, by aberrant signaling in a
wide range of solid tumors.39
JAK2 is a nonreceptor tyrosine kinase that plays a major role in
myeloid development by transducing signals from diverse cyto-
kines and growth factor receptors, including those for interleukin
(IL)–3, IL-5, erythropoietin, granulocyte-macrophage–colony-
stimulating factor (GM-CSF), G-CSF, and thrombopoietin.39,40 It
seems likely that a mutation which interferes with the negative
regulation of JAK2 could account for the observed hypersensitivity
of myeloid cells from MPD patients to growth factors. However it
is not clear why different individuals withV617F show preferential
expansion of erythroid, granulocyte, megakaryocyte, monocyte,
or eosinophil lineages. Potentially, this could be due to the
identity of the cell in which the mutation arises, the constitu-
tional genetic background of the individual, or to other,
secondary acquired changes.
In addition to secondary or constitutional differences, V617F
itself may also play a role in specifying disease phenotype since we
found homozygosity to be signiﬁcantly less common in ET
comparedwithotherMPDsubtypes.However,deﬁnitiveidentiﬁca-
tion of V617F zygosity in individual cases is complicated by the
fact that it is not possible to distinguish between a relatively small
homozygous clone and a larger heterozygous clone when mixed
populations of cells are analyzed. Nevertheless, we found a wide
range (5%-100%) in the relative proportion of mutant alleles in
V617F-positive cases by Pyrosequence analysis. The fact that (1)
the mutation was present at a level substantially less than the
wild-type allele in many heterozygous cases, (2) the wild-type
allele was detectable in the great majority of homozygous patients,
and (3) the age of homozygous cases (median, 63 years; range,
17-69 years) was not signiﬁcantly different from heterozygous
cases (median, 62 years; range, 5-88 years) strongly suggests that
the mutation was acquired. Other studies have shown thatV617F is
absent inTcells and the great majority of buccal epithelial samples,
clearly indicating that the mutation was acquired in these individu-
als.16-19 However, we cannot exclude the possibility that V617F
might be inherited in occasional cases, although this seems unlikely
as linkage to chromosome 9p has been excluded in MPD
families.30,41
Although V617F accounts for an important subset of cases
with CML-like diseases and atypical MPDs, the pathogenesis of
the majority of these cases remains unknown. In our original
series of 40 CML-like cases, only one-third of those that were
negative for rare tyrosine kinase fusion genes were found to
have the V617F JAK2 mutation or an activating NRAS mutation
(no case had a JAK2 and RAS mutation). PV and IMF are both
considered to be clonal diseases, suggesting that the molecular
basis of roughly 20% and 60%, respectively, of these diseases
remain to be elucidated. However, these ﬁgures may be
overestimates since it is likely that some of the cases in our
study had an unrecognized reactive condition. It is known that
the clinical diagnostic precision varies between clinicians and it
is possible therefore that the true incidence of V617F in PV and
IMF is somewhat higher than we found in this study.42 On the
other hand, it is likely that technical differences relating to the
sensitivity of V617F detection are also a contributory factor to
the published differences in the proportions of positive cases
within MPD subtypes. As for ET, approximately half of cases
have clonal disease and half are polyclonal, and therefore
presumably reactive.43 Although we did not perform clonality
assays, we found the V617F mutation in 41% of ET cases,
suggesting that the great majority of clonal ET is V617F
positive. We did not observe V617F in patients with CML or
AML; however, the numbers of cases analyzed were relatively
small and therefore we cannot exclude the possibility that a
small subset of cases might carry this mutation. Interestingly, 6
of the patients in our series had chronic neutrophilic leukemia, 2
of which were V617F positive.
We found that homozygosity for V617F in all disease subtypes
was closely associated with chromosome 9 UPD, conﬁrming
previous results and suggesting a selective advantage for 2 copies
of mutant JAK2.17 We also found signiﬁcant 9p homozygosity in 4
MPD cases without V617F, which could indicate a mutation in a
different region of JAK2. Although gain of chromosome 9p is
known to be associated with MPDs,44-46 UPD for this region is
much more common. Recently, UPD for diverse chromosomal
regions has been identiﬁed in acute leukemia47,48 and, although
most of these regions have not yet been associated with speciﬁc
acquired mutations, it is possible that reduction of oncogenic
mutations to homozygosity by cytogenetically cryptic mitotic
recombination is widespread in malignancy.
The fact that V617F was found in the great majority of cells and
was homozygous in many cases suggests that it is probably the
primary abnormality driving myeloproliferation. As such, it is
clearly a very attractive target for signal transduction therapy with
small molecule inhibitors, although at the time of writing no
clinically available JAK2 inhibitors have been described. JAK
family members play a crucial role in the immune system; for
example, inherited JAK3 deﬁciency causes severe combined
imunodeﬁciency,49,50 and JAK2 also plays an important role in
cardiovascular signaling systems.51 Development of inhibitors that
inhibit V617F without undesirable side effects may therefore be
challenging.
Diagnosis of MPDs is often complex, expensive and in the case
of ET, based solely on exclusion criteria. Since the detection of
acquired V617F is simple to perform and unambiguously estab-
lishes the presence of a clonal disorder, we believe that JAK2
mutation testing will rapidly become a frontline test for individuals
with a suspected diagnosis of an MPD.
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